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Abstract 
The present thesis outlines our latest findings on the reactivity of the Burgess 
reagent with oxiranes. Structural, mechanistic, and computational studies are 
presented. Included is the development of a (-)-menthyl version of the Burgess 
reagent and its application to the synthesis of enantiomerically pure ~-amino alcohols. 
This methodology has been exploited in the formal enantiodivergent synthesis of the 
(+)- and (-)-isomers of balanol. Also described is a second generation approach to 
both balanol enantiomers; each commencmg with the chemoenzymatic 
dihydroxylation of bromobenzene. This study also describes the steric and functional 
limitations of the toluene dioxygenase-mediated oxidation of benzoate esters. The 
metabolite derived from ethyl benzoate was employed in a formal synthesis of 
oseltamivir. Finally, several synthetic approaches to oseltamivir and its analogs are 
presented, each proceeding through a different vinyl aziridine derived from 
bromobenzene and ethyl benzoate. 
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1. Introduction 
The majority of natural products and other compounds targeted by synthetic 
organic chemists contain at least onechiral carbon center. Early accomplishments, 
such as equilenin! and quinine,2 have relatively few chiral atoms; two and four 
respectively. The most complex molecules synthesized to date, highlighted by the 
linear polycyclic ether marine toxins including the brevetoxins, contain more than 20 
stereo genic centers. Without exception all of the chiral carbon atoms in such 
synthesized molecules are incorporated through use of either chiral starting materials 
or chiral reagents. Optically active starting materials have traditionally included 
amino acids, sugars and alkaloids isolated from natural sources. The stereosel~tivity 
of chiral reagents, either organic or metal based, arises from steric and electronic 
effects operating during the mechanistic pathway of the reaction. 
The central dogma of synthetic organic chemistry is that the discovery and 
application of asymmetric materials and reagents will lead to the synthesis of new 
target molecules, and will improve the brevity of previously accomplished syntheses. 
The Hudlicky group has always followed this philosophy in the pursuit of 
synthetically challenging alkaloids. The present study outlines our work on the 
synthesis of two molecules, namely balanol (1) and oseltamivir (2). An 
enantiodivergent synthesis of the former will be achieved through the development of 
an asymmetric version of the Burgess reagent 3, whose reaction with 1,3-
cyclohexadiene oxide (4) provides syn-sulfamidates 5 {Figure 1). Balanol will also be 
prepared through the application of a homochiral diene diol 6 derived from the 
enzymatic dihydroxylation of bromo benzene. 
1 
0 000 0 II e's' <±l II~O 
_ O./'-..N~ 'NEt O-S'" * do A 3 3 0' )~-{OM 
-------------. 0 ~ 
.h- M* = (-)-menthyl .h-
HO 
HO 
4 (+/-)-5 balanol (1) 6 
Figure 1. Two synthetic routes to balanol (1) 
Our isolation and identification of the homochiral diol 7 from the fermentation of 
ethyl benzoate yields an asymmetric compound suitable for the synthesis of 
oseltamivir (2) (Figure 2). 
7 
r 
"'N2Z0-c HNy 
o oseltamivir (2) 
( 
o 0 
"'X'"' ... OH ~ 
UOH 
Figure 2. Synthetic route to oseltamivir (2) 
The Burgess reagent (8) was originally designed and used as a mild 
dehydrating agent for secondary and tertiary a1cohols.4-7 The Hudlicky group's work 
with the Burgess reagent (8) began in 2003 with the discovery that oxiranes 10, 
originally thought to be inert to the reagent,3 reacted to form cyclic syn--sulfamidates 9 
(Figure 3).8 The present study evaluates the mechanistic options of the Burgess 
reagent (8) in its reactions with oxiranes and 1,2-diols to form 5- and 7-membered 
cyclic sulfamidates. 
10 9 
Figure 3. Reaction of the Burgess reagent (8) with oxiranes 
2 
It was theorized that replacement of the methoxy functionality with an 
asymmetric auxiliary group would lead to a pair of syn-sulfamidate diastereomers 
(+/-)-11. The present study outlines our development of a (-)-menthyl version of the 
Burgess reagent 3 and explores its reactions with epoxides 10. The products of this 
reaction are separable by column chromatography and thus give access to both cis-
and trans-p-amino alcohols 12a and 12b in enantiomerically pure forms (Figure 4). 
An effective application of this methodology will be presented in the enantiodivergent 
synthesis of the fungal metabolite (-)-balanol (1) with the R,R stereochemistry, and 
its S,S enantiomer (+ )-balanol. 
o 00 0 )l e 's' cv 0-$,,/0 OM* o *MO N' 'NEt3 -~ __ 3 __ ~.,Ni ~ 
~ M* = (-)-menthyl ~ 
10 (+/-)-11 
QH 
~'NH2 + 
12a 12b 
Figure 4. Synthesis of enantiomerically pure cis- and trans-p-amino alcohols 12a/b 
In the early 1990's Sphinx Pharmaceuticals, now part of Eli Lilly and Company, 
isolated balanol (1) from the Verticillium balanoides species of fungi. 9 Subsequent 
assays revealed its potent inhibitory activity against members of the protein kinase C 
(PKC) family of isozymes. The overactivity of PKCs have been implicated in a 
number of diseases including arthritis, diabetes, and some types of cancer. I 0 Potent 
and selective inhibitors of PKC, such as balanol, have wide-ranging therapeutic 
. I II potentia. 
The first strategy discussed will take advantage of the sulfamidate 
diastereomers 5a/b produced from reacting vinyl oxirane 4 with the (-)-menthyl 
version of the Burgess reagent 8. The desired trans functionality will be achieved 
3 
through inversion of the sulfamidate oxygen (Figure 5). An oxidative cleavage and 
reductive amination procedure will be employed in order to form the azepane 
functionality. Removal of the chiral auxiliary group and subsequent fictionalization 
will allow for the synthesis of both the naturally occurring (-)-isomer and unnatural 
(+)-isomer ofbalanol (1) from a single achiral starting material. 
o 
11 .... 0 
9-5,'" OM' 
~ ,N-{ (-)-balanol(1)~ Q" 0 
inversion of 
sulfamidate oxygen 
5a ~ oxidative cleavage and J 
reductive amination 
5b 
~ (+)-balanol (1) 
Figure 5. Strategy for the enantiodivergent synthesis of (-)- and (+ )-balanol from 
vinyl sulfamidates 5a/b 
Our second generation approach will initiate from the homochiral 
cyclohexadiene-cis-I,2,-diol 6 obtained from the toluene dioxygenase (TDO) 
mediated dihydroxylation of bromobenzene. This reaction is performed by a 
recombinant Escherichia coli strain, developed by Dr. David Gibson, which 
overexpresses the TDO genes.12- 13 Many cis-dihydrodiol metabolites, isolated from 
the whole-cell fermentation of arene substrates, have been employed by the Hudlicky 
group and others in the enantioselective synthesis of a number of naturally occurring 
products. 14 
The strategy presented in this thesis relies on the preparation of diastereomeric 
aziridines 13 and 14 from cis-dihydrodiol 6. Both vinyl aziridines are susceptible to 
regioselective openings with oxygen nucleophiles (Figure 6). This is followed by 
4 
saturation of the vinyl bromide moiety, oxidative cleavage of the 1,2-diol and a 
reductive amination protocol. 
( 
aziridine opening with oxygen :J 
nucleophile 
oxidative cleavage and 
reductive amination 
ACN~ -OR ) t RO ,,\~Ts (-)-balanol(1)~ 'J ~Yl ~ (+)-balanol(1) (1r "'OR. _ RO~ 
13 ~eductio~ 14 
Figure 6. Strategy for the enantiodivergent synthesis of(-)- and (+)-balanol from 
vinyl aziridines 13 and 14 
This study will also focus on a new series of cis-cyclohexadiene diols 16 
derived from the enzymatic dihydroxylation of various benzoate esters 15 (Figure 7). 
o OR 0 OR 2) E. coli JM1 09(pOTG601) 2XOH __ pseudo-sugars, amino cyclitols, I • - and bicyclic ring systems 
~ ~ OH 
15 R = alkyl, allyl, propargyl 16 
Figure 7. TDO catalyzed oxidations of benz oates to cis-dihydrodiols 
Investigations into the steric and functionality limitations of the TDO-catalyzed 
dihydroxylation of benzoate esters are discussed. The absolute stereochemistry of the 
diol metabolites 16 will be established by comparing the physical properties of their 
derivatives with those of known compounds. The versatility of the metabolites as 
intermediates in the synthesis of pseudo-sugars, amino cyclitols and bicyclic ring 
systems will be evaluated. Specifically, a short enantioseJ.ective synthesis of carba-a-
L-galactopyranose (17) from the TDO-catalyzed oxidation product of methyl 
benzoate 18 is discussed. This pseudo-sugar will be synthesized through reduction of 
5 
the acrylate and ester functionalities in addition to a stereoselective dihydroxylation 
reaction (Figure 8). 
reduction~ 
~2XOMe HO& ~ OH_ ·. OH 
-~ ,. dihydroxylation~ OH HO' = OH 
OH 
18 carba-a-L-galactopyranose (17) 
Figure 8. Strategy for the synthesis of carba-a-L-galactopyranose (17) 
Highlighting the value of these metabolites will be the synthesis of oseltamivir 
(2) from the cis-dihydrodiol derived from ethyl benzoate (7). Tamiflu (phosphate salt 
of oseltamivir) is an essential antiviral drug in the treatment I 5 and prophylaxis16 of the 
influenza viruses, especially the avian H5NI and H9N2 strains. 17 Our approach to 
oseltamivir (2) converts cis-dihydrodiol 7 into derivative 19, which possesses an 
amide anti in relation to the stereochemistry of the diol (Figure 9). Translocation of 
the acrylate olefin, introduction of the trans nitrogen functionality, and alkylation of 
the distal hydroxyl gives access to the target molecule. 
( elimination and O~Oc '",,'oca';O" of o'efi" 
~ OR 
elimination ~. U . ~ oseltamivir (2) 
RO"). OH 
. ./ HN \..- alkylation 
nitrogen Y 
nucleophile 
o 
19 
Figure 9. Strategy for the synthesis of ose1tamivir (2) 
The final portion of this thesis will discuss our approach to the synthesis of 
several oseltamivir (2) analogs. The two examples presented aim to replace the amide 
functionality with a 4-toluenesulfonyl and an N-tert-butoxycarbonyl group. 
6 
2. Historical 
The following historical chapter is divided into four sections which cover; 1. 
the Burgess reagent, 2. balanol, 3. enzymatic dihydroxylations of arene substrates, 
and 4. oseltamivir. The reactivity of the Burgess reagent and its application in 
synthesis are reviewed. The existing synthetic routes to balanol, a fungal metabolite 
with significant activity against protein kinase C, will be evaluated. The substrate 
specificity of the toluene dioxygenase enzyme and the known metabolites are 
discussed. Finally, the previous syntheses of the anti-influenza agent oseltamivir are 
assessed in detail. 
2.1 Burgess Reagent 
The Burgess reagent was originally employed in the dehydration of secondary 
and tertiary alcohols and the production of urethanes from primary alcohols. 
Subsequently, it was demonstrated to be useful in a variety of other transformations 
leading to numerous additional functionalities. Furthermore, the reactivity of the 
Burgess reagent has been exploited in the synthesis of several natural products and 
other complex molecules. 
2.1.1 Discovery and Initial Applications 
During his work on the cycloadditive reactivity of electrophilic N-
sulfonylamines with olefins, Edward M. Burgess described the preparation of 
ethyl(carboxysulfamoyl)triethylammonium hydroxide inner 'Salt (20) and its reaction 
with tetramethylallene (21) to form isomeric cycloadducts 22 and 23 (Figure 1{).18 
7 
o 0 0 )1,,8 \' " (±) :t~'CO'E' 10yOE' EtO N~S'NEt3 H 20 # S02 4 S~N + MeCN,60°C O2 
21 22 23 
Figure 10. Cycloadditions of inner salt 20 with tetramethylallene (21).18 
Also included were the reactions with aniline (24), 2-propanol (25), and N-
vinylpyrolidinone (26) in benzene to produce sulfamide 27, sulfamate 28, and vinyl 
pyrrilidone 29 respectively (Figure 11). 
0 20 o 0 O~ \' 1/ benzene EtOAN~S'N :::,... H H 
24 27 
OH J O,p ,( A 20 EtO N~S~O 
benzene H 
25 28 
o jI J O,p 0 0 20 EtO ~~S~O benzene 
26 29 
Figure 11. Reactions of ethyl ( carboxysulfamoyl)triethylammonium hydroxide inner 
salt (20).18 
Soon after, Burgess reported the preparation of the methyl( carboxysulfamoyl) 
triethylammonium hydroxide inner salt (8), a reagent that now bears his name. He 
demonstrated its use in the dehydration of secondary and tertiary alcohols. 19 Burgess 
described inner salt 8 as means to produce, upon reaction with alcohols, N-
carboalkoxysulfamate anions 35, whose intramolecular elimination produced olefins 
in high yields (Figure 12). As a ptobe of the stereochemical requirements, the 
8 
dehydration of erythro- (30) and threo-2-deuterio-l,2-diphenyl ethanol (31) was 
examined. The former produced only trans-stilbene (32), while the latter gave only 
protio-trans-stilbene (33). These results supported a syn-elimination mechanism. 
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H'H"Ph 
Ph H 
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• >=< fast H Ph 
32 
Ph 0 
>=< 
8 
H Ph 
33 
Figure 12. Kinetic and stereochemical considerations of the Burgess reagent (8).19 
It was suggested that formation of the initial ion pair 34 is rate determining, followed 
by a relatively fast cis-p-proton transfer to create the olefin. Consistent with this 
kinetic and stereochemical prediction was a small, but measurable, kinetic isotope 
effect. As expected, when tertiary alcohols are treated with the Burgess reagent (8), 
product formation follows Zaitsev's rule in the majority of cases. 
In contrast to the dehydration of secondary and tertiary alcohols, primary 
alcohols 36 react to form carbamates 37 (Figure 13). This is understandable 
considering that the SNi pathway is energetically favourable compared to the Ei 
elimination during decomposition of the triethylammonium N-carboalkoxysulfamate 
38. 
HO H 
H"H"R 
H R 
36 
• 
902Me 
HN H 
H"H"R 
H R 
37 
Figure 13. Burgess reagent-mediated carbamate formation from primary alcohols 
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Burgess also demonstrated that allylic alcohol 39 reacts with the Burgess reagent (8) 
to form intermediate 40 which can either produce diene 41 or carbamate 42 
depending on the reaction conditions utilized (Figure 14). The former is produced at 
room temperature as a triglyrne solution, while the latter results from thermal 
decomposition in solid form at 80°C. After his initial rep0l1s, Burgess published more 
comprehensives accounts on the synthesis of olefins from secondary and tertiary 
alcohols and urethanes from primary alcohols.2o,21 
41 
path a 
BO°C 
path b 
triglyme 
solution 42 
Figure 14. Reactivity of allylic alcohol 39 with the Burgess reagent (8) 
2.1.2 Accessible Functionalities 
In addition to the aforementioned transformations, the Burgess reagent (8) has 
been used in the preparation of many other functional groupS.22 The first reaction 
reviewed is the dehydration of primary amides 43 to the corresponding nitriles 44 first 
described by Claremon and Phillips (Figure 15).23 These reactions proceed with 
excellent chemoselectivity, resulting from the relatively fast kinetic formation of 45. 
The production of nitriles was demonstrated to be selective over epoxide openings 
and dehydration of secondary alcohols. 
10 
45 44 
Figure 15. Conversion of primary amides to nitriles.23 
During an investigation into the dehydration of p-trialkylsilyloxyformamides, 
McCarthy encountered undesired desilylations when traditional halide-based system 
were employed. Out of necessity, he developed a method to dehydrate formamides 46 
to isocyanides 47 through application ofthe Burgess reagent (8) (Figure 16).24 
0yH c8 
R NH 8 
R ~(±) 
RXOTMS RXOTMS 
46 47 
Figure 16. Synthesis ofisocyanides from formamides.24 
Nitrile oxides readily undergo 1,3-dipolar cyc1oadditions with alkenes to create 
isoxazolines. In most cases the nitrile oxide species is generated in situ in the 
presence of a dipolarophile.25 Mioskowski published a method for the preparation of 
nitrile oxides 48 from primary nitroalkanes 49 (Figure 17).26 In the presence of a 
terminal alkene 50, the corresponding isoxazolines 51 were obtained in moderate 
yield, with some dimerization of 48 occurring. 
~ 
8 [ (±)8] R 4:-0 
R' 
50 
51 
Figure 17. Isoxazoline 51 formation from nitroalkanes 49 via a nitrile oxide 
intermediate 48 
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Wipf developed a cyclodehydration method to produce a variety of heterocycles 
through use of the Burgess reagent (8). First to be developed was a protocol for the 
synthesis of 4,5-dihydrooxazolines 52 from p-hydroxy-a-amino acids 53 via 
cyclodehydration of intermediate 54 (Figure 18).27 Peptide analogs of serine and 
threonine were converted to dihydrooxazolines without any detectable side products, 
in contrast to the traditional Mitsunobu conditions attempted.28 
52 
Figure 18. Synthesis of dihydrooxazolines 52 from P-hydroxy-a-amino acids 53.27 
Wipf has also prepared a series of thiazoline peptide analogs using a similar 
methodology.29 The Burgess reagent (8) was used to facilitate the rapid formation 
(~1O mins) of thiazoline ring 55 from p-hydroxythioamide 56 {Figure 19). The 
reaction proceeds without any epimerization of the C2 position. The same reaction 
under TsCIINEt3, SOCh or Mitsunobu conditions suffer from low yields in addition 
to the undesired epimerization.3o 
S (OH 
cbz/~0~~OMe 
Ph/" 0 
56 
8 cbz/~0~OMe 
Ph/" 0 
55 
Figure 19. Formation ofthiazoline rings 55 fromp-hydroxythioamides 56.28 
Magnus used Wipfs cyclodehydration procedure on several 2-acylamino ketones 57 
while synthesizing oxazoline rings 58 (Figure 20).31 
12 
8 
57 
R 
/:::N 
O~Y)3lj NH 
N /; 7 
~I 
58 
Figure 20. Synthesis of oxazolines 58 from 2-acylamino ketones 57?l 
In 1996, Wipf developed a poly( ethylene glycol)-linked version of the 
Burgess reagent 59 and employed it in the cyclodehydrations of ~-hydroxyamides 53 
and ~-hydroxythioamides 56 to again form 4,5-dihydrooxazolines 52 and thiazolines 
55.32 Increased yields were obtained with this PEG version of the Burgess reagent; 
attributed to improved solubility and stability. Soon after, the PEG-Burgess reagent 
59 was used to cyclize 'Y- 60 and 8- 61 and E-hydroxythioamides 62 to their 
corresponding 6-, 7-, and 8-membered heterocycles, 63, 64 and 65 respectively 
(Figure 21).33 Unfortunately, only the 'Y -hydroxyamides 66 could be successfully 
converted into dihydrooxazines 67. 
S R1 59 Ph)lN~OH --------------
H R2 R3 n 
S3f~3 
PhANn R1 
60 n = 1 
61 n = 2 
62 n = 3 
63 n = 1 
64 n = 2 
65 n = 3 
59 
66 67 
Figure 21. Synthesis of 6-, 7- and 8-membered heterocycles.33 
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Brain extended the methodology of the PEG-Burgess reagent 59 to include the 
preparation of 1,3,4-oxadiazoles 68 from 1,2-diacylhydrazines 69 using a microwave 
reaction vessel (Figure 22).34 
o H 
Ar)lN,NyAr __ 59 __ 
H g microwave 
69 
Figure 22. Synthesis of 1,3 ,4-oxadiazoles 68 from 1,2-diacylhydrazines 69.34 
In some instances the Burgess reagent's reactivity can be quite unpredictable. 
While attempting to dehydrate cyclopropanol 70, Schwarz isolated the unusual 
etherified product 71 instead of olefin 72 (Figure 23)?5 
8 S OH elf 8 . // 
72 70 71 
Figure 23. Unexpected etherification of cyclopropanol 70?5 
Similar unexpected reactivity was observed by Hudlicky while attempting to react the 
Burgess reagent (8) with primary thiols 73.36 Unexpectedly, disulfides 74 were 
produced from primary thiols, while secondary and teliiary thiols 75 also produced 
disulfides 77, in addition to some trisulfides 76 (Figure 24). 
R1 R2~SH 
R3 
75 
R1 = alkyl 
R2 = alkyl 
R3 = alkyl or H 
8 
8 
R~S/S~R 
74 
R R1 R2~S/S--+R2 + 
R3 R3 
77 
R1 R1 R2~S/S'S--tR2 
R3 R3 
76 
Figure 24. Synthesis of disulfides 74 and 77 and trisulfides 76.36 
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Miller has successfully employed the Burgess reagent (8), and its PEG version 59, in 
the synthesis of nit riles 79 from aromatic aldoximes 78.37 
8 or 59 
78 79 
Figure 25. Synthesis of nit riles 79 from aldoximes 78.37 
Makara explored the reactivity of the Burgess reagent (8) against aryl carboxylic 
acids 80?8 The resulting mixed sulfocarboxy anhydrides 81 were treated with primary 
amines 82 to yield acyl ureas 83 and amides 84 (Figure 26). The ratio of the two 
products was dependent on temperature and the use of microwave conditions. 
8 
80 
R2R3NH 
o 0 
_8-,-2_. )l. A + 
R1 N NR2R3 
H 
83 84 
Figure 26. Preparation of acyl ureas 83 and amides 84 from carboxylic acids 80.38 
Raghavan prepared several different Burgess analogs 85 and employed them in the 
synthesis of sulfilimines 86 from sulfoxides 87 (Figure 27).39 The carbamate portion 
of the sulfilimines is can be varied by changing the carbamate portion of the Burgess 
reagent (R3). 
87 86 
R3 = allyl, benzyl, Me or CH2CI3 
Figure 27. Preparation ofsulfilimines 86 from sulfoxides 87.39 
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Li used the cyclodehydration ability of the Burgess reagent (8) to create N-bridg.ed-
5,6-bicyclic pyridines 88, including pyrolo-, imidazo- and triazolopyridines, from 
pyridines 89 (Figure 28).40 
89 
8 
x = N, CH 
y= N, CH 
H ,H 
'X~Y 6 ;)-R I N 
~ 
88 
Figure 28. Preparation ofpyrolo-, imidazo- and triazolopyridines 88, fi-om pyridines 
89.40 
Other uses for the Burgess reagent (8) include the one-step production of 
carboxybenzyl (CBz) carbamates from primary alchols,41 oxidation of benzoins to 
benzils,42 and the conversion of Baylis-Hillman adducts into carbamates of 
d n. . 'd 43 unsaturate !-I-ammo aCI s. 
The Nicolaou group has utilized the Burgess reagent in the synthesis of a 
variety of sulfonyl-containing heterocycles.44 The first to be disclosed was the 
preparation of sulfamidates 90 (major) and 91 {minor) from I,2-diols 92 (Figure 
29).45 A series of chiral I,2-diols 92 were prepared from styrene, via Sharpless 
asymmetric dihydroxylation, and treated with the Burgess reagent (8). Production of 
the sulfamidates proceeded with excellent regio- and st.ereoselectivity except when 
strong electron withdrawing groups were present {R = N02, CF3)' Acidic hydrolysis 
of the sulfamidates gave clean conversion to the corresponding {3-amino alcohols 93 
and 94. 
16 
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Figure 29. Two step synthesis of p-amino alcohols 93 and 94 from 1 ,2-diols 92.45 
Nicolaou subjected epoxy alcohols 95 and 96 to the Burgess reagent (8) and 
found that, upon displacement of triethylamine, the intramolecular epoxide opening 
could be directed by the substituent at the C3 position (methyl in 96). The products 
were either 5- or 6-membered sulfamidates, 97 or 98 respectively (Figure 30). 
o ~OH 8 
95 
8 
96 98 
Figure 30. Synthesis of 5- and 6-membered sulfamidates from epoxy alcohols 95 and 
96.44 
Drawing from their work with 1,2-diols, the Nicolaou group attempted the same 
protocol on 1,2-aminoalcohols 99 (Figure 31 ).46 Unsubstituted sulfamides 100 were 
17 
produced from pnmary ammes, while mono-substituted sulfamides were also 
prepared from various secondary amines. 
99 
8 
R1 = H, Ph 
R2 = H, Me 
n = 1-2 
100 
Figure 31. Synthesis ofsulfamides 100 from 1,2-aminoalcohols 99.46 
In 2003, the Hudlicky group published preliminary work on the reactions of 
epoxides with the Burgess reagent (8).47 Originally thought to be inert to the Burgess 
reagent,48 it was demonstrated that epoxides yielded cyclic sulfamidates. Aliphatic 
epoxides 101 yield 5-membered cyclic sulfamidates 102 while styrene oxide (103) 
gave mostly 7- membered sulfamidate 104 and only trace amounts of 5-membered 
sulfamidate 105 (Figure 32). 
101 102 
o ~ 8 
103 104 (major) 105 (minor) 
Figure 32. Synthesis of 5- and 7-membered cyclic sulfamidates from 
epoxides.47 
Initially it was though that 104 was the minor regioisomer 91 (Figure 29) obtained by 
Nicolaou through reaction of the Burgess reagent with styrene diol 92. However, the 
18 
IR of 104 lacked a carbonyl signal at ~ 1600 em-I, indicating that another functionality 
was present (e.g. C=N double bond). Adding to the confusion, an authentic sample of 
91 was obtained from the Nicolaou group and found to be identical to 104. 
Ultimately, an x-ray crystal structure established that the structure of the minor 
product is the 7-membered sulfamidate 104 and not the regioisomer 91 (Figure 33). 
MeO 
~N ~o ~t~ ":: 0 Ih-
104 
Figure 33. X-ray crystal structure of sulfamidate 104.47 
Nicolaou and Hudlicky proposed mechanisms for the formation of trans-fused 
cyclic sulfamidates 106 from 1,2-diols 10745 and oxiranes 10847 respectively (Figure 
34). In the first case, each alcohol of 107 attacks an equivalent of the Burgess reagent 
(8) displacing triethylamine and forming intermediate 109. This is followed by SN2 
displacement at the more activated position. In the second case, epoxide 108 is 
opened with one equivalent of the Burgess reagent (8), followed by attack of the 
oxyanion 110 on the sulfamidate. 
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Figure 34. Proposed mechanism for formation of trans-sulfamidate 106 from 1,2-diol 
107 and epoxide 108.45,47 
Hudlicky also proposed a route to the 7-membered sulfamidate 104 from either 
styrene diol 111 or styrene oxide (103).47 The diol 111 reacts with the Burgess 
reagent (8) to form intermediate 112, which undergoes an intramolecular 
deprotonation to give 113 (Figure 35). The resulting oxyanion then eliminates the 
sulfamidate to form styrene oxide 103. The 7-membered sulfamidate 104 arises from 
opening of the epoxide with the resonance hybrid form of the Burgess reagent 8a and 
subsequent elimination of triethylamine. 
(8 P0 2Me ,?o2Me 
OH OH ~ 8 NH 0) I ~OH ~o,~,=o ~o,~,=o 8 I~ 0 1 ~ '--'" 0 1.0 
.0 .0 
111 112 113 
MeO MeO 0 0 8 j )=N 0 h 'S'(£) o 00 . .h \\// o \ /".. o N' 'NEt MeO :"'N'S'~Et3 ~h) ~ad~' 0 ~ 0 I~ 8a ~ 1 • .0 .0 
104 114 103 
Figure 35. Proposed mechanism for the formation of7-membered sulfamidate 104 
from 1,2-diols and epoxides.47 
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2.1.3 Application of the Burgess Reagent in Synthesis 
Since its discovery, the Burgess reagent (8) has proven to be a highly useful 
tool in the synthesis of complex molecules. It is soluble in most common organic 
solvents, even non-polar ones, despite its zwitterionic character. Many of its reactions 
are performed at room temperature and neutral pH. These characteristics, in addition 
to the wide variety of accessible functional groups, have been exploited in several 
syntheses. 
The first application of the Burgess reagent (8) in synthesis was reported by 
Crabbe in 1970.49 Dehydration reactions were performed on steroidal alcohols 
substrates, such as 3a-hydroxy-5a-androstan-17-one (115), to gIve their 
corresponding ole fins (Figure 36). 
HO"~ 
H 
~ 
H 
115 116 
Figure 36. Dehydration of steroidal a1cohols.49 
Capri also employed the Burgess reagent (8) in the dehydration of steroidal alcohols. 
One example, steroid 117, appeared to have undergone a trans-dehydration to olefin 
118 (Figure 37).50 The authors acknowledge that this mechanism is doubtful, and in 
all likelihood a cis-elimination was followed by isomerisation to the more substituted 
olefin. 
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Figure 37. Apparent trans-dehydration of steroidal alcohol. 50 
Rigby employed the Burgess reagent (8) in the total synthesis of (+ )-narcic1asine 
(119).51 The selective cis-dehydration of alcohol 120 produced allylic acetate 121, a 
difficult transformation to perform under standard acidic dehydration conditions. 
QAe QAe OH 
~o ~OH I H >< ~ 8 0,,: 0 __ <0 I ": . OH • ~ I h NPMB • o h NH 
OAe 0 OH 0 
120 121 119 
Figure 38. Rigby's synthesis of (+ )-narcic1asine (119).51 
The mild dehydrations facilitated by the Burgess reagent (8) have been 
frequently used in the total synthesis of various terpene-type molecules. While 
investigating the synthesis of several sesquiterpene lactones, Jacobson encountered 
problems trying to produce the precursors for Nazarov cyc1izations of 122.52 
Treatment of alcohol 123 with p-toluenesulfonic acid resulted in the production of 
hydrofuranone 124 and not the desired diene 122 (Figure 39). This problem was 
circumvented through the use of the Burgess reagent (8). 
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Figure 39. Jacobson's synthesis of sesquiterpene lactones.52 
Daniewski utilized the Burgess reagent (8) in the penultimate step in the synthesis of 
pravastatin (126).53 The dehydration of alcohol 127 under acidic conditions proved 
troublesome, however, the two-step mild dehydration with 8 and subsequent 
desilylation procedure successfully produced the target molecule (Figure 40). 
0 HO 0 
1.8 
2. F-
tBuPh2SiO HO 
OH 
127 126 
Figure 40. Daniewski's synthesis ofpravastatin (126).53 
A key step in Holton's synthesis of the C and D rings in taxol involved a selective 
dehydration of alcohol 128, a compound with several acid sensitive protecting groups 
(Figure 41 ).54 The Burgess reagent-mediated dehydration provided the temlinal 
alkene 129 and not its more substituted isomer. 
128 129 
Figure 41. Holton's synthesis oftaxol.54 
23 
Other notable total syntheses exploiting Burgess reagent dehydrations are; Nicolaou's 
synthesis of efrotomycin,55 Rigby's synthesis of cedrene,56 and Nakamura and 
Kuwajima's synthesis of cortisone.57 
As discussed previously, the Burgess reagent (8) has been employed in the 
synthesis of an assortment of oxygen, nitrogen and sulfur containing heterocycles. 
This methodology has been exploited in the synthesis of several heterocyclic natural 
products. Wipf used the Burgess reagent cyclodehydration procedure in the synthesis 
of cyclopeptides, including lissoclinamide 7 (130).58 The oxazoline and thiazoline 
rings seen in the target molecule were each installed using this method (Figure 42). 
Wipfalso synthesized the cyclopeptide westiellamide in a similar manner. 59 
Figure 42. Wipfs synthesis oflissoclinamide 7 (130).58 
During research on the preparation of macrolide antibiotic derivatives, Nagel 
uncovered one of the more unusual Burgess reagent-mediated transformations.6o The 
dehydration of the diacetate derivative of oleandomycin 132 was expected to yield 
olefin 133 resulting from elimination of one of two axial protons (Figure 43). 
Strangely, only the ring contraction product 134 was isolated; resulting from an 
oxonium shift. 
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Figure 43. Unusual ring contraction of oleandomycin derivative 132.60 
Raghaven used a Cbz version of the Burgess reagent 135 to produce 
sulfilimine 136 from sulfoxides 137 during his synthesis of (-)-deoxocassine (138) 
(Figure 44).61 Treatment of olefin 136 with N-bromosuccinimide (NBS) produced a 
bromonium ion which was stereo- and regioselectively opened with the N-CBz 
carbamate anion (not shown). 
98 OTBS 
'G)' ~ 
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Figure 44. Raghaven' s synthesis of (-)-deoxocassine (138).61 
Nicolaou has presented work on the preparation of both a- and p-
glycosylamines from a single carbohydrate. 62 Synthesis of the former can be 
completed through reactions of the Burgess reagent (8) with substrates such as 
alcohol 139 (Figure 45). The resulting sulfamidate 140 was opened with azide to give 
a protected a-glycosylamine 141. If the initial carbohydrate is protected as its benyl 
derivative 142 before treatment with an allyloxycarbonyl (alIoc) version of the 
Burgess reagent 143 then p-glycosylamine 144 is formed. The alloc protecting group 
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can be removed by hydrogenated with Pd(OAc)2 and the resulting free amine can 
alkylated to synthesize various glycosylamine derivatives 145. 
OBn OBn C02Me OBn CO2 Me MO" N"" a Xl" 8 's~ BnO'" "'OH BnO'" '0 0 
OBn OBn 
139 140 !BZCI 0 0 0 ®;s~e)l 
OBn Et3N N O~ OBn ~lIoc 
yOyOH 143 yO'r',NH 
BnO"'Y"'OBn • BnO"'Y"'OBn 
OBn OBn 
142 144 
e N3 
BnO" N3 
OBn 
141 
OBn alkyl 
1. Pd(OAch/H2 ~Ol::"~~H 
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OBn 
145 
Figure 45. Nicolaou's synthesis of a- and ~-glycosylamines.62 
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2.2 Balanol 
Protein kinase C (PKC) is a family of serine and threonine-specific kinases 
vital to the signal transduction pathways that regulate almost every cellular function. 
Numerous diseases have been attributed to the actions of these enzymes, making their 
inhibitors valuable tools for research and therapy. One example is balanol (1), a 
structurally unusual metabolite isolated from several different fungal strains. 
Highlighting its importance are the more than 30 total and formal syntheses 
completed to date. 
2.2.1 Signal Transduction Pathways and the Role of Protein Kinases 
Signal transduction is the means by which a cell mediates the sensing and 
processing of internal and external stimuli. This system amplifies and integrates 
diverse external signals in order to generate the appropriate reaction. In response to 
stimuli, signaling molecules interact with specific membrane-associated receptors. 
These receptors are coupled to enzymes, or have intrinsic enzymatic activity 
themselves, and catalyze the release of other enzymes or small molecules (Figure 
46).63 These are referred to as 'secondary messengers' and their role is to initiate a 
cellular response or activate another protein! small molecule to do so. Numerous 
secondary messengers are activated, amplifying the original signal causing 
widespread results from a minuscule stimulus. The response could be changes in gene 
transcription, metabolism, cell proliferation, membrane potential, apoptosis, or 
locomotion. The net effect is that environmental signals such as ions and large 
molecules, which can not passively cross lipid bilayers, can elicit intracellular events. 
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Figure 46. Basic model of the signal transduction pathway.64 
The vast majority of cellular functions are under the control of signal 
transduction pathways. Therefore, it is no surprise that many diseases are a result of 
malfunctions in these pathways. Some examples include proliferation diseases such as 
cancers, atherosclerosis and psoriasis, in addition to inflammatory conditions such as 
sepsis, rheumatoid arthritis, multiple sclerosis, and tissue rejection.65 Compounds 
which target proteins in the signal transduction pathway are crucial to research and 
drug development. 
Commonly targeted are the protein kinases, a super family of enzymes which 
catalyze the addition of a phosphate (POl-) group from adenosine 5' -triphosphate 
(ATP) to other proteins. The phosphorylation or dephosphorylation of proteins is the 
biological equivalent of an "on" or "off' switch. In eukaryotic cells phosphorylation 
occurs on the hydroxyls of serine, threonine, or tyrosine residues. In prokaryotes the 
phosphorylation can also take place on the imine nitrogen of the imidazole ring in 
h· ·d· 66 P . k· . d· 1 . 11 M 2+ M 2+ C 2+ Ish me. rotem mases reqmre a IVa ent atom, typlca y g, n, or a ,to 
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cooperate with acidic resides and polarize the y-phosphate of ATP prior to is addition 
to the substrate (Figure 47). 
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Figure 47. Initial binding of ATP and substrate with a protein kinase.66 
2.2.2 Protein Kinase C 
In the late 1970's, Nishizuka identified a new phosphorylating enzyme which 
he termed protein kinase C (PKC) after its dependence on calcium.67 Subsequently it 
was established that PKC is actually a large enzyme family consisting of at least 11 
distinct isozymes,68 with one PKC isoform present in almost every cell type in the 
human body.69 PKC isozymes differ in structure, cellular location, co-factor 
requirements, and substrate specificity. Every PKC is composed of a catalytic and a 
regulatory domain containing four conserved regions (Figure 48).70 
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Figure 48. Schematic representation of protein kinase C isozyme structure and 
classification.45 
Each catalytic domain contains an A TP and a substrate binding region, while the 
regulatory domains are far more varied in structure and function. The regulatory 
domain is where signaling molecules upstream bind to and activate PKc.68 Domain 
composition of the regulatory moiety is the basis for the three subclasses which each 
isozyme falls under; 1. conventional, 2. novel and 3. atypica1.7 l Conventional PKCs 
(cPKC; PKCu, PKC~I, PKC~II, and PKCy), are calcium dependent and are activated 
by both phosphatidylserine (PS) and diacylglycerol (DAG).72 
Novel PKCs (nPKCs; PKC8, PKCE, PKCll, and PKC8) are calcium 
independent and do not require DAG for activation. Atypical PKCs (aPKCs; PKCt;, 
PKCA) are calcium independent and do not require DAG for activation, although PS 
can regulate their activities. The activation of any particular protein kinase C enzyme 
is tremendously complex. The activation and resulting actions of PKC is dependent 
on the isozyme type, tissue location, or upstream signal concentration.72 The initiation 
and actions of the conventional PKC subclass is the best understood. The following 
life cycle description is specific for cPKC. However, many of the same events occur 
30 
with the other subclasses. A more detailed description can be found in reviews by 
Jaken,71 and Nishizuka.73 cPKC enzymes are synthesized as a single polypeptide and 
then spliced into the two aforementioned domains and a third autoinhibitory domain. 
Initially cPKC is located in the cytoplasm of a cell as an inactive protein. The 
auto inhibitory domain is a pseudo substrate bound to the catalytic domain preventing 
uninitiated phosphorylation. External stimulus, a hormone or neurotransmitter for 
example, binds to and initiates a G-protein-coupled receptor (GPCR) (Figure 49). 
This activates a stimulating G-protein, which in turn activates phospholipase C 
(PLC).74 PLC cleaves a membrane bound phosphoinositol-4,5-bisphosphate (PIP2) 
molecule into 1,2-diacylglycerol (DAG), which remains attached to the membrane 
while PIP2 relocates to the endoplasmic reticulum (ER) where it stimulates an ion 
channel to release Ca+. This prompts cPKC to translocate to the plasma membrane 
where it associates with DAG. It is has been demonstrated that calcium greatly 
increases cPKC's affinity for DAG.75 The interactions with DAG facilitate the 
dissociation of the pseudosubstrate, thus activating cPKC for enzymatic activities. 
PKCs then function to phosphorylate and thus activate or deactivate other kinases in 
the cell. 
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Figure 49. The activation of conventional protein kinase C.76 
2.2.3 Isolation and Characterization of Balanol 
Inhibitors that selectively target PKC isozymes have wide-ranging therapeutic 
potentia1.47 The challenge of identifying such agents was taken on by researchers at 
Sphinx Pharmaceuticals, now part of Eli Lilly, in the early 1990's. Their work led to 
the isolation and characterization of 2-[2,6-dihydroxy-4-[(3R,4R)-3-[( 4-
hydroxybenzoy l)amino ] azepan-4-y I ]oxycarbony lbenzoyl]-3 -hydroxybenzoic acid (1), 
which they named 'balanol' after the Verticillium balanoides fungal species it was 
isolated from. 9 Balanol (1) recorded ICso values of 4-9 nM in assays against human 
PKC enzymes a, ~I, ~II, 'Y, 8 ,I.> and TJ. At the same time, workers at the Nippon 
Roche Research Center were also perusing novel compounds with activity against 
PKCs. They too isolated azepane 1 from two species, Fusarium merismoides Corda 
and Fusarium aquaeductuum Lagh, which belong to a different genus than 
Verticillium balanoides.77 The authors named the compound 'azepinostatin' but 
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acknowledged that it IS identical to 'balanol' isolated months earlier by Sphinx 
Pharmaceuticals. 
Ironically neither the Roche nor the Sphinx group was actually the first to 
isolate metabolite 1. In 1977, Kneifel and coworkers published the isolation and 
characterization of a metabolite from the Cordyceps ophioglossoides fungal strain. 78 
They named it 'ophiocordin' and demonstrated its potent antibiotic activity against 
members of the Zygomycetes, Ascomycetes, and Deuteromycetes phylums of fungi. 
In a subsequent publication, Kneifel and coworkers proposed a structure for 
ophiocordin (146) after extensive decomposition and derivatization studies (Figure 
50).79 The Sphinx group made reference to ophiocordin (146) in their 1993 paper, 
noting that it is a structural isomer ofbalanol (1).9 
o 
HO ~O ~ 
HO)l) ~ 
~N~ 
HO 
OH 
o 
balanol (1), aka azepinostatin ophiocordin (146) 
Figure 50. Structure ofbalanol (1), aka azepinostatin, compared to ophiocordin (146) 
The Sphinx group solved the structure of 1 through detailed analysis of JH, I3C, and 
2D NMR (COSY, NOESY, TOCSY, HMQC, and HMBC) experiments. The absolute 
stereochemistry was determined by x-ray analysis of a derivative 147 synthesi;zed 
from an authentic sample of 1 (Figure 51). However, in order to clarify whether or not 
balanol (1) and ophiocordin (146) were different compounds samples of each were 
collected and compared.8o A mixed NMR experiment (600 MHz, DMSO-d6) 
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confirmed that they were both the same compound, with the correct strudure being 
that proposed by the Sphinx group. 
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ar~o.--h 0 par p o ~I H I ONO h 0 
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Figure 51. X-ray crystal structure ofbalanol derivative 147.9 
As outlined previously, protein kinases utilize a phosphate obtained from ATP 
to phosphorylate their protein substrates. Balanol competes with A TP for the binding 
pocket in the catalytic domain of PKC, in addition to some members of the cyclic-
AMP-dependant protein kinases (PKA).81 Comparisons between the crystal structures 
of bound balanol to that of bound ATP illustrate this fact. 82 When the two structures 
are superimposed it is clear that balanol adopts a similar conformation as ATP in the 
catalytic domain (Figure 52). Specifically, the p-hydroxybenzamide group (A-ring) 
occupies the adenine ring subsite of ATP, the hexahydroazepine ring (B-ring) 
occupies the ribose subsite, and the benzophenone group (C- and D-rings) mimics the 
triphosphate portion of A TP, although it exists in a separate portion of space. It has 
been calculated that balanol has a 3000 times greater affinity for the PKC catalytic 
domain compared to ATP.81 
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Figure 52. Balanol (ball and stick) and ATP (atom frame) superposition. 82 
2.2.4 Balanol - Structure Activity Relationships 
A significant number of balanol analogs have been synthesized in an attempt 
to discover a more potent and selective inhibitor. 83 Another goal is the design of a 
inhibitor with improved physical properties including LogP octfwat and bioavailability. 
Modifications to the three major portions (Figure 53) were designed to identify the 
pharmacophore structure in balanol (1) and gain information on the structure-activity 
relationship (SAR). 
benzophenone fragment 
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HO 
HO r-<. H 
OH l.~J·"Nrr---0-/A!J OH 
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H I \ 
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p-hydroxybenzamide 
fragement 
Figure 53. Ring nomenclature ofbalanol (1). 
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The first analogs produced provided variations to the carboxylic acid site on 
the D_ring.84 Replacement with a hydroxyl or proton drastically reduced activity 
while amides, sulfonamides and tetrazoles substitutions bearing an acidic proton (pKa 
-:::;'7.6) showed improved selectivity for PKC over PKA. Crane prepared a series of 
benzophenone ester analogs of varying steric size and hydrolytic stability.85 The 
analogs with increased activity were the small alkyl esters 148 and the 
pivaloyloxymethyl ester 149 (Figure 54). 
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Figure 54. Balanol analogs with modified carboxylic acid groups. 85 
Lai constructed analogs in which only the hexahydroazepine ring was exchanged for 
a pyrrolidine or cyclopentane (with and without substituents).86 In general, these 
compounds were more active than balanol itself. In a related publication, Lai replaced 
the nitrogen in the B-ring with other heteroatoms.87 Although not as potent as balanol 
(1), those analogs bearing oxygen or sulfur atoms were found to display increased 
selectivity among the PKC isozymes tested. It was concluded that five-membered 
heterocycles are more potent than the parent compound, while 4-, 6- and 8-membered 
rings are unfavourable. Lai also established that any heterocyclic ring that maintained 
the correct orientation of the ester and amide functionalities retains activity.88 
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Hu and coworkers have made extensive modifications to the p -
hydroxybenzamide A-ring with mixed results.89 Substitution of the 4-hydroxyphenyl 
group with various phenyl rings, amides, sulfamides, or esters all reduced potency. 
Hu did observe some improvement in PKC isozyme selectivity when an indane ring 
was inserted in place of the azepane ring.9o 
Jagdmann and Defauw replaced the amide linkage between the B and A rings 
with methylene and amine groupS.91 It was concluded that a methylene linkage in 
concert with a cyclopentane ring B-ring display excellent selectivity for PKC over 
PKA enzymes. The same researchers also replaced the ester linkage with amide, 
methylene and methyleneoxy groups.92 Although these analogs suffered from a 
decrease in activity, they were more stable to serum esterases. 
Analogs in which the perhydroazepine ring and the p-hydroxybenzamide 
moiety were combined into an acyclic linked unit were made and tested.93 In general 
these compounds, such as 150, were low-micromolar to low-nanomolar inhibitors of 
a, ~I, ~II, y, () ,8 and 11 PKC isozymes. In the same publication, a number of analogs 
were produced in which the amide linkage had been amended. This led to the 
discovery of 151, a compound with exceptional selectivity for PKC- ~I (lCso value of 
0.003 JlM) over other PKC isozymes {Figure 55). 
HO HO 
HO 
o 0 ~ ~ 0 OH HO-~n 
OH ~
HO 
151 
R1 = NHS02C6Hs, H 
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Figure 55. Acyclic linked analog 150 and cyclopentane analog 151.93 
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Lampe and coworkers modified the benzophenone portion with the hope of 
reducing the overall polarity of the parent compound.94 The results indicated that the 
benzophenone moiety was essential for activity against PKC but not PKA enzymes. 
Other essential features are a free 4-hydroxyl group in the benzamido moiety and the 
relative configuration of the two 'arms' in the analogs. 
2.2.5 Total Syntheses of Balanol 
Retrosynthetic analysis of balanol (1) reveals three distinct fragments arising 
from the most obvious disconnections at the amide and ester linkages; 1. the highly 
congested benzophenone derivative 152 (C- and D-rings), 2. the hexahydroazepine 
core 153 (B-ring), and 3. the p-hydroxyamide portion 154 (A ring) (Figure 56). 
HO esterification 
fC~ :) 
HO ( amidation 
OH 
152 8 8 ., 'NH2 R. t:'\-OH 
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. Figure 56. Nomenclature and retrosynthetic analysis ofbalanol (1). 
The majority of published balanol (1) syntheses focus on the construction of the 
hexahydroazepine core with the anti relationship between substituents at C3 and C4, 
while others have divulged methods to construct only the benzophenone portion. 
Every total synthesis disclosed thus far manufactures the azepane amide (A- and B-
rings) fragments together prior to a coupling reaction with the benzophenone (C- and 
D-rings) portion. The ensuing discussion is organized into three sections; 1. total 
syntheses, 2. syntheses of the azepane core, and 3. syntheses of the benzophenone 
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portion. Each section is presented chronologically, from the earliest to the latest 
accomplishments, and will highlight the key strategies employed. 
The first total synthesis of balanol (1) was reported by Lampe and Hughes95 
shortly after its structural elucidation.9 Since that time, another six total syntheses 
have been reported. 
Lampe and Hughes (1994)95 
Synthesis of the benzophenone portion of balanol (1) began with the 
differential protection of benzoic acid derivative 155 in three steps (Scheme 1). 
Perbenzylation with benzyl bromide was followed by basic hydrolysis of the resulting 
benzyl ester, and reesterification with 1,1 '-carbonyldiimidazole (CDI). The resulting 
aryl bromide 156 was treated with n-butyllithium at -78°C. Subsequent trapping of the 
aryl lithium species with carbon dioxide afforded an acid, which was treated with 
oxalyl chloride to produce 157. Acylation of aryl bromide 158 with acid chloride 157 
gave the highly functionalized ester 159. Exposure of 159 to n-butyllithium promoted 
a homo-Fries rearrangement which constructed benzophenone 160. Oxidation of 
alcohol 160 with pyridinium dichromate (PDC) gave an aldehyde which was further 
oxidized with tetrabutylammonium permanganate in pyridine. The resulting 
carboxylic acid was converted to its acid chloride and then protected with benzyl 
bromide. Thermolysis of tert-butyl ester 161 was followed by treatment with oxalyl 
chloride to give the fully protected benzophenone fragment 162. 
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Reagents and conditions: (i) BnBr, K2C03; (ii) NaOH; (iii) cm, t-BuOH, DBU; (iv) n-BuLi, -78°C; 
(v) CO2; (vi) (COCl)2; (vii) t-BuOK, THF; (viii) n-BuLi, THF, -78T; (ix) PDC, DMF; (x) BU4NMn04, 
pyr; (xi) BnBr, K2C03; (xii) quinoline, 205°C; (xiii) (COCl)z, DMF 
Scheme 1. Lampe and Hughes' synthesis of the benzophenone fragment. 95 
In a preceding paper, Hughes described the synthesis of (2S,3R)-3-
hydroxylysine 163 and anticipated its application in the synthesis of balanol (1) 
(Figure 57).96 The key step was a Sharpless asymmetric dihydroxylation of acrylate 
164. 1,2-Diol 165 was then converted in five steps to the aforementioned lysine 
derivative 163. 
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Figure 57. Hughes' synthesis of (2S,3R)-3-hydroxylysine 163.96 
Synthesis of the hexahydroazepine core ofbalanol (1) began with the addition 
of (2S,3R)-3-hydroxylysine 163 to hexamethyldisilazane (HMDS) in refluxing 
xylenes followed by the addition of 2-propanol (Scheme 2). This sequence produced a 
caprolactam which was separated from the epimeric byproduct via ion exchange 
chromatography and then reduced with borane to furnish azepane 166. Selective 
protection of the secondary amine with di-tert-butyl dicarbonate (BOC20) and 
protection of the primary amine with 4-(benzyloxy)benzoyl chloride produced the 
fully protected A- and B-ring fragment 167. Acylation with acid chloride 162 
produced advanced intermediate 168. Deprotection by hydrogenolysis and treatment 
with trifluoroacetic acid afforded (-)-balanol (1). 
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Scheme 2. Lampe and Hughes' synthesis ofbalanol (1).95 
Nicolaou (1994)97,98 
Nicolaou's synthesis of the benzophenone fragment began with the formation 
of benzyl alcohol 169 and carboxylic acid 170, formed from m-hydroxybenzaldehyde 
(171) and aryl bromide 170 respectively (Scheme 3). A Mitsunobu coupling reaction 
between 169 and 170 with diethyl azodicarboxylate (DEAD) and triphenylphosphine 
produced ester 173. Treatment with n-butyllithium provided an aryl lithium species 
which rearranged to a benzophenone derivative. Subsequent oxidation with 
tetrapropylammonium perruthenate (TP AP) yielded aldehyde 174. Deprotection with 
tetrabutylammonium fluoride (TBAF) followed by sodium chlorite oxidation 
produced the balanol benzophenone component 175. 
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CHO Q ~ OH 
171 ! i-iii 
H02xB. 
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Reagents and conditions: (i) BnBr, K2C03, DMF; (ii) a) n-BuLi, MeNHCH2CH2NMe2, PhH, O°C; b) 
CF3SrCF3Br, THF, -78°C; c) 10% HCl; (iii) DISALH, OCM, -78°C; (iv) SnBr, K2C03, DMF; (v) 
DIBALH, DCM, -78°C; (vi) TPSCl, imidazole, DMF; (vii) a) n-BuLi, THF, -78°C; b) CO2; c) 10% 
HCl; (viii) DEAD, PPh THF; (ix) n-BuLi, THF, -78°C, NH4Cl (aqueous); (x) NMO, TPAP, MeCN; 
(xi) NaCl02, NaH2P04, 2-methyl-2-butene, THF, t-BuOH, H20; (xii) BnBr, K2C03, DMF; (xiii) 
TBAF, THF; (xiv) NMO, TPAP, MeCN; (xv) NaCl02, NaH2P04, 2-methyl-2-butene, THF, t-BuOH, 
H20. 
Scheme 3. Nicolaou's synthesis ofbenzophenone fragment 175.97,98 
Nicolaou's synthetic approach to the azepane core ofbalanol (1) initiated from 
the homochiral amino acid D-serine (176) (Scheme 4). DitTerential protection of the 
carboxylic acid, amme and alcohol provided 177. Reduction with 
diisobutylaluminium hydride (DIBALH) afforded an amino aldehyde, which was then 
treated with Brown's diisopinocamphenylborane reagent (Allyl-B(i1pc)2). The 
resulting syn-amino alcohol was protected as its acetonide and then subjected to a 
hydroboration procedure with 9-borabicyclo[3.3.1]nonane (9-BBN) with an alkaline 
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hydroperoxide workup. The resulting alcohol 179 was converted to 180 VIa a 
mesylation and azide displacement protocol. Mild hydrogenolysis was followed by 
treatment with benzyl chloroformate (CbzCI) to provide 181, a precursor to the 
cyclization that furnishes the azepane ring. This was achieved by desilylating 181, 
mesylating the resulting alcohol, and using tert-butoxide to promote a 7-exo-tet 
cyclization. Acidic hydrolysis of the acetonide and tert-butyl carbamate protecting 
groups was followed by derivatization with 4-(benzyloxy)benzoyl chloride afforded 
azepane 183. The two fragments, azepane 183 and benzophenone 175, were coupled 
via a Mukaiyama esterification procedure99 using 2-chloro-l-methylpyridinium 
iodide. Hydrogenolysis catalyzed by palladium on charcoal removed the benzyl 
groups in addition to the Cbz group to afford (-)-balanol (1). 
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~ } ___r OTPS 
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179 ! viii-ix 
Reagents and conditions: (i) (BOC)20, NaOH, 1,4-dioxane, H20, 0-25 °C; (ii) K2C03, Mel, DMF, 0-
25°C; (iii) TPSCl, imidazole, DMF, 25T; (iv) DIBALH, toluene, -78°C; (v) Allyl-Belpch, Et20, -
78°C, ethanolamine; (vi) 2,2-dimethoxypropane, CSA, CH2C1 2, 25°C; (vii) a) 9-BBN, THF; b) NaOH, 
H20 2; (viii) MsCl, Et3N, CH2C1 2, OT; (ix) NaN3, DMF, 25°C; (x) H2, Pd/C, THF; (xi) Benzyl 
chlorocarbonate, NaOH, 1,4-dioxane, H20, O°C; (xii) TBAF, THF, 2YC; (xiii) MsCI, Et3N, CH2C1 2, 
O°C; (xiv) KOtBu, THF, 25°C; (xv)TFA, CH2C1 2, 25°C; (xvi) p-(benzyloxy) benzoyl chloride, Et3N, 0-
25°C; (xvii) 175, 2-chloro-l-methylpyridinium iodide, DMAP, NEt3, DCM; (xviii) H2, Pd black, THF, 
H20, AcOH. 
Scheme 4. Nicolaou's synthesis ofbalanol (1).97,98 
Vicker (1995)100 
Vicker constructed the benzophenone portion by first reacting the Grignard 
reagent of 185 with 2,6-dimethoxy-4-methylbenzoyl chloride (186) (Scheme 5). The 
resulting benzophenone 187 was oxidized with potassium permanganate, but could 
only be pmiially demethylated to yield diacid 188. The solution was a three step 
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procedure of esterification with thionyl chloride in methanol, benzyl protection, and 
universal deprotection with tribromoborane to afford triphenolic diacid 189. Two 
further steps provided benzophenone 175, the coupling partner previously employed 
by Nicolaou.97,98 
r1 ~oMe 
Br 
185 
+ o 
MeO¥OMe 
COCI 
186 
i 
-
BnO 
ii-iv 
-
187 188 
1 v-vii 
HO 
viii-ix 
175 189 
Reagents and conditions: (i) Mg, THF; (ii) KMn04, pyridine (ag.); (iii) SOCh, MeOH; (iv) BBr3, 
DCM; (v) SOC12, MeOH; (vi) NaH, BnBr, DMF; (vii) BBr3, DCM; (viii) NaH, BnBr, DMF; (ix) 
Na2C03 (ag.), EtOH. 
Scheme 5. Vicker's synthesis of the benzophenone fragment. 100 
Vicker's synthesis of the azepane fragment began with the ring expansion of 
ketone 190 to ester 191 through use of ethyl diazoacetate and boron trifluoride diethyl 
(BF3'OEt2) as the Lewis acid (Scheme 6). Acidic hydrolysis and decarboxylation was 
followed by treatment with sodium azide to provide ketone 192. Reduction with 
sodium borohydride gave a 2.4:1 mixture of the cis and trans-diastereomers 193a and 
193b, easily separable via column chromatography. The undesired azido alcohol 
193b was recycled back to 193a via Mitsunobu inversion with p-nitrobenzoate 
followed by hydrolysis. Azide reduction with lithium aluminum hydride (LAH) 
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afforded amino alcohol 19'5 which was converted in two steps to azepane 183. The 
coupling steps to join 183 with 17'5 were identical to those used by Nicolaou.97,98 
Subsequent hydrogenolysis and high performance liquid chromatography (HPLC) 
separation provided both enantiomers ofbalanol (1). 
o Et02C 0 d-N' OH d~'N' a·'; V·' ;,;;; iv O"'N3 + -- -- --
N N N N N 
Ts Ts Ts Ts Ts 
190 191 192 193a (+/-) 193b (+/-) 
OH 
(-)- and (+)-balanol (1) ix-xiii 
-
O"'~rO-oBn~ 
N 0 
Cbz 
183 (+/-) 195 (+/-) 194 (+/-) 
Reagents and conditions: (i) N2CHC02Et, BF3'OEt2, OCM; (ii) HCI, dioxane; (iii) NaN3, AcOH, 
DMF; (iv) NaBH4' EtOH; (v) PPh3, DIAD, THF, p-nitrobenzoic acid; (vi) NaOH (aq.), MeOH, 
dioxane; (vii) LiAIH4' THF; (viii) HBr (aq.); (ix) NEt3, DCM, 18-crown-6, benzyl chloroformate; (x) 
p-(benzyloxy) benzoyl chloride, Et3N, DCM; (xi) 175, 2-chloro-I-methylpyridinium iodide, DMAP, 
NEt3, DCM; (xii) H2, Pd black, EtOAc, H20, AcOH; (xiii) HPLC separation. 
Scheme 6. Vicker's synthesis of (-)- and (+ )-balanol (1). I 00 
Tanner (1995)101,102 
Tanner assembled the benzophenone fragment using the same building blocks 
(compounds 156 and 158) as Lampe and Hughes.95 The procedure employed is a 
variation of work previously reported by Hollinshead,103 and avoids the homo-Fries 
rearrangement used by Lampe and Hughes. Alcohol 158 was oxidized with 2,2,6,6-
tetramethylpiperidine-l-oxyl (TEMPO), protected as its cyclic ketal, and converted to 
aldehyde 197 via lithiation and a dimethylformamide (DMF) quench (Scheme 7). The 
coupling reaction with aryl bromide 156 fumishedcarbinoll98, which was oxidized 
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with tetrapropylammonium penuthenate (TP AP) and converted to acid 175 using a 
previously described protoco1.95 
OSn OSn OSn 
6( i Cr"' ii-iii 6c;0 iv OSn ::::,...1 - ::::,... 1 CHO - ::::,... 1 a l 197 O=.J trsr 158 OH 196 ::::,...1 t-SU02C OSn 156 
SnO v-ix 
175 198 
Reagents and conditions: (i) TEMPO, THF, NaBr, NaOCI, O°C; (ii) HO(CH2)30H, p-TSA, PhMe, 
reflux; (iii) n-BuLi, THF, -78°C, DMF; (iv) 156, n-BuLi, THF, -llOoC; (v) TPAP, NMO, DCM; (vi) p-
TSA, acetone, H20, reflux; (vii) NaCI02, H2NS03H, MeCN, H20; (viii) BnBr, K2C03, DMF; (ix) 
quinoline, 20S-C. 
Scheme 7. Tanner's synthesis ofbenzophenone fragment 175. 101 ,102 
Tanner produced the azepane core by converting olefin 199 to epoxide 200 
with a Sharpless asymmetric epoxidation procedure developed by Suzuki. 104 
Desilylation followed by tosylation of both alcohols set up a cesium carbonate-
catalyzed cyclization to provide azepane 201 . Opening of epoxide 201 with lithium 
azide in DMF proceeded with excellent regioselectivity (97:3). Reduction of azide 
202 with LiAIH4 provided an amino alcohol which was converted in two steps to 
aziridine 203. Opening of the aziridine, exclusively at the C4 position, was 
accomplished with p-toluenesulfonic acid and water. The coupling reaction employed 
by Nicolaou was used to join azepane 204 with benzophenone 175.97,98 A sodium 
amalgam protocol removed the tosyl protecting group and subsequent hydrogenolysis 
afforded (-)-balanol (1). 
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1 vi-viii 
o 
a~>-O-OB" 
N 
Ts 
203 
Reagents and conditions: (i) Ti(Oipr)4, (+)-DET, t-BuOOH, DCM; .(ii) p-TsCl, NEt3, DMAP, DCM; 
(iii) N-tosylimidazole, Bli4NF, THF; (iv) p-TolS02NH2, CS2C03, DMF, r.t.; (v) LiN3, DMF, 90°C; (vi) 
MsCl, NEt3, DCM; (vii) LiAIH4' THF, 50°C; (viii) p-MeOC6H4COCl, NEt3, DCM; (ix) p-TsCl, H20, 
THF; (x) 175, 2-chloro-I-methylpyridinium iodide, DMAP, NEt3, DCM; (xi) Na(Hg), Na2HP04, 
MeOH; (xii) Pd black, HC02H. 
Scheme 8. Tanner's synthesis of(-)-balanol (1).101,102 
Barbier (1996)105 
As with the Lampe and Hughes synthesis,95 production of the benzophenone 
fragment begins with the differential protection of benzoic acid derivative 155. The 
phenols were protected as methoxymethyl (MOM) ethers and the carboxylic acid as a 
tert-butyldimethylsilyl (TBDMS) ether (Scheme 9). Lithiation of 205 with n-
butyllithium was followed by the addition of the benzyl derivative of 3-
hydroxyphthalic anhydride 206 and benzyl bromide. The result was a separable 
mixture of isomers that included benzophenone 207. Desilylation with TBAF was 
followed by a two step oxidation with manganese dioxide and then magnesium 
bis(monoperoxyphthalate) hexahydrate (MMPP) to afford benzophenone 208. 
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206 0 BnO 
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155 205 207 
1 vi-viii 
BnO 
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Reagents and conditions: (i) MeOH, HCl (g); (ii) a) NaH, THF, DMF; b) MOM-Cl; (iii) LiAIH4' THF; 
(iv) TBDMS-Cl, imidazole, DMF; (v) a) n-BuLi, THF; b) 206; c) BnBr; (vi) (BU)4NF, THF; (vii) 
Mn02, DCM; (viii) MMPP, DMF. 
Scheme 9. Barbier's synthesis of the benzophenone fragment 208. 105 
Barbier prepared the hexahydroazepine ring by first converting tri-O-acetyl-D-
glucal into ether 209 through use of a procedure developed by Molina (Scheme 
10).106 Olefin reduction, ester hydrolysis and introduction of an azide functionality 
provided tetrahydropyran 210. Mitsunobu inversion installed the O-benzyl group and 
was followed by acidic ester hydrolysis to furnish alcohol 211. Hydrogenation of the 
azide initiated a ring-forming reaction, which was followed by treatment with di-tert-
butyl dicarbamate to provide azepane 212. Another Mitsunobu reaction with sodium 
azide installed the C3 azide, which was reduced and converted to amide 214. 
Esterification with the previously synthesized benzophenone fragment 208 afforded 
advanced intermediate 215. Completion of the synthesis was accomplished with 
benzyl hydrogenolysis, carbamate/ ether hydrolysis and desilylation with TBAF. 
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Reagents and conditions: (i) H2, Pt02, AcOEt; (ii) NaOEt, EtOH; (iii) p-TsCI, pyridine; (iv) NaN3, 
TBAHS, DMF; (v) 4-02N-C6H4-C02H, PPh3, DEAD, THF; (vi) KOH, EtOH; (vii) a) NaH, THF; b) 
BnBr, (Bu)4NI, THF; (viii) IN H2S04, (CH3)2CO; (ix) a) H2, Pd/C, THF; b) .(BOC)20, dioxane; (x) 4-
02N-C6H4-C02H, PPh3, DEAD, THF; (xi) KOH, EtOH; (xii) HN3, PPh3, DEAD, THF, PhH; (xiii) a) 
H2, Pd/C, THF; (xiv) p-TBDMSO-C6H4-C02H, EDC, DMAP, DCM; (xv) 208, p-TsOH, DMAP, 
DCM; (xvi) TBAF, THF; (xvii) H2, Pd/C, THF; (xviii) i-PrOH, DME. 
Scheme 10. Barbier's synthesis of (-)-balanol (1).105 
Naito (1997)107-109 
Naito prepared the benzophenone portion of balanol (1) from the naturally 
occurring chrysophanic acid (216) (Scheme 11). Methylation of the phenols followed 
by a reductive methylation procedure provided the corresponding anthracene 217. 
Using a protocol described by Berger-Lohr, 110 irradiation of 217 in the presence of 02 
produced an oxygen adduct that, upon treatment with a catalytic amount of sulfuric 
acid, provided two benzophenone reglOlsomers that were separable after methyl 
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esterification. The desired isomer 218 underwent radical bromination with N-
bromosuccinimide (NBS) prior to conversion to tetrabenzyl derivative 219. The 
remaining steps used the same TPAP oxidation described by Nicolaou97 to afford 
carboxylic acid 175. 
OH 0 OH 
~ ~Me 
o 
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i-ii 
-
BnO 
~~ ~Me 
OMe 
217 
viii-x 
-
175 
MeO 
BnO 
218 
V-Vii! 
219 
Me 
Reagents and conditions: (i) Me2S04, K2C03, (CH3)2CO, reflux; (ii) a) Na2S204, BU4NBr, THF, H20; 
b) 6N KOH, Me2S04, r.t.; (iii) O2/ hv, Et20, H2S04, acetone; (iv) NaH, Mel, DMF; (v) NBS, AIBN, 
CCI4, reflux; (vi) BBr3, DCM, r.t.; (vii) BnBr, K2C03, DMF; (viii) CaC03, H20, dioxane, reflux; (ix) 
Pr4NRu04, NMO, MeCN; (x) NaCI02, NaH2P04, 2-methyl-2-butene, THF, t-BuOH, H20. 
Scheme 11. Naito's synthesis of the benzophenone portion 175. 108,109 
Naito prepared the azepane fragment from the commercially available 4-
aminobutanol (220). Alkylation with a-chloroacetaldoxime benzyl ether under 
Schotten-Baumann conditions was followed by tert-butyl carbamate formation. 
Alcohol 221 was oxidized with chromium(VI) oxide-pyridine to provide aldehyde 
222. Naito discovered that a samarium(II)iodide-catalyzed radical cyclization 
provided the best ratio of cis- and trans- isomers (1 :6.6), which were 'separated by 
column chromatography. Hydrogenolysis and amide formation with p-{benzyloxy) 
benzoyl chloride afforded an intermediate 167 in the Lampe and Hughes synthesis.95 
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Resolution of the trans-enantiomers 167 was accomplished via an immobilized lipase 
protocol in the presence of vinyl acetate. Separation and hydrolysis provided the 
desired 3R,4R intermediate, which was converted to (-)-balanol (1) using previously 
described procedures.97 
OH OH h O C~ UNOBn ---.l!L- UNOBn 
NH2 N N 
Boc 
220 221 
(-)-balanol (1) vii-x 
--
Boc 
222 
OO':C(}-OBO 
Boc 6~ 
224 
~ 
vi 
--
OH 
d " 'NHOBn 
N 
Boc 
223 (+/-) 
167 (+/-) 
Reagents and conditions: (i) a-chloroacetaldoxime benzyl ether, Et20, H20; (ii) (Boc)zO, NaHC03, 
(CH3)2CO; (iii) Cr03-pyridine, DCM; (iv) SmI2, HMPA, t-BuOH, _78°C; (v) a) H2, Pt02, MeOH; b) p-
(benzyloxy) benzoyl chloride, NaHC03, H20, DCM; (vi) immobilized lipase, vinyl acetate, t-BuOMe, 
45°C; (vii) a) TFA, DCM; b) CBz-Cl, Na2C03, Hz), acetone; (viii) KOH, MeOH, r.t.; (ix) 175,2-
chloro-I-methylpyridinium iodide, DMAP, NEt), DCM; (x) H2, Pd black, HC02H, r.t. 
Scheme 12. Naito's synthesis of (-)-balanol (1).107-109 
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2.2.6 Syntheses of the Azepane Fragment of Balanol 
Interest in synthesizing the azepane fragment of balanol has resulted in many 
formal syntheses. In each case, the fonnal target is one consisting of the azepane (B-
ring) with a p-(benzyloxy)-benzamido (A-ring) already in place. The predominant 
formal targets are the N-Boc 167,95 N-Cbz 183,97 and N-Ts 204 101 protected azepanes. 
The most notable syntheses thus far are discussed in chronological order. 
Lampe, Hughes and Hu (1996)111,112 
In their second approach to balanol (1), Lampe and Hughes began with the 
benzyl protection of 8-caprolactam (225) followed by its conversion to olefin 226 
through use of a selenation and oxidative elimination procedure (Scheme 13). This 
approach is an extension of work described by their colleague Hu in 1995. 112 Osmium 
tetroxide dihydroxylation afforded a mixture (1: 1) of cis-enantiomers 227. Selective 
protection of the p-hydroxyl with trimethyl orthobenzoate was followed by triflate 
formation and displacement with azide at the a-hydroxyl. Treatment of lactam 229 
with LiAIH4 reduced the lactam, benzoate and azide functionalities to provide 
azepane 230 which was then treated with p-{benzyloxy) benzoyl chloride. Conversion 
of 231 to (S)-Mosher's esters 232a and 232b facilitated the separation of the trans-
diastereomers. Concomitant hydrolysis of the Mosher's esters pemlitted the synthesis 
of both (+)- and (-)-balanol (1), after coupling reactions with benzophenone 162 and 
hydrogenolysis. 
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N 0 Bn 
231 (+/-) 
Reagents and conditions: (i) NaH, BnBr, THF; (ii) LiHMDS, PhSeCl, THF; (iii) pyridine, H20 2, 
DCM; (iv) OS04, NMO, (CH3hO; (v) PhCH(OCH3h. BF3oEt20, DCM; (vi) H20; (vii) DBU, DCM; 
(viii) Tf20, 2,6-lutidine, DCM; (ix) NaN3, t-BuNBr, MeOH; (x) LiAIH4' THF; (xi) p-(benzyloxy) 
benzoyl chloride, Et3N, DCM; (xii) (S)-Mosher's acid chloride, NEt3, DMAP, DCM; (xiii) Si02 
chromatography (3% NEt3, 30% EtOAc, 66% hexanes); (xiv) KOH, MeOH; (xv) 162, NEt3, DCM; 
(xvi) H2, Pd(OH)2/C, MeOH. 
Scheme 13. Lampe and Hughes synthesis of (+)- and (-)-balanol (1).111,112 
Le Merrer (1996)113 
Le Merrer's approach to balanol (1) employs D-isoascorbic acid (233) as the 
starting material. In a preceding publication, the transformation of 233 into amino 
diol 236 via an oxidative cleavage approach was described. 114 Ketalisation of 236 
followed by a Swem oxidation and in situ condensation with formylmethylene 
triphenylphosphorane provided an u,p-ethylenic aldehyde intelmediate (Scheme 14). 
Hydrogenolysis and treatment with TBAF afforded diol 238 which cyclized upon 
sequential treatment with trifluoromethanesulfonic anhydride (Tf20) and then benzyl 
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amine. Hydrogenolysis and reprotection of the azepane nitrogen with benzyl 
chloroformate yielded azepane 182, an intermediate in Nicolaou's synthesis.97 
HO HO~r EtO EtO i-iii 0~0 iv-v --;-.to vi-viii HO~OTBDPS 
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-tcf ''oH 
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233 234 235 236 ! ix-xi 
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xiii-xiv d OH 
HO~OTBDPS 
ref 97 O"NBoe xii :\ H-balanol (1) 
- - X NBoe O~BOC N Cbz 
182 238 237 
Reagents and conditions: (i) (CH3hC(OCH3)2, CUS04, (CH3)2CO; (ii) K2C03, H20 2, H20; (iii) C2HsI, 
CH3CN, reflux; (iv) (CF3SOZ)zO, 2,6-1utidine, CHCh, -60·C; (v) TMGA, -60·C; (vi) LiAIH4' THF 
reflux; (vii) TBDPSCI, Et3N, DMAP, DCM, rt.; (viii) TFA/H20 111, -5°C; (ix) (CH3)2C(OCH3)2, 
(CH3)2CO, TsOH, rt.; (x) a) (COCI)z DMSO, Et3N, DCM; b) PPh3=CHCHO; (xi) Hz, Ni, EtOH; (xii) 
nBu4NF, THF, rt; (xiii) a) (CF3S02)20, CH2Clz, 2,6-lutidine; b) PhCH2NHz, 20·C; (xiv) a) Hz, PdlC, 
EtOH; b) PhCHzOCOCl, DCM, Et3N. 
Scheme 14. Le Merrer's formal synthesis of (-)-balanol (1). JJ3 
Jacobsen (1997)115 
Jacobsen has developed a chromium-salen ligand 239 capable of catalyzing 
the enantioselective ring opening of meso-epoxides with trimethylsilyl azide. 1 16 This 
methodology was applied to the formal enantiose1-ective synthesis of (-)-balanol (1) 
from 1,4-cyc1ohexadiene oxide (240). The ring opening product 241, obtained in 92% 
e.e. , was deprotected prior to a molybdenum-catalyzed directed epoxidation {Scheme 
15). Subsequent treatment with triisopropylsilyl chloride afforded oxirane 242. 
Selective ring opening was accomplished with 'sodium phenyl selenate and was 
followed by an oxidative elimination sequence. The resulting alcohol was oxidized 
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with TEMPO and then converted into oxime tosylate derivative 243. A Beckmann 
rearrangement catalyzed by TiCh(O-iPr) provided a mixture of amides 244 and 245, 
which were treated with potassium hydride and benzyl bromide to provide lactam 246 
as the sole product. Reduction of the lactam and azide functionalities, amide 
formation and desilylation afforded azepane 231, an intermediate in Lampe and 
Hughes synthesis. III 
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Reagents and conditions: (i) 7.5 mol% 239, Et20, -lOoC.; (ii) TFA, MeOH, r.t; (iii) MO(CO)6, TBPH, 
PhH, reflux; (iv) TIPSCI, KH, THF, O°C; (v) PhSeSePh, NaBH4' EtOH; (vi) a) H20, NaHC03, THF; 
b)iPr2NH, PhH, reflux; (vii) TEMPO, NaOCI, DCM; (viii) a) H2NOH'HCI, pyridine, DCM; b) TsCI, 
Et3N, DCM; (ix) TiCh(O-iPr), DCM, rt; (x) KH, BnBr, THF; (xi) AIH3, THF, O·C; (xii) a) H2, Pt02, 
EtOAc; b) p-(benzyloxy) benzoyl chloride, Et3N, DCM, O·C -r.t.; (xiii) TBAF, THF, r.t. 
Scheme 15. Jacobsen's formal synthesis of (-)-balanol (1).115 
Kato (1998)117 
Kato's formal synthesis ofbalanol (1) begins with a baker's yeast reduction of 
ketone 247 to alcohol 248, a procedure first described by Momose. Jl8 Protection of 
248 as its methoxymethyl (MOM) ether setup a series of reductions with BH3-THF 
57 
and DIBALH. Subsequent mesylation afforded piperidine 249 which was heated to 
reflux in the presence of sodium azide. The resulting intermediate aziridinium cation 
250 is susceptible to nucleophilic attack by the azide anion at two positions. The 
desired path 'b' provides azepane 252, while path 'a' gives piperidine 251. 
Deprotection and a Mitsunobu inversion yielded azido alcohol 253, which was 
converted to advanced intelmediate 183 from Nicolaou's synthesis.97 
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Reagents and conditions: (i) baker's yeast, tap water; (ii) MOMCl, DIPEA, CHCh, reflux; (iii) 
BH3-THF, THF, r.t.; (iv) 1 % ag. HCl, reflux; (v) MOMCl, DIPEA, CHCI3, reflux; (vi) DIBALH, THF, 
O°C; (vii) MsCl, NEt3, OCM, 5OC; (viii) NaN3, MeCN, reflux; (ix) CbzCl, PhMe, r.t.; (x) 10% ag. 
HCl, THF, reflux; (xi) DIAD, PPh3, 4-N02-C6H4-C02H, THF, O°C-r.t.; {xii) 2N ag. NaOH, MeOH-I ,4-
dioxane, r.t.; (xiii) PPh3, H20, THF, r.t.; (xiv) p-(benzyloxy) benzoyl chloride, Et3N, DCM, r.t. 
Scheme 16. Kato' s fomlal synthesis of (-)-balanol (1).117 
Cook (1999)119 
Cook's synthesis begins with a diisobutylaluminum hydride reduction of D-
senne derivative 254 followed by treatment of the crude aldehyde with 
vinylmagnesium bromide (Scheme 17). Alcohol 255 was converted into a cy.cIic 
carbamate intermediate which was then acylated with p-(benzyloxy)benzoyl chloride 
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to afford 5-vinyloxa?:olidinone 256. Subsequent palladium-catalyz.ed oxazoline 
formation! epimerization provided 258 in a 94:6 (trans:cis) ratio. This methodology 
has been extensively investigated by Cook, who believes that the high selectivity is 
rationalized by an equilibrium between 1t-allyl palladium complexes 257a and 257b; 
favouring the formation of the thermodynamic product 258. 120 Deprotection and a 
Mitsunobu reaction with diphenylphosphoryl azide (DPPA) furnished oxazoline 259. 
Azide reduction with triphenylphosphine and water provided a free amine which was 
reacted with benzyl chloroformate and then allyl bromide to afford diene 260. A 
Grubb's ring closing metathesis reaction formed a tetrahydroazepine ring which was 
reduced with potassium azodicarboxylate (PAD). Oxazoline hydrolysis under mildly 
acidic conditions provided Nicolaou's azepane intermediate 183. 119 
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Reagents and conditions: (i) DIBALH, PhH, -78°C; (ii) vinyl magnesium bromide, THF; {iii) NaH, 
THF; (iv) p-(benzyloxy)benzoyl chloride, NaH; (v) Pd2(dbah, CHCI3, dppp, THF, 35°C (vi) TBAF, 
THF; (vii) DPPA, PPh3, DEAD; (viii) a) PPh3 THF-H20; b) BnOCOCI, Et3N; (ix) NaH, allylbromide; 
(x) Cb(PCY3)2Ru=CHPh, DCM; (xi) PAD, AcOH, (xii) a) IN HCI, EtOH; b) NEt3, MeOH, r.t. 
Scheme 17. Cook's formal synthesis of(-)-balanol (1).119 
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Genet (2000)121 
Genet's approach to the azepane core of (-)-balanol (1) relies on a dynamic 
kinetic resolution of a racemic a-amido ~-keto ester using a ruthenium-catalyzed 
hydrogenation. The synthesis begins with the preparation of ~-keto ester 262 from 
carboxylic acid 261 through use of the magnesium salt of monomethyl malonic acid 
(Scheme 18). Oxime formation was achieved by first reacting ester 262 with 'Sodium 
nitrite and then with acetic acid and water. Acylation with p-(benzyloxy) benzoyl 
chloride provided the racemic a-amido ~-keto ester 263. Genet has developed a 
method for stereoselective ruthenium-catalyzed hydrogenations122 and applied this to 
the reduction of 263. Hydrogenation with ruthenium catalyst 264 in the presence of 
MeO-BIPHEP provided syn ~-hydroxy a-amino acid derivative 265 with high 
stereo selectivity (e.e. 94%, d.e. 93%). Amide 265 was protected as its oxazolidine 
derivative before reduction and mesylation reactions afforded 266, which was 
cyclized through treatment of 266 with tert-butoxide. Subsequent acidic hydrolysis 
provided intermediate 183 in Lampe and Hughes' synthesis.95 
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Reagents and conditions: (i) a) Im2CO, THF, 25°C; b) Mg(02CCH2C02Meh, THF, 25°C; (ii) NaN02, 
AcOHlH20, O°C; (iii) H2, Pd/C, p-TsOH, MeOH; (iv) p-(benzyloxy) benzoyl chloride, Et3N, DCM, 
WC to r.t. ; (v) 264, Hz (130 bars), (R)-MeO-BIPHEP, HBr, DCM, 50°C; (vi) 2,2-DMP, DCM,p -TsOH, 
25°C; (vii) Ca(BH4)2, EtOH/THF, -20 to 25°C; (viii) MsCl, NEt3, DCM; (ix) t-BuOK, THF, 25°C; (x) 
p-TsOH, MeOH, 25°C. 
Scheme 18. Genet's formal synthesis (-)-balanol (1).121 
Aggarwal (2006)123 
Aggarwal published one of the shortest formal synthesis of (-)-balanol (1) in 
2006. The reaction of hemiaminal 267 with (R)-tert-butyl sulfamide provides aminal 
268, which can exist in two resonance forms, 268a and 268b. The sulfinimine form 
268b undergoes an aziridine annulation reaction with diphenyl vinyl sulfonium salt 
269 to afford azepane 270 as a 3: 1 mixture of diastereomers. Treatment with aqueous 
hydrochloride acid followed by ammonia provided the secondary amine 271. 
Acylation with p-(benzyloxy) ben;lOyl chloride was followed by an acidic aziridine 
opening with water to furnish Tanner's intermediate 204. 
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Reagents and conditions: (i) Ti(OEt)4, (R)-tert-butyl sulfamides, DCM, reflux; {ii) 269, NaH, DMF, 
O°C; (iii) a) IN HCl, dioxane; b) NH3; (iv) p-(benzyloxy) benzoyl chloride, Et3N, DCM, O°C to r.t.; (v) 
p-TsCl, H20, THF. 
Scheme 19. Aggarwal's formal synthesis of (-)-balanol (1).123 
Trost (2007)123 
Trost's strategy employs a palladium catalyzed dynamic kinetic asynlmetric 
allylic amination and acyl migration reaction to successfully fuse vinyl aziridine 272 
with imido carboxylate 273. The stereochemistry of the resulting diene 275 arises 
from use a diphosphine ligand 274. Ring closing metathesis with Grubbs' 2nd 
generation catalyst provides tetrahydroazepine 276. Hydrogenation followed by a 
hydroboration-oxidation protocol and exchange of azepane protecting groups 
afforded a formal intermediate in the synthesis of (+ )-balanol (1). III 
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Reagents and conditions: (i) 6 mol % 274, 2 mol % [{(Tj3-C3H5)PdClhJ, 10 mol % Et3N, CH2CI2, 
35'C; (ii) 5 mol % Grubb's II catalyst, CH2CI2, 35'C; (iii) a) BH3-THF; b) NaB03-H20, O'C; (iv) H2, 
Pd(OH)2, MeOH, then HCl; (v) BnCl, NEt3, DCM. 
Scheme 20. Trost's formal synthesis of (+)-balanol (1).123 
Other formal syntheses 
Other formal syntheses were completed by Mueller in 1994,123 Pollini in 
1996/24-125 Herdeis in 1999/26 Fiirstner in 2000,127 Panek in 2000,128 Skrydstrup in 
2000,129 Yadav in 2002,130 Raghaven in 2006, 13l Chattopadhyay in 2008,132 and 
Panda in 2008. 133 Several syntheses of the benzophenone portion of balanol (1) have 
been completed as well. 134-142 
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2.3 Dihydroxylations of Arene Substrates by Toluene Dioxygenase 
While investigating the metabolism of aromatic substrates by Pseudomonas 
putida, David Gibson isolated a cis-dihydrodiol metabolite from the fermentation of 
p-chlorotoluene. Subsequent research identified toluene dioxygenase (TDO) as the 
enzyme responsible for this transformation. The following chapter will review the 
substrate specificity ofTDO, and the applications of its metabolites in synthesis. 
2.3.1 Historical 
It is impossible to know precisely when humans observed the natural process 
of fermentation. The earliest evidence of mankind controlling this process dates back 
over 8000 years ago. Ancient pottery containing the residue of red wine suggests that 
Neolithic man fermented grapes in Shulaveri (part of the modern day Georgian 
republic).143 Throughout history, the remarkable oxidative power of fermentation has 
been exploited in the production of alcoholic beverages, cheese, bread, yogurt and 
many other consumables. 
In 1857, Louis Pasteur identified yeast as the orgamsm responsible for 
alcoholic fermentations. 144 Soon after, Adrian J. Brown reported the oxidation of 
mannitol to lrevulose (fructose) by Bacterium aceti. 145 Pasteur believed that these 
transformations were effected by a vital force in the microbes called 'ferments', 
which were only active in living organisms. 146 Perhaps unknown to Pasteur, Rene 
Antoine Ferchault de Reaumur observed the digestion of meat by hawk stomach 
secretions (a non-living entity) in 1752. 147 In 1833, Anselme Payen and Jean-Francois 
Persoz precipitated a white, water soluble substance from a barley malt solution. They 
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termed the substance 'diatase' and demonstrated its ability to digest star-ch into 
maltose.148 Diatase is believed to be the first enzyme ever isolated, and is the source 
for the commonly used '-ase' suffix. In 1878, Wilhelm Kiihne coined the term 
'enzyme', from the Greek to leaven, in order to distinguish it from bacteria. 149 Shortly 
afterwards, Edward Buchner demonstrated that a yeast extract, termed 'zymase', was 
capable of performing cell-free sugar fermentations. 15o James B. Sumner was the first 
to identify enzymes as proteins when he crystallized jack bean urease in 1926. 151 
In 1890, Hermann Emil Fischer sought to explain why enzymes could react 
with some materials and not others. He proposed that both the enzyme and its 
substrate contain complementary geometric shapes, known as the 'lock and key' 
model. 152 This model explained specificity, but failed to explain how an enzyme could 
react with the same functional group on two compounds that are drastically different 
in size. Consequently, Daniel Koshland amended the theory to an 'induced fit' model 
in which interactions between the enzyme and the substrate induce a conformational 
change. 153 In 1946, Linus Pauling published a transition state theoryl54 to explain 
enzyme catalysis based on earlier work by Erying. 155 They proposed that enzymes 
catalyze reactions by stabilizing the transition state, and thus lower the activation 
energy required. 
To date, more than 4000 different enzymes have been identified. 156 Each is 
classified by the reaction it performs and belongs to the oxidoreductase, transferase, 
hydrolase, lyase, isomerase or ligase family. Enzymes are invaluable tools in the 
food, manufacturing and pharmaceutical industries. Of interest to this thesis is their 
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application in the organic chemistry field. Specifically, the use of cis-dihydrodiols 
isolated from the fermentation of aromatic substrates. 
2.3.2 Dihydroxylation of Arene Substrates 
In 1908, Stormer became the first to demonstrate the microbial assimilation of 
aromatic hydrocarbons. 157 He isolated Bacillus hexacarbovorum, an organism capable 
. of utilizing toluene and xylene for growth. Soon after, Wagner characterized 
Bacterium benzoli a and b, and observed their growth on hydrocarbons. 158 Bacterium 
benzoli a grew on benzene, phenol, and pyrocatechol while Bacterium benzoli b 
digested samples of crude oil, which probably contained naphthenic, aliphatic and 
aromatic hydrocarbons. In 1957, Haccius and Helfrich identified pyrocatechol as the 
major metabolite from the fermentation of benzene by Nocardia coralline. 159 Initially, 
it was proposed that pyrocatechol is produced through a phenol intelmediate. Marr 
and Stone argued that trans-l,2-dihydrocyc1ohexa-3,5-diene, resulting from 
hydrolysis of an epoxide, was more likely to be the intermediate in the bacterial 
catabolism of benzene. 160 Their theory was based on the inability of two benzene-
processing bacterial strains (Pseudomonas aeruginosa and Mycobacterium 
rhodochrous) to oxidize phenol, and on a similar pathway suggested by Young for 
naphthalene catabolism. 161 In 1968, Gibson proposed that Pseudomonas putida 
produced pyrocatechol (280) through a cis-l,2-dihydrocyc1ohexa-3,5-diene (279) 
intermediate; based on a considerably higher rate of oxygen consumption compared 
to the trans-isomer. 162 This observation, along with an inability to detect phenol, led 
to a proposed mechanism of pyrocatechol (280) synthesis from benzene (Figure 58). 
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Figure 58. Gibson's proposed mechanism of pyrocatechol (280) synthesis from 
benzene (277).162 
Gibson also discovered that P. putida could oxidize halobenzene substrates to their 
corresponding 3-halogenated catechol derivatives. 163 When p-chlorotoluene (281) 
was employed as a substrate, Gibson isolated two metabolites identified as {+ )-cis-4-
chloro-2,3-dihydroxy-l-methylcyclohexa-4,6-diene (282) and 4-chloro-2,3-
dihydroxy-I-methylbenzene (283) (Figure 59). This result provided further evidence 
that the metabolic processing of benzene derivatives by P. putida proceeds through a 
cis-dihydrodiol intermediate. 
P. putida 
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h OH + ~OH 
282 
)yOH 
YOH 
283 
Figure 59. Metabolism of p-chlorotoluene by P. putida. 163 
Gibson also proposed that the cis-dihydrodiols were produced by an iron-mediated 
reaction with molecular oxygen. l64 Incubation of P. putida with benzene and 180 2 
provided cis-l,2-dihydrocyclohexa-3,5-diene, whose mass spectral analysis revealed 
the incorporation of two atoms of atmospheric oxygen (presumably from the same 
molecule). 
In 1970, Gibson developed a mutant strain (P. putida 39/D) which 
accumulated (+ )-cis-2,3-dihydroxy-l-methylcyclohexa-4,6-diene (284) in the culture 
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media when grown in the presence of toluene (285).165 Gibson hoped that full 
analysis of this metabolite would unequivocally establish cis-dihydrodiols as 
metabolites of P. putida and not the trans-isomers. Nuclear magnetic resonance 
(NMR) analysis of diol 284 was inconclusive, and it was determined that a more rigid 
derivative would be necessary. The acetylated derivative of 284 was condensed with 
maleic anhydride to provide I-methyl-2,3-diacetoxybicyclo(2,2,2)-7-hexene-5,6-
dicarboxylic anhydride (286) (Figure 60). Hydrogenation afforded saturated 
derivative 287; analysis of which established a syn relation between vicinal protons 
P. putida. ~OH 
UOH 
1. (AC)20 ~OAC_P_d/_C_ O~"oA' 
2. maleic O~OAC H2 '~OAC 
anhydride 0 H 0 Hs 
285 284 286 287 
Figure 60. Relative stereochemical proof of P. putida metabolite. 165 
In a subsequent study, Gibson sought to confirm the absolute stereochemistry of cis-
dl'hydrodl'ol 284.166 H dr t ' 'd d . t Y ogena IOn provl e ClS, rans- and cis,cis-3-
methy1cyclohexane-l,2-diols, 288a and 288b respectively, which were separable as 
their Cl monobenzoates (Figure 61). Hydrolysis provided a pure sample of 288b 
which was oxidized with Jones' reagent to provide (R)-(-)-methyladipic acid (289), a 
compound whose absolute stereochemistry has been established. 167 This confirmed 
that the stereochemistry of diol metabolite 284 as 1 S,2R. 
CeoH 1. hydrogenation ec::+ Cc Jones oxidation HO~OH . ~ OH 2. BzCI 
3. separation OH 0 
284 4. hydrolysis 288a 288b (R)-(-)-methyladipic acid (289) 
Figure 61. Absolute stereochemistry proof of P. putida metabolite 284. 166 
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2.3.3 Toluene Dioxygenase 
As the field of molecular biology progressed, it became possible to identify 
the genes, and the encoded proteins, responsible for the processing of benzene 
derivatives by P. putida. In 1989, Gibson was able to use sequencing infonnation to 
construct clones of Escherichia coli JM109 that overexpressed the enzymes 
responsible for the oxidation of toluene to 3-methylcatechol. 168 This allowed for 
complete disclosure of the metabolic pathway employed in the catabolism of aromatic 
substrates. First, molecular oxygen is incorporated into an arene substrate (Figure 62). 
This reaction is perfonned by a multi-component enzyme system designated as 
toluene dioxygenase (TDO). The oxidation of nicotinamide adenine dinucleotide 
(NADH) supplies electrons which are initially accepted by a flavoprotein 
(reductaseToL). Transfer of the electrons to a small iron-sulfur protein (ferredoxinToL) 
precedes a reduction by another iron-sulfur enzyme (ISPTOL), which ultimately 
reduces molecular oxygen before substrate oxidation. 3-Methylcatechol (290) 
fonnation is mediated by an NAD+ reducing enzyme (cis-(1S, 2R)-dihydroxy-3-
methylcyclohexa-3,5-diene dehydrogenase) which oxidizes cis-dihydrodiol 284. 
Another enzyme, 3-methylcatechol 2,3-dioxygenase, oxidizes 290 into an acyclic 
metabolite 291, which is eventually digested into acetate. 
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Figure 62. Metabolic pathway for the oxidation of toluene (285) to 2-hydroxy-6-oxo-
2,4-heptadienoate (291) (gene designations for individual proteins in parentheses). 168 
Gibson developed an E. coli JM 1 09 strain which carries the recombinant 
pDTG601 plasmid with the genes for the toluene dioxygenase complex (todCIC2, 
todB and todA) under control of the tac promoter. This organism lacks the genes 
responsible for downstream processing (todD and todE) and therefore accumulates 
cis-dihydrodiols. The mutant P. putida strain, which also lacks todD and todE, 
requires chlorobenzene or toluene as an inducer. This made screening new substrates 
problematic; as the inducer itself is a substrate, leading to a mixture of diols. The E. 
coli JM 1 09 (pDTG60 1) strain is induced by isopropyl ~-D-l-thiogalactopyranoside 
(IPTG), thus avoiding the problem. The expression system allows for the selective 
growth of only those organisms which contain the plasmid; which contains intrinsic 
ampicillin resistance. This recombinant strain overproduces TDO and hence cis-
dihydrodiol metabolites. 
The precise mechanism of TDO dihydroxylation remams unsolved. The 
original 1,2-dioxetane mechanism proposed by Gibson ~Figure 58) involves high 
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energy intermediates and is therefore unlikely.14 The absence of a TDO-crystal 
structure has hampered mechanistic research. The x-ray structure of naphthalene 
dioxygenase (NDO), an enzyme which performs similar cis-dihydroxylations on 
fused aromatics, was solved and discosed in 1998.169 TDO and NDO both utilize a 
Rieske [2Fe-2S] center and mononuclear iron in the active site to catalyze the 
addition of dioxygen to their respective substrates. In 2003, Ramaswamy used x-ray 
crystallography to determine the structure NDO complexes with substrate, oxygen, 
substrate plus oxygen and product. 170 It was concluded that the reaction sequence 
probably involves the three complexes depicted in Figure 63 .. Previous research had 
revealed that indole dihydroxylation by NDO proceeds through an indole C3 peroxide 
species, 171 although it is unclear where this structure would fit in the sequence. 
ASP'0-Q 
I ' O2 
0----Fe2+ 
\ 
~ I ~ OH2CO 
~ h 
Figure 63. Proposed complexes in the dihydroxylation of naphthalene by NDO. 170 
2.3.4 Application of TDO Metabolites in Synthesis 
Toluene dioxygenase is capable performing cis-dihydroxylations on a variety 
of different substrates. Since Gibson's initial findings, hundreds of metabolites have 
been identified. The dihydroxylations follow a similar pattern of regio-, stereo- and 
enantioselectivity. In 1993, Boyd screened a series of 1,4-disubstituted benzene 
derivatives against TDO.172 The results aided in the development of a model which is 
useful for predicting the stereo- and regioselectivity of the dihydroxylations (Figure 
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64). In general, larger differences in relative size between RLarge and Rsmall result in 
higher enantiomeric excess values. 
Figure 64. Boyd's model for predicting the stereo- and regioselectivity ofTDO 
dihydroxylations. l72 
The TDO enzyme accepts substrates containing an assortment of different 
functionalities including; halogen, alkane, alkene, alkyne, nitrile, phenyl, carboxylic 
acid, and trifluoromethyl substituents. 173 Also oxidized are fused aromatics such as 
quinolines, indoles, anthracenes, phenylanthracenes, and phenylpyridines. 174 Despite 
the immense collection of cis-dihydrodiol metabolites available, only a few have 
found use in synthesis. 14 The most frequently employed are those derived from 
benzene, toluene, chlorobenzene, and bromobenzene. 
The first recorded application of TDO metabolites was accomplished by 
researchers at Imperial Chemical Industries PIc in 1983. 175 The cis-dihydrodiol 
derived from benzene 279 was derivatized as a carbamate or ester and then heated to 
initiate the formation of polyphenylene (293) (Figure 65). 
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Figure 65. First application of a TDO metabolite. 175 
In 1987, Ley reported the synthesis of (+I-)-pinitol (294) from cis-dihydrodiol 279, 
marking the first chiral application of a TDO metabolite. 176 Esterification and 
epoxidation of 279 provided a vinyl oxirane which was selectively opened with 
methanol in the presence of (+)-camphorsulfonic acid (CAS) (Scheme 21). 
Dihydroxylation of olefin 296 with osmium tetroxide followed by basic hydrolysis 
completed the synthesis. 
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Reagents and conditions: (i) BzCl, pyr., DMAP, O·C; (ii) m-CPBA, CICH2CH2Cl, pH 8 (phosphate 
buffer); (iii) MeOH, (+)-CSA; (iv) OS04, NMO, t-BuOH/THF/H20 (10:3:1); (v) NEtiMeOHlH20 
(1:5:1), 
Scheme 21. Ley's synthesis of (+1-)-pinitol (294). 176 
In 1988, Hudlicky reported an enantioselective synthesis of PGE2a (297) from 
the TDO metabolite of toluene 284. 177 Ozonolysis followed by a reductive workup 
with dimethyl sulfide provided tetrahydrofuran 298 (Scheme 22). Treatment with 
aluminum oxide effected oxidative cleavage and an aldol condensation to afford 
cyclic enone 300, a compound previously converted to PGE2a (297).178 This synthesis 
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was remarkably sh'Orter than th'Ose reported at the time, highlighting the synthetic 
value 'OfTDO metab'Olites. 
(x'OH i,ii ~'OH 'OX iii ['O):'OX] Q'O '0 ~ ~o ""~ 
-- '0 -- -- ~ ~-- C'02H :::,... . 
'OH '0 ~ '0 0 ,----H'O '0 H'O: 
284 298 299 300 297 OH 
Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH, r.t.; (ii) a) 0 2/03, EtOAc, -78·C; b) 
Me2S, O·C; (iii) AI20 3 (neutral), DME, reflux 
Scheme 22. Hudlicky's enanti'Oselective f'Ormal t'Otal synthesis 'OfPGE2a (297)177 
Hudlicky has empl'Oyed several different TDO metab'Olites in the synthesis 'Of 
vari'Ous Amaryllidaceae alkal'Oids. 179 The first enanti'OseJective synthesis 'Of (+)-
pancratistatin (301) was acc'Omplished by Hudlicky in 1995 thr'Ough intermediacy 'Of 
the br'Om'Obenzene dihydr'Odi'Ol 302 (Scheme 23).180 The acet'Onide derivative 'Of 302 
was subjected t'O a c'OPper(II)-catalyzed nitrene aziridinati'On pr'Ocedure f'Oll'Owed by 
radical debr'Ominati'On t'O aff'Ord 'Olefin 303. Directed 'Orth'O metalati'On 'Of amide 304, 
f'Oll'Owed by treatment with c'OPper(I)cyanide, f'Ormed a lithium cyan'Ocuprate species 
(Ar2Cu(CN)Li2) which selectively 'Opened the t'Osyl aziridine. C'Onversi'On 'Of the 
carbamate in 305 t'O an aldehyde, exchange 'Of nitr'Ogen pr'Otecting gr'OUPS, then 
desilylati'On and benzylati'On 'Of the phen'Olic alc'Oh'Ol pr'Ovided 'Olefin 306. C'Onversi'On 
'Of the aldehyde int'O a methyl carbamate was achieved via a diaz'Omethane pr'Ot'Oc'OI, 
acet'Onide hydr'Olysis and ep'Oxidati'On furnished di'Ol 307. Treatment with aque'Ous 
s'Odium benz'Oate at 100°C resulted in the stere'Oselective 'Opening 'Of the ep'Oxide, 
thermal cleavage 'Of the B'OC carbamate, and initiated 8-lactam cyclizati'On. 
Palladium(II)hydr'Oxide catalyzed hydr'Ogen'Olysis rem'Oved the benzyl gr'OUP and 
provided (+ )-pancratistatin (301). 
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Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH, DCM; (ii) Phl=NTs, Cu(acach, CH3CN; 
(iii) nBu3SnH, AIBN, THF, PhMe, reflux; (iv) a) s-BuLi, TMEDA, THF, -90°C; b) CuCN, -90T to -
20°C; c) 303, BF3-Et20, -78°C to r.t.; (v) a) s-BuLi, THF; b) (BOC)20; (vi) Nal anthracene, DME, -
78°C; (vii) TBAF, THF, O°C; (viii) SMEAH, THF, morpholine, -45"C; (ix) BnBr, K2C03, DMF; (x) a) 
NaCI02, KH2P04, 2-methyl-2-butene, t-BuOH, H20; b) CH2N2, Et20; (xi) AcOH, THF, H20, 60°C; 
(xii) t-BuOOH, VO(acach, PhH, 60°C; (xiii) H20, BzO-Na+ (cat), IOO°C; (xiv) Pd(OH)2/C, H2(latm), 
EtOAc 
Scheme 23. Hudlicky's synthesis of (+)-pancratistatin (301).180 
Boyd has demonstrated the versatility of cis-dihydrodiols in the synthesis of 
pseudosugars. The metabolite of iodobenzene 308 served as the starting material in 
the synthesis of a series of pyranose carbasugars, including carba-p-D-altropyranose 
(309) and carba-a-L-galactopyranose (310) (Scheme 24).181 Dihydroxylation of the 
acetonide derivative of 308 with osmium tetroxide provided diol 311. Treatment with 
carbon monoxide and methanol, in the presence of palladium(II)acetate, effected the 
synthesis of acrylate 312. A rhodium/ alumina-catalyzed hydrogenation protocol 
afforded a mixture of diastereomers, which were separated as their benzoate 
derivatives 313a and 313b. Ester hydrolysis with lithium aluminum hydride and 
acidic acetonide hydrolysis yielded pseudo sugars 309 and 310. 
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Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH; (ii) OS04, NMO, Me2CO, H20; (iii) 
Pd(OAc)2, CO (1 atm) , NaOAc'3H20, MeOH; (iv) 5% RhlA120 3, EtOH, H2 (55 psi); (v) BzCI, 
pyridine; (vi) LiAIH4' THF, reflux; (vii) TFA-THF-H20 (1 :8:2), 50'C 
Scheme 24. Boyd's synthesis of pyranose carbasugars 309 and 310.181 
Recently, Hudlicky has synthesized the unnatural (+)-isomer of codeine (314) 
from the TDO-mediated dihydroxylation product of p-bromobenzene 315. 182 
Reduction of the unsubstituted olefin with potassium azodicarboxylate (PAD) under 
acidic conditions was followed by exposure to acetic anhydride (Ac20). The resulting 
diacetate 316 was treated with methylamine and di-tert-butyl dicarbonate under basic 
conditions. This effected the displacement of the alkyl bromide, carbamate formation 
and concomitant hydrolysis of the acetates. The homoallylic alcohol of 317 was 
protected as its tert-butyldimethylsilyl ether prior to Mitsunobu coupling between the 
allylic alcohol and isovanillin derivative 318. A palladium(II)acetate-catalyzed 
intramolecular Heck reaction formed dihydrofuran 320. The aldehyde functionality 
was converted into vinyl bromide 321 through use of a Wittig reagent. A second Heck 
reaction effected closure of the fourth ring, and provided tetrahydrophenanthrene 
derivative 322. Desilylation followed by 2-iodoxybenzoic acid (IBX) oxidation and 
sodium borohydride reduction effected the inversion of the allylic alcohol. Carbamate 
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hydrolysis and then oxymercuration of the styrene olefin produced a mercurium ion 
which was attacked by the amino group. Reduction of the mercury-carbon bond with 
LiAIH completed the synthesis of (+ )-codeine (314). 
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Reagents and conditions: (i) PAD, AcOH, MeOH; (ii) AC20, NEt3, DMAP, DCM, O'C; (iii) a) 
MeNH2, K2C03, THF, -40'C to r.t.; b) (BochO, NEt3, MeOH; (iv) TBS-CI, imidazole, DCM, -7ST to 
r.t.; (v) n-Bu3P, DIAD, THF, Q'C; (vi) Pd(OAc)2, Ag2C03, dppf, PhMe, I JO'C; (vii) PPh3CH2Br2, t-
BuOK, THF, -60'C; (viii) Pd(OAch, Ag2C03, dppf, PhMe, 110'C; (ix) TBAF, THF, r.t.; (x) IBX, 
DMF, r.t.; (xi) NaBH4' CeCh'7H20, MeOH, O'C; (xii) TFA-DCM (1 :4), O'C; (xiii) a) Hg(OAch, NEt3, 
THF; b) LiAIH4' r.t. 
Scheme 25. Hudlicky's synthesis of (+ )-codeine (314).182 
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Other cis-dihydrodiol products of TDO which have found applications in the 
synthesis of natural products include those derived from styrene 324, 1,3-
dibromobenzene 325, and chlorobenzene 326 (Figure 66). The targets prepared, 
zeylena (327),183 narciclasine (328),184 and (-)-cladospolide B (329)185 respectively, 
exemplify the synthetic value of TDO metabolites. For a more comprehensive review 
of products made, see excellent reviews by Hudlicky in 1993 186 and 2009.14 
CC Hudlicky (1989) 183 ~~OH Ph/I~ :::,... OH . '0 
0 
324 327 
OH 
Br ~OH b OH Hudlicky (1999) 184 t I -...;:;:, 1= OH Br:::"" OH o .0 NH 
OH 0 
325 328 
CI 
(x0H Banwell (2005) 185 
:::,... OH 59 "" 0 '. "OH o .0 
326 329 
Figure 66. Natural products derived from the cis-dihydrodiol products ofTDO. 
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2.4 Oseltamivir 
Throughout history, infectious diseases caused by influenza VIruses have 
haunted mankind. The Spanish flu pandemic of 1918 resulted in an estimated 40-50 
million human fatalities. Recently, the avian 'bird flu' spread rapidly throughout 
Europe, Asia, and most of Africa, killing over half of those infected. The only 
pharmaceuticals that both treat and prevent infection ar-e those which target the viral 
neuraminidase enzyme, essential for the release of viral progeny. The most potent 
member of this drug class is Tamiflu, the phosphate salt of oseltamivir. Many 
governments have elected to stockpile this drug in order to safeguard against another 
influenza pandemic. Given its vital role, oseltamivir was fast-tracked into production 
and promptly approved by most national drug departments. It is currently produced 
from (-)-shikimic acid, a scarcely available plant metabolite. Despite several 
excellent attempts by academic and industrial groups, no new practical synthetic route 
has been identified. 
2.4.1 Infectious Diseases 
Since the beginning of agriculture and urbanization, infectious diseases have 
been the major overall cause of human mortality. One early account is the death of 
one-quarter of the Athenian population over a four year period around 430 Bc. 187 In 
fact, the term pandemic is derived from the Greek pan demos, meaning 'all people'. 
Throughout history, disease pandemics have influenced war, religion, politics, 
economics, medicine and many other aspects of society. They have also been the 
leading stabilizer of human populations. In thirteenth century Europe, fatalities 
79 
attributed to the Black Death have been estimated at 25-50 million, translating to 30-
60% of the total population at the time. 188 Historical belief was that such pandemics 
had spiritual or supernatural origins. An accurate understanding of infectious disease 
etiology did not transpire until the late nineteenth century. 
The theory that diseases were a result of factors undetected by the naked eye 
began in ancient Rome. In the 1st century, Marcus Terentius Varro believed that 
minute creatures which floated through the air could enter the body and cause serious 
diseases. 189 Many scholars proposed similar hypotheses, but no one could provide 
direct evidence for the existence of microbes. This would change with the 
development of the compound microscope (2 or more lenses) by Zaccharias Janssen 
and his father Hans in 1590. This new device caught the interest ofa Dutch tradesman 
named Anton van Leeuwenhoek, who started to construct his own microscopes. 
Beginning in 1668, van Leeuwenhoek observed 'tiny animals' he termed animalcules 
(most likely bacteria and algae ).190 This discovery paved the way for Louis Pasteur 
and Robert Koch, whose combined work provided a rational basis for the clean water, 
sewage systems, food sanitation, and medicinal practices which exist today. Pasteur 
showed that microbes were responsible for the spoilage of food, and in tum refined 
the 'germ theory' of disease first proposed by Varro. Koch identified Mycobacterium 
tuberculosis and Vibrio cholerae as the causative bacteria responsible for tuberculosis 
and cholera respectively. He also developed a criterion to establish a relationship 
between a causative microbe and a disease, known as Koch's postulates. At the time 
it was understood that a porcelain filter (Chamberland filter) could exclude bacteria 
from a media. Consequently, it was a great surprise to Dmitry Ivanovsky that the 
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mottling and discolouration of tobacco leaves was caused by something capable of 
permeating a filter. 191 Shortly afterwards, Martinus Beijerinck made a similar 
observation. He named this new pathogen virus, meaning toxic or poison in Latin. 
Eventually it was revealed that many infectious diseases (e.g. small pox, measles, 
yellow fever, poliomyelitis) were caused by viruses. 
2.4.2 Viruses 
Viruses are among the most numerous microorganisms on the planet. They are 
ubiquitously distributed throughout all eco-systems, and infect every type of -cellular 
life. l92 All viruses are obligatory intracellular pathogens, capable of replicating 
independently of a cell's chromosomes but not independently of the cell itself. 
Outside of a host cell, a virus particle (virion) exists as little more than a 
macromolecular package. A complete virion consists of nucleic acid enclosed in a 
protein shell known as a capsid. Some viruses have an additional glycoprotein-rich 
lipid layer, called an envelope, derived from a membrane in the host cell from which 
it carne. 
Viruses exist in a wide variety of shapes and sizes, most being between 10 and 
300 nrn (~1/100th the size of a typical bacterium). 193 The most predominant 
morphologies are; helical, isometric, enveloped, and complex. Helical viruses (Figure 
67, A) are composed of a single repetitive subunit, known as a capsomer, assembled 
around a central axis. The result is a hollow helical tube which is packed with the 
nucleic acid. Isometric viruses (Figure 67, B) are quasi-spheri-cal hollow structures 
composed of a minimum of 12 capsomers, each forming a face of the structure. For 
example; twenty triangular faces fOlm an icosahedron structure, while twelve 
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pentagon faces form a dodecahedron structure. An enveloped virus (Figure 67, C) 
surrounds its nucleic acid-containing capsid with a membrane derived from the outer 
or internal bilayer (i.e. nuclear membrane or endoplasmic reticulum) of a host. The 
three major parts composing a complex viruses (Figure 67, D) are the; capsid head, 
tail sheath and tail fibers. The head is often an isometric capsule and houses the 
nucleic acid. These viruses use their tail fibers to recognize and dock on to a cell 
membrane, while the tail sheath acts as a hypodermic needle to inject the nucleic acid 
into the cell. 
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Figure 67. Predominant viral morphologies: A. helical, B. isometric, C. enveloped, 
D. complex. 194 
The variation in composition and structure of viral genomes is unlike any 
other type of organism. Their genomic material can be single or double stranded 
DNA or RNA. The polarity of the singled-stranded nucleic acid can be either 
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positive- or negative-sense. The obvious advantage of positive-sense RNA is that it 
can be translated immediately by a host. Viral genomes can be linear, circular or even 
segmented. The smallest genomes encode as few as four proteins, while the largest 
encode hundreds. 194 The proteins encoded are either structural or nonstructural in 
nature. The former form cap somers or are glycoproteins embedded in the envelope, 
while the latter have regulatory and accessory functions. 
The life cycle of all viruses can be divided into five basic stages; 1. 
attachment, 2. penetration, 3. uncoating, 4. replication and synthesis, 5. assembly and 
release. Attachment is the highly specific interaction between the outermost viral 
proteins and receptors on the host's cell surface. Viral proteins are either cap somers 
or envelope glycoproteins, while the host receptors are normal surface components 
such as carbohydrates, glycoproteins, lipids, and lipoproteins. Viral attachment to a 
host cell is the most common basis for cell specificity. 
In order to replicate, a virus must release its genome, and in some cases viral 
proteins, into the cell. For cells lacking a cell wall this can occur through endocytosis 
or membrane fusion. The former involves the engulfing of the virus into a section of 
the cell membrane, followed by release of that section into the intracellular fluid. 
Membrane fusion occurs when the lipid bilayers of an enveloped virus and a host cell 
merge into a single continuous membrane. Plants and some other eUkaryotic cells 
(e.g. bacteria, fungi, algae) are protected by a rigid carbohydrate-based layer. Viruses 
can only enter these cells through disturbances in the cell wall caused by either 
environmental trauma or the aforementioned injection process used by the complex 
viruses. Some plant viruses are able to move between cells via pores {plasmodesma) 
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III the cell wall normally used for cell-to-cell communication. Uncoating is the 
process of removing the protective capsid from the viral genome. Typically, this 
involves the unfolding and hydrolysis of the proteins by viral digestive enzymes, or 
comparable enzymes found in the host cell. 
In order for a virus to create progeny, it must first replicate its genome and 
acquire the various proteins needed to construct new virions. Replication of the 
genome, either DNA or RNA, is accomplished by nucleic acid specific polymerase 
enzymes. A host cell does not typically contain a RNA-dependant RNA polymerase, 
consequently this enzyme is packaged into the virion. Protein biosynthesis is 
relatively straightforward for positive-sense RNA viruses, given that their genome 
serves directly as mRNA. In the case of double-stranded DNA viruses, the mRNA is 
produced in the same manner as it would be for the host genome. The RNA 
polymerase of a host cell requires double-stranded DNA in order to construct mRNA. 
Therefore, single-stranded DNA viruses must first rely on the production of a 
complementary DNA strand. Neither double-stranded RNA nor negative-sense RNA 
can serve as mRNA. As a result, viruses containing these types of nucleic acid 
necessarily package their own RNA-dependent RNA polymerases. Retroviruses are 
RNA viruses whose genomes exist as positive-sense RNA, but are not used in 
translation. These viruses replicate and produce mRNA through a double-stranded 
DNA intermediate. The process of copying the information in RNA into DNA is 
performed by a viral reverse transcriptase enzyme. 
Once genomic replication and protein synthesis is complete, a virus can be 
assembled and released from the host cell. This process is highly variable and 
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dependent on the type of virus. In general, a virus can exit a cell through one of three 
methods; 1. budding, 2. apoptosis, and 3. exocytosis. Enveloped viruses require the 
insertion of their own proteins into the membrane of a host cell prior to departure. 
The nucleic acid-containing capsids of these viruses gather themselves at the portion 
of the membrane containing these viral proteins. Through a process called budding, 
the virus is engulfed in the bilayer and released into the extracellular fluid. Each viral 
particle liberated takes a portion of the host's membrane with it, eventually causing 
the death of the cell. Viruses can also initiate programmed cell death (apoptosis) in 
order to escape a cell. This process involves the digestion of the cell's genome and 
the sequestering of that material in irregular membrane bulges called apoptotitic 
bodies. These bulges, which also contain viral particles, are absorbed by 
macrophages. This serves as an excellent way for viruses to travel throughout the 
body, or to infect macrophages themselves. Finally, viruses can use a cell's own 
transport system to breakout. Through a process known as exocytosis, viral particles 
can become enclosed in vacuoles and then released into the extracellular fluid. Since 
no cell membrane is taken, this process keeps the host cell alive longer to produce a 
greater quantity of viruses. 
2.4.3 Influenza 
Influenza, also known as the flu, is the term for any infectious disease caused 
by the influenza viruses. The three species, influenza virus A, Band C, all belong to 
the Orthomyxoviridae family of RNA viruses and are the only members of their 
respective genera. 195 Influenza virus A and C infect numerous bird and mammalian 
species, while influenza virus B almost exclusively infects humans. They are similar 
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in structure and size, all being quasi-spherical enveloped viruses with a diameter of 
approximately 80-120 nm. All species have negative-sense RNA genomes, which are 
typically segmented into seven or eight fragments, each containing one or two genes. 
Of the three species, influenza virus A is by far the most infamous species. It is 
responsible for yearly epidemics and has produced dozens of deadly pandemics 
throughout history. 
Influenza species are subdivided into different serotypes based on the 
antibody response to two transmembrane glycoproteins, namely hemagglutinin (H or 
HA) and neuraminidase (N or NA). All influenza viruses contain both proteins, but 
structural variations change their antigenic properties. Influenza nomenclature uses 
these antigens followed by number to distinguish between serotypes. For example, 
both the 1918 Spanish flu and the 2009 swine flu outbreaks were caused by the HINI 
serotype of influenza A. Sixteen hemagglutinin (HI-HI6) and nine neuraminidase 
(NI-N9) subtypes have been identified thus far. l97 High rates of mutation within each 
serotype give rise to countless different strains. This explains how the same serotype 
(HINl) can cause outbreaks 91 years apart. Many HINI strains are relatively 
harmless and are largely responsible for the 'seasonal flu' experienced during the fall 
and winter months. The vast majority of human illnesses are caused by influenza A 
(HI-3 and NI-2) and influenza B strains. 
Both the influenza A and B genomes are organized into 8 separate linear 
segments ranging in size from 890 to 2341 nucleotides. The nine functionally 
important proteins encoded in these segments are depicted in Figure 68. The genomic 
fragments are protected by nucleocapsid proteins (NP) to fmm the ribonucleoprotein 
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complex. The RNA-dependant RNA polymerase is fashioned from the PA, PBI and 
PB2 proteins. This complex also has endonuclease activity, and cuts a primer from 
the mRNA precursors. Projecting from the lipid bilayer are the hemagglutinin 
(HA1I2) and neuraminidase (NA) proteins, in addition to the M2 protein. A matrix 
formed by MI proteins is situated around the inside of the lipid layer. 
Figure 68. Diagram of the influenza AlB virus. 197 
Hemagglutinin is a transmembrane glycoprotein containing either two or three 
glycosylation sites. The name is derived from its ability to aggregate red blood cells, a 
process called hemagglutination. It functions by binding to the sialic acid (N-acetyl-
neuraminic acid) residues protruding from glycoproteins on the surface of respiratory 
tract mucous membrane cells. Binding induces penetration of the virus via membrane 
fusion mechanism. The major portion (HAl) contains at least five antigenic sites 
labeled A, B (carrying the receptor binding site), C, D, and E. These are the 
predominant influenza virus antigens targeted by the human immune system. 
Neuraminidase is the other transmembrane glycoprotein found on the surface of 
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influenza viruses, also with antigenic properties. It is the enzyme responsible for 
cleaving sialic acid residues from; 1. hemagglutinin, 2. other NA proteins and 3. 
glycoproteins and glycolipids on the host cell. Mutations of the antigenic sites on 
hemagglutinin and neuraminidase reduce or inhibit the binding of neutralizing 
antibodies. This process, termed antigenic drift, creates new strains of an influenza 
virus serotype. The RNA-dependant RNA polymerase responsible for replicating the 
viral genome lacks a proofreading mechanism. As a result, approximately one out of 
every 10,000 nucleotides is incorporated incorrectly. Such errors, or mutations, occur 
in almost every single new virus produced. The effect is the abnormally high 
mutation rate seen in viruses compared to other organisms. Another way in which a 
new strain can arise is through a process called antigenic shift. This occurs when two 
or more different influenza serotypes infect the same cell. During viral assembly, 
genome segments from different serotypes can combine. For example, infection by 
HINI and H3N2 strains could lead to the formation of new HIN2 and! or H3Nl 
viruses. 
The influenza replication cycle follows the same general order outlined 
earlier. The influenza virus binds to the sialic acid of a cell's glycoproteins and 
glycolipids (Figure 69). Host cell specificity is determined by the penultimate 
galactose residue, either a-2,3 (birds) or a-2,6 (humans).197 After binding, the virus is 
taken up the cell via a clathrin-coated receptor-mediated endocytosis process. Once 
inside, the clathrin protein molecules are released and the vesicle containing the 
whole virus fuses with a membrane-bound compartment called an endosome. In 
response, the cell attempts to digest the endosome by acidifying its interior. The viral 
88 
M2 proteins act as ion channels and allow the influx of protons into the viral 
envelope. The increased acidity partially denatures hemagglutinin, inducing the 
fusion of the viral and vesicle membranes. Consequently, the ribonuc1eoproteins and 
RNA-dependant-RNA polymerase proteins (PA, PBI and PB2) are released into the 
cytoplasm. They are then transported into the nucleus, where the viral polymerase 
begins transcribing positive-sense RNA nucleotides. The newly constructed viral 
mRNA is moved out of the nucleus where translation occurs. Some of the synthesized 
proteins enter the nucleus and form new ribonucleoproteins, while others (e.g. HA 
and NA) are processed in the endoplasmic reticulum and Golgi apparatus, where 
glycosylation occurs. The glycosylated proteins are relocated to the cell membrane 
where they insert into the cell's lipid bilayer. When the local concentrations reach a 
threshold, the ribonucleoproteins and M I proteins aggregate and condense to form 
new viral particles. The membrane protrusions, which contain the viral components, 
bud off of the host cell membrane. Once again the enveloped viruses are attached to 
the cell via a sialic acid-hemagglutinin linkage. Neuraminidase cataiyses the 
hydrolysis of this linkage, liberating newly formed virion. 
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Influenza viruses are easily transmitted between people via three ways; 1. 
direct contact with an infected individual, 2. contact with a contaminated object, and 
3. inhalation of virus containing aerosols produced by coughing or sneezing. The time 
between entry and the production of new viral particles is approximately six hours. 197 
Symptoms include; fever, headache, fatigue to complete exhaustion, myalgia (muscle 
pain), chills, sore throat, rhinitis (runny nose), sneezing, and coughing. Influenza 
attacks the cells lining the airways and alveoli. Their replication cycle kills these 
cells, retarding the flow of oxygen to the blood. Additional damage results from the 
immune response to the infection. White blood cells, lymphocytes in particular, 
activate immunomodulating agents known as cytokines. This causes the alveoli to fill 
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with fluid, further disrupting the transport of oxygen. The collective effects of the 
fluid and cell destruction can be fatal to many patients. Influenza mortality is 
typically restricted to the elderly, children, or individuals weakened by other illnesses 
such as AIDS, cancer, heart disease, asthma, emphysema, cystic fibrosis, chronic 
obstructive pulmonary disease or diabetes. Some influenza strains, including the 
HINI Spanish flu strain, actually killed more young adults than any other 
demographic group. These deaths resulted from an overly 'strong immune response to 
the infection.2oo 
The first human influenza VIruS was isolated in 1933 by Christopher 
Andrewes, Wilson Smith, and Patrick Laidlaw.201 Consequently, it is difficult to 
determine the impact influenza has had on man throughout history. Many ancient 
disease pandemics have been attributed to influenza, based on the symptoms recorded 
at the time.203 It is certain that four major influenza pandemics have occurred in the 
20th century alone; 1918 Spanish flu, 1957 Asian flu, 1968 Hong Kong flu, and 1977 
Russian flu. Despite the names, all of these outbreaks likely originated in China 
where people are in close proximity to livestock (i.e. pigs and poultry). This increases 
the chance of viral infection crossing from one species to another.204 Contemporary 
research estimates that the 1918 Spanish flu infected 500 million people, resulting in 
the death of 40-50 million. 199 Recently, an outbreak of a swine flu strain began in 
April 2009. It induced worldwide panic and resulted in the closure of Mexico City, a 
metropolis of nearly 20 million people. In 1999, the Centre for Disease Control and 
Prevention used a Monte Carlo mathematical model to predict the effect of a new 
influenza outbreak.205 It was estimated that 89,000 to 207,000 deaths, 314,000 to 
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734,000 hospitalizations, 18 to 42 million outpatient visits, and 20 to 47 million 
additional illnesses would occur in the United States alone. The estimated economic 
impact was predicted to be between $71.3 to $166.5 billion USD. 
Every year, a new influenza vaccine is prepared from the glycoprotein 
components of the influenza A H3N2, HINI, and influenza B strains. Their 
production is predicated on the isolation and identification of the annual influenza 
mutant strains. It takes six to eight months to develop a new influenza vaccine and 
another one to two months to produce and distribute worldwide. This makes it 
impossible to stock pile vaccines in preparation of an outbreak. Furthermore, 
influenza vaccines are only effective when administered four weeks prior to exposure 
and thus have no effect on people who have already contracted the virus. Anti-
influenza drugs offer a more realistic way to control the spread of influenza. Treating 
those already infected is far more practical than treating everyone who is not. 
The two classes of anti-influenza drugs currently available are the M2 
inhibitors and the neuraminidase inhibitors. The former class includes Symmetrel 
(amantadine, 330) and Flumadine (rimantadine, 331) (Figure 70). These 
pharmaceuticals prevent the final 'uncoating' process by which the virus releases its 
genome into the cell nucleus. At low concentrations «1 ~g/mL), they inhibit the viral 
M2 ion channel from transporting protons into the viral core. At higher concentrations 
(>50 ~g/mL), the basic nitrogen buffers the pH of the endosomes, thus preventing the 
fusion of viral and cell membranes. Both drugs exclusively target influenza A, which 
is the only strain to contain the M2 protein. Present research as indicated that 
approximately 93% of all influenza A strains found today are resistant to these 
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drugs.202 It has also been reported that amantadine and rimantadine cause adverse 
central nervous system (CNS) side effects.206 Given such issues, researchers have 
been searching for new influenza proteins to target. The neuraminidase enzyme has 
emerged as the leading target because of available structural information and its 
presence in all influenza strains. Exhaustive research led to the discovery and 
development of the anti-influenza drugs Relenza (zanamivir, 332) and Tamiflu 
(oseltamivir, 2). 
330 331 
Figure 70. M2 inhibitor anti-influenza drugs. 
2.4.4 Neuraminidase 
Neuraminidase (exo-a-sialidase EC 3.2.1.18) is an exoglycohydrolase that 
cleaves a-ketosidically linked N-acetylneuraminic acid (Neu5Ac, 333) residues that 
cap various glycoconjugates. This releases newly formed influenza virions from host 
cells, thus propagating the viral infection. Neuraminidase inhibitors, such as 
zanamivir (332) and oseltamivir (2), prevent this from occurring (Figure 71). 
Neuraminidase may also assist in the movement of the influenza virus through the 
upper respiratory tract. In order for the virus to reach the epithelial host cells, it must 
negotiate a layer of protective mucus containing sialic acid-rich glycoproteins and 
glycolipids. It has been proposed that hydrolysis of these residues by neuraminidase 
helps the virus pass through these mucosal secretions.207 
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Figure 71. Neuraminidase-mediated inhibition.208 
The vital role of the influenza neuraminidase enzyme made it an attractive 
target for drug development. A screening program for neuraminidase inhibitors began 
as early as 1966, although without success.209 Soon after, Meindl and Tuppy 
synthesized 2-deoxy-2,3-dehydro-N-acylneuraminic acid (Neu5Ac2en, 334) and 
demonstrated its anti-neuraminidase activity (Figure 72).210 Analogs of Neu5Ac2en, 
including various esters and trifluoroacetate derivatives, were prepared and tested.211 
Using electron microscopy, Palese and Compans observed the inhibitors interfering 
with the release of progeny virions from infected cells.212 Unfortunately, these 
inhibitors performed poorly in vivo and were active against mammalian and bacterial 
sialidases.213 Nevertheless, Neu5Ac2en (334) served as the starting point for all 
neuraminidase inhibition research. 
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Figure 72. Neuraminidase substrate Neu5Ac (333) and inhibitor Neu5Ac2en (334) 
Kinetic isotope studies have suggested that the neuraminidase mechanism 
proceeded through an endocyc1ic sialosyl cation transition-state intermediate (Figure 
74).214 It was proposed that the olefin functionality in Neu5Ac2en (334) mimicked the 
sialosyl cation, a likely intermediate in most glycolysis reactions.2lS The hope was 
that a mechanism-based transition-state inhibitor could be developed from this parent 
compound. The neuraminidase crystal structure available at the time had a resolution 
of ~3A, and hence was oflimited value in structural based drug design.216-7 Although, 
it was determined that neuraminidase is a mushroom-shaped tetrameric protein, 
anchored to a membrane via a single hydrophobic tail, 29 amino acids in length. As a 
result, this enzyme can be divided and studied with no effect on antigenic or 
enzymatic activity. Nearly a decade later, x-ray crystallography of the neuraminidase 
enzyme structure in complex with Neu5Ac (333) and Neu5Ac2en (334) were 
successfully completed.218 Subsequent molecular modeling studies revealed valuable 
details of the essential binding interactions. 
The neuraminidase active site is a deep pocket located in the centre of each 
subunit. Although variation exists elsewhere, all residues which make direct -contact 
with the substrate are strictly conserved among all influenza neuraminidases. These 
residues, 18 in total, make similar interactions with both substrate and inhibitor 
molecules. Specifically, the carboxylate of N-acetylneuraminic acid (333) interacts 
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strongly with the side chains of an arginine triad (Arg 118, 292 and in particular 371) 
(Figure 73). In order to achieve these interactions, Neu5Ac (333) is distorted by the 
active site environment from its native chair confirmation into a pseudo-boat 
conformer, as depicted in both Figure 73 and 74. There are two more significant 
binding regions, or pockets, within the active site. First, the glycerol side chain of 
Neu5Ac fits into a pocket where it makes hydrogen bonding interactions with at least 
one glutamate residue (Glu276). The second is a hydrophobic pocket containing a 
tryptophan (Trp 178), and an isoleucine (Ile222) residue. This pocket is vital for 
molecular recognition and is in close proximity to the acetamide and the hydrocarbon 
backbone of the glycerol side chain. 
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Figure 73. Interactions of N-acetylneuraminic acid with influenza virus 
neuraminidase.219 
Based on x-ray crystallography, molecular modeling and kinetic studies, a 
complete mechanism of hydrolysis was proposed.220 As previously described, binding 
of the substrate induces a conformation change in the pyranose ring (Figure 74). This 
rotates the glycosidic bond at C2 from its native equatorial position to an axial 
position where it hydrogen bonds to an aspartate residue (Asp 151). This initiates the 
departure of the aglycon compound and formation of an oxocarbocation (sialosyl 
cation) transition-state intermediate; presumably stabilized by local negatively 
charged residues (i.e. Asp151, Glu119 and Glu227). It has been proposed that the 
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cation intennediate is trapped to fonn a glycosyl-enzyme covalent intennediate, a 
common feature of glycohydrolases.22I Refonnation of the sialosyl cation would then 
precede stereoselective water hydrolysis to provide the a-anomer of Neu5Ac (333), 
which mutarotates to the thennodynamically favourable f3-anomer. 
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Figure 74. Enzymatic mechanism of influenza virus neuraminidase.219 
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2.4.5 Development of Zanamivir and Oseltamivir 
In the early 1990's, the newly acquired neuraminidase structural information 
initiated a structure-based drug design effort. Computational chemistry techniques 
were used to probe the active site for structural analogs of Neu5Ac2en (334) that 
could be more potent. 222-3 This technique involves the creation of a series of grid 
points inside of the active site using a system developed by Goodford.224 Multi-atom 
probes, representing various functional groups, were inserted to measure the binding 
interactions. In order to determine the most favourable interactions, each probe atom 
was rotated to all possible orientations. The most important information obtained 
from this search concluded that the binding pocket into which the C4 hydroxyl of 
Neu5Ac (333) and Neu5Ac2en (334) inserts could interact with basic functional 
groups. It was predicted that such groups would form a salt-bridge with a proximal 
glutamate residue (Glu119), resulting in a higher affinity for the neuraminidase 
enzyme. The first example, 4-amino-Neu5Ac2en (335), was synthesized and tested 
for activity. It proved to be more potent than the parent compound (Ki (M) 4 x 10-6 vs. 
4 x 10-8) and was active in vivo. The molecular modeling studies also suggested that a 
larger basic group could fit inside this active site pocket. Insertion of a guanidinium 
group at C4 was predicted to form even greater hydrogen bonding interactions. The 
resulting compound, 4-guanidino-Neu5Ac2en (;z:anamivir, 332), was even more 
potent (Ki (M) 3 x 10-11 ) and was also active in vivo. Fortunately, zanamivir was 
found to be inactive towards mammalian and bacterial neuraminidase enzymes. It was 
fast tracked by the US FDA and approved for sale in 1999 by Glaxo Wellcome (now 
part of GlaxoSmithKline) under the trade name Relenza. 
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Zanamivir is a relatively polar compound, suffering from low oral 
bioavailability «3%). Therefore, the drug is administered by inhalation. Researchers 
felt that the carbohydrate core of zanamivir partially explained its high rate of 
metabolism and that cydohexene-based compounds were the logical replacement. 
Based on previous computational chemistry research, three key concepts were 
exploited in the development of the next series of neuraminidase inhibitors. First, the 
olefin was shifted in order to more closely replicate the sialosyl cation transition-state. 
Second, the glycerol side chain was replaced by an ether group. The hope was that 
this increase in lipophilicity would help improve oral bioavailability. Furthermore, it 
was known that the glycerol hydrocarbon backbone interacted with the hydrophobic 
region in the active site. The belief was that the hydrocarbon portion of an ether could 
exploit this fact. An extensive structure-activity investigation identified the 3-pentyl 
ether as the most potent inhibitor.226-7 The result was the synthesis of GS4071, the 
carboxylic acid analog of oseltamivir (2). Finally, although a carboxylate was 
essential it was clearly too polar for oral administration. Instead, a prodrug approach 
was developed that would utilize an ester as a direct precursor to the active form. The 
acid functionality would be revealed upon hydrolysis by endogenous esterases. The 
ethyl ester of GS4071 displayed the best balance of in vivo activity and oral 
bioavailability. Developed by Gilead Sciences, oseltamivir (2) was approved by the 
Food and Drug Administration (FDA) in late 1999 and was subsequently marketed by 
Hoffmann-La Roche under the trade name Tamiflu. 
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Figure 75. Influenza neuraminidase inhibitors. 
The possibility of another influenza pandemic, and the discovery of 
oseltamivir-resistant mutant strains,228 has necessitated an aggressive drug-
development program. The next generations of neuraminidase inhibitors are currently 
under development. A cyclopentane derivative, peramivir (336), is currently under 
development by BioCryst Pharmaceuticals. 
2.4.6 Oseltamivir Syntheses 
During extensive structural-activity studies, researchers at Gilead Sciences 
identified carboxylic acid 337, named GS4071, as a potent and selective inhibitor of 
influenza neuraminidase.229 Subsequent in vivo studies led to the development of 
ethyl ester prodrug GS4104, later named oseltamivir (2).230 Since that time, many 
well-designed and clever syntheses have been developed by industrial and academic 
groups. 
l'O2 
Gilead Sciences (1997i 29 
For their first synthesis of carboxylic acid 337, Gilead selected the structurally 
similar (-)-shikimic acid (338) as the starting material (Scheme 26). Esterification 
was followed by epoxide formation using a protocol previously described by 
Berchtold.231 The free alcohol of 339 was protected as its methoxymethyl ether, and 
then treated with sodium azide in the presence of ammonium chloride. The resulting 
hydroxyl was derivatized with methane suI fonyl chloride (MsCI) to provide 340. 
Treatment with triphenylphosphine, and then base, reduced the azide and effected the 
formation of aziridine 341. Ring opening with azide, acidic ether hydrolysis, and 
reaction with triphenylmethyl chloride provided azide 342. Simultaneous treatment 
with MsCI and triethylamine resulted in the formation of N-trityl aziridine 343. Ring 
opening with 3-pentanol was catalyzed by boron trifluoride etherate, this procedure 
also hydrolyzed the trityl protecting group. Azide reduction and basic ester hydrolysis 
yielded carboxylic acid 337. Gilead Sciences have also described the synthesis of 
epoxide intermediate 339 and acid 337 from (-)-quinic acid (345).229 
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Reagents and conditions: (i) MeOH, SOCI2; (ii) EtC02N=NC02Et, PPh); (iii) MeOCH2CI, DIPEA, 
DCM, reflux; (iv) NaN), NH4CI, MeOH/H20, reflux; (v) MeS02C1, NEt), DCM, DOC; (vi) a) PPh), 
THF, DOC-r.t.; b) NEt), H20; (vii) NaN3, NH4CI, DMF, 6S-7DoC; (viii) HCI, MeOH, r.t.; (ix) TrCI, 
NEt), DCM, DOC; (x) MeS02C1, NEt), DCM; (xi) BF),OEt2, 3-pentanol, 7D-7SoC; (xii) AC20, DMAP, 
pyr., r.t.; (xiii) PPh), THF/H20, 5DoC; (xiv) a) KOH, THF, r.t.; b) Dowex SDWX8 
Scheme 26. Gilead Sciences' synthesis of carboxylic acid 337.229 
Gilead Sciences (1998)232 
In 1998, Gilead Sciences described a large-scale procedure for preparing 
oseltamivir (2) from (-)-quinic acid (345).232 Protection of 345 as its acetonide was 
followed by treatment with sodium ethoxide. This resulted in the formation of lactone 
346 and ester 347 in a ratio of 5:1. The mixture was reacted with methanesulfonyl 
chloride, a which point the undesired lactone could be removed by crystallization. 
Treatment with sulfuryl chloride and pyridine effected the formation of ethyl acrylate 
349. Transketalization with 3-pentanone and perchloric acid furnished ketal 350, 
which was selectively opened with trimethylsilyl trifluoromethanesulfonate 
(TMSOTt) and BH3' Me2S complex. This procedure provided a mixture of several 
ethers, including the desired 351, which could be selectively extracted in hexanes. 
Exposure to potassium bicarbonate furnished epoxide 352, which was opened with 
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sodium azide. This procedure yielded a mixture of regiomeric alcohols, both of which 
were converted to aziridine 353 upon treatment trimethylphosphine. Ring opening 
with azide was followed by acylation with acetic anhydride. Azide reduction and 
treatment with phosphoric acid in ethanol provided Tamiflu (2). 
345 346 
353 
x-xi 1 
'1 ~Et xii-xiii 
~O\"Y"/N3 
NHAc 
354 2 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, reflux; (ii) NaOEt, EtOH; (iii) MsCI, NEt3, 
DCM, O°C; (iv) S02CI2, pyr., DCM, -20°C; (v) 3-pentanone, HCI04, 40T, 25 mmHg; (vi) TMSOTf, 
BH),Me2S, DCM, -lOT; (vii) KHC03, EtOH/H20, 55T; (viii) NaN3, NH4CI, EtOHIH20; (ix) Me3P, 
MeCN, 38°C; (x) NaN3, NH4CI, DMF, 70°C; (xi) AC20, NaHC03, hexanes/DCM; (xii) Raney-Ni, H2 
(1 atm), EtOH; (xiii) H3P04, EtOH, 5YC 
Scheme 27. Gilead Sciences' synthesis of Tamiflu (2).232 
In 1996, F. Hoffman-La Roche signed a contract for the co-development of 
oseltamivir (2). Shortly afterwards, they published two improved routes to the key 
epoxide intermediate 352 from (-)-shikimic acid and (-)-quinic acid.233 Also 
published was an azide-free route to Tamiflu (2) (Scheme 28).234 The process begins 
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with the selective openmg of epoxide 352 with allylamine in the presence of 
MgBr2·0Et2. Deallylation of 355 was accomplished with palladium on charcoal to 
provide amino alcohol 356. Amine 357 was produced in three operations via an 
aziridine intermediate. A second deallylation provided oseltamivir, which was then 
converted to Tamiflu. F. Hoffman-La Roche published another azide-free approach 
which used tert-butylamine, instead of allylamine, for the epoxide opening.235 
~O,.0~H' 
OH 
356 
357 
Reagents and conditions: (i) allylamine, MgBr2·0Et2, MTBE/MeCN, 55·C; (ii) 10% Pd/C, 
ethanolamine, EtOH, reflux; (iii) a) PhCHO, MTBE, reflux; b) MsCI, NEt3, O·C; c) allylamine, II O·C , 
3.5 bar; d) HCI, H20; (iv) AC20, AcOH, MeS03H, MTBE, OT; (v) 10% Pd/C, ethanolamine, EtOH, 
reflux; (vi) H3P04, EtOH, 50·C 
Scheme 28. F. Hoffman-La Roche's azide-free synthesis of Tamiflu (2).234 
Corey (2006i37 
Inspired by a Diels-Alder approach to Tamiflu published by F. Hoffinan-La 
Roche,236 Corey completed the first academic synthesis in 2006 (Scheme 29).237 The 
synthesis begins with a stereoselective Diels-Alder reaction between 2,2,2-
trifluoroethyl acrylate (358) and l,3-butadiene (359) catalyzed by the S-proline 
derived catalyst 360. Ammonolysis of cyclohexene adduct 361 quantitatively 
provided amide 362. Iodolactamization, tert-butyl carbamate protection, and 
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elimination of the halogen furnished lactam 364. Allylic bromination with N-
bromosuccinimide and treatment with cesium carbonate in ethanol afforded diene 
intermediate 366. Formation of bromodiamide 367 was achieved via a tin(lV) 
bromide catalyzed reaction with N-bromoacetamide (NBA). This reaction presumably 
proceeds through a bromonium ion intermediate, which is possibly opened by 
acetonitrile, the solvent, in a Ritter-type reaction. Exposure to potassium 
bis(trimethylsilyl)amide (KHMDS) resulted in the formation of acetylaziridine 368. 
Selective opening with 3-pentanol III the presence of copper(II) 
trifluoromethanesulfonate provided advanced intermediate 369, which was converted 
to Tamiflu (2) in a one step procedure. 
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Reagents and conditions: (i) 360, neat, 23°C; (ii) NH3, CF3CH20H, 40°C; (iii) a) TMSOTf, NEt3, 
pentane; b) h, Et20/THF; (iv) (BOC)20, NEt3, DMAP, DCM; (v) DBU, THF, reflux; (vi) NBS, AIBN, 
CCI4, reflux; (vii) CS2C03, EtOH; (viii) SnBr2, N-bromoacetamide, MeCN, -40°C; (ix) n-Bu4NBr, 
KHMDS, DME, -20°C; (x) CU(OTf)2, 3-pentanol, O°C; (xi) H3P04, EtOH 
Scheme 29. Corey's synthesis of Tamiflu (2).237 
Kanai and Shibasaki (2006i38 
Kanai and Shibasaki of the University of Tokyo have developed several 
distinct strategies towards the synthesis of Tamiflu.238-242 Their first route utilized a 
stereoselective ring opening of a meso-aziridine 371 with trimethylsilyl azide through 
use of chiral ligand 372. The resulting amide was treated with di-tert-butyl 
dicarbonate and then subjected to basic hydrolysis to provide cyc10hexene 374. Azide 
reduction and tert-butyl carbamate formation was followed by a Se02-Dess-Martin 
periodinane allylic oxidation. Further oxidation with Dess-Martin periodinane 
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preceded a Ni(CODh-catalyzed 1,4 addition oftrimethylsilyl cyanide to afford TMS-
enolate 377. An N-bromosuccinimide bromination followed by a selective reduction 
with LiAIH(Ot-Bu)3 gave allylic alcohol 378. Mitsunobu conditions yielded an 
aziridine, which was opened with 3-pentanol in the presence of BF3'OEt2 to furnish 
advanced intermediate 379. Acidic carbamate hydrolysis and regioselective acylation 
provided 381. The vinyl nitrile functionality was subjected to ethanolic-hydrogen 
chloride to yield Corey's intermediate 369.237 
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Reagents and conditions: (i) a) Y(Oi-Prh 372, TMS-N3, CH3CH2CN, r.t.; b) recrystallization from 
IPA; (ii) BOC20, MeCN, DMAP, r.t.; (iii) 4 M NaOH, r.t.; (iv) a) PPh3, MeCN, 50°C; b) H20, 40°C; (v) 
BOC20, NEt3, DCM, r.t.; (vi) Se02, Dess-Martin periodinane, dioxane, 80°C; (vii) a) Dess-Martin 
periodinane, DCM; b) recrystallization from IPAlhexanes; (viii) Ni'(COD)2, COD, TMSCN, THF, 
60°C; (ix) a) NBS, THF; b) NEt3; (x) LiAIH(Ot-Bu)3, THF, 4°C; (xi) DEAD, PPh3, THF; (xii) 
BF3'OEt2, 3-pentanol; (xiii) TFA, DCM, O°C; (xiv) BOC20, NEt3, DCM, r.t.; (xv) AC20, DMAP, pyr.; 
(xvi) a) 4.2 M HCI'EtOH, 60°C; b) H20; (xvii) H3P04, EtOH 
Scheme 30. Kanai and Shibasaki's synthesis of Tamiflu (2).238 
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Y 30 (2006)243 
The Yao group prepared advanced Tamiflu intermediate 395 from a more 
readily available starting material, L-serine (382), compared to many other syntheses. 
Using procedures developed by Lewis244 and himself45, Yao converted L-serine (382) 
to alkene 384 in 7 steps (Scheme 31). Osmium tetroxide-mediated dihydroxylation, 
benzyl formate formation and selective protection of the primary hydroxyl with tert-
butyl( chloro )diphenylsilane afforded 386. A Swem oxidation and subsequent Wittig 
olefination provided terminal alkene 387. Hydrolysis of the N,O-acetal was achieved 
with bismuth bromide and was followed by another Swem oxidation to yield 
aldehyde 388. 
~H2 Ref 244 'J-~BOC Ref 245 'J-~BOC O~ ---.l..-
HO~C02H o ~ 3 steps ~CHO 4 steps HN, 
PMB 
382 383 384 
NHBoc 'J-~BOC 
O~ ~ 
Cbz~NH OTBDPS 
O~ v-vi 
CbZjH lOTBDP:--
388 387 
'J-~BOC 
o ~ OH ~OH PMB 
385 
! ii-iv 
'J-~BOC 
o ~ OH ~OTBDPS 
386 
Reagents and conditions: (i) OS04, NMO, acetone/H20; (ii) Pd(OH)2, H2, MeOH, 35'C; (iii) CbzCl, 
NaHC03, EtOAc/H20; (iv) TBDPSCl, imidazole, DCM; (v) (COCl)2, NEt3, DMSO, DCM, -78T; (vi) 
Ph3PCH3Br, n-BuLi, THF, -78'C; (vii) BiBr3, MeCN; (viii) (COClho NEt3, DMSO, DCM, -78'C 
Scheme 31. Yao's synthesis of Tamiflu intermediate 388.243 
Aldehyde 388 was reacted with vinylmagnesium bromide in the presence of zinc 
(II)bromide to provide a separable mixture of alcohol 390 and the undesired 
stereoisomer 389 (Scheme 32). Protection with chloromethyl methyl ether preceded a 
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ring-closing metathesis with Grubbs' 2nd generation catalyst. Desilylation, then a 
pyridinium chlorochromatel NaCI02 two-step oxidation procedure afforded 
carboxylic acid 393. Esterification and two deprotections yielded amino alcohol 394, 
which was converted to 395 in two steps. Although this intermediate was not 
converted to oseltamivir (2), it does posses most of the required functionality and 
stereochemistry . 
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Reagents and conditions: (i) vinylMgBr, ZnBr2' THF, -78·C; (ii) MOMCI, DIPEA, DCM; (iii) Grubb's 
II catalyst, DCM, r.t.; (iv) TBAF, THF; (v) PCC, 4A MS, DCM; (vi) NaCI02, K2HP04, 2,3-
dimethylbuta-l,3-diene, f-BuOH/THF/H 20 (4:1:1), lOT; (vii) EtOH, HOBt, EDCI, DIPEA, DCM; 
(viii) 5% HCI/EtOH, O·C; (ix) AcCI, Na2C03, EtOH, O·C; (x) Pd(OAc)2, Et3SiH, NEt3, DCM, O·C 
Scheme 32. Yao's synthesis of Tamiflu intermediate 395.243 
Fukuyama (2007)246 
Fukuyama has developed a synthetic route to Tamiflu from pyridine (396), a 
relatively available and economic starting materia1.246 The synthesis employs a Diels-
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Alder reaction between the Cbz-protected dihydropyridine 397 and acrolein (398). 
The stereochemistry was controlled through the use . of catalyst 399, previously 
developed by MacMillian.247 The resulting aldehyde 400 was oxidized with sodium 
chlorite and then subjected to a bromolactonization procedure to provide 401. 
Protecting group manipulation (Boc for Cbz) and a ruthenium(IV) oxide oxidation 
afforded imide 402. Exposure to ammonia, and then methanesulfonyl chloride 
furnished amide 403, which underwent a Hofmann rearrangement in the presence of 
allyl alcohol and iodobenzene diacetate to yield bicyclic compound 404. Treatment 
with ethoxide effected the ethanolysis of the lactam, elimination of the bromide, and 
aziridine formation. Ring opening with 3-pentanol, carbamate hydrolysis and 
acylation provided alloc-oseltamivir 407, which was deprotected and reacted with 
H3P04 to complete the synthesis. 
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Reagents and conditions: (i) NaBH4' CbzCI, MeOH, -50'C; (ii) acrolein, 399, MeCN, H20; (iii) 
NaCI02, NaHP04'2H20, 2-methyl-2-butene, t-BuOH, H20; (iv) Br2, NaHC03, DCM; (v) PdlC, H2, 
(Boc)20, EtOH, THF; (vi) Ru02'nH20, NaI04, CICH2CH2CI, H20, 80'C; (vii) NH3, .f-BuOH, THF, 
O'C; (viii) MsCI, NEt3, DCM; (ix) allyl alcohol, PhI(OAch, 4 A MS, PhMe, 60'C; (x) NaOEt, EtOH, 
O'C; (xi) 3-pentanol, BF3'OEt2, -20'C; (xii) TFA, DCM, O'C; (xiii) AC20, pyr,; (xiv) a) PdlC, Ph3P, 
I ,3-dimethylbarbituric acid, EtOH, reflux; b) H3P04 
Scheme 33. Fukuyama's synthesis of Tamiflu (2).246 
Fang (2007i48 
The Fang group's synthesis of Tamiflu (2) commences from xylose derivative 
408 (Scheme 34).248 Reaction with pivaloyl chloride, followed by a pyridinium 
dichromate oxidation afforded ketone 409. Exposure to hydroxylamine hydrochloride 
prepared oxime 410. Reduction with LiAIH removed the pivaloyl ester and reduced 
the oxime functionality. Acylation, acidic hydrolysis in the presence of benzyl alcohol 
and acetonide formation yielded N,O-ketal 412. Sequential treatment with 
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trifluoromethanesulfonic anhydride (Tf20) and then triethylphosphonoacetate and 
sodium hydride gave phosphoryl ester 413. A clever intramolecular Horner-
Wadsworth-Emmons reaction was used to prepare ethyl acrylate 414. Mitsunobu 
conditions with diphenylphosphoryl azide (DPPA) were employed to install the azide, 
then acidic hydrolysis provided allylic alcohol 415. A second Mitsunobu reaction 
inverted the hydroxyl group, which was then reacted with O-pentyl 
trichloroacetimidate under acidic conditions to afford 3-pentyl ether 417. Azide 
reduction with Lindlar's catalyst provided oseltamivir (2). 
HOLo __ 
)----<'0 
HO 'o-t-
408 
416 
PiVO~ ... PiVO~ HO 
i-ii III ~ '] 0 
- .,0- I. .,0 ~O 
o 'o-t- HO-N 'o-t- AcHN 'o-t-
409 410 411 
417 
Reagents and conditions: (i) PivCI, pyr., D'C; (ii) PDC, AC20, reflux; (iii) HONH2"HCI, pyr., 6D'C; 
(iv) LiAIH4' THF, D'C - reflux; (v) AC20, pyr., r.t.; (vi) BnOH, 4 M HCI in dioxane; (vii) 2,2-DMP, p-
TsOH, PhMe, 8D'C; (viii) Tf20, pyr., DCM, -lS'C; (ix) triethylphosphonoacetate, NaH, lS-crown-S, 
DMF, r.t.; (x) a) H2, PdlC, EtOH; b) NaH, THF; (xi) DPPA, DIAD, Ph3P, THF; (xii) HCI, EtOH, 
reflux; (xiii) a) Tf20, pyr., DCM, lS'C; b) KN02, 18-crown-6, DMF; (xiv) ChCC(=NH)OCHEt2, 
CF3S03H, DCM; (xv) a) H2, Lindlar's catalyst, EtOH, r.t.; b) H3P04, EtOH, 4D'C 
Scheme 34. Fang's synthesis of Tamiflu (2).248 
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Trost (2008)249 
One of the shortest syntheses reported to date was accomplished by the Trost 
group in 2008.249 The first step is a palladium-catalyzed asymmetric allylic alkylation 
of alkene 418 with trimethylsilylphthalimide in the presence of Trost's (R,R)-chiral 
ligand 419. The reaction mixture was then treated with ethanol, under acidic 
conditions, to provide ethyl ester 420. Sulfenylation with PhSS02Ph afforded a 
diastereomeric mixture of ester 421. Sulfur oxidation with m-CPBA and subsequent 
elimination with DBU provided diene 422. 
g02Et P(:5""'t ;ii C02Et o ii 6·.'NPhth ~ "'NPh;-- ~ "'NPht~ 
418 420 421 422 
Reagents and conditions: (i) a) 419 [(ll-C3H5PdCI)2] , trimethylsilylphthalimide, THF, 40·C; b) p-
TsOH 'H20 , EtOH, reflux; (ii) KHMDS, PhSS02Ph, THF, -78T; ( iii) a) m~CPBA, NaHC03, O·C; b) 
DBU, PhMe, 60·C 
Scheme 35. Trost's synthesis of oseltamivir intermediate 422.249 
The chiral aziridination of diene 422 was accomplished through a nitrene reagent 
formed in situ by reacting 2-(trimethylsilyl)ethanesulfonamide (SES-NH2) with 
PhI(02CCMe3)2. After extensive research with copper, gold, and silver catalysts, it 
was found that chiral rhodium complex 423 provided the best selectivity. Opening of 
the SES-aziridine with 3-pentanol and acylation provided protected oseltamivir 
intermediate 426. Sequential treatment with TBAF and then hydrazine completed the 
synthesis of oseltamivir (2). 
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U= -0 o \ \-O-Rh-O 
O':"'Rh-t6-\ I \ 0 0-
7"1 
C02Et ~ 6 423 ~ ··'Nphth---------- AEt .. 'I AEt V"'NPhth ~ ~O"·y··'NPhth 
SESN NHSES 
422 424 425 
oseltamivir (2) 
v 'I AEt iv 
- ~O"'Y"'NPhth -
NHAc 
C02Et 
~O"'¢"'NPhth 
AC .... NSES 
427 426 
Reagents and conditions: (i) a) 423, 2-(trimethylsilyl)ethanesulfonamide, Phl(02CCMe3h. MgO, PhCI, 
O°C; (ii) 3-pentanol, BF)'OEt2, 75°C; (iii) DMAP, pyr., AC20, MW, 150°C; (iv) TBAF, THF, r.t.; (v) 
NH2NH2, EtOH, 68°C 
Scheme 36. Trost's synthesis of oseltamivir (2).249 
Fang (200SisO 
The second Tamiflu synthesis published by the Fang group employs the 
commercially available cis-dihydrodiol 302, obtained from the TDO-dihydroxylation 
of bromobenzene.25o The acetonide derivative of 302 was subjected to the 
bromoacetamidation-aziridination procedure used in Corey's Tamiflu synthesis 
(Scheme 37). Next, an aziridine opening reaction with 3-pentanol was catalyzed by 
boron trifluoride etherate. Acidic cleavage of the acetonide provided a free diol which 
was reacted with a-acetoxyisobutyryl bromide to afford dibromide 431. The allylic 
bromide and the acetyl group were both reduced with lithium triethylborohydride to 
yield homoallylic alcohol 432. 
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LOH 
U OH 
302 
Br 
~ h OX 
AeHNYO 
Br 
428 429 
~O"~OH 
NHAe 
432 
430 
1 v-vi 
~ .¢:Br ."Br 
-!'!L. 
0" OAe 
NHAe 
431 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, O°C; (ii) N-bromoacetamide, SnBr4, 
MeCN/H20, O°C; (iii) LiHMDS, THF, _lOoC; (iv) 3-pentano), BFj"OEt2, _lOoC; (v) conc. HC), MeOH, 
50°C; (vi) AcOCMe2COBr, THF, O°C; (vii) LiBHEt3, THF, OT 
Scheme 37. Fang's synthesis ofTamiflu intermediate 432.250 
Fang described two strategies to synthesize Tamiflu from alcohol 432. In the first 
route, Mitsunobu conditions and diphenylphosphoryl azide were used to install the 
azide functionality. The vinyl bromide was reacted with a nickel-carbonyl-
triphenylphosphine complex in ethanol to furnish ethyl ester 417, an intermediate in 
Fang's first synthesis.248 The second route described has one additional step but is 
azide-free. Alcohol 432 was reacted with tetrabutylammonium cyanate in the 
presence of triphenylphosphine and 2,3-dichloro-5,6-dicyanobenzoquinone. The 
resulting isocyanate intermediate was treated with tert-butanol to provide Boc-
protected derivative 434. Halogen exchange provided vinyl iodide 435, which was 
subjected to a palladium-catalyzed carbonylation, esterification and deprotection 
sequence to yield oseltamivir (2). 
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JO"~OH 
NHAc 
432 
J o'.¢.'", 
NHAc 
433 
iii 
I 
oseltamivir (2)· H3P04 
iv 
Br I t 
'l¢ v 'l¢ ~ ~O\" "'NHB:-- ~O\" o"NHBoc 
NHAc NHAc 
434 435 
Reagents and conditions: (i) DPPA, DIAD, PPh3, THF, 40'C; (ii) [Ni(COMPPh3h], DlPEA, EtOH, 
THF, 80T; (iii) a) H2, Lindlar's catalyst, EtOH; b) H3P04, EtOH, 50'C; (iv) a) DDQ, PPh3, n-
BU4NOCN, MeCN, r.t.; b) t-BuOH, reflux; (v) CuI, KI, N,N'-dimethylethylenediamine, n-BuOH, 
120'C; (vi) Pd(OAc)2, CO, NaOAc, EtOH, r.t.; (vii) H3P04, EtOH, 50'C 
Scheme 38. Fang's two approaches to Tamiflu from 432.250 
Banwell (2008is1 
As with Fang's second synthesis of Tamiflu,250 Banwell employed the cis-l,2-
dihydrodiol 302 derived from the whole-cell oxidation of bromobenzene (Scheme 
39).251 Treatment of 302 with 4-methoxybenzaldehyde dimethyl acetal gave ketal 
436, which was reduced with diisobutylaluminum hydride to provide a 6: 1 mixture of 
monoprotected diol 437 and its regioisomer. The allylic alcohol was reacted with 1,1 '-
carbonyldiimidazole (CDI) and then hydroxylamine to form a carbamate derivative 
which was then O-tosylated. The 3-pentyl group was installed by reacting carbamate 
438 with 3-pentanol in the presence of Cu(MeCN)4PF 6. The authors suggested that an 
intramolecular aziridination between a nitrene intermediate and the unsubstituted 
olefin creates 439, which is then attacked by 3-pentanol at the allylic position. The 
resulting cyclic carbamate 440 was then hydrolyzed with LiOR to furnish y-amino 
alcohol 441. Acylation of the primary amine and acidic hydrolysis of the p-
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methoxybenzyl group yielded diol 443, a formal intermediate from Fang's 
synthesis.250 
LOH 
U OH 
302 436 
Br 
J¢C 0"< OPMB 
NH2 
441 
vii ! 
Br 
J¢C 0"< OPMB 
NHAc 
442 
vi 
-
viii 
-
Br 
OTs 
I 
)yOH iii-iv, U OPMB 
BrOyNH 
)yo 
U OPMB 
437 
B}fr;/ '/ NH 
° n OPMB 
440 
Br 
J ¢(" 0"< OH 
NHAc 
443 
438 
° Br~01 
~N 
OPMB 
439 
Ref 250 
--..... oseltamivir (2)· H3P04 
5 steps 
Reagents and conditions: (i) 4-methoxybenzaldehyde dimethyl acetal, (+)-camphorsulfonic acid, 
PhMe, O°C; (ii) DIBAL-H, NEt3, PhMe, -78°C; (iii) a) CDI, MeCN, O°C; b) NH20H'HCI, imidazole, 
O°C; (iv) p-TsCl, NEt3, Et20, O°C; (v) Cu(MeCN)4PF6, K2C03, MeCN, 3-pentanol, O°C; (vi) LiOH, 
1,4-dioxane/H20, lOOT; (vii) AcCl, NEt3, O°C; (viii) HCl, MeOH, 3SOC 
Scheme 39. Banwell's formal synthesis ofTamiflu (2).251 
Kanai and Shibasaki (2009i41 
Kanai and Shibasaki have recently published their 4th generation approach to 
Tamiflu.241 The synthesis begins with an asymmetric barium-catalyzed Diels-Alder 
reaction between Danishefsky's diene (444) and dimethyl fumerate (445) using chiral 
ligand 372 (Scheme 40). The resulting allylic alcohol 446 was obtained in a 6: 1 
mixture of the a-OR/ P-OR diastereomers. Basic ester hydrolysis of the mixture was 
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followed by exposure to DPP A. The authors report that only the a-OH diastereomer 
was obtained, and suggest that the ~-OH decomposed (possibly via a Curti us 
rearrangement). Synthesis of carbamate 449 was achieved by first heating carboxylic 
azide 448 to 80°C in tert-butanol and then reacting the carbamate nitrogen with acetic 
anhydride. Alkene 449 was then subjected to a regioselective allylic substitution with 
dicyanomethyl acetate (450), catalyzed by a palladium-dibenzylideneacetone-
chloroform complex. Epoxidation with trifluoroperacetic acid afforded a-epoxide 452 
as the lone product. Treatment with ethanolic potassium carbonate transformed the 
acetoxydicyanomethyl functionality into an ethyl ester and initiated an E2 epoxide 
opening! elimination sequence to provide allylic alcohol 453. Mitsunobu conditions 
inverted the hydroxyl group and effected the formation of aziridine 368, an 
intermediate in Corey's synthesis.237 
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r TMSO 372 
444 445 446 447 
~CN OAc NcQCNOAC o ~ I 
"'NHBoc "'NHBoc 
- vi 
NHAc NHAc 
452 451 
viiil 
HO A:NI HBOC~ A:N1 HBO-CXi ~ AC~ NHAc osellamivir (2)· H3P04 
453 368 369 
Reagents and conditions: (i) a) Ba(Oi-Pr)z, 372, CsF, THF, -20T; b)1 M HC1; (ii) 2 M NaOH, MeOH, 
60·C; (iii) DPPA, NEt3, THF, O·C; (iv) t-BuOH, 80T; (v) a) Ac20, NEt3, DMAP, DCM; b) 
recrystallization from DCM/cyclopentyl methyl ether; (vi) 450, {Pd(dba),),CHCI3, dppf, PhMe, 60·C; 
(vii) tritluoroperacetic acid, urea/H20, Na2HP04, DCM, 4·C; (viii) K2C03, EtOH, r.t.; (ix) a) DEAD, 
PPh3, p-nitrobenzoic acid, THF, -20·C; b) LiOH, EtOH, 20·C; (x) DIAD, Me2PPh, NEt3, DCM, 4·C; 
(xi) 3-pentanol, BF30Et2, -20 'C; (xii) a) TFA; b) H3P04 
Scheme 40. Kanai and Shibasaki's fourth generation approach to Tamiflu (2).241 
Other Syntheses 
Several other syntheses of oseltamivir have been published smce Gilead 
Sciences initial approach was released in 1998.230 Briefly, Kann employed a cationic 
iron carbonyl complex,252 Groaning developed a 'greener' version of the Gilead 
synthesis,253 Okamura published a shorter Diels-A1der route to Corey's diene 
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intermediate 366,254 a F. Hoffmann-La Roche group, led by Zutter, used an enzymatic 
desymmetrization strategy,255 Fukuyama released a second generation approach,256 
Hayashi developed a high-yielding synthesis via three 'one-pot' procedures,257 
Mandai completed an azide-free synthesis from L-methionine,258 and Shi developed 
two short syntheses from (-)-shikimic acid.259-6o Comprehensive reviews on the 
synthesis of Tamiflu have been compiled by Kanai and Shibasaki and Magano.261 
Additionally, the Tamiflu syntheses completed before 2009 have been reviewed and 
subjected to environmental metric analysis by Andraos.262 
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3. Results and Discussion 
The following chapter reviews the latest efforts in seven areas of research; 1. 
reactivity of the Burgess reagent with oxiranes, 2. development of a chiral auxiliary 
version of the Burgess reagent, 3. enantioselective synthesis of balanol, 4. 
chemoenzymatic synthesis of balanol, 5. enzymatic cis-dihydroxylation of benzoate 
esters, 6. synthesis of oseltamivir, and 7. synthesis of oseltamivir analogs. The 
reactivity of the Burgess reagent with oxiranes, including mechanistic considerations 
is presented. Additionally, the development of a chiral version of the Burgess reagent 
and its application to the synthesis of cis and trans enantiomerically pure ~-amino 
alcohols is covered. The synthetic utility of this methodology will be evaluated in the 
enantiodivergent synthesis of (+)- and (-)-balanol. Also discussed is a second-
generation approach to both balanol enantiomers, each beginning from the cis-
dihydrodiol metabolite of bromobenzene. Next, the steric and functional limitation of 
the toluene dioxygenase-mediated dihydroxylation of various benzoate esters is 
assessed. The synthetic value of these transformations is demonstrated in the 
synthesis of oseltamivir from the cis-dihydrodiol metabolite of ethyl benzoate. 
Finally, recent work in the preparation of several oseltamivir analogs is outlined. 
3.1 Burgess Reagent 
Initially, the Burgess reagent (8) was used for the dehydration of secondary 
and tertiary alcohols and for the production of urethanes from primary alcohols. 
Subsequent research has discovered a wide variety of other useful transformations 
performed by the Burgess reagent (see Chapter 2). 
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o C02Me o 0 0 Ie {j) )le '5'0 o--'s' ,N NHEt3 MeO N' ' NEt3 I 
8 0 H 
-----... R'''H''R' 
R' R' 
R R 
>=< R' R' 
454 455 456 457 
Figure 76. Dehydration of secondary and tertiary alcohols by the Burgess reagent (8) 
3.1.1 Reactivity of the Burgess Reagent with Oxiranes 
The Hudlicky group, led by Dr. Uwe Rinner, described the first reaction 
between an oxirane and the Burgess reagent (8) in 2003. Cyclic sulfamidate 459 was 
prepared from the corresponding oxirane 458.8 At the time, the relative 
stereochemistry of the product was assumed to be trans (Figure 77). The mechanism 
was thought to involve the nucleophilic opening of the epoxide with the nitrogen 
anion of the Burgess reagent to provide intermediate 463 (Figure 78). The resulting 
oxyanion would then attack the sulfur atom and displace triethylamine. 
458 
actual 
(+/-)-459 
Me02C, ~,O 
6b 
(+/-)-460 
Figure 77. Assumed and actual relative stereochemistry 
The Nicolaou group also reported the preparation of cyclic sulfamidates using the 
Burgess reagent (8), in this case from 1,2-diols.44-6 They too proposed that trans-fused 
cyclic sulfamidates were produced (Figure 78). It was believed that each hydroxyl 
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attacked an equivalent of the Burgess reagent (8) displacing triethylamine. The 
resulting intermediate 463 would then displace a sulfite species, through an 
intramolecular attack, to provide the trans-fused sulfamidate 459. 
f:l=G 0" /p N-CH20 2Me 
HO OH Me02C'N~s,0 --8-
ts o 0- p 11-0 8 . - 0 0 + 
461 (+/-)-462 O,p 
's' 
<J(f) 
MeO,C-S 
0,~Et3 
o;s~ (+/-)-459 0 'N 00 (j 8 Me02C~ 0 t 
458 (+/-)-463 
Figure 78. Initial mechanism proposed for the formation of trans-sulfamidate 459 
from epoxide 458 and 1,2-diol 461 using the Burgess reagent (8) 
In order to confirm the relative stereochemistry of the cyclic sulfamidates, Dr. 
Hannes Leisch converted the commercially available trans-2-aminocyclohexanol 
(464) into both the trans- and cis-cyclic sulfamidates 459 and 460* respectively 
(Scheme 41). Using a method originally developed by Jacobsen,263 the trans-isomer 
464 was easily converted into the cis-isomer 467. Treatment with methyl 
chloroformate afforded ~-hydroxy carbamates 465 and 468, which were reacted with 
thionyl chloride. The resulting sulfoxides 466 and 469 were oxidized using 
ruthenium(III) chloride and sodium periodate in aqueous acetonitrile. Comparative 
analysis of the two products revealed that the trans-isomer 459 did not match the 
product we obtained from the reaction of the Burgess reagent (8) with cyclohexene 
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oxide (458). Clearly the mechanism involving one equivalent of the Burgess reagent 
could not operate (Figure 78). 
Me02C, 19 0 Me02C, II~O 
NH2 NHC02Me 6~b 6~b 6·"OH iv 6·"OH v vi ¢ 460 
- - -
464 465 466 459 
i-iii! 
0 0 Me02C, II Me02C, 11,0 
600 iv c5~: v &"h vi c5b 460 - - -
467 468 469 460· 
Reagents and conditions: (i) AC20; (ii) SOCh; (iii) 10% HCI, 68% over 3 steps; (iv) methyl 
chloroformate, NaHC03, CHCli H20, 87%; (v) SOCI2, MeCN, -40°C, 78%; (vi) RuCI3 'H20, NaI04, 
MeCNI H20, 87% 
Scheme 41. Relative stereochemical proof for cyclic sulfamidate 460 
An amended mechanism, using two equivalents of the Burgess reagent (8), 
was proposed in order to explain the formation of the cis-isomer 460.264 Not 
surprisingly, at least two equivalents of the Burgess reagent (8) were required for 
optimal yields. As with the first proposed mechanism, the nitrogen anion of the first 
equivalent opens the epoxide. However, the resulting oxyanion does not attack the 
sulfonyl group to displace triethylamine, but rather reacts with a second equivalent of 
the Burgess reagent (8) to form intermediate 472 (Figure 79). The resulting nitrogen 
anion then intramolecularly displaces the Burgess reagent to afford cis-cyclic 
sulfamidate 460. The mechanism involving the formation of cydic-sulfamidates from 
1,2-diols remains the same, although it is now apparent that only trans 1,2-diols react 
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to give cis-cyclic sulfamidates. The bis-sulfonated intermediate formed from a cis-
1,2- diol would be incapable of undergoing an intramolecular SN2 displacement. 
(;j,e 0" /,.0 N ..... C02Me 
"0" 8 ~o,c'~'S~tr~"o 
+ 
470 471 O,p 
's' 
Me02C-N: ''..0 
<V 0 q, /NEt3 e 
O=S ~ N ..... C02Me 
6 
I I 460 MeO~-N O ..... S::::O 
8 Co b t 
458 472 
Figure 79. Mechanism for the formation of cis-sulfamidate 460 from epoxide 458 
and 1,2-diol 470. 
3.1.2 Computational Studies 
We theorized that computational studies might provide further insight into the 
mechanism of cis-cyclic sulfamidate formation. This led to a collaboration with Prof. 
Travis Dudding and Branden Fonovic at Brock University.265 Their study used 
(GGA)-hybrid Kohn-Sham density functional theory (KS-DFT) at the B3L yp266 -6-
31 G( d)267 level in order to ascertain a possible mechanism. Briefly, this study 
examined two possible pathways to reach the cis-cyclic sulfamidate 460. First, the 
previously proposed backside SN2, attack and subsequent oxyanion sulfonation 
mechanism, would proceed through intermediate 474. However, all optimized 
geometries scanned possessed unrealistically high activation barriers (~Gt >50 
kcal/mol). Conversely, a front side [3+2] concerted asynchronous attack (path A) 
provided a significantly lower activation barrier (~Gt = 38.9 kcal/mol). 
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p,," A (:) po," B 
473 458 474 
:j: 
~G = 38.9 kcal/mol 
:j: 
~G = 52.0 kcal/mol 
! 
460 472 
Figure 80. Possible mechanistic pathways from oxirane 458 to cis-sulfamidate 460. 
The computational study also revealed the possible metrics of the five-membered-
TSI (Figure 81). Multiple bond-forming and bond-breaking events occur 
simultaneously. Specifically, one C---O bond of the epoxide breaks at a distance of 
2.10 A, while the C---N and O---S bonds form at a distance of 2.62 A and 1.84 A 
respectively. 
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Figure 81. Five-membered-TS I corresponding to cis-cyclic sulfamidate 460 
formati on. 265 
3.1.3 Preparation of cis and trans p-Amino Alcohols 
The synthetic value of the cis-cyclic sulfamidates is best exemplified in the 
preparation of both cis and trans-j3-amino alcohols (Figure 82). Acidic hydrolysis of 
sulfamidate 460 provides the protected cis-j3-amino alcohol isomer 468. Inversion of 
the oxygen, accomplished through a reaction with ammonium benzoate and 
subsequent acidic hydrolysis, provides the trans-j3-amino alcohol isomer 475. 
0 MeOzC, II~O 
c5?~' (fb NHCOzMe ® e ® 6·"OBZ H30 1. PhCOz NH4 ® 
2. H30 
(+1-)-468 (+1-)-460 (+1-)-475 
Figure 82. Synthesis of protected cis and trans-j3-amino alcohols from cis-cyclic 
sulfamidates. 
Practical application of this methodology is hindered by the poor yields obtained « 
40%) for the synthesis of cis-cyclic sulfamidates from oxiranes using the Burgess 
reagent (8). Inspired by a study on the reactions of indole derivatives with 
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epoxides,268 we explored Si02 and Ah03 catalysis as a means to improve the yield 
(Figure 83). The results of this study (Table 1) revealed no improvements when either 
Si02 or Ah03 were used, in the presence or absence of solvent. In all cases, no 
product could be detected (TLC monitoring) at temperatures below 7{fC. The highest 
yields for either catalyst were obtained when THF was used as the solvent. 
d Table 1 8 
458 (+1-)-460 
Figure 83. Attempts to improve isolated yield of cis-cyclic sulfamidate 460 
Table 1. Attempts to improve isolated yield of cis-cyclic sulfamidate 460 
Entry Catalyst 
1 Si02 
2 Ah03 
3 Si02 
4 Ah03 
5 Si02 
6 Ah03 
7 Si02 
8 Ah03 
[aj small traces detected in lH NMR 
Solvent 
THF 
THF 
DCM 
DCM 
MeOH 
MeOH 
Temp. 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
r.t. to 70°C 
3.1.4 Development of a Chiral Version of the Burgess Reagent 
Isolated Yield 
24% 
21% 
17% 
6% 
trace amounts[a] 
trace amounts[a] 
We became interested in preparing enantiomerically pure p-amino alcohols 
from meso-epoxides through use of the Burgess reagent (8). Our first attempts 
employed Jacobsen's (476)269 and Bolm's (477)270 catalysts; both are known to act as 
chiral Lewis acids in epoxide opening reactions (Figure 84). Neither catalyst, 
regardless of the equivalency (0.1 to 1 eq.), showed any asymmetric induction. Three 
possible explanations were considered. First, the Burgess reagent (8) itself could be 
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acting as a pseudo acid, outcompeting the chiral catalysts. Computational studies 
suggested that the Burgess reagent (8) undergoes rapid decomposition in the presence 
of either chiral catalyst. The resulting excess achiral degradation species would also 
outcompete the chiral catalysts for coordination to the epoxide. Finally, during the 
asynchronous concerted five-membered-TS 1 (Figure 81) the Burgess reagent (8) 
occupies the majority of the space adjacent to the oxirane, making it impossible for a 
Lewis acid to coordinate. 
476 
Sc(OTfb 
477 
Figure 84. Chiral Lewis acids 
Our second strategy was to prepare enantiomerically pure ~-amino alcohols 
using a chiral auxiliary based approach to introduce stereo selectivity. Two cyclic 
Burgess-type reagents, 478 and 479, were prepared from cis-dihydrodiol 302 by Dr. 
Kevin Finn (Figure 85). A third reagent (480) was prepared from camphor. 
Unfortunately, cyclic sulfamidate formation using these three reagents proved to be 
unreliable and they were abandoned in favour of a (-)-menthol-derived Burgess 
reagent (3). 
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302 
478 479 480 
Figure 85. Chiral auxiliary versions of the Burgess reagent. 
The (-)-menthyl Burgess reagent (3) was prepared by adding a benzene/ (-)-
menthol solution to an excess of chlorosulfonyl isocyanate (482) (Scheme 42).264 The 
resulting (-)-menthyl chlorosulfony1carbamate 483 was added to benzene solution 
containing two equivalents of triethylamine. The first equivalent displaces a chloride, 
while the second deprotonates the nitrogen allowing for the formation of the inner 
salt. 
~ 
481 
o 
11 
O=C=N-S-CI 
II 
o 
482 
483 
~)l0 eo..'f,9$ ~O N~ 'NEt3 
~ 
3 
Reagents and conditions: (i) benzene, 20·C, 87%; (ii) NEt3, benzene, 10·C, 85% 
Scheme 42. Preparation of (-)-menthyl Burgess reagent (3) 
Although no chiral induction was seen, reacting the (-)-menthyl Burgess reagent (3) 
with oxiranes did provide a pair of separable diastereomers (Figure 86). The two 
cyclic sulfamidate diastereomers 9a and 9b give access to all four ~-amino alcohol 
stereoisomers. Acidic hydrolysis provides both of the cis-~-amino alcohols 12a and 
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12b, while inversion of the oxygen with ammonium benzoate followed by hydrolysis 
provides the trans-~-amino alcohols 485a and 485b. 
10 
1. 3, THF reflux, 1.5h 
2. separation 
9 H 0-S02 0-S02 OH 
(j."NH2 ~ ~NC02Men ~Nc02Men HCI <:CNH2 ~ dioxane + --dioxane 
12a 9a 9b 12b 
(±) G! NH4 PhC02 ! (±) G NH4 PhC02 
OH OBz OBz 9H 
~."NH2~ ~ "NHC02Men ~NHC02Men~ ~NH2 ~ dioxane ~ ~ dioxane 
485a 484a 484b 485b 
Figure 86. Access to all four ~-amino alcohol stereoisomers from a single meso-
epoxide 
The next step was to determine the absolute stereochemistry of the two 
diastereomeric cyclic cis-sulfamidate products 486a and 486b. This was achieved by 
converting each diastereomer to its corresponding trans-cyclic carbamate, 488a and 
488b, those specific rotations had been previously reported (Scheme 43).270 Using the 
previously described ammonium benzoate sulfamidate inversion procedure, the two 
protected trans- ~-amino alcohols 487a and 487b were prepared. Basic ester 
hydrolysis afforded free hydroxyls which, upon exposure to sodium hydride, 
underwent an intramolecular ring closure displacing (-)-menthol. The physical 
properties of the resulting cyclic carbamates 488a and 488b were in complete 
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agreement with the literature values.27o Conversion to (S)-(+)-Mosher's amide 
derivatives 489a and 489b allowed for determination of the enantiomeric excess of 
the products by 19F NMR (489a = 93% e.e.; 489b = 98% e.e.). 
& 000 0 0'\11 0 
: O)lN~s'NEt3 I'~O 
d 9-
s," OM* 
,/"""-.... 3 O·,Ni 
458 486a 
M* = (-)-menthyl ! 
O-{O OBz H 6 ,NH 6··,NrOM* . ~ 
488a 487a 
93%ee 
Vi! 
o OMe 
o-{ -{1' 'CF3 6·,N 0 Ph 
489a 
+ 
ii-iii 
486b 
1 
o 
9Bz H 9-{ 
: N OM* 0 NH ()r~() 
487b 488b 
98%ee 
489b 
Reagents and conditions: (i) 3 (2 equiv.), THF, reflux, 30%; (ii) PhC02-NH/, DMF, 45°C; (iii) THF, 
H20, cone. H2S04, r.t., 49% over 2 steps; (iv) 1M NaOH in MeOH; (v) NaH, THF, reflux, 70% over 2 
steps; (vi) a) nBuLi, O°C; b) (S)-(+)-Mosher's acid chloride, _78°C to r.t., 83%. 
Scheme 43. Determination of absolute stereochemistry and enantiomeric excess of 
sulfamidates 486a and 486b 
As with the reaction between the Burgess reagent (8) and oxiranes, the yields 
for the same reaction with the (-)-menthyl Burgess reagent (3) were poor (-30%). We 
tried using dimethoxyethane (DME) as the solvent and varied the equivalents of the 
reagent without success (Table 2, Entries 1 and 2). We also used dioxane and 
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dichloromethane (DCM) as solvents, with and without the additives scandium(III) 
triflate and hexamethylphosphoramide (HMP A), both of which have been known to 
promote epoxide openings.271 -2 The only promising results employed 
dichloromethane or dimethoxyethane as the solvent with scandium(lII) 
trifluoromethanesulfonate as the additive (Table 2, Entries 4 and 9). 
Table 2. Attempts to improve yield of sulfamidate 486 production 
Entry Equiv.of3 Solvent Additive Temp. Isolated Yield 
1 2.3 DME r.t. to 70°C 15% 
2 4.6 DME r.t. to 70°C 22% 
3 2.3 DME Sc(OTt)3 r.t. to 70°C 22% 
4 4.6 DME Sc(OTt)3 r.t. to 70°C 26% 
5 2.3 DME HMPA r.t. to 70°C 
6 2.3 dioxane r.t. to 70°C 11% 
7 2.3 dioxane Sc(OTt)3 r.t. to 70°C 13% 
8 2.3 dioxane HMPA r.t. to 70°C 
9 2.3 DCM Sc(OTt)3 r.t. to 70°C 28% 
10 2.3 DCM HMPA r.t. to 70°C 
11 2.3 THF Sc(OTt)3 r.t. to 70°C 
12 2.3 THF HMPA r.t. to 70°C 
We questioned whether the order of addition contributed to the unfavourable yields. 
Previous results demonstrated that the (-)-menthyl Burgess reagent (3) did not react 
with oxirane 458 at room temperature. We speculated that the reagent itself degrades 
at elevated temperatures; subsequent studies273 confirmed this hypothesis. Using an 
automated syringe pump, the order of addition and the solvent were varied (Table 3). 
Unfortunately, we were unable to improve upon the initial conditions reported by 
Hudlicky in 2003 (Table 3, Entry 3).8 Experiments in which the oxirane was added to 
the reagent (Table 3, Entries 2 and 5) suffered from the lowest yields; likely resulting 
from the degradation of the (-)-menthyl Burgess reagent (3). 
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Table 3. Attempts to improve yield via automated syringe pump 
Entry Equiv. of3 Solvent Mode of Syringe Pump Temp. Yield 
Addition Time (hrs) 
1 2.3 THF 3 to 458 0.5 reflux 24% 
2 2.3 THF 458 to 3 0.5 reflux 17% 
3 2.3 THF at once reflux 30% 
4 2.3 DCM 3 to 458 0.5 reflux 14% 
5 2.3 DCM 458 to 3 0.5 reflux 11% 
6 2.3 DCM at once reflux 26% 
We sought to expand the (-)-menthyl Burgess reagent (3) methodology to 
include other epoxides (Table 4).264 Pentene and heptene oxide, 490 and 493 
respectively, were both respectable substrates with modest yields for cyclic 
sulfamidate formation. As expected, the aliphatic I-hexene oxide 496 and the 
unsaturated 1,3-cyclohexadiene oxide (4) substrates each produced a single 
regioisomer. All cyclic sulfamidates produced were converted to their corresponding 
benzoates and then separated via flash column chromatography, the lone exception 
being the aliphatic substrate. 
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Table 4. Oxiranes reacted with the (-)-menthyl Burgess reagent (3) 
Oxirane 
d 
458 
490 
d 
493 
496 
d 
4 
Su[famidates (%)[a] 
486a 
491a 
494a 
497a 
5a 
30% 486b 
37% 491b 
o 
M'O CN-'S"'-O O,'b 
35% 494b 
22% 497b 
36% 5b 
Benzoates (%) ee(%)[b] or de(%)[c] 
I::!HC02M' 
cj0BZ 
98 and 93[b] 
487a 49% 487b 
98 and 93[c] 
492a 52% 492b 
93 and 92[c] 
495a 75% 495b 
NHC02M' 
~OBZ 
C4Hg 
498a[d] 36% 498b[d] 
94 and 84[e] 
499a 51% 499b 
[a] yields are isolated; [b] enantiomeric excess determined by Mosher's amide 
formation of cyclic carbamates, derived from the corresponding benzoates by 
hydrolysis and cyclization; [c] diastereomeric excess determined by GC/MS analysis 
of benzoates after separation by flash column chromatography; [d] not separable by 
flash column chromatography; [e] diastereomeric excess determined by GC/MS of 
separated benzoates after hydrogenation. 
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3.1.5 Reaction between N-tosyl aziridine and the Burgess Reagent 
A natural progression from reacting oxiranes would be to use aziridines as 
substrates for this methodology. Cyclohexene (502) was converted into its N-tosyl 
aziridine derivative 502 using chloramine-T (501) (Scheme 44). Unfortunately, its 
reaction with the Burgess reagent (8) failed to produce either the cis- or trans cyclic 
products. 
500 502 (+1-)-503 (+1-)-504 
Reagents and conditions: (i) 12, MeCN, r.t., 82%; (ii) 8 (2 equiv.), THF, reflux 
Scheme 44. Reaction between the Burgess reagent (8) and N-tosyl aziridine 502 
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3.2 Enantiodivergent Synthesis of Balanol 
In order to illustrate the synthetic value of (-)-menthyl Burgess reagent 
methodology, we sought to find a natural product accessible from one of the cyc1ic-
sulfamidates. Obviously, the added alkene functionality in the unsaturated products 
Sa and 5b offered the greatest opportunity for success. Eventually it was concluded 
that both the natural (-)-isomer and the unnatural (+)-isomer ofbalanol (1) could be 
obtained from the two sulfamidate diastereomers Sa and 5b. Balanol (1) is a potent 
and selective inhibitor of protein kinase C, a protein implicated in a number of disease 
states. J J Inversion of the oxygen functionality in Sa and 5b would install the correct 
relative stereochemistry seen in (-)- and (+)-balanol (1) respectively (Figure 87). We 
anticipated that an oxidative cleavage/ reductive amination reaction sequence could 
be used to prepare the azepane ring. 
HO 
HO 
HO 
HO dO H OH . "N, F\-OH 
I/\J N 0 H 
(-)-balanol (1) 
HO 
P HO ,- H 
OH UNrO-0H 
~ 0 
(+)-balanol (1) 
OR 
d"'~g-oM* ====> 
N 0 R 
505a 
PR 
(j-~g-OM' 
~ 0 
505b 5b 
Figure 87. Retrosynthetic analysis ofbalanol (1) from 1,3-cyclohexadiene oxide (4) 
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3.2.1 Cyclization Model Study 
Our initial approach was to oxidatively cleave olefin 5 via an ozonolysisl 
reduction protocol and to cyclize the resulting diol 506 to the a2epane ring (Figure 
88). Inversion of the sulfamidate oxygen would give an advanced intermediate 505 
which could be converted into one of the formal intermediates of balanol (see 
Sections 2.2.5 and 2.2.6). 
5 
oxidative 
cleavage 
o 
11/0 
9-s," OM* 
~. ,Ni cyclization 
'i 'OH 
OH 
506 
o 
11/0 
9-S," OM* 00 .,N-i oxygen o inversion 
N 
R 
507 
Figure 88. First strategy to synthesis balanol (1) 
OR H 6,'NtMO 
N 
R 
505 
The first step was to evaluate the feasibility of generating an azepane 
heterocycle from an aliphatic diol. To this end, 1,6-hexanediol (508) was selected as a 
model compound. It was established that exposure of its O-tosyl derivative 509 to 
benzyl amine in refluxing ethanol provided N-benzyl azepane (510). Alternatively, 
diol 508 could be directly converted into azepane 510 using an iridium catalyst, 
[Cp*IrChb developed by Fujita.274 
HO~OH 
508 
o 
\) 
510 
TSO~OTS 
509 
~ 
Reagents and conditions: (i) pTsOH, pyr., DMAP, DCM, O°C, 87%; (ii) [Cp*IrChh, NaHCOJ, 
toluene, reflux, 20%; (iii) Bn-NH2, EtOH, reflux, 67% 
Scheme 45. Cyclization model study 
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Both cyc1ization routes reqUIre a nucleophilic nitrogen, such as benzyl amme. A 
review of the literature identified balanol formal intermediate 231 from the Lampe 
and Hughes synthesis 1 11-2 as a suitable target (Figure 89). 
5a 
-
5b 
OH d'''~rO--0B" Rof 111 
~n 0 
231a 
pH 
o-~rO--oBn Bn 0 
231b 
Ref 111 
Figure 89. Balanol formal intermediates 
3.2.2 Ozonolysis Strategies 
(-)-balanol (1) 
(+)-balanol (1) 
The most concise approach to aliphatic diol 506 is through an ozonolysis 
procedure (Figure 90). Our first strategy followed standard conditions in which the 
ozonide species is formed by exposing olefin 5 to ozone in DCM at low temperature; 
followed by reductive work-up with dimethyl sulfide and hydride reduction of the 
intermediate dialdehyde. We attempted several procedures, which varied the 
temperature of each stage of the reaction sequence (Table 5). Frequent monitoring of 
the reaction by TLCI 2,4-dinitrophenylhydrazine staining identified multiple (20+) 
aldehyde species formed. Regardless of the procedure employed, no identifiable 
aldehyde or hydroxyl-containing compounds could be identified. 
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1. 0 3• oeM 0-( 11 ... 0 , 
2. Me2S 
3. NaBH4• EtOH ~~~i°-q )( 
Table 5 
(+1-)-5 
'i "OH 
OH 
(+1-)-506 
Figure 90. First ozonolysis strategy 
Table 5. First ozonolysis strategy 
Entry Temp. of 0 3 Temp. ofMe2S 
1 -78°C -78°C to O°C 
2 -78°C -78°C to O°C 
3 -78°C -40°C 
4 -78°C -40°C 
5 -40°C -40°C 
6 -78°C -78°C to O°C 
7 -78°C -40°C 
La] TLC evidence of multiple aldehydes 
Temp. of NaBH4 
-78°C to r.t. 
-40°C to r.t. 
-78°C to r.t 
-40°C to r.t 
-40°C to r.t 
O°C to r.t. 
O°C to r.t 
Result 
decOInpositionLa] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
We tested whether or not the addition of a protic solvent would affect the outcome of 
the reaction (Figure 91). We varied the ratio of methanol and DCM but did not 
observe an improvement (Table 6). 
(+1-)-5 (+1-)-506 
Figure 91. Second ozonolysis strategy 
Table 6. Second ozonolysis strategy 
Entry Temp. of 0 3 DCM:MeOH Temp. of Temp. of Result 
Ratio Me2S NaBH4 
1 -78T 8:2 -78°C to O°C -78°C to r.t. decomposition1a] 
2 -78°C 2:8 -78°C to O°C -78°C to r.t. decompositionLa] 
3 -78°C 8:2 -40°C -40°C to r.t decomposition{a] 
4 -78°C 2:8 
La] TLC evidence of multiple aldehydes 
-40°C -40°C to r.t decomposition.[a] 
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We questioned whether a different hydride reducing agent would produce a different 
result (Figure 92). Three hydride sources were tested; 1. sodium cyanoborohydride, 2. 
lithium aluminum hydride and 3. diisobutylaluminum hydride (Table 7). 
Unfortunately, this strategy had no effect on the results. 
-./ 
1. 03, DCM:MeOH ~/O ~ 2. Me28 9-8,/ 0-q 
3. Reduction 0~' ,N~ )( ° 
Table 7 OH 
OH 
(+1-)-5 (+1-)-506 
Figure 92. Third ozonolysis strategy 
Table 7. Third ozonolysis strategy 
Entry Temp. of 0 3 Temp. of Reducing Temp. of Result 
Me2S Agent Reduction 
1 -78°C -78 to O°C NaBH3CN -78°C to r.t. decompositionLa) 
2 -78°C -78 to O°C LAH -78°C to r.t. decomposition[a) 
3 -78°C -78 to O°C DIBAL -78°C to r.t. decomposition[a) 
4 -78°C -78 to OT NaBH3CN -20°C to r.t decomposition[a) 
5 -78°C -78 to O°C LAH -20°C to r.t decomposition[a) 
6 -78°C -78 to O°C 
La) TLC evidence of multiple aldehydes. 
DIBAL -20°C to r.t decomposition[a) 
We speculated that the cyclic sulfamidate functionality of 5 was reacting with one of 
the intermediate species formed during the ozonolysis procedure. For this reason, we 
chose to employ the O-benzyl derivative 499 in the next series of experiments (Figure 
93). Once again the results were discouraging as we observed multiple aldehyde 
species via TLC/ 2,4-dinitrophenylhydrazine staining (Table 8). 
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1. 0 3, DCM:MeOH '-..../ 
2. Me2S OBz H :-
)(. II 3. NaBH3CN,EtOH ¢C.'\NVOy. 
(+/-)-499 (+/-)-511 
Figure 93. Fourth ozonolysis strategy 
Table 8. Fourth ozonolysis strategy 
Entry Temp. of 0 3 Temp. of Me2S Temp. of 
NaBH3CN 
I -78°C -78°C to O°C -78°C to r.t. 
2 -78°C -78°C to O°C -40°C to r.t. 
3 -78°C -40°C -40°C to r.t 
4 -78°C -40°C O°C to r.t 
5 -40°C -40°C O°C to r.t 
6 -78°C -78°C to -20°C -20°C to r.t. 
[a] TLC evidence of multiple aldehydes, 20+ compounds 
Result 
decomposition{a] 
decompositionla] 
decompositionla] 
decompositionla] 
decomposition[a] 
decompositionla] 
As with the first substrate, we tried our ozonolysis procedure with methanol as a 
cosolvent and employed different reducing agents (Figure 94). Not surprisinly, we 
were unable to identify any compounds from these reactions (Table 9). 
1. 0 3, DCM:MeOH '-..../ 
2. Me2S OBz H :-
3. Reduction c0'\NV Oy. )(. II 
(+/-)-499 
Figure 94. Fifth ozonolysis strategy 
Table 9. Fifth ozonolysis strategy 
Entry Temp. of 0 3 Temp. of Reducing Temp. of Result 
Me2S Agent Reduction 
I -78°C -78 to O°C NaBH3CN -78°C to r.t. decomposition[a] 
2 -78°C -78 to O°C LAH -78°C to r.t. decompositionl a] 
3 -78°C -78 to DOC NaBH4 -78°C to r.t. decompositionla] 
4 -78°C -78 to O°C NaBH3CN -20°C to r.t decomposition[a] 
5 -78°C -78 to OT LAH -20°C to r.t decomposition1a] 
6 -78°C -78 to OT NaBH4 -20°C to r.t decomposition[a] 
[a] evidence of multiple aldehydes 
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3.2.3 Model Study 
As described earlier, synthesis of carbamates Sand benzoate 499 is hindered 
by the low yields of the (-)-menthyl Burgess reaction with oxirane 4. From a 
logistical standpoint, it made sense to use a model compound which is easier to 
prepare in large quantities. We concluded that the simplest compound to use in place 
of the (-)-menthyl carbamate 499 is the methyl carbamate 512 (Figure 95). 
(+/-)-499 (+/-)-512 
Figure 95. (-)-Menthyl carbamate and methyl carbamates 499 and 512 
The synthesis of methyl carbamate 512 began with the epoxidation of cyclohexa-l ,3-
diene (513) with peracetic acid. Opening of the vinyl oxirane 4 with benzylamine 
provided amine 514, which was then reacted with methyl chloroformate. A dissolving 
metal reduction removed the benzyl group and subsequent benzoyl protection 
completed the synthesis of carbamate 512. 
o 
513 (+/-)-4 
OH .~ 6·'\~JV ... --'lL-
.0 
(+/-)-514 
OBz H 6·,\Ny O ........ iv-v 
-- .0 0 
(+/-)-515 (+/-)-512 
Reagents and Conditions: (i) AcOOH, Na2C03, DCM, O'C, 71 %; (ii) BnNH2, iso-propanol, 80'C, 
88%; (iii) methyl chloroformate, THF, pyr., r.t., 86%; (iv) Na, NH3, -40'C; (v) BzCI, NEt3 DMAP, 
DCM, O'C, 92% over 2 steps 
Scheme 46. Synthesis of methyl carbamate 512 
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We wondered if any products could be identified from ozonolysis of the model 
compound (Figure 96). As before, the procedures used only provided complex 
mixtures and no identifiable compounds (Table 10). 
(+/-)-512 
1. °3, DCM:MeOH 
2. Me2S 
3. Reduction 
)( 
Table 10 
OBz H A ·"NrO, 
~ \H 
OH 
(+/-)-516 
Figure 96. Ozonolysis of methyl carbamate 512 
Table 10. Ozonolysis of methyl carbamate 512 
Entry Temp. of 0 3 Temp. of Reducing Temp. of 
Me2S Agent Reduction 
1 -78°C -78 to O°C NaBH3CN -78°C to r.t. 
2 -78°C -78 to O°C LAH -78°C to r.t. 
3 -78°C -78 to O°C NaBH4 -78°C to r.t. 
4 -78°C -78 to O°C NaBH3CN -20°C to r.t 
5 -78°C -78 to O°C LAH -20°C to r.t 
6 -78°C -78 to O°C NaBH4 -20°C to r.t 
[aJ TLC evidence of multiple aldehydes, 20+ compounds 
Result 
decomposi ti ont a J 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decompositionla] 
decomposition[a] 
We speculated that the carbamate nitrogen could be reacting with one of the 
intermediate ozonide speCIes. Therefore, we prepared N-Boc 517 and N-Bz 
derivatives 518 (Scheme 47). 
(+/-)-517 (+/-)-512 (+/-)-518 
Reagents and conditions: (i) (BOC)2' THF, NaH, reflux, 77%; (ii) BzCI, DCM, DMAP, pyridine, reflux, 
82% 
Scheme 47. N-Bz and N-Boc protection of methyl carbamate 512 
The N-Boc derivative 517 was treated with the same ozonolysis conditions employed 
previously (Figure 97). Hydride reductions perfOlmed at temperatures below O°C 
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gave similar results as before. However, when the reduction was carried out at O°C 
(Table 11, Entries 3 and 4) we were able to isolate a compound tentatively identified 
as dio1519. 
Table 11 
~osz Soc ."NrO ...... 
OH 
1. 03. DCM:MeOH 
2. Me2S 
3. Reduction 
OH 
(+/-)-517 (+/-)-519 
Figure 97. Ozonolysis of N-Boc protected carbamate 517 
Table 11. Ozonolysis of N-Boc protected carbamate 517 
Entry Temp. of 0 3 Temp. of Reducing Temp. of 
Me2S Agent Reduction 
1 -78°C -78 to O°C NaBH3CN -40°C to r.t. 
2 -78°C -78 to O°C NaBH4 -40°C to r.t. 
3 -78°C -78 to O°C NaBH3CN O°C to r.t. 
4 -78°C -78 to O°C NaBH4 O°C to r.t 
5 -78°C -78 to O°C NaBH4 -78°C to r.t 
YielJa] 
~5%[bl 
~5%[bl 
[a] yield estimated, product not pure by IH NMR, [b] tentative identification CH and 
13CNMR, MS) 
We subjected the N-Bz derivative 518 to the successful ozonolysis procedures used 
for the N-Boc derivative 517 (Table 12). Once again we were able to isolate a 
compound tentatively assigned as diol 520. 
1. 03. DCM:MeOH 
2. Me2S 
3. Reduction 
Table 12 
(+/-)-518 
OBz S A·"NrO ...... 
~ \H 
OH 
(+/-)-520 
Figure 98. Ozonolysis of of N-Bz protected carbamate 518 
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Table 12. Ozonolysis of of N-Bz protected carbamate 518 
Entry Temp. of 0 3 Temp. of Reducing Temp. of Yield-a] 
Me2S Agent Reduction 
1 -78°C -78 to O°C NaBH3CN O°C to r.t. 10%[6] 
2 -78°C -78 to O°C NaBH4 O°C to r.t. 10%[b] 
[a] yield estimated, product not pure by IH NMR, [b] tentative identification CH and 
l3C NMR, MS) 
3.2.4 Step-wise Oxidative Cleavage 
As this stage of the project we decided to abandon all ozonolysis chemistry in 
favour of a step-wise dihydroxylation and then oxidative cleavage approach. 
Dihydroxylation of olefins 517 and 518 with osmium(VIII) oxide provided diols 521 
and 522 respectively (Scheme 48). 
(+/-)-517 R = Boc 
(+/-)-518 R = Bz 
OBz R 
-L A·,N1o,-
~OH 
OH 
(+/-)-521 R = Boc 
(+/-)-522 R = Bz 
Reagents and conditions: (i) OS04, NMO, DeM/H20, 87% 
Scheme 48. Dihydroxylation of olefins 517 and 518 
Oxidative cleavage of 1,2-diols 521 and 522 with sodium periodate provided 
dialdehyde intermediates which were subjected to a series of reduction procedures 
(Figure 99). This method provided aliphatic diols 519 and 520 in modest yields 
(Table 13). Regardless, these experiments demonstrated the validity of the step-wise 
approach. The best results (Table 13, Entries 1 and 2) were obtained when sodium 
borohydride was added to the reaction mixture at -40°C. Starting at cooler 
temperatures (Table 13, Entries 5 and 6) generated more side products (crude IH 
NMR identification) and lowered the isolated yields. 
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OBz R 
[ ~:1('l OBz R ~N1(' NalO4 reduction (\N1(, acetonel H2O Table 13 OH OH 
OH OH 
(+/-)-521 R = Boc (+1-)-523 R = Boc (+/-)-519 R = Boc 
(+1-)-522 R = Bz (+1-)-524 R = Bz (+/-)-520 R = Bz 
Figure 99. Oxidative cleavage of carbamates 521 and 522 
Table 13. Oxidative cleavage of carbamates 521 and 522 
Entry R= Reducing Agent Solvent Temp. Yield (% over 2 steps) 
1 Boc NaBH4 EtOH -40°C to r.t. 51 
2 Bz NaBH4 EtOH -40°C to r.t. 55 
3 Boc NaBH3CN EtOH -40°C to r.t. 25 
4 Bz NaBH3CN EtOH -40°C to r.t. 26 
5 Boc NaBH4 EtOH -78°C to r.t. 44 
6 Bz NaBH4 EtOH -78°C to r.t. 49 
7 Boc NaBH3CN EtOH -78°C to r.t. 33 
8 Bz NaBH3CN EtOH -78°C to r.t. 39 
We subjected aliphatic diols 519 and 520 to the cyclization protocols developed at the 
onset of the project (Figure 100). We first attempted direct cyclization of the diols 
using the iridium catalyst ([Cp*IrCbh) but isolated only starting material (Table 14). 
We encountered problems generating the di-tosyl derivatives of 519 and 520 and 
could only isolate a mixture of mono and di-tosylated compounds. Nevertheless, the 
mixture was submitted to the cyclization protocols with DCM and DME as the 
solvent. In no instance were we able to find evidence for the formation of the azepane 
derivatives 525 and 526. 
(+/-)-519 R = Boc 
(+1-)-520 R = Bz 
cyclization 
with Bn-NH2 
)( 
Table 14 
(+1-)-525 R = Boc 
(+1-)-526 R = Bz 
Figure 100. Attempted azepane cyclization 
15{) 
Table 14. Attempted azepane cyclization 
Entry R= Reagents Solvent Temp: Result 
1 Boc [Cp*IrClzb NaHC03 toluene reflux SM 
2 Bz [Cp*IrClzb NaHC03 toluene reflux SM 
3 Boc p-TsCI, pyridine, DMAP[a] DCM reflux SMlb] 
4 Bz p-TsCI, pyridine, DMAP[a] DCM reflux SM[b] 
5 Boc p-TsCI, pyridine, DMAP[a] DME reflux SM[b] 
6 Bz p-TsCI, pyridine, DMAP[a] DME reflux SM[b] 
7 Boc p-TsCI, pyridine, DMAP[a] MeCN reflux SM[b] 
8 Bz p-TsCI, pyridine, DMAP[a] MeCN reflux SM[b] 
La] benzyl amine was added to the reaction after the complete consumption of diol; 
[b] referrers to the isolation of a mixture of mono and di-tosylated derivatives 
3.2.5 Reductive Amination 
We considered the next logical approach to be a direct reductive amination 
procedure of the intermediate dialdehyde species. Painter had constructed similar 
azepane rings using an oxidative cleavage/ reductive amination sequence.275 We 
employed his procedure on the N-Boc carbamate 521 and were able to isolate the 
azepane derivative 525, albeit in a modest yield of 16% (Scheme 49). 
~B" [OBZB ] 6&' .. ,NrO ....... i ~:ro, ii N .. ,NrO, - -
OH 
OH Bn 
(+1-)-521 (+1-)-523 (+1-)-525 
Reagents and conditions: (i) NaI04, acetone/H20 (8:2); (ii) Bn-NH2, AcOH, NaBH3CN, 3A mol. 
Sieves, MeOH, _78°C to r.t., 15% 
Scheme 49. Reductive amination of N-Boc protected carbamate 521 
The N-Bz derivative proved to be a slightly more successful substrate with an isolated 
yield of 23%. 
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OBz B 
[ 0& B ] 
OBz B <x-ro, ---.l.- c0:ro, --'i- 6"NyO, 
. 0 
OH N 
OH Bn 
(+/-)-522 (+/-)-524 (+/-)-526 
Reagents and conditions: (i) NaI04, acetone/H20 (8:2); (ii) Bn-NH2, AcOH, NaBH3CN, 3A mol. 
Sieves, MeOH, -78°C to r.t., 23% 
Scheme 50. Reductive amination of N-Bz protected carbamate 522 
We were able to synthesize the balanol formal intermediate 231 in racemic form 
through strong basic hydrolysis of azepane526 followed by reacting the crude 
mixture with 4-(benzyloxy)benzoyl chloride. Subsequent chromatography identified a 
small amount «5%) of the formal intermediate 231. 
i 
-
[ ~"NH' 1 ii 
-
OH 
d"~rO-°B" 
~n 0 
(+/-)-526 (+/-)-527 (+/-)-231 
Reagents and conditions: (i) 50% KOH in glycerol, 120T; (ii) p-BnOC6H4COCI, IN NaOH, Na2C03, 
DCM, r.t., ~5% over 2 steps 
Scheme 51. Racemic formal synthesis ofbalanol (1) 
3.2.6 Cyclic Carbamate 
The strong conditions required to hydrolyze the protecting groups of azepane 
526 necessitated a different strategy. We sought to find a compound that could be 
accessed from either the methyl carbamate 530 model route or the (-)-menthyl 
carbamate 499 route. The simplest solution was to convert both into cyclic carbamate 
derivative 529. Screening of various O-benzoyl hydrolysis procedures identified 
methanolic sodium hydroxide at ambient temperature as the most effective (Table 15, 
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Entries 4). In each instance, exposure of carbamates 528 and 530 to sodium hydride 
led to the formation of cyclic carbamate 529 resulting from the expulsion of (-)-
menthol and methanol respectively (Scheme 52). 
° OBz H 
ester OH H o-f OH H 
6·"Ny OM* hydrolysis 6·"Ny OM* i 6·\NH 
--L 6 ·"Ny 0"-
--~ ° Table 15 ~ ° ~ ° 
(+/-)-499 (+/-)-528 (+/-)-529 (+/-)-530 
Reagents and conditions: (i) NaH, THF, reflux 
Scheme 52. Synthesis of cyclic carbamate 529 
Table 15. O-benzoyl hydrolysis of 499 
Entry Reagent Solvent Temp. Yield 
1 trifluoroacetic acid r.t 14% 
2 INKOH MeOH r.t. 76% 
3 INKOH MeOH 40°C 71% 
4 IN NaOH MeOH r.t. 94% 
5 IN NaOH MeOH 40°C. 88% 
Our prevIOus studies had identified that; 1. the carbamate nitrogen should be 
derivatized, and 2. N-benzoyl protection is preferred to N-Boc protection. Hence, 
cyclic carbamate 529 was first converted into N-Bz carbamate 531 prior to 
dihydroxylation with osmium(VIII) oxide (Scheme 53). The resulting 1,2-diol 532 
was then subjected to the oxidative cleavage/ reductive amination protocol to afford 
azepane 534. 
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° ° ° oJ(° OJ( OJ( OJ( 0-(0 
6·,NH i 6·,NBZ ii <XN~ iii 0N~ ~d·"NBZ 
- - -
OH "'0 N I Bn OH 
° (+/-)-529 (+/- )-531 (+/-)-532 (+/-)-533 (+/-)-534 
Reagents and conditions: (i) BzCI, NEt3, DMAP, DCM, r.t., 77%; (ii) OS04, NMO, DCM/H20, 89%; 
(iii) NaI04, acetone/H20 (8:2); (iv) Bn-NH2, AcOH, NaBH3CN, 3A mol. sieves, MeOH, -78'C to r.t., 
62% over 2 steps 
Scheme 53. Synthesis of cyclic carbamate azepane 534 
The next step was to develop a high yielding method to hydrolyze cyclic carbamate 
534 to p-amino alcohol 535 (Figure 101). Our first attempt employed potassium 
hydroxide in ethylene glycol (Table 16, Entry 1) and surprisingly provided a mixture 
of fully and partially hydrolyzed products, namely 535 and 527. Further experiments 
identified a mild method (Table 16, Entry 5) to hydrolyze only the cyclic carbamate 
functionality. We speculated that if cyclic carbamate 534 was alternatively protected 
with the 4-(benzyloxy)benzoyl moiety, partial hydrolysis could give direct access to 
formal intermediate 231. 
0-(0 OH OH 
d·"NBZ 
carbamate 
d·"NHBZ d'''NH2 
hydrolysis 
+ • 
N Table 16 N N Bn Bn Bn 
(+/-)-534 (+/-)-535 (+/-)-527 
Figure 101. Hydrolysis of cyclic carbamate 534 
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Table 16. Hydrolysis of cyclic carbamate 534 
Entry Reagent Solvent 
I IN KOH ethylene glycol 
2 IN NaOH ethylene glycol 
3 IN NaOH MeOH 
4 IN NaOH THF 
5 1NNaOH THF 
La) ratio estimated from crude IH NMR 
Temp. 
40°C 
r.t. 
r.t 
r.t 
-2WC 
Approx. Ratio 535:527 
I5:85La) 
15 :85[a) 
30:70[a) 
30:70[a) 
>99:1 raj 
Derivatization of cyclic carbamate 529 with 4-(benzyloxy)benzoyl chloride afforded 
amide 536 (Scheme 54). Following the identical reaction sequence used to prepare 
azepane 534 (Scheme 53), we synthesized azepane 539. As anticipated, our mild 
basic hydrolysis procedure did provide us with balanol intermediate 231 in the 
racemic form. 
(+/-)-529 (+/-)-536 
-f.0 (i0Bn 
cl° .,N-r """ ° ~ 
OH 
OH 
(+/-)-537 
v 
(+/-)-231 
P OBn IP ~ ~ ¢l0~ ° =--
""0 I 
° (+/-)-538 
! iv 
0°'1'° "rrrOBn ".,\NyV 
N ° Bn 
(+/-)-539 
Reagents and conditions: (i) p-BnOC6H4COCI, DCM, DMAP, NEt3, O'C, 72%; (ii) OS04, NMO, 
OCM, Lt., 83%; (iii) NaJ04, acetone/H20 (8:2), r.t.; (iv) Bn-NH2, AcOH, NaBH3CN, 3A mol. sieves, 
MeOH, -78'C to r.t. , 68% over 2 steps; (v) IN NaOH, THF, -20'C, 81% 
Scheme 54. Synthesis ofbalanol intermediate 231 
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3.2.7 Completion of an Enantiodivergent Formal Synthesis of Balanol 
With an established route to balanol intermediate 231, we sought to complete 
the formal syntheses of (-)- and (+)-balanol from cyclic sulfamidates 5a and 5b 
respectively. The exhausting process of separating diastereomers 499a and 499b, in 
large enough quantities, was undertaken by Jacqueline Gilmet.276 Before proceeding, 
we wanted to determine the optical purity of the two diastereomers. The 
corresponding cyclic carbamates 529a and 529b were converted into their (S)-(+)-
Mosher amide derivatives 540a and 540b (Scheme 55). 
0 
0-1
0 o OMe II~O 9-s,.... OM* 6--f -(,'<OF, O·,Ni ~ 6·,NH v .,N Ph 
- 0 
.0 
d 5a 529a 540a 0 0 o OMe 11 .... 0 
9-1 9-1 -(,' ~F3 4 6~-t· ii-iv c)NH v ON Ph 
- - 0 
.0 
540b 
5b 529b 
Reagents and conditions: (i) 3 (2.3 equiv.), THF, reflux; (ii) PhCOz-NH/, DMF, 45T; (iii) THF, H20, 
conc. H2S04, r.t. ; (iv) 1M NaOH in MeOH; (v) NaH, THF, reflux; (vi) (S)-(+)-Mosher's acid chloride, 
NEt3, DMAP, DCM, QOC to r.t. 
Scheme 55. Synthesis of (S)-(+)-Mosher derivatives 540a and 540b 
For the (-)-balanol (1) synthesis, gas chromatography/ mass spectroscopy analysis 
indicated a 96:4 ratio of diastereomers 540a to 540b (Figure l02). We suspect that 
incomplete separation of the 499a and 499b diastereomers by column 
chromatography accounts for this ratio, which results from enantiomeric impurities 
carried throughout the synthesis following removal of the (-)-menthyl group 
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100 
100 
35.16;1)13234 
I 
o OMe 9-f )"CF3 ON1 'Ph 
540b 
( +)-balanol 
stereochemistry 
~.81 
I (- )-balanol stereochemistry 
Figure 102. GC/MS analysis of (S)-(+)-Mosher derivatives 540a and 540b 
41.Q6 
Carbamates 529a and 529b were each converted into their corresponding formal 
intermediates via the aforementioned cyclic carbamate route (Scheme 56).277-8 This 
completed an enantiodivergent synthesis of (+)- and (-)-balanol from 1,3-
cyclohexadiene oxide (4) in 8 steps. 
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0 
O-{ dTpOBO OH 6·,NH i-iii .. ,N " ~I iv d"~rO-°BO - - . ~ Ii N 0 ~n 0 Bn 
529a 539a 231a 
Q-{O c5-1POBO pH c)NH i-iii iv o-~rO-0Bn 
- -N 0 Bn 0 Bn 
529b 539b 231b 
Reagents and conditions: (i) p-BnOC6H4COCl, DCM, DMAP, NEt3, O°C; (ii) OS04, NMO, DCM, r.t.; 
(iii) a) NaI04, acetoneIH20 (8:2), r.t.; b) Bn-NH2, AcOH, NaBH3CN, 3A mol. sieves, MeOH, _78°C to 
r.t.; (iv) IN NaOH, THF, -20°C 
Scheme 56. Formal enantiodivergent synthesis of (+)- and (-)-balanol. 277-8 
The optical purity of each formal intermediate was confirmed through conversion to 
their (S)-(+)-Mosher esters 541a and 541b (Scheme 57). In each case, 19F NMR 
analysis established ratios greater than 95%. 
OH 
d"~rO-OBO 
~n 0 
231a 
pH 
o-~rO-oBn Bn 0 
231b 
F3C 0 
Meol·H 
Ph 0 ~ d"~rO-°BO 
~n 0 
541a 
19F NMR>95% 
F3C 0 
Meol·H 
Ph .P 
~ o-~rO-0BO Bn 0 
541b 
19F NMR >95% 
Reagents and conditions: (i) (S)-(+)-Mosher's acid chloride, NEt3, DMAP, DCM, 40°C. 
Scheme 57. Synthesis of (S)-(+)-Mosher ester derivatives 541a and 541b 
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3.2.8 Azepane Epoxide Route 
We questioned whether our (-)-menthyl Burgess reagent methodology could 
be extended to include azepane epoxide 542 as a substrate. This route would 
circumvent the oxidative cleavage/ reductive amination procedure (Figure 103). 
OH P-S~O 
(-)-balanol (1) ==> d"~rO-°B" ==> O,,'NyOM" 
==n ~oc 0 N 0 Boc 
543a 544a 0 0 N 
Boc 
0 542 
pH C/~O ~ o-~rO-oBn NOM" (+)-balanol (1) ==> ==> Y 
N 0 Boc 0 Boc 
543b 544b 
Figure 103. Azepane epoxide approach balanol (1) 
The preparation of oxirane 542 began with the displacement of alkyl bromide 546 
with the tert-butyl carbamate derivative of allyl amine 545 (Scheme 58). The 
resulting diene 547 was then subjected to a series of ring closing metathesis 
procedures (Table 17). We obtained higher yields when Grubbs' 15t generation 
catalyst was used compared to the 2nd generation catalyst. Epoxidation of olefin 548 
with mCPBA completed the synthesis of oxirane 542. 
i ReM ii BocHN~ +Br~ 
- If 0 -N Table 17 N 
545 546 Boc Boc 
547 548 
Reagents and conditions: (i) NaH, DMF, O·C, 77%; (ii) mCPBA, DCM, O·C, 86% 
Scheme 58. Synthesis of azepane epoxide 542 
0 0 N 
Boc 
542 
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Table 17. Ring closing metathesis of diene 547 
Entry Catalyst Solvent Temp. Yield 
1 Grubbs' 1 st gen. benzene . reflux 80% 
2 Grubbs' 1st gen. DCM reflux 86% 
3 Grubbs' 2nd gen. benzene reflux 64% 
4 Grubbs' 2nd gen. DCM reflux 71% 
Unfortunately, the reaction between oxirane 542 and the (-)-menthyl Burgess reagent 
afforded a mixture (~1: 1) of the regioisomers 544 and 549. We were unable to 
separate the two isomers and did not pursue this approach further. 
i 
-
542 (+1-)-544 (+1-)-549 
Reagents and conditions: 3 (2.3 equiv.), THF, reflux 
Scheme 59. Reaction between azepane 542 epoxide and the (-)-menthyl Burgess 
reagent (3) 
3.3 Chemoenzymatic Synthesis of Balanol 
We completed our first generation formal syntheses of (+)- and (-)"-balanol by 
preparing azepanes 231a and 231b,277-8 intermediates in the Lampe and Hughes 
synthesis. III -2 The physical and spectral properties of our samples were in complete 
agreement with those previously reported. However, we were unable to locate optical 
rotations for either compound in the literature. This was puzzling considering several 
asymmetric syntheses of these intermediates have been reported. I 11-2, 115, 130 Our own 
samples suffered from contamination of the opposite isomer, a consequence of the 
less than perfect separation of diastereomers 499a and 499b. Analysis of our 231a 
1-6D 
and 231b samples, VIa Ge/ MS and 19F NMR techniques, indicated >95% 
enantiomeric excess. 
For our second generation synthesis we sought to employ a starting material 
which would guarantee accurate optical data for formal intermediates 231a and 231b. 
To this end, we selected cis-dihydrodiol 6, which is available in large quantities279 
from the whole-cell oxidation of bromobenzene with a recombinant E. coli strain 
overexpressing the toluene dioxygenase enzyme.13 The optical purity of this material 
has been well established through its use in the synthesis of several natural products. 14 
3.3.1 Vinyl Aziridine Approach to Balanol 
Our enantiodivergent approach relied on the preparation of diastereomeric 
vinyl aziridines 550 and 551 from cis-dihydrodiol 6 (Figure 104). Opening of each 
with an appropriate oxygen nucleophile and reduction of the vinyl halide 
functionalities would provide 1,2-diols 552 and 553. These would serve as substrates 
for the oxidative cleavage/ reductive amination procedure developed in our first 
generation syntheses. 
OH OR d"~rQ-°B" = .,\~R (-)-balanol (1) ===> 6:'\NHR ===> Br~"'OR , ~n 0 : "OH 
OH OR 
231a 552 550 J) 
Br : "'OH 
OH 
pH QR 6 
. H NR ~ VNrQ-osn ===> . NHR B,f)"OR (+)-balanol (1) ===> Y'OH ===> Bn 0 
OH OR 
231b 553 551 
Figure 104. Retrosynthetic analysis ofbalanol (1) from cis-dihydrodiol 6 
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3.3.2 Vinyl Aziridine Approach to (-)-Balanol 
Synthesis of the (-)-balanol formal intermediate 231a began with the 
preparation of vinyl aziridine 429 (Scheme 60).280 Reaction between the acetonide 
derivative of cis-dihydrodiol 554 and N-bromoacetamide afforded ~-bromo amide 
428. Exposure to potassium bis(trimethylsilyl)amide in the presence of tin(IV) 
bromide effected the formation of aziridine 429. 
~HAC 
"NAc : Br 
BrD"'OH 
i Br~"'o ii Br~o iii Br~" 'o - - -
OH b~ b~ b~ 
6 554 428 429 
Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH, acetone, r.t.; (ii) N-bromoacetamide, 
SnBr4, MeCN, -30°C, 76% over 2 steps; (iii) KHMDS, n-BuNBr, DME, OT, 67% 
Scheme 60. Preparation of N-acetyl vinyl aziridine 429 
We began to screen oxygen nucIeophiles which would open the aziridine and provide 
the necessary trans disposition seen in balanol (1). Our first attempts employed 
benzyl alcohol and a series of Lewis acid catalysts (Figure 105). In each instance, we 
obtained a mixture consisting of the trans 555 and cis 556 isomers (Table 18). With 
the exception of ammonium chloride, each catalyst produced a similar isolated yield. 
The most favourable ratio was seen when copper(II) triflate was employed. 
aziridine OBn gBn .,,~Ac opening 
D:"NHAC D::,NHAC Br~" 'o with Bn-OH . + Table 18 Br : "0 Br :'0 
b~ b-}- b~ 
429 555 556 
Figure 105. Opening of vinyl aziridine 429 with benzyl alcohol 
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Table 18. Opening of vinyl aziridine with 429 benzyl alcohol 
Entry Catalyst Solvent Temp. Yield Ratio (555:556jlaJ 
1 BF3'OEt2 DCM r.t. 82% 2:1 
2 Cu(OTf)2 DCM r.t. 72% 5:1 
3 NH4CI DMF r.t. 
4 NH4CI DMF 75°C 
5 TMSOTf DCM r.t. 80% 3.5:1 
6 TBSOTf DCM r.t. 81% 3.5:1 
[aJ approximate ratio determined by IH NMR 
Complete separation of O-benzy1 isomers 555 and 556 via column chromatography 
proved troublesome. Hence, the mixture was subjected to a hydrogenation protocol 
with Adams' catalyst (Scheme 61). Unfortunately, the trans isomer 557 could not be 
completely separated from the minor cis isomer 558 to an acceptable level ,(GCI MS 
analysis). Therefore, this route was abandoned in favour of using another oxygen 
nuc1eophile. 
OBn gBn OBn gBn 
D:"NHAC + ~:"NHAC i 6:"NHAC + O :"NHAC 
-
Br : -'0 Br : -'0 : -'0 : -'0 
b~ b~ bi-- b~ 
555 556 557 558 
Reagents and conditions: (i) H2 (1 atm), Pt02, MeOH, NEt3, 88% 
Scheme 61. Hydrogenation of trans and cis O-benzyl derivatives 555 and 556 
When we employed acetic acid as the oxygen nuc1eophile, we obtained a 
mixture containing the trans 559 and cis 560 isomers (Figure 106). Fortunately, these 
diastereomers could be separated to a satisfactory level (>99% by GCI MS analysis). 
Again we screened a series of Lewis acid catalysts in an attempt to improve upon the 
ratio (Table 19). Unlike our studies with benzyl alcohol, copper(II) triflate produced 
an unfavourable ratio. Ytterbium(III) triflate afforded a higher ratio (3: 1) but suffered 
from a lower isolated yield. When we employed silyl-based catalysts (Table 19, 
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Entries 4 to 8) we observed a significant improvement in the ratio. We found that 
trimethylsilyl trifluoromethanesulfonate (TMSOTf), in either DCM or THF, provided 
the best results. A final experiment employing a large excess of acetic acid offered a 
slight improvement in yield. 
429 
aziridine 
opening 
with AcOH 
• 
Table 19 
559 
QAc 
0:"NHAC 
Br~"o 6-} 
560 
Figure 106. Opening of vinyl aziridine 429 with acetic acid 
Table 19. Opening of vinyl aziridine 429 with acetic acid 
Entry Catalyst Solvent Equiv. AcOH Yield Ratio (559:560}aJ 
1 BF3·OEt2 DCM 5 82% 2:1 
2 CU(OTf)2 DCM 5 72% 2.5:1 
3 Yb(OTf)3 DCM 5 66% 3:1 
4 TBSOTf DCM 5 77% 3.5:1 
5 TBSOTf THF 5 84% 3.5:1 
6 TMSOTf THF 5 85% 4:1 
7 TMSOTf DCM 5 82% 4:1 
8 TMSOTf DCM 20 88% 4:1 
[aJ approximate ratio determined by lH NMR 
We were satisfied with the 4: I ratio, but questioned whether or not we ' could find 
conditions that provided exclusively the trans isomer 559. Lewis acid catalysis 
proceeds through an SN I mechanism in which an allylic cation is attacked from either 
face. We attempted to develop a SN2 method through use of various acetate 'salts 
(Table 20). We screened various solvents and temperatures with limited success. 
Dimethoxyethane, with either sodium or potassium acetate, only provided minute 
amounts of product. The best results employed potassium acetate in N,N-
dimethylformamide (DMF) at 80°C but were still not practical. 
1-64 
Table 20. Opening of vinyl aziridine 429 with acetate salts 
Entry Nucleophile Solvent Concentration Temp. Yield-a] 
1 NaOAc DME 1M 35°C 5 
2 KOAc DME 1M 35°C 5 
3 Ca(OAc)2 DME 1M 35°C 
4 KOAc DMF 1M 80°C 10 
5 KOAc DMF 5M 80°C 10 
6 KOAc DMF 
La] yield estimated from crude IH NMR 
conc. slurry 80°C 
We moved on with the synthesis and attempted to hydrogenate the vinyl 
bromide functionality of 559 (Scheme 62). Our initial conditions produced the O-Ac 
product 561 and the hydrolysis product 562 (Table 21, Entry 1). We treated the crude 
mixture with acetic anhydride to obtain O-Ac 561 exclusively, but we wanted to 
develop a method that would avoid this extra operation. When isopropyl alcohol was 
used in place of methanol we saw a dramatic improvement in the ratio of O-Ac 
product 561. Palladium on charcoal did not yield either 561 or 562, only the saturated 
hydrogenolysis product (no OAc, not shown) could be isolated. Fortunately, we 
obtained only the desired product when ethyl acetate and Adams' catalyst were used. 
559 
hydrogenation 
Table 21 
Reagents and conditions: (i) AC20, NEt3, oeM 
OAc 
6:"NHAC + 
: "0 
6~ 
561 
t 
Scheme 62. Hydrogenation of vinyl bromide 559 
562 
165 
Table 21. Hydrogenation of vinyl bromide 559 
Entry Catalyst Solvent Yield (%) Ratio 561:56ia} 
1 Pt02 MeOH 88 10:90 
2 Pt02 i-PrOH 71 70:30 
3 5% Pd/C MeOH 52[b] 
4 Pt02 EtOAc 84 >99:1 
[a] approximate yield determined by lH NMR; [b] hydrogenolysis product 
Hydrolysis of acetonide 561 afforded 1,2-diol 563, which was subjected to the 
sodium periodate oxidative cleavage method developed earlier. Only starting material 
was isolated, necessitating the use of another method. Regardless of the solvent used, 
elevated temperatures resulted in the decomposition of the starting material. We also 
attempted oxidative cleavage protocols using lead(lV) acetate without success. 
OAe OAe 
6:"NHAe~ 6:"NHAe oxidative cleavage )( 
: "0 - "OH Table 22 
o~ OH 
561 563 
Reagents and conditions: (i) AcOH/THF/H20 (4:1:2), reflux, 86% 
Scheme 63. Attempted oxidative cleavage of 1,2-diol 563 
Table 22. Attempted oxidative cleavage of 1,2-diol 563 
OAe ¢("AO 
'-':0 I 
0 
564 
Entry Reagent Solvent Temp. Result 
1 NaI04 acetone/ H20 r.t. SM 
2 NaI04 acetone/ H20 reflux decompositionla] 
3 NaI04 H20 reflux decomposition[a] 
4 NaI04 0.1 M AcOH r.t. decomposition[a] 
5 NaI04 THF r.t. SM 
6 Pb(OAc)4 acetone/ H20 r.t. SM 
7 Pb(OAc)4 acetone/ H20 reflux decomposition[a] 
8 Pb(OAch 0.1 M AcOH r.t. decomposition[a] 
[a] complex mixture, no evidence for aldehydes (TLC/ 2,4-DNP staining and NMR ) 
We elected to intercept our own formal intemlediate, namely azepane 539, through 
cyclic carbamate 567. Strong basic hydrolysis of 561 afforded amino alcohol 565 
which was exposed to methyl chloroformate without purification. The resulting 
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carbamate 566 underwent an intramolecular cyclization upon treatment with sodium 
hydride. 
OAc 6 ·"NHAC i 
-
: -"0 
b~ 
561 
ii 
-
565 566 567 
Reagents and conditions: (i) NaOMe, MeOH, reflux; (ii) methyl chloroformate, NEt3, DCM, DMAP, 
r.t., 73% over 2 steps; (iii) NaH, THF, reflux, 83% 
Scheme 64. Synthesis of cyclic carbamate 567 
Cyclic carbamate 567 was reacted with 4-(benzyloxy)benzoyl chloride to afford 
amide 568 (Scheme 65). Acetonide deprotection provided 1,2-diol 569 which proved 
to be an acceptable substrate for the oxidative cleavage/ reductive amination protocol. 
Mild hydrolysis of azepane 539 completed the formal synthesis of (-)-balanol. We 
established the optical purity of 231a via 19F NMR analysis of its (S)-(+)-Mosher 
ester derivative in an identical manner employed in our first synthesis (Scheme 57). 
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231a 
(l0i-P 
~o I 
° 
538 
1 iv 
OBn 
d°y-o filOBn ,,'NyV 
N ° Bn 
539a 
Reagents and conditions: (i) p-BnOC6H4COCI, DCM, DMAP, NEt3, O'C, 82%; (ii) AcOH/THF/H20 
(9:3: I), reflux, 88%; (iii) NaI04, acetone/H20 (8:2), r.t.; (iv) Bn-NH2, AcOH, NaBH3CN, 3A mol. 
sieves, MeOH, -78'C to r.t., 64% over 2 steps; (v) IN NaOH, THF, -20'C, 81% 
Scheme 65. Synthesis of(-)-balanol intermediate 231a.278-8o 
3.3.3 Vinyl Aziridine Approach to (+)-Balanol 
Synthesis of the (+)-balanol intermediate 231b from cis-dihydrodiol 6 was 
accomplished by Jacqueline Gilmet.278,281 This strategy employed the anti-disposed 
N-tosyl vinyl aziridine 570, prepared via a copper(II) acetylacetonate catalyzed 
nitrene protocol (Scheme 66).282-3 Opening with hydroxide provided allylic alcohol 
571 which was subsequently reduced with Adams' catalyst. The resulting 
cyclohexanol derivative 572 was exposed to triphosgene to provide cyclic carbamate 
573. A dissolving metal reduction removed the tosyl functionality, and treatment with 
4-(benzyloxy)benzoyl chloride furnished amide 574. Acetonide hydrolysis, oxidative 
cleavage and reductive amination with benzyl amine yielded azepane 539b. Mild 
hydrolysis of the cyclic carbamate completed the formal synthesis of (+ )-balanol. 
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539b 231b 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) PhI=NTs, Cu(acach, MeCN, O°C, 
77% over 2 steps; (iii) DMSO, KOH, H20, 30°C, 94%; (iv) Pt02, H2 (I atm), MeOH, 77%; (v) 
triphosgene, NEt3, DCM, O°C, 93%; (vi) Na/ naphthalene, DME, -78°C; (vii) p-BnOC6H4COCI, NaH, 
THF, r.t., 91% over 2 steps; (viii) AcOHITHF/H20 (9:3:1), reflux; (ix) a) NaI04, acetone/H20 (8:2), 
r.t.; b) Bn-NH2, AcOH, NaBH3CN, 3A mol. sieves, MeOH, _78°C to r.t., 72% over 3 ,steps; (x) IN 
NaOH, THF, -20°C, 56% 
Scheme 66. Synthesis of (+)-balanol intennediate 231b.278 
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3.4 Enzymatic Dihydroxylation of Benzoate Esters 
Dihydroxylations catalyzed by the toluene dioxygenase (TDO) enzyme 
provide enantiopure cis-dihydrodiols from their corresponding arene substrates. The 
most significant research in this field has been conducted by David Gibson, who 
isolated the first stable metabolite in 1968. 12 Since that time, numerous new cis-
dihydrodiol metabolites have been isolated and characterized. Many have served as 
building blocks in the synthesis of several naturally occurring productS. 14 The most 
frequently employed are the diol metabolites derived from the oxidation of benzene, 
toluene, chlorobenzene, bromobenzene, and (2-bromoethyl)benzene. Milestones 
include Ley's synthesis of (+/-)-pinitol, 176 and Hudlicky's synthesis of (+)-
pancratistatinl80 (see Section 2.3.4 for further details). 
In addition to synthetic efforts, the Hudlicky group has long been involved in 
the identification of new cis-dihydrodiol metabolites. With that goal in mind, we 
became interested in the dihydroxylation of benzoate esters. We speculated that such 
products would provide short access to pseudo-sugars, amino cyclitols and bicyclic 
ring systems (Figure 107). 
°OOR 
7' I TDO-dihydroxylation 
~ 
o OR (XoH pseudo-sugars, amino cyclitols, 
• ~ and bicyclic ring systems 
~ OH 
15 R = alkyl, allyl, propargyl 16 
Figure 107. TDO catalyzed oxidations of benz oates 15 to cis-dihydrodiols 16 
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3.4.1 Isolation and Stereochemical Proof 
As part of our research involving a synthetic route to oseltamivir (Section 
3.5), the first substrate tested was ethyl benzoate. To our delight, the corresponding 
cis-dihydrodiol 7 was obtained by Lena Rochon. Spectral analysis confirmed the 
regiochemistry of the dihydroxylation as being in the C5 and C6 positions. We then 
wished to determine the absolute stereochemistry of ds-dihydrodiol 7. To this end, 
we wanted to convert diol 7 to acrylate 592, a product also accessible from the cis-
dihydrodiol 6 derived from bromobenzene. 14 Reduction of the distal olefin of 6 with 
potassium azodicarboxylate (PAD) and subsequent protection of the diol functionality 
provided vinyl bromide 590 (Scheme 67). Sequential treatment with tert-butyllithium, 
and carbon dioxide at -78°C afforded carboxylic acid 591. Exposure of this 
intermediate to EDC in absolute ethanol yielded acrylate 592. This product was also 
obtained via a PAD reduction! acetonide protection sequence on cis-dihydrodiol 7. 
lO OH 1 Br Br Br ~ 2X~ te°H i (x0H ii 6::x - -:::,... OH OH 
6 589 590 591 
2);' 2X' 2X' ~ ~ OH v ~ OH vi ~ . Ox - -
:::,... OH OH 0 
7 593 592 
Reagents and conditions: (i) PAD, AcOH, MeOH, -IYC, 88%; (ii) 2,2-DMP, p-TsOH, acetone, r.t., 
95%; (iii) a) t-BuLi, Et20, _78°C; b) CO2, _78°C to r.t.; (iv) Abs. EtOH, EDC, DMAP, DCM, O°C, 50% 
over 2 steps; (v) PAD, AcOH, MeOH, -15°C, 84%; (vi) 2,2-DMP, p-TsOH, acetone, r.t., 92% 
Scheme 67. Absolute stereochemical proof of cis-dihydrodiol 7. 
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3.4.2 Steric and Functional Limitations 
Following the successful completion of the first stereochemical proof in the 
benzoate series, we elected to explore the steric and functional limitation of this group 
of substrates. In concert with Dr. Fabrizio Fabris, a visiting professor from the 
Universita Ca' Foscari Venezia, we screened a series of benzoate esters.284 The steric 
limitations were probed using alkyl esters of increasing size (methyl to tert-butyl), 
while the functional limitations were tested using two unsaturated esters (Table 23). 
The only substrates not accepted by the TDO were the n-butyl 579 and t-butyl 580 
esters, indicating the steric limits of the enzyme. Both unsaturated esters, allylic 581 
and prop argyl 582, were excellent substrates. 
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Table 23. Dihydroxylation of benzoate esters by TDO 
Substrate Product Conversion (%)Ib] Yield (gIL) (;M' 2:(' ~I ~ OH 95 1.30 
~ ~ OH 
575 18 (;E' 2X' ~I ~ OH 56 0 .80 ~ ~ OH 
576 7 
(;~P' (;P' 
~I ~ OH 78 0.07 
~ ~ OH 
577 583 (;'-P' 2XP' ~I ~ OH 41 0.05 
~ ~ OH 
578 584 (;- (;B' ~I ~ OH 
~ ~ OH 
579 585 (;'_B' (;B' ~I ~ OH 
~ ~ OH 
580 586 
(;~ ~~ ~I ~ OH 89 0."60 
~ ~ OH 
581 587 
(;~ ~~ ~I ~ OH 91 1.00 
~ ~ OH 
582 588 
[aJ 10.0g of substrate was slowly injected into the fennentor containing 9L of broth; 
[bJ percent conversion is defined as: -(mass substrate fed - substrate recovered)! mass 
substrate fed x 100 
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As with the ethyl ester metabolite, the absolute configuration of the remaining 
cis-dihydrodiols was established through conversion to a fully characterized product 
(Scheme 68). Diimide reduction of the methyl 18, n-propyl 583 and i-propyl 584, 
followed by ethanolic transesterification provided acrylate 593. Treatment of the 
allylic 581 and prop argyl 582 metabolites with excess PAD reagent provided ester 
595, which was subsequently converted to ethyl ester 593. 
2X 2X 2);' 2XP' ~ OH i ~ OH ii ~ OH ii . ~ OH i - - - -~ OH OH OH OH 
18 R = Me 594 R = Me 593 595 
583 R = n-Pr 595 R = n-Pr 
584 R = i-Pr 596 R = i-Pr 
Reagents and conditions: (i) PAD, AcOH, MeOH, -IS'C; (ii) Abs. EtOH, H2S04, r.t. 
Scheme 68. Absolute configuration of benzoate ester metabolites 
2X ~ OH ~ OH 
581 R = allyl 
582 R = propargyl 
To demonstrate the synthetic value of the ester benzoate cis-dihydrodiol 
metabolites a short route to carba-a-L-galactopyranose (17) was developed by 
Jonathan Collins. Although other pseudo-sugars have been prepared from TDO-
metabolites,181, 285-8 they rely on the conversion of a vinyl halide moiety to a 
carboxylate intermediate. The cis-dihydrodiols derived from benzoate esters 
circumvent this additional step. Our route began with the treatment of the acetonide 
derivative of methyl ester 18 with osmium(VIII) tetroxide (Scheme 69). The resulting 
1,2-diol was converted to acetylated derivative 597 prior to a rhodium on alumina-
catalyzed hydrogenation protocol. This reaction furnished a 4: 1 mixture of 
diastereomers 598 and 599, which were separated via flash column chromatography. 
Reaction of the former with excess LiAlH4 yielded the protected derivative 600 of 
pseudo-sugar carba-a-L-galactopyranose (17). 
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02XOMe ~ OH 
:::,.... OH 
i-iii 
-
18 
):x 
ACO"'C;CO 
OAc 
597 
°xo~e 
ACO,,·C;CJ< 
OAc 
598 
lv 
+ 
4:1 
.CX· Ox 
AcO" : 0 
OAc 
599 
Ho~&:X_H_'_- HO~?x:: 
OH OH 
600 carba-a-L-galactopyranose (17) 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) OS04, NMO, acetone/H20, r.t.; (iii) 
AC20, pyr., r.t., 69% over 3 steps; (iv) 5% RhlA120 3, H2 (60 psi), EtOH, 70%; (v) LAH, THF, reflux, 
86% 
Scheme 69. Synthetic route to carba-a-L-galactopyranose (17) 
3.5 Chemoenzymatic Synthesis of Oseltamivir 
There is a distinct possibility that another world-wide influenza pandemic will 
occur in the near future. Oseltamivir (administered as its phosphate salt, Tamiflu) 
offers the best hope to control the spread of the virus. Although industrial-scale 
preparations of the drug exist; there is still the need for a synthesis which would allow 
for rapid and large-scale production (see Section 2.4.3 for further details). The 
following section reviews the Hudlicky group's efforts to develop a route to 
oseltamivir. 
175 
3.5.1 Preliminary Strategies 
Our initial interest in the TDO-mediated dihydroxylation of benzoate esters 
stemmed from our pursuit of a synthetic route to oseltamivir (2). We envisioned a 
synthesis employing cis-dihydrodiol 7, which already 'contains the necessary ethyl 
ester functionality. Our first efforts began with the production of acetonide 601 and 
its subsequent epoxidation with mCPBA (Scheme 70). In principle, opening of 
epoxide 602 with a nitrogen nucleophile would provide a homo allylic alcohol which 
could be converted into N-acetyl 604 via two Mitsunobu reactions. Opening of the 
ketal using the reduction procedure described by Gilead Sciences232 would give 
access to oseltamivir (2). Although we obtained epoxide 602 in exc-ellent yield and as 
a single diastereomer, we elected to abandon this approach given the proposed length 
of the synthesis. 
C02Et 
6:::<::: ~ 
7 601 602 
H'NE:~ _----- Et~ RHN . ° 
NHAc NHAc 
oseltamivir (2) 605 
epoxide 
opening 
.-------- ... 
ketal 
opening 
.. ---------
C02Et 
RHNO::<::: 
OH 
603 
: double 
: Mitsunobu 
• 
604 
Reagents and conditions: (i) 3,3-dimethoxypentane, p-TsOH, 3-pentanone, r.t., 97%; (ii) m-CPBA, 
DCM, OT, 69% 
Scheme 70. Route to oseltamivir (2) via vinyl epoxide 602 
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Our second idea was to improve upon the route to epoxide 352, an 
intermediate in the industrial synthesis employed by F. Hoffman-La Roche.234 This 
approach began with the silylation of the distal hydroxyl group of cis-dihydrodiol 7 
(Figure 108). We screened conditions using various nitrogenous bases, each 
employing tert-butyldimethylsilyl chloride (Table 24). All of our procedures utilizing 
pyridine or triethylamine provided mixtures of the two mono-protected regioisomers 
and some di-protected product. Ultimately, we found that imidazole in DMF at -lSoC 
produced the desired silyl ether 606 as the lone product. 
cS:~H silylation with C02Et &' ----- p::~ TBS-CI (j0H reduction )( -------~ ~ OH Table 24 ~ OTBS Table 25 ~ OTBS 
7 606 607 352 
Figure 108. Proposed route to F. Hoffman-La Roche epoxide intermediate 352 
Table 24. Attempted silylation of cis-dihydrodiol 7 with TBS-CI 
Entry Base Solvent Catalyst Temp. Result 
1 pyridine DMAP -5 to r.t. mixture1a1 
2 pyridine -5 to r.t. mixture[a] 
3 pyridine DCM DMAP -5 to r.t. mixturela] 
4 pyridine DCM -S to r.t. o mixture[a] 
5 NEt3 DCM DMAP -5 to r.t. mixture[a] 
6 NEt3 DCM -5 to r.t. mixture[a] 
7 imidazole DMF O°C to r.t. mixturela] 
8 imidazole DMF -15°C 606 (52 %) 
[aJ mixture of mono-protected and di-protected products 
To intercept the F. Hoffman-La Roche synthesis, we needed to translocate the 
acrylate olefin and displace the free hydroxyl of ester 606 (Figure 108). We explored 
the possibility of using o-nitrobenzenesulfonylhydrazide (NBSH); a reagent know to 
effect 1,3-reductive transpositions of allylic alcohols.289 Standard conditions {Table 
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25, Entry 1) did not provide any new products, while all other methods decomposed 
the starting material. 
Table 25. Attempted 1 ,3-reductive transposition of allylic alcohol 606 
Entry Reagents 
1 PPh3, NMM, DIAD, NBSH 
2 PPh3, NMM, DIAD, NBSH 
3 PPh3, NMM, DIAD, NBSH 
4 PPh3, NMM, DIAD, NBSH 
[aJ complex mixture of elimination products 
Solvent 
THF 
THF 
toluene 
toluene 
Temp. 
r.t. 
35°C 
35°C 
r.t. 
Result 
SM 
decomposition[a] 
decomposition[a] 
decomposition[a] 
Our third strategy sought to utilize the selective opening of vinyl epoxide 610 
with a suitable nitrogen nucleophile (Scheme 71). For this study, cis-dihydrodiol 6 
was exposed to 3,3-dimethoxypentane and 3-pentanone under acidic conditions. The 
resulting acetonide 608 was reacted with dibromodimethylhydantoin (DBDMH) in 
aqueous acetone. Bromocyclohexanol derivative 609 was treated with 10% NaOH in 
DME to effect the formation of epoxide 610. Although this approach was not pursued 
further, we speculate that opening of epoxide 610, followed an intramolecular 
Mitsunobu reaction, would provide an aziridine derivative 612. Opening with a 
nitrogen nucleophile would install the necessary trans-amino moiety seen III 
oseltamivir (2). 
178 
oseltamivir (2) 
JvOH~ 
UOH 
6 
613 
Br 
I 0:><= 
608 
Br 
~ HOn:><= 
612 
Br 
609 
iii 
-
610 
: epoxide i opening 
611 
Reagents and conditions: (i) 3,3-dimethoxypentane, p-TsOH, 3-pentanone, r.t., 91%; (ii) DBDMH, 
acetone, H20, r.t., 56%; (iii) 10% NaOH, DME, r.t., 44% 
Scheme 71. Route to oseltamivir (2) via vinyl epoxide 610 
3.5.2 Symmetry-based Design 
The aforementioned preliminary approaches helped refine our strategy to 
construct to oseltamivir (2). When the target molecule is depicted in either 
configuration A or B, a latent symmetry axis290 can be drawn through the C 1 and C4 
positions (Figure 109). If the substituents at C3, C4 and C5 are not defined, then the 
two structures represent an 'enantiomeric switch' dependent on the posItion of the 
double bond. We theorized that oseltamivir (2) could be accessed through two vinyl 
aziridine approaches. Approach A would rely on an opening of syn-aziridine 614 with 
an oxygen nucleophile in order to install the ether functionality. Reduction of the C6-
oxygen bond and inversion of the C5 position with a nitrogen nucleophile would 
install the correct substituents. In this strategy, the olefin would remain in its original 
position. Conversely, approach B relies on the opening of anti-aziridine 615 with a 
nitrogen nucleophile. This strategy relies on the translocation of the acrylate double 
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bond, ideally with concomitant elimination of the C6 oxygen. The synthesis would 
conclude with the alkylation of the C5 oxygen. 
-- latent symmetry axis-
A 
C02Et:" reduction ~(OR) f' ==> 
RO RN ~OR 
R2N 
614 
approach A 
oseltamivir (2) 
7 
B 
OC02 elimination ~ (OR) ¢::::= '-J 
f' . 
R2N RN"· z: R 
615 
approach B 
Figure 109. Symmetry-based approach to oseltamivir (2) 
With envisioned this approach commencing with the production of N-acetyl 
aziridine 13 from a cis-dihydrodiol derivative 618 (Figure 110). Opening with 3-
pentanol and a palladium-catalyzed carbonylation would provide advanced 
intermediate 617. Reduction of the allylic carbon-oxygen bond and inversion of the 
homo allylic position with an azide anion would give access to oseltamivii (2). This 
strategy was extensively studied by Dr. Michael Moser. 
lvOR 
U OR 
616 617 13 618 
Figure 110. Approach to oseltamivir (2) via vinyl aziridine 13 
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Using the procedure described in our second generation approach to balanol (Section 
3.3), the acetonide derivative of cis-dihydrodiol 6 was reacted with N-
bromoacetamide and then potassium bis(trimethylsilyl)amide to provide N-acetyl 
aziridine 429 (Scheme 72). We screened a series of catalysts to ascertain the most 
effective method of opening aziridine 429 with 3-pentanol. We found that BF3'OEt2 
and Cu(acach provided 5:2 and 3:1 mixtures of diastereomers 619 and 620 
respectively (Table 26). More favourable ratios were obtained when Cu(OTf)2 was 
used as the catalyst; particularly when the reaction was run at -20°C. Although 
tedious, we were able to separate the diastereomers via flash column chromatography. 
Br Br (x0H i-iii teo x 
-~ OH 0 
AcN 
6 429 
aziridine 
opening 
with 3-pentanol 
. 
Table 26 
619 620 
Reagents and conditions: (i) 2,2-dimethoxypropane, p-TsOH, acetone, r.t.; {ii) N-bromoacetamide, 
SnBr4, MeCN, -30°C; (iii) KHMDS, n-BuNBr, DME, O'C, 72% over 3 steps 
Scheme 72. Opening of aN-acetyl aziridine 429 with 3-pentanol 
Table 26. Opening of aN-acetyl aziridine 429 with 3-pentanol 
Entry Catalyst Solvent Temp. Yield (%) Ratio 619:620[b] 
1 BF3'OEt2 DCM r.t. 73 5:2 
2 Cu(acac)2 DCM r.t. 75 3:1 
3 Cu(acach _[a] r.t. 71 3:1 
4 Cu(acac)2 _[a] O°Ctor.t. 79 3:1 
5 Cu(OTf)2 _[a] O°C 87 4:1 
6 Cu(OTf)2 _I a] -20°C 84 6:1 
[a] reaction performed in 3-pentanol; [b] estimated ratio determined from lH NMR 
Vinyl bromide 619 was converted into ethyl ester 621 through use of a carbonylation 
procedure employing two palladium catalysts, Pd(PPh3)4 and Pd[(Clh(PPh3)2] 
(Scheme 73). Acetonide hydrolysis with hydrochloric acid afforded 1,2-diol 622 . 
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619 621 622 
Reagents and conditions: (i) Pd(PPh3)4, Pd[(ClMPPh3)2], CO, NEt3, EtOH, toluene, reflux, 68%; (ii) 
6N HCl, EtOH, 71% 
Scheme 73. Palladium-catalyzed carbonylation of vinyl bromide 619 
Our next goal was to invert the homoallylic hydroxyl with an azide anion. To 
this end, we prepared OMs derivative 624 and OTs derivative 625 by reacting 623 
with one equivalent the appropriate sulfonyl chloride (Scheme 74). Using sodium 
azide and various solvents, we performed a temperature gradient (0 - 80°C) for each 
experiment (Table 27, Entries 1 to 4). In each instance, we did not observe the 
formation of any new compounds (TLC analysis) until the temperature exceeded 
60°C, at which point 10 or more new compounds were produced. Although some 
evidence of azide 626 was found during IH NMR analysis of the crude mixture, no 
clean compound could be isolated. When we employed either trimethylsilyl azide 
(TMS-N3) or diphenylphosphoryl azide (DPPA) we did not obtain any new 
compounds at ambient temperature, while an increase to 50°C decomposed the 
starting material. 
"I . h~H 
~O\"VOH 
NHAc 
622 
i or ii 
624 R = OMs 
625R=OTs 
azide 
displacement 
)( 
Table 27 
Reagents and conditions: (i) MsCl, NEt3, DCM, 86%; (ii) TsCl, NEt3, DCM, 76% 
626 
Scheme 74. Attempted inversion of sulfonyl derivatives 624 and 625 with azide 
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Table 27. Attempted inversion of sulfonyl derivatives 624 and 625 with azide 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
Azide 
NaN3 
NaN3 
NaN3 
NaN3 
TMS-N3 
TMS-N3 
DPPA 
DPPA 
Solvent 
DMSO 
DMF 
i-propanol 
acetone 
THF 
THF 
THF 
THF 
Temp. 
0- 80°C 
0- 80°C 
0- 80°C 
0- 80°C 
r.t. 
50°C 
r.t. 
50°C 
(aJ complex mixture of sulfonyl group containing products 
Result 
decomposition(aJ 
decomposition[a] 
decomposition[a] 
decomposition[a] 
SM 
decomposition[a] 
SM 
decomposition[a] 
As stated earlier, some evidence existed that azide 626 was formed during the 
reaction. We reacted OTs derivative 625 with sodium azide at 80°C in DMF, and then 
submitted the crude mixture to a borohydride reduction protocol (Scheme 75). This 
method provided the undesired oseltamivir isomer 628, with the olefin in the incorrect 
position resulting from a 1,3 reduction of the carbon-oxygen bond. Ultimately, we 
were able to synthesize azide 626 through use of tetra-n-butylammonium azide 
procedure, but we were unable to make oseltamivir via this approach. 
i 
-
625 626 
ii-iii! 
628 
Reagents and conditions: (i) n-BuNN3, DME, reflux; (ii) NaN3, DMF, 80·C; (iii) NaBH4' EtOH, r.t. 
Scheme 75. Synthesis of oseltamivir isomer 628 
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Failing to construct oseltamivir (2) from vinyl aziridine 429, we turned our 
attention to a cycloaddition strategy. We theorized that oxazine 631 could be prepared 
from cis-dihydrodiol 7 (Figure 111). A SN2' reaction with a nitrogen nucleophile and 
reduction of the nitrogen-oxygen bond would provide advanced intermediate 630. 
Subsequent translocation of the double bond, and alkylation of the free hydroxyl 629 
would give access to oseltamivir (2). 
oseltamivir (2) ~ 
629 630 631 7 
Figure 111. Cycloaddition approach to oseltamivir (2) 
Ignacio Carrera discovered that the acetonide derivative of 1,2-diol 7 
underwent an inverse electron-demand hetero-Diels-Alder reaction with a nitroso 
species; created in situ through a reaction between N-hydroxyacetamide and sodium 
periodate (Scheme 76). We then screened a series of conditions in an attempt to effect 
an SN2' reaction on oxazine 632. Our first attempts utilized NaN3 and TMS-N3 (Table 
28, Entries 1 to 4). We were unable to obtain any new compounds, even under 
palladium catalyzed conditions. We were also unsuccessful when using similar 
conditions and protected-nitrogen nucleophiles, namely Boc-NH2 and Bn-NH2. Our 
final attempts employing a rhodium catalyst ([Rh(COD)2]OTt) and did not produce 
any new compounds. 
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C02Et dX~ C02Et 6:0H~ SN2' box 16 X )( ~ OH ACN(-: 0 Table 28 N3 : ° 
NHAC 
7 632 633 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) MeCONHOH, NaI04, MeOH, r.t., 
70% over 2 steps 
Scheme 76. Attempted SN2' reactions on oxazine 632 
Table 28. Attempted SN2' reactions on oxazine 632 
Entry Reagents Solvent Temp. Result 
1 NaN3 acetone r.t. - reflux SM 
2 NaN3, Pd(PPh3)4 acetone r.t. - reflux SM 
3 TMSN3 THF r.t. - reflux SM 
4 TMSN3, Pd(PPh3)4 THF r.t. - reflux SM 
5 BocNH2 THF r.t. - reflux SM 
6 BocNH2, Pd(PPh3)4 THF r.t. - reflux SM 
7 BnNH2 THF r.t. - reflux SM 
8 BnNH2, Pd(PPh3)4 THF r.t. - reflux SM 
9 BnNH2, [Rh(CODh]OTf THF r.t. - reflux SM 
10 BnNH2, [Rh(CODh]OTf, dppf THF r.t. - reflux SM 
11 TMSN3, [Rh(CODh]OTf, dppf THF r.t. - reflux SM 
At this stage, we abandoned using oxazine 632 for SN2' reactions in favour of 
another substrate. Reduction of nitrogen-oxygen linkage with molybdenum 
hexacarbonyl provided allylic alcohol 634 (Scheme 77). Subsequent ~xposure to 
acetic anhydride afforded O-acetyl derivative 635. We ran experiments using the 
same conditions employed with our first substrate. The reactions utilizing NaN3 
returned starting material, as did the reaction with TMS-N3. However, when 
tetrakis(triphenylphosphine)palladium(O) was added we were able to isolate the syn-
azide isomer 636. We tried varying the amount of catalyst added, 0.1 to 10 
equivalents, but were never able to isolate the desired trans isomer. All other 
conditions resulted in the decomposition of the starting material. 
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C02Et 
Nt·6::x 
NHAc 
632 634 635 636 
Reagents and conditions: (i) MO(CO)6, MeCN/H20 (15:1), reflux, 75%; (ii) AC20, NEt3, DMAP, 94% 
Scheme 77. Attempted SN2' reactions on allylic acetate 635 
Table 29. Attempted SN2' reactions on allylic acetate 635 
Entry Reagents Solvent Temp. 
1 NaN3 acetone r.t. - reflux 
2 NaN3, Pd(PPh3)4 acetone r.t. - reflux 
3 TMSN3 THF r.t. - reflux 
4 TMSN3, Pd(PPh3)4 THF r.t. - reflux 
5 BocNH2 THF r.t. - reflux 
6 BocNH2, Pd(PPh3)4 THF r.t. - reflux 
7 BnNH2 THF r.t. - reflux 
8 BnNH2, Pd(PPh3)4 THF r.t. - reflux 
9 BnNH2, [Rh(CODh]OTf THF r.t. - reflux 
10 BnNH2, [Rh(COD)2]OTf, dppf THF r.t. - reflux 
11 TMSN3, [Rh(COD)2]OTf, dppf THF r.t. - reflux 
[a] complex mixture of compounds, mostly elimination products 
Result 
SM 
SM 
SM 
636 (77%) 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
We sought to take advantage of the undesired reactivity of 635 by employing a TMS-
halide instead. The resulting syn-halide product 637 could be inverted with an azide 
anion (Figure 112). 
NHAc 
635 
Pd-catalyzed 
SN2' 
-----------~ 
C02Et 
x,Ci:x 
NHAc 
637 
C02Et 
~O>< N3)ylO 
NHAc 
633 
Figure 112. Inversion of allylic halide 637 
We reacted O-acetyl 635 with either TMS-CI and TMS-I under the same conditions 
that yielded azide 636 (Table 30, Entries 1 and 2). The former yielded 1,3-diene 
derivative 638, while the latter afforded phenol 639. We tried the same experiments in 
toluene without success. 
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Et02C PAc Pd-catalyzed ¢C~>< + <l' 6::>< SN2' Table 30 ~ 0 OH 
NHAc NHAc NHAc 
635 638 639 
Figure 113. Attempted palladium-catalyzed SN2' reactions on allylic acetate 635 
Table 30. Attempted palladium-catalyzed SN2' reactions on allylic acetate 635 
Entry Reagents Solvent Temp. Result 
1 TMS-CI, Pd(PPh3)4 THF r.t. - reflux 638 (83%) 
2 TMS-I, Pd(PPh3)4 THF r.t. - reflux 639 (81 %) 
3 TMS-CI, Pd(PPh3)4 DME r.t. - reflux 639 (54%) 
4 TMS-CI, Pd(PPh3)4 toluene r.t. - reflux decomposition{a] 
5 TMS-I, Pd(PPh3)4 toluene r.t. - reflux decomposition[a] 
[aJ complex mixture of compounds 
At this stage, we questioned whether our failures were a result of the O-acetyl 
functionality. We wondered if a better leaving group would yield the desired product. 
When allylic alcohol 634 was reacted with methanesulfonyl chloride, we did not 
obtain the OMs derivative 640. Instead, we obtain an unknown product with an 
acrylate functionality. Initially we believed the compound to be N-acetyl aziridine 
642, which we hoped to obtain in order to test our latent symmetry approach (Scheme 
78). However, careful spectral analysis identified the compound as oxazoline 
derivative 641, a structural isomer. 
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Et02exC pH o . I >< --.!..-
_ 0 
NHAc NHAc 
634 640 
642 
Reagents and conditions: (i) Ms-CI, NEt3, DMAP, DCM, 54% 
Scheme 78. Synthesis of oxazoline 641 
---
641 
We hoped that the reactivity of oxazoline 641 would be similar to that of vinyl 
aziridine 642. Theoretically, opening of either with an appropriate nuc1eophile would 
yield the same product. 
---
---
642 641 
Figure 114. Structural isomers; vinyl aziridine 642 and vinyl oxirane 641 
We sought to open oxazoline 641 with an azide source in order to obtain the 
necessary trans-azide product 633 (Figure 115). We tested four sets of conditions 
with three separate azide sources. The first three series of trials all produced allylic 
alcohol 643, presumably through a reaction between oxazoline 641 and minuscule 
amounts of opportunistic water in the reaction (Table 31, Entries 1 to 9). When we 
tested the three azide reagents in tert-butanol, we obtained small amounts of the 
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desired azide 633. However, the majority of the reaction mixture contained the allylic 
alcohol 643, and complete separation proved difficult. 
C02Et C02Et C02Et 
,l:x)< oxazoline HO,,(i:>< box opening + 
° : Table 31 N3 ; ° TN NHAc NHAc 
641 643 633 
Figure 115. Opening of oxazoline 641 
Table 31. Opening of oxazoline 641 
Entry Azide Catalyst Solvent Temp. Result 
1 NaN3 acetone r.t. 643 (67%) 
2 DPPA acetone r.t. 643 (71%) 
3 TMSN3 acetone r.t 643 (75%) 
4 NaN3 CU(OT±)2 THF r.t. 643 (41 %) 
5 DPPA CU(OT±)2 THF r.t 643 (29%) 
6 TMSN3 CU(OT±)2 THF r.t. 643 (36%) 
7 NaN3 BF3•OEt2 THF r.t. 643 (33%) 
8 DPPA BF3·OEt2 THF r.t. 643 (56%) 
9 TMSN3 BF3·OEt2 THF r.t. 643 (44%) 
10 NaN3 t-butanol 60°C 643 (40%), 633 (5%ia) 
11 DPPA t-butanol 60°C 643 (70%), 633 (15%ia) 
12 TMSN3 t-butanol 60°C 643 (70%), 633 (5%)la) 
[a] approximate yield, estimated from crude IH NMR 
We were unsure of the relative stereochemistry of oxazoline 641, ,assuming it 
was cis, but not ruling out the possibility of trans. To this end, we hydrolyzed 
oxazoline 641 with calcium carbonate in ethanol! water (Scheme 79). This reaction 
was originally performed using Lindlar's catalyst. Melissa Drouin discovered that the 
CaC03 in the catalyst was responsible for the transformation. Spectral analysis 
suggested we obtained the cis isomer 643. However, we could not exclude the 
possibility that we had the trans isomer 644. 
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C02Et C02Et 
f):°x i "Ci:><~ ~ 
HO . ° ° ~ NHAc rN 
644 641 
Reagents and conditions: (i) CaC03, EtOH! H20, reflux, 72% 
Scheme 79. Hydrolysis of oxazoline 641 
C02Et Ciox 
HO"·. ° 
NHAc 
643 
We speculated that reduction of the acrylate olefin would allow for a more definitive 
structural analysis (Figure 116). Palladium on carbon cleanly provided 1,3-diol 646, 
resulting from hydrogenolysis of the acetonide moiety. We performed several 
experiments with Stryker's reagent ({(PPh3)CuH]6), but did not acquire any new 
products. Adams' catalyst afforded two hydrogenolysis products, namely 646 and 
647, with the ratio dependant on the solvent used. We found success with a rhodium 
on alumina protocol, particularly when the experiment was performed at 65 psi. 
Fortunately, these reaction conditions provided ester 645 as the lone diastereomer. 
C02Et C02Et C02Et 
HO"Ci:>< 
acrylate 
.c):°x HO,,00H reduction + + Table 32 HO" . ° 
NHAc NHAc NHAc NHAc 
643 645 646 647 
Figure 116. Reduction of acrylate 643 
Table 32. Reduction of acrylate 643 
Entry Catalyst Solvent Pressure TemE· Result 
1 5% Pd/C 95% EtOH 1 atm r.t. 646 (83%) 
2 [(PPh3)CuH]6 THF reflux SM 
3 [(PPh3)CuH]6 MeCN reflux SM 
4 [(PPh3)CuH]6 toluene reflux SM 
5 Pt02 95% EtOH 1 atm r.t. 646 (30%), 647 (40%ia] 
6 Pt02 EtOAc 1 atm r.t. 646 (35%), 647 (40%ia] 
7 5% RhlAb03 95% EtOH 1 atm r.t. 645 (56%) 
8 5% Rh/Ah03 95% EtOH 65 esi 
[aJ approximate yield, estimated from crude lH NMR 
r.t. 645 {90%) 
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We confirmed the absolute configuration of hydroxyl 645 through conversion to its 
O-mesyl derivative 648 (Scheme 80). Using the IH NMR coupling constants we were 
able to assign the correct stereochemistry. We measured the J coupling between HA 
and Hs as 9 Hz, indicative of axial-axial coupling. Furthermore, we did not observe a 
large axial-axial coupling between He and either Hs, Hoa or HOb. This confirmed that 
the O-mesyl group occupies the axial position; thus placing it cis in relation to N-
acetyl group. 
645 648 
Reagents and conditions: (i) Ms20, NEt3, DCM, 73% 
Scheme 80. Spectral analysis of OMs derivative 648 
( 
o 
. ___ ,----.01::. 
--<----~ 0 ~ H~ A 
o - L 
"s ... 6 II ~ H 
"""" 0 A o 
He 
648* 
JAB - 9 Hz (axial-axial) 
JBe - 3 Hz (axial-equitorial) 
JeDa - 4 Hz (equitorial-equitorial) 
JeDb - 5 Hz (equitorial-axial) 
Continuing with the synthesis, we hoped to invert the allylic hydroxyl of 643 
with a nitrogen nucleophile. The simplest method would be an SN2 reaction on a 
sulfonylated derivative (Figure 117). Unexpectedly, reactions using pyridine 
exclusively provided allylic chloride 651. Hiinig's base (N,N-diisopropylethylamine, 
DIPEA) provided a mixture of sulfonylated products, 649 or 650, and the allylic 
chloride product 651. Ultimately, we found that triethylamine produced 649 and 650 
without the chlorination product. 
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C02Et C02Et C02Et 
HO,.(Xj< sulfonylation (X°X jjox . + Table 33 RO"·. 0 CI . 0 
NHAc NHAc NHAc 
643 649 R = OTs 651 
650 R= OMs 
Figure 117. Sulfonylation of allylic alcohol 643 
Table 33. Sulfonylation of aUylic alcohol 643 
Entry Reagent Solvent Base Temp. Result 
1 TsCI DCM pyridine O°C - r.t. 651 (85%) 
2 MsCI DCM pyridine O°C - r.t. 651 (88%) 
3 TsCI DCM DIPEA O°C - r.t. 649 (5%), 651 (25%ia) 
4 MsCl DCM DIPEA O°C - r.t. 650 (5%), 651 (20%ia) 
5 TsCI DCM NEt3 O°C - r.t. 649 (66%) 
6 MsCI DCM NEt3 WC - r.t. 
La] approximate yield, estimated from crude IH NMR 
650 (90%) 
We envisioned two routes which could provide us with azide 633; 1. 
displacement of a sulfonyl derivative with an azide anion, and 2. Mitsunobu-type 
reaction performed on allylic alcohol 643 with an azide reagent. For the first method 
we elected to use the OMs product 650, simply because it was available in a higher 
yield compared to the OTs product 649. We employed sodium azide in acetone, 
DMSO and DMF. At ambient temperatures no reaction took place, while elevated 
temperatures decomposed the starting material (Table 34). All of our attempts using 
TMS-N3 were unsuccessful, even at higher temperatures. We did observe the 
formation of azide 633 when DPPA was used; however, only in trace amounts. When 
a solution of sodium azide in acetone/ H20 was utilized, we obtained the desired 
product in a nearly quantitative yield. We explored the possibility of a Mitsunobu-
type reaction, which would reduce our synthesis by one step. Unfortunately, all 
attempts using either triphenylphosphine or n-tributylphosphine were unsuccessful 
(Table 35). 
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NHAc 
643 
Mitsunobu 
Table 35 
NHAc 
650 
azide 
displacement 
Table 34 
Reagents and conditions: (i) MsCI, NEt3, DCM, O'C - r.t., 90% 
Scheme 81. Two routes to allylic azide 633 
Table 34. Displacement of allylic mesylate 650 
1 
~~X N3~O 
NHAc 
633 
Entry Azide Solvent Temp. Result 
1 NaN3 acetone r.t. SM 
2 NaN3 acetone 50°C decomposition[a] 
3 NaN3 DMSO r.t. SM 
4 NaN3 DMSO 50°C decomposition[a] 
5 NaN3 DMF r.t. SM 
6 NaN3 DMF 50°C decomposition[a] 
7 TMS-N3 THF reflux SM 
8 TMS-N3 MeCN reflux SM 
9 TMS-N3 DCM reflux SM 
10 TMS-N3 t-BuOH80°C SM 
11 DPPA t-BuOH 80°C 633 (lO%ib] 
12 NaN3 acetone/H20 r.t. 633 (91 %) 
[a] complex mixture of sulfonylated products; [b] approximate yield, estimated from 
crude IHNMR 
Table 35. Attempted Mitsunobu reactions on allylic alcohol 643 
Entry 
1 
2 
3 
4 
Reagents 
TMS-N3, DIAD, PPh3 
DPP A, DIAD, PPh3 
TMS-N3, DIAD, n-Bu3P 
DPPA, DIAD, n-Bu3P 
Solvent 
THF 
THF 
THF 
THF 
Temp. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
Result 
SM 
SM 
SM 
SM 
With the allylic azide 633 in hand, we sought to reduce and protect the functionality 
as its tert-butyl carbamate prior to the necessary acrylate reduction (Figure 118). We 
first explored a hydrogenation and then carbamate protection approach. Our attempts 
with Lindlar's catalyst, Pt02 and Pd/C did not cleanly provide amine 652. Regardless, 
the crude reaction mixture was treated with BOC20 and NEt3. We were unable to 
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identify any products from these reactions. We also exposed azide 633 to 
triphenylphosphine, with the hope that we could derivatize the Staudinger 
intermediate. This approach also proved futile, no evidence for the formation of either 
the iminophosphorane species or the carbamate species was found. 
C02Et 
azide 
C02Et C02Et 
box ,(i°x Boc reduction protection ,(i°x )( • 
N3 : ° Table 36 H2N : ° BocHN . ° 
NHAc NHAc NHAc 
633 652 653 
Figure 118. Reduction of allylic azide 633 
Table 36. Allylic azide reduction 
Entry Catalyst Reagents Solvent Pressure Results 
1 Lindlar's Boc20, NEt3 EtOH 1 atm decompositionLa] 
catalyst 
2 Pt02 Boc20, NEt3 EtOH latm decompositionLa] 
3 5% Pd/C Boc20, NEt3 EtOH 1 atm decomposition[a] 
4 PPh3, Boc20, NEt3 THF decomposition[a] 
5 PPh3, Boc20, NEt3 
La] complex mixture of products 
THF decomposition[a] 
As a result of our failed attempts to reduce and protect allylic azide 633, we 
decided to purse its saturated derivative. Previous studies had provided us with 
cyclohexanol 645, which we sought to convert to an azide derivative. Screening the 
same sulfonylation protocols used for allylic alcohol 643 were problematic, as we 
obtained a mixture of the sulfonyl product and the corresponding chloride (Table 37, 
Entries 1). Employing pyridine as the base provided tosylate 654 as the lone product. 
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002Et .c02Et 002Et 
HO"lx:>< protection RO"lx:>< box + Table 37 01 : 0 
NHAc NHAc NHAc 
645 654 R = OTs 655 
648 R = OMs 
Figure 119. Sulfonylation of cyc1ohexanol derivative 645 
Table 37. Sulfonylation of cyc1ohexanol derivative 645 
Entry Reagent Solvent Base Temp. 
1 TsCI DCM NEt3 DOC - r.t. 
2 TsCI DCM pyridine DOC - r.t. 
3 Ms20 DCM NEt3 DOC - r.t. 
[a] approximate yield, estimated from crude IH NMR 
Result 
654 (45%), 655 (15%ia] 
654 {55%) 
648 (73%) 
We attempted a series of azide displacement reactions on the OTs 654 and OMs 648 
derivatives (Scheme 82). Surprisingly, sodium azide in DMSO did not provide the 
corresponding azide. Instead we obtain allylic alcohols 657 and 658, a result of the 
base-induced collapse of the acetonide moiety. The procedures using acetone and 
H20, which had worked for allylic substrate 650, afforded the desired azide 656 in 
both instances (Table 38, Entries 2 and 4). 
C02Et C02Et 
azide 
C02Et &' lx°x~ lx°x displacement box + HO"': 0 RO"': 0 Table 38 N3 : 0 RO'" . OH 
NHAc NHAc NHAc NHAc 
645 654 R = OTs 656 657R=OTs 
648 R = OMs 658 R = OMs 
Reagents and conditions: (i) TsCI, NEt3, DCM, O'C - r.t., 55%; (ii) Ms20, NEt3, DCM, O°C - r.t., 73% 
Scheme 82. Azide displacement of mesylate 648 and tosylate 654 
Table 38. Azide displacement of mesylate 648 and tosylate 654 
Entry R= Azide Solvent Temp. Result 
1 Ts NaN3 DMSO 6DoC 657 (37%) 
2 Ts NaN3 acetone/H2O r.t. 656 (71 %) 
3 Ms NaN3 DMSO 60°C 658 (24%) 
4 Ms NaN3 acetone/H2O r.t. 656 (86%) 
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All that remained was to collapse acetonide 656 in order to construct allylic alcohol 
416, an intermediate in Fang's synthesis248 of oseltamivir (2) (Figure 120). Our first 
attempts employed 1,8-diazabicyc1o[5.4.0]undec-7-ene (DBU) in either acetone, 
DCM or without the addition of a solvent (Table 39, Entries 1 to 3). A significantly 
high isolated yield was observed when DCM was used as the solvent. Similar results 
were achieved using a sodium ethoxidel ethanol procedure. We found that our sample 
of allylic alcohol 416 was in complete agreement with the physical data reported by 
the Fang group, thus completing our formal synthesis of oseltamivir (2).291 
DC02Et acetonide Ox _e_lim_i_na_tio_n_ 
N3 : ° Table 39 
NHAc 
656 
;5' 
N3 : OH 
NHAc 
416 
Figure 120. Elimination of acetonide 656 
Table 39. Elimination of acetonide 656 
Entry Base Solvent 
1 DBU acetone 
2 DBU -tal 
3 DBU DCM 
4 EtONa EtOH 
La] reaction performed with DBU as the solvent 
ref 248 
..c..::..:-=....:..=--. oseltamivir (2) 
Temp. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
O°C - r.t. 
Yield 
34% 
51% 
88% 
91% 
After publishing our initial formal synthesis of oseltamivir (2), we discovered 
an alternative route which reduced the total number of steps. Careful sulfonylation of 
allylic alcohol 634 at -78°C allowed for the direct production of OMs derivative 650 
via a [l,3]-sigmatropic rearrangement (Scheme 83). This reaction, developed by Dr. 
Lukas Werner, has not been optimized and suffers from production of oxazoline 641. 
196 
Et02C PH C02Et C02Et 6::X i ,.6:)< (i°x - + 
o " 
MsO'" _ 0 
NHAc TN NHAc 
634 641 650 
Reagents and conditions: (i) Ms-CI, NEt3, DCM, -78°C 
Scheme 83. Sigmatropic rearrangement of allylic alcohol 634 
Mesylate 650 was converted into Fang's intemlediate 416 by first reducing the 
acrylate moiety with a rhodium! alumina hydrogenation procedure to produce OMs 
diastereomers 648 and 660. Exposure to sodium azide and then DBU afforded formal 
intermediate 416 (Scheme 84). 
650 648 
<;':02Et 
+ ~Ox~ MSO"'~o 
NHAc 
660 
E' 
N3 ; OH 
NHAc 
416 
Reagents and conditions: (i) 5% Rh/AI20 3, 85% EtOH, H2 (65 psi); (ii) NaN3, acetone/H20, r.t.; (iii) 
DBU, DCM, QOC to r.t. 
Scheme 84. Formal synthesis of oseltamivir (2) 
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3.6 Synthetic Approaches to Oseltamivir and its Analogs 
We explored several routes to oseltamivir (2) and its analogs initiating from 
cis-dihydrodiol 6. We speculated that much of the same chemistry developed 
previously could be utilized; all beginning from an anti-aziridine species 663 where 
the N-substituent could be a tosyl or Boc group (Figure 121). 
oseltamivir (2) ===> 
661 662 
LOR U ===> R~\" OR 
663 
Figure 121. Retrosynthetic analysis of oseltamivir (2) from cis-dihydrodiol6 
3.6.1 N-tosyl Aziridine Approach 
Br 
)-yOH 
U OH 
6 
We began by preparing N-tosyl aziridine 570, an intennediate in our second 
generation approach to (+ )-balanol (Scheme 66). We ran a series of experiments 
hoping to find optimal aziridine opening conditions (Scheme 85). Our initial efforts 
utilized Cu(OTf)2 as the catalyst and various azide sources. In each case, the starting 
material decomposed (Table 40, Entries 1 to 3). Switching to ammonium chloride, we 
were able to isolate the desired azide 664; with the best results employing sodium 
azide. 
LOH i-ii 
U OH 
6 570 
aziridine 
opening 
Table 40 
hex 
N3 : 0 
NHTs 
664 
Reagent and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) PhI=NTs, Cu(acac)2' MeCN, ODC, 
77% over two steps 
Scheme 85. Opening of N-tosyl aziridine 570 with azide 
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Table 40. Opening of N-tosyl aziridine 570 with azide 
Entry Azide Catalyst Solvent Temp. Result 
1 NaN3 CU(OTt)2 THF r.t. decomposition[aJ 
2 TMS-N3 CU(OTt)2 THF r.t. decomposition[a] 
3 DPPA CU(OTt)2 THF r.t. decomposition[a] 
4 NaN3 NH4CI DMF r.t. 664 (92%) 
5 TMS-N3 NH4Cl DMF r.t. 664 (34%) 
6 DPPA NH4Cl DMF r.t. 664 (55%) 
[aJ complex mixture of products 
We explored the possibility of opening N-tosyl aziridine 570 with a protected 
nitrogen, specifically tert-butyl carbamate (Figure 122). We tested NH4Cl and TBAF 
as catalysts and varied the concentration of the starting material (Table 41). In each 
instance the dimer product 665 was obtained, resulting from the opening of two 
molecules ofaziridine 570 with one molecule of Boc-NH2. 
aziridine 
Br opening ex with 
_
_ ~ ooX _B_OC_-N_H_2_ 
Table 41 
Tsii;'" 
570 
Br Br 
><°1"9 ~ox 
0'" "'N¥O 
Boc = NHTs NHTs 
665 
Figure 122. Opening of N-tosyl aziridine 570 with tert-butyl carbamate 
Table 41. Opening of N-tosyl aziridine 570 with tert-butyl carbamate 
Entry Catalyst Cone. [aJ Solvent Temp. YielJbJ 
1 NH4Cl 1 M THF r.t. 82% 
2 NH4Cl 0.1 M THF r.t. 75%lb] 
3 TBAF 1 M THF r.t. 85%lb] 
4 TBAF 0.1 M DMF r.t. 85%lb] 
5 TBAF 0.05 M DMF r.1. 80%[b] 
[aJ refers to concentration of starting material; [bJ approximate yield, estimated from 
crude IHNMR 
We attempted to find an alternative route to N-Boc derivative 667 by first opening N-
tosyl aziridine 570 with ammonia and then treating the amine intennediate 666 with 
BOC20 (Figure 123). We perfonned these experiments in a sealed tube with an 
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approximate 1: 1 a volumetric ratio of ammonia to solvent (Table 42). These efforts 
proved troublesome; only the ytterbium(III) tritlate catalyzed reactions produced 
minuscule amounts of the desired product. 
570 
aziridine 
opening 
with 
NH3 
Table 42 
Lox H2N~O 
NHTs 
666 
Boc 
protection Lox 
BOCHN¥O 
NHTs 
667 
Figure 123. Opening of N-tosyl aziridine 570 with ammonia 
Table 42. Opening of N-tosyl aziridine 570 with ammonia 
Entry Catalyst Reagents Solvent Temp. Results 
1 CU(OTf)2 BOC20, NEt3 DCM -78 to aoc decompositionLa] 
2 TBAF BOC20, NEt3 THF -78 to aoc decomposition[a] 
3 NH4CI BOC20, NEt3 DMF -78 to aoc decomposition[a] 
4 TMSOTf BOC20, NEt3 THF -78 to aoc decomposition[a] 
5 Yb(OTQ3 BOC20, NEt3 THF -78 to O°C 667 (5% )lbJ 
La] complex mixture of products; [b] approximate yield,estimated from crude lH NMR 
Unsatisfied, we sought to develop a more practical route to N-Boc derivative 
667. Exposure of azide 664 to triphenylphosphine provided us with a Staudinger 
intermediate 668, which was easily converted to the desired product upop treatment 
with BOC20 (Scheme 86). 
Br 
N,Jx:X i -
NHTs 
664 
Ph,P. h:x N . 
NHTs 
668 
~ LoX BOCHN~O 
NHTs 
667 
Reagents and conditions: (i) PPh3, THF/H20 (15 :1); (ii) (Boc)P, DCM, NEt3, 0'C to r.t. , 77% over 
two steps 
Scheme 86. Alternative synthesis of N-Boc derivative 667 
2Da 
At this stage, we elected to install the acrylate functionality through use of a metal-
catalyzed carbonylation protocol (Figure 124). Using a dual palladium catalyst 
procedure, we isolated ethyl ester 669 (Table 43, Entry 1). We also made two 
attempts with a nickel catalyst (Ni[(PPh3)2(CO)2]) which did not require the addition 
of carbon monoxide gas. In each instance, the reduction product 670 was the lone 
product obtained. 
Lox 
BOCHN¥O 
NHTs 
carbonylation 
Table 43 
• 
~O>< 
+ BOCHN~O 
NHTs 
667 669 670 
Figure 124. Carbonylation of vinyl bromide 667 
Table 43. Carbonylation of vinyl bromide 667 
Entry Catalyst(s) Reagents Solvent Temp. Result 
1 Pd(PPh3)4, NEt3, CO to]uene/EtOH reflux 669 (45%) 
Pd[(Clh(PPh3)2], 
2 Ni[ (PPh3h( CO )2] DIPEA toluene/EtOH reflux 670 (50%ia] 
3 Ni[(PPh3h(CO)2] DIPEA THF/EtOH reflux 670 (79%) 
4 Ni[(PPh3h(CO)2] DIPEA EtOH reflux 670 (60%ia] 
La] approximate yield, estimated from crude IH NMR 
We also attempted to prepare acrylate 669 from cis-dihydrodiol 7, thus avoiding the 
carbonylation reaction (Scheme 87). Using the identical sequence employed with 
vinyl halide 6, aziridination of olefin 7 was followed by selective opening with azide. 
We were able to obtain N-Boc derivative 669 via Staudinger intermediate 673, albeit 
in a lower yield compared to our previous substrate 664. 
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i-ii iii 
-- --
7 671 
C02Et 
~oX~ N3~O 
NHTs 
672 673 
669 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) Phl=NTs, Cu(acac)2' MeCN, O°C, 
41% over 2 steps; (iii) NaNJ, NH4CI, DMF, r.t., 79%; (iv) PPh3, THFIH20 (15 :1), r.t.; (v) (BochO, 
NEt3, O°C to r.t., 32% over two steps 
Scheme 87. Alternative synthesis of ethyl ester 669 
We decided to examine an alternative route to N-Boc derivative 669 from azide 672 
through use of a hydrogenation protocol (Figure 125). We tested several 
hydrogenation procedures without success (Table 44). Consequently, we elected to 
prepare ester 669 from our original route (Scheme 86) despite the additional step. 
C02Et 
azide 
C02Et Boc CO#t hox reduction ,(i°x protection ,(i°x )( )( 
N3 : ° Table 44 H2N : ° BocHN . ° 
NHTs NHTs NHTs 
672 674 669 
Figure 125. Attempts to synthesis ethyl ester 669 from vinyl azide 672 
Table 44. Attempts to synthesis ethyl ester 669 from vinyl azide 672 
Entry Catalyst Reagents Solvent Pressure Results 
I Lindlar's EtOH 1 atm decompositiorita] 
catalyst 
2 Pt02 BOC20, NEt3 EtOH 1 atm 
3 5% Pd/C BOC20, NEt3 EtOH 1 atm 
[a] complex mixture of amines (TLC/ ninhydrin staining) 
decomposition[a] 
decomposition[a] 
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In order to access oseltamivir (2), the tosyl group of 669 needed to be replaced 
with an acetyl group (Figure 126). To this end, we first acetylated sulfonyl amine 664. 
We screened several conditions; ultimately concluding that neat acetic anhydride is 
the best method (Table 45). 
Lox ,e,''''oo N3~O Table 45 
NHTs 
664 675 
Figure 126. Acetylation of sulfonyl amine 664 
Table 45. Acetylation of sulfonyl amine 664 
Entry Reagent Base Solvent Temp. Yield (%) 
1 AC20 DIPEA DCM WC - r.t. 31 
2 AC20 pyridine DCM aoc -r.t. 44 
3 AC20 NEt3 DCM aoc -r.t. 77 
4 AC20 NEt3 THF aoc -r.t. 79 
5 AC20 NEt3 O°C - r.t. 90 
We attempted a series of detosylation procedures on the N-AcTs derivative 675 
(Scheme 88). A sodium/ naphthalene dissolving metal reduction decomposed the 
starting material into several unidentified products, each with the tosyl group intact 
(Table 46). As was the case with the sodium amalgam and zinc dust reduction 
protocols we had tested. Samarium(II)iodide preferentially reduced the azide 
functionality to an intermediate which underwent an intramolecular acetyl-transfer 
reaction to afford 676. 
2'03 
Br Br Br box box tosyl hox i deprotection 
---
N3 : ° N3 : ° Table 46 AcHN . ° 
NHTs NAcTs 
664 675 
Reagents and conditions: (i) AC20, DoC - Lt., 90% 
Scheme 88. Attempted detosylation of N-AcTs derivative 675 
Table 46. Attempted detosylation of N-AcTs derivative 675 
Entry Reagent(s) Solvent 
1 Na/ naphthalene DME 
2 SmI2 THF 
3 Na/Hg MeOH 
4 Zn DME 
La] complex mixture oftosylated products 
Temp. 
-78°e - r.t. 
-78°e - r.t. 
ooe - r.t. 
ooe - r.t. 
NHTs 
676 
Result 
decompositionLa] 
676 (93%) 
decomposition[a] 
decomposition[a] 
As a result of the failed detosylation procedures, we elected to pursue the 
synthesis of an N-Ts oseltamivir analog. To this end, we attempted to reduce the 
acrylate moiety of vinyl aziridine 671 in order to simplify a subsequent azide 
reduction (Figure 127). Unfortunately, our hydrogenation procedures only produced 
the hydrogenolysis product 677, while Stryker's reagent did not produce any new 
compounds (Table 47). 
C02Et 6: acrylate 
_
. ~ °o X _r_ed_uc_ti_on ... 
Table 47 
TsN"· . 
671 
NHTs 
677 
Figure 127. Attempted reduction of acrylate 671 
Table 47. Attempted reduction of acrylate 671 
Entry 
1 
2 
3 
Catalyst 
Pt02 
Stryker's reagent 
5% RhlAb03 
Solvent 
95% EtOH 
THF 
95% EtOH 
H2 Pressure 
I atm 
65 psi 
Temp. 
r.t. 
reflux 
r.t. 
Result 
677 (84%) 
SM 
677 (73%) 
2D4 
We also attempted to reduce acrylate 669 with the same reduction protocols (Figure 
128). Platinum(IV) oxide yielded hydrogenolysis product 679, while Stryker's 
reagent returned starting material (Table 48). The rhodium/alumina hydrogenation 
protocol, which we used in our formal synthesis of oseltamivir (2), resulted in 
successful reduction of acrylate 669 to provide a 8:1 mixture of diastereomers 678a 
and 678b. 
C02Et 
acrylate 
C02Et g02Et box reduction £):°X )):°X + 
BocHN . ° Table 48 BocHN . ° BocHN : ° 
NHTs NHTs NHTs 
669 678a 678b 
Figure 128. Reduction of acrylate 669 
Table 48. Reduction of acrylate 669 
Entry 
1 
2 
3 
Catalyst 
Pt02 
Stryker's reagent 
5% Rh/Ah03 
Solvent 
95% EtOH 
THF 
95% EtOH 
H2 Pressure 
1 atm 
65 psi 
Temp. 
r.t. 
reflux 
r.t. 
+ 
C02Et 
BocHNDOH 
NHTs 
679 
Result 
679 (92%) 
SM 
678a:678b (8:1) 
We also prepared ester 669 from the cis-dihydrodiol derived from 
iodobenzene 308 (Scheme 89). The reaction sequence employed is identical to that 
used for the brominated 1,2-diol 6. Unfortunately, the yields for most transformations 
were slightly lower. The lone exception is the carbonylation procedure which 
proceeded more efficiently with the iodo derivative 683 compared to the 
vinylbromide 667. 
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)yOH 
UOH 
308 
i-ii 
-
iii 
-
680 
I 
hOX~ N~O . 3 : 
NHTs 
681 682 
vi 
-
669 683 
Reagents and conditions: (i) 2,2-DMP, p-TsOH, acetone, r.t.; (ii) PhI=NTs, Cu(acac)2' MeCN, O·C, 
55% over 2 steps; (iii) NaN3, NH4CI, DMF, r.t., 90%; (iv) PPh3, THF/H20 (15:1), r.t.; (v) (BOC)20, 
NEt3, O·C to r.t., 68% over 2 steps; (vi) (PPh3)4, Pd[{CIMPPh3)2], CO, NEt3, EtOH, toluene, reflux, 
77% 
Scheme 89. Synthesis of ethyl ester 669 from cis-dihydrodiol 308 
We submitted vinyl iodide 681 to the same acetylation! deprotection sequence 
employer earlier (Scheme 90). Once again Na/naphthalene decomposed our starting 
material and Smh gave us an azide reduction-acetyl transfer product 685 (Table 49). 
The zinc protocol cleanly reduced the halogen-carbon bond to afford olefin 686. 
I I I 
box box tosyl box + i deprotection 
-
N3 : ° N3 : ° Table 49 AcHN . : . ° 
NHTs NAcTs NHTs 
681 684 685 
Reagents and conditions: (i) AC20, NEt3, r.t., 87% 
Scheme 90. Attempted detosylation of N-AcTs derivative 684 
Table 49. Attempted detosylation of N-AcTs derivative 684 
Entry Reagent Solvent 
1 Nal naphthalene DME 
2 Smh THF 
3 Na/Hg MeOH 
4 Zn DME 
[a] complex mixture of tosylated products 
Temp. 
-78°e - r.t. 
-78°e - r.t. 
ooe - r.t. 
ooe - r.t. 
,Cc°x 
AcHN . ° 
NHTs 
686 
Result 
decompositionla] 
685 {88%) 
decomposition[a] 
686 (66%) 
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We treated ester 678 with access acetic anhydride and attempted to removal the tosyl 
group (Scheme 91). All methods employed decomposed our starting material (Table 
50). 
C02Et 
tosyl ~_d_;a,-P~~~;~~:_oio_n_. BOcACN~J< 
NHTs 
678 
NAcTs 
687 
Reagents and conditions: (i) AC20, NEt3, DCM, r.t., 81 % 
Scheme 91. Attempted detosylation of N-AcTs derivative 687 
Table 50. Attempted detosylation of N-AcTs derivative 687 
Entry 
1 
2 
3 
4 
Reagent 
Na/ naphthalene 
Smh 
Na/Hg 
Zn 
Solvent 
DME 
THF 
MeOH 
DME 
[a] complex mixture oftosylated products 
Temp. 
-78°C - r.t. 
-78°C - r.t. 
O°C - r.t. 
O°C - r.t. 
NHAc 
688 
Result 
decompositionla] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
Convinced that our tosyl deprotection route was futile, we elected to collapse 
the acetonide of ester 678 and attempt to complete the synthesis of an N-tosyl 
oseltamivir analog (Figure 129). We tested the same conditions utilized previously; 
again finding sodium ethoxide was the most efficient method to furnish allylic 
alcohol 689. 
C02Et C02Et D acetonide ,6 ° elimination ~ 
BocHN . ;;< -Ta-b-le-S-1- BocHN : OH 
NHTs NHTs 
678 689 
Figure 129. Elimination of acetonide 678 
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Table 51. Elimination of acetonide 678 
Entry Base Solvent Temp. Yield 
1 DBU acetone O°C - r.t. 15% 
2 DBU ~ O°C - r.t. 49% 
3 DBU DCM O°C - r.t. 32% 
4 EtONa EtOH we - r.t. 76% 
La] reaction performed with DBU as the solvent 
In order to complete the synthesis of the N-Ts oseltamivir analog, the allylic alcohol 
689 needed to be alkylated. Our first attempts utilized the method developed by Fang 
in his synthesis of oseltamivir (2).248 Trichloroacetimidate 692 was prepared by 
treating 3-pentanol (690) with 2,2,2-trichloroacetonitrile (691) in the presence of 
sodium hydride (Scheme 92). 
i 
-
690 691 692 
Reagents and conditions: (i) 690, 691, Et20, NaH, -SoC, 73% 
Scheme 92. Preparation of 3-pentyl trichloroacetimidate 692 
Fang's alkylation procedure calls for the repetitive addition of 
trifluoromethanesulfonic acid and the alkylating agent 692; however, this method 
rapidly decomposed the starting material (Table 52, Entry 1). Spectral analysis 
indicated the Boc-group was removed under these conditions. All other procedures 
attempted decomposed the starting material or did not produce any new compounds. 
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689 
692 
alkylation 
)( 
Table 52 
693 
Figure 130. Alkylation of allylic alcohol 689 
Table 52. Alkylation of allylic alcohol 689 
Entry Reagent(s) Solvent Temp. 
I 692, CF3S03H DCM r.t. 
2 692, CF3S03H DCM -40 - O°C 
3 692, AcOH DCM -40 - O°C 
4 692, AcOH DCM -40 - O°C 
5 692 r.t. 
La] complex mixture of products 
3.6.2 N-Boc Aziridine Approach 
Result 
decompositionLa] 
decomposition[a] 
decomposition[a] 
decomposition[a] 
SM 
We explored the possibility of preparing either oseltamivir (2) or an analog 
from an N-Boc aziridine. For this purpose, we prepared sulfonyloxycarbamate 696 by 
reacting tert-butyl hydroxycarbamate (695) with 4-nitrobenzene-I-sulfonyl chloride 
(Scheme 93). This reagent, when treated with base, provides a nitrene intermediate 
capable of aziridinating olefins. 
i 
-
BocHN-OH ii 
-
694 695 
Reagents and conditions: (i) Na2C03, Et20/ H20, O·C to r.t.; (ii) p-NOr C6H4-S02CI, NEt3, Et20, O·C 
to Lt., 77% 
Scheme 93. Preparation of sulfonyloxycarbamate reagent 696 
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We tested several biphasic (DCMI H20) conditions to prepare N-Boc aziridine 697 
from 1,3 diene 554 (Figure 131). The best result was obtained when a high excess of 
696 was used (Table 53, Entry 3). 
554 
aziridination 
with 696 
Table 53 
697 
Figure 131. Preparation of N-Boc aziridine 697 
Table 53. Preparation of N-Boc aziridine 697 
Entry Reagents 
1 696, NaHC03, BnNEt3CI 
2 696, NaHC03, BnNEt3CI 
3 696, NaHC03, BnNEt3CI 
[aJ equivalents of 696 
Equiv.[aJ 
1 
5 
10 
Solvent 
DCM/H20 
DCM/H20 
DCM/H20 
Temp. 
r.t. 
r.t. 
r.t. 
Yield (%) 
12 
24 
44 
We tested a series of aziridine opening reactions with various azide sources (Figure 
132). Reactions catalyzed by Cu(OTf)2 decomposed the starting material, while 
ammonium chloride catalysis successfully provided allylic azide 698 (Table 54). 
Although pleased with the result, we saw this route as impractical and did not pursue 
it further. 
697 
aziridine 
opening 
Table 54 
698 
Figure 132. Opening of N-Boc aziridine 697 
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Table 54. Opening of N-Boc aziridine 697 
Entry Azide Catalyst 
1 NaN3 NH4CI 
2 TMS-N3 CU(OTf)2 
3 DPPA CU(OTf)2 
[aJ complex mixture of products 
Solvent 
DMF 
THF 
THF 
Temp. 
r.t. 
r.t. 
r.t. 
Result 
698 (77%) 
decomposi tion:[a) 
decomposition[a) 
We explored the possibility of removing the Boc carbamate of 697, with the hope that 
it could be replaced with an acetyl group (Figure 133). However, treatment with 
trifluoroacetic acid resulted in the formation of cyclic carbamate 699, while thermal 
deprotection returned starting material (Table 55). 
Br 
Cx:>< 
BoeN'" 
697 
Boe 
preproteetion 
• 
Table 55 
Br 
,,6::>< 
o " }-NH 
o 
699 
Figure 133. Attempted Boc deprotection of 697 
Table 55. Attempted Boc deprotection of 697 
Entry 
1 
2 
3 
Reagent 
TFA 
TFA 
Solvent 
DCM 
toluene 
Temp. 
O°C - r.t. 
O°C - r.t. 
60°C 
Result 
699 (89%) 
699 (66%) 
SM 
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4. Conclusions and Future Work 
The preceding study reviewed our latest efforts in seven areas of research; 1. 
reactivity of the Burgess reagent with oxiranes, 2. development of a chiral auxiliary 
version of the Burgess reagent, 3. enantioselective synthesis of balanol, 4. 
chemoenzymatic synthesis of balanol, 5. enzymatic cis-dihydroxylation of benzoate 
esters, 6. synthesis of oseltamivir, and 7. synthesis of oseltamivir analogs. 
We have elucidated a plausible mechanism for reactions between the Burgess 
reagent and oxiranes. The relative stereochemistry of the resulting cyclic sulfamidates 
was established as cis. We developed a chiral auxiliary version of the Burgess reagent 
and demonstrated its application in the synthesis of all four ~-amino alcohol 
stereoisomers from a single meso-epoxide. This methodology was exploited in an 
enantiodivergent approach to both enantiomers of balanol. Formal intermediates for 
(+)- and (-)-balanol were each prepared in eight steps from 1,3-cyclohexadiene oxide. 
The same formal intermediates were prepared from a single cis-dihydrodiol derived 
from the bio-oxidation of bromobenzene by the toluene dioxygenase enzyme. The 
(+ )-balanol intermediate was constructed in 10 steps, while the (-)-balanol was 
formulated in 12 steps. The ~-amino alcohol moiety is common among naturally 
occurring products. In the future, we hope to develop a route to such a compound 
utilizing the (-)-menthyl Burgess reagent methodology. 
We examined the steric and functional limitations of the toluene dioxygenase-
mediated dihydroxylation of benzoate esters. It was concluded that methyl, ethyl, i-
propyl, and n-propyl benzoate were acceptable substrates, while n- and t-butyl were 
not oxidized by TDO. Benzoates bearing propargyl and allyl functionalities were also 
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accepted by the enzyme. The absolute stereochemistry of each diol metabolite was 
confirmed through their conversion to a single known intermediate. In the future we 
hope to screen benzoates with various substituents (e.g. halogen, alkyl) on the arene 
ring. 
We employed the cis-dihydrodiol obtained from the enzymatic 
dihydroxylation of ethyl benzoate in an eight step formal synthesis of oseltamivir. We 
also developed several potential approaches, each employing a vinyl aziridine 
intermediate. In the future, we hope to conclude these strategies and prepare the N-
tosyl and N-Boc analogs of oseltamivir. Furthermore, we plan to submit all of the 
intermediates for biologically testing against all known influenza neuraminidase 
enzymes. 
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5. Experimental Section 
5.1 General experimental procedures 
Viable cells of E. coli JM 109 (pTDG 601) were prepared as previously reported.279 
Substrate was fed in 1 g increments over the course of ~2 h with metabolites being 
harvested in the usual manner. All non-aqueous reactions were carried out in an argon 
atmosphere using standard Schlenk techniques for the exclusion of moisture and air. 
Methylene chloride was distilled from calcium hydride. Tetrahydrofuran and benzene 
were dried over sodium/benzophenone. Analytical thin-layer chromatography was 
performed on Silicycle 60 A 250 )lm TLC plates with F-254 indicator. Flash column 
chromatography was performed using 200-400 mesh silica gel. Melting points were 
recorded on a Hoover Unimelt apparatus and are uncorrected. IR spectra were 
recorded as thin films on NaCI plates and were obtained on a Perkin-Elmer One FT-
IR spectrometer. Optical rotation was measured on a Perkin Elmer 341 polarimeter 
using a sodium (589, D line) lamp and are reported as follows: [aJ,.. T °C (c = gil 00 
mL, solvent). IH NMR spectra were recorded on a Bruker (300 MHz or 600 MHz) 
spectrometer and are reported in ppm using tetramethylsilane (0.00 ppm) or solvent 
(CDCh: 7.24 ppm, acetone-d6: 2.05 ppm, DMSO-d6: 2.50, CD30D: 3.31 ppm, D20: 
2.80) as an internal standard. Data are reported as (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, br = broad; coupling constant(s) in Hz, integration. Proton-
decoupled l3C NMR spectra were recorded at 150 or 75 MHz and are reported in ppm 
using solvent as an internal standard (CDCh: 77.23 ppm, acetone-d6: 206.68 ppm, 
DMSO-d6: 39.51 ppm, CD30D: 49.15 ppm). Combustion analyses were performed 
by Atlantic Microlabs, Norcross, GA. Mass spectra were recorded on Kreatus/MsI 
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Concept 1 S mass spectrometer at Brock University. The GC/MS data was obtained on 
a Perkin-Elmer Clarus SOO Gas Chromatograph and Mass Spectrometer using a 
Perkin Elmer Elite-SMS column, 10 m, 0.2S mmID, 2 mLi min helium flow. 
General procedure for the reaction of oxiranes with the Burgess reagent (8) 
To a stirred solution of oxirane (4.0 mmol) in THF (20 mL) was added 
(methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt (8) (2.38 g, 9.2 
mmol) at r.t. in a single portion. The resulting reaction mixture was immediately 
brought to reflux by submerging it into a preheated oil bath (70°C). The reaction 
mixture was stirred until complete consumption of the oxirane (TLC), then cooled to 
r.t. and filtered through a plug of silica to remove salts formed during the reaction. 
The reaction solution was then concentrated and the resulting residue was purified by 
flash column chromatography using an appropriate solvent gradient (hexanes: ethyl 
acetate) to yield the corresponding sulfamidate products. 
General procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) 
To a stirred solution of oxirane (2.0 mmol) in THF (S mL) was added (-)-menthyl 
Burgess reagent (3) (4.60 mmol) at r.t. in a single portion. The resulting reaction 
mixture was immediately brought to reflux by submerging it into a preheated oil bath 
(70°C). The reaction mixture was stirred until complete 'consumption of the oxirane 
(TLC), then cooled to r.t. and filtered through a plug of silica to remove salts formed 
during the reaction. The reaction mixture was then concentrated and the resulting 
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residue was purified by flash column chromatography using an appropriate solvent 
gradient (hexanes: ethyl acetate) to afford a 1: 1 mixture of sulfamidate diastereomers. 
General procedure for the syntheses of benzoates from sulfamidates. 
To a stirred solution of sulfamidate (1.25 mmol) in dry DMF (5 mL) was added 
ammonium benzoate (346 mg, 2.50 mmol). The solution was heated at 55°C and 
stirred for 18 h before the solvent was evapourated, and the resulting residue was 
dissolved in THF (3 mL). Three drops of water and three drops of cone. H2S04 were 
added, and the reaction mixture was stirred at r.t. for 12 h. The reaction mixture was 
diluted with water and the pH was adjusted to 9, using a sat. aqueous solution of 
NaHC03, before the layers were separated. The aqueous layer was extracted with 
DCM (3 x 5 mL), then the organic layers were combined and washed with brine (1 x 
5 mL), dried over Na2S04, filtered, and the solvent was evapourated. The resulting 
benzoate diastereomers were separated via flash column chromatography (hexanes: 
ethyl acetate) using an appropriate solvent system. 
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S.2 Detailed Experimental Procedures 
3 
N,N-Diethyl-N-[[[[[(lR,2S,SR)-S-methyl-2-(1-methylethyl) cyclohexyl]oxy] 
carbonyl] amino]sulfonyl]-ethanaminium, inner salt (3) 
To a stirred solution of chlorosulfonyl isocyanate (5.21 g, 36.8 mmol) in benzene (15 
mL) was added a solution of (-)-menthol (481) (5.00 g, 32 mmol) in benzene (15 mL) 
dropwise over 30 min while keeping the internal temperature between 25 - 30°C, 
using an ice-water bath. The reaction mixture was then stirred at r.t. for an additional 
30 min, before ice cold hexane .(40 mL) was added while cooling the reaction mixture 
to 0-5 °C. The product was filtered and washed with ice cold hexanes (2 x 20 mL) 
and dried under reduced pressure to yield 8.29 g (87%) of (-)-menthol sulfamoyl 
chloride (483) as colourless crystals (87%): mp 86-88 °C (hexanes); [a]D23 -64.5 (c 
0.8, CHCh); IH NMR (300 MHz, CDCh) 0 8.38 - 8.55 (bs, IH), 4.81 (ta, J = 11.2, 
4.6 Hz, IH), 2.07 - 2.16 (m, IH), 1.83 - 2.01 (m, IH), 1.61 - 1.77 (m, 2H), 1.39 - 1.58 
(m, 2H), 1.04 - 1.22 (m, 2H), 0.93 (t, J= 6.8 Hz, 6H), 0.83 (d, J= 6.8 Hz, 3H) ppm. 
To a stirred solution of triethylamine (6.53 mL, 47.0 mmol) in benzene (20 mL) was 
added a solution of (-)-menthol sulfamoyl chloride (483) (7.00 g, 23.5 mmol) in 
benzene (40 mL) dropwise over I h, keeping the internal temperature between 10-15 
°C, using an ice-water bath. The reaction mixture was stirred at r.t. for an additional 
30 min and then filtered to remove the triethylamine hydrochloride salt. The filtrate 
was evapourated under reduoed pressure, then dissolved in THF (50 mL) at 30°C and 
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cooled to 0-5 °C and treated with hexanes (50 mL) to precipitate out 7.24 g (85%) of 
the title compound 3 as a colourless solid. mp 87-89 °C (THFlhexanes); {a]D23 -48.7 
(c 0.48, CHCh); IR (film) v 3426, 3020, 2958, 2872, 1682, 1457, 1389, 1369, 1340, 
1285, 1253, 1216, 1105,982,922,891 em-I; IH NMR (300 MHz, CDCh) 84.51 (td, 
J = 11.0, 4.6 Hz, IH), 3.45 (q, J = 7.7 Hz, 6H), 3.14 - 3.26 (m, IH), 1.93-2.08 (m, 
2H), 1.65 (d, J = 11.9 Hz, 2H), 1.30 - 1.44 (m, IIH), 0.92 - 1.03 (m, 2H), 0.87 (t, J = 
7.7 Hz, 6H), 0.76 (d, J= 6.6 Hz, 3H) ppm; l3C NMR (75 MHz, CDCh) 8 157.7,76.4, 
50.7,47.3,46.7,41.3,34.6,31.8,26.4,23.7,21.2, 16.6,9.8,8.8 ppm. 
d 
4 
1,3-cyclohexadiene oxide (4) 
To a mechanically stirred solution of 1 ,3-cyclohexadiene (33.6 g, 0.419 mol), Na2C03 
(177 g, 1.68 mol) in DCM (400 mL) was added peracetic acid (104.5 g, 0.440 mol) 
dropwise at 0 °C over 1 h. The reaction was stirred for 12 h at r.t. before removing the 
~ 
salts by filtration. The organic layer was distilled off at 1 atm. The product was 
collected by fractional distillation under reduced pressure to yield 21.2 g (56%) of the 
title compound as a clear oil. IH NMR (300 MHz, CDCh) 8 1.43-2.41 (m, 4H), 3.11-
3.28 (m, IH), 3.42-3.53 (m, IH), 4.93 (d, J = 4 Hz, 2H) ppm; l3C NMR (75 MHz, 
CDCh) 8 20.5, 20.8, 46.9, 123.1, 132.9 ppm 
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5a 5b 
(3aR, 7aS)-2,2-Dioxo-3a,6, 7,7 a-tetrahydro-U6-1,2,3-benzoxathiazole-3-carboxylic 
acid-(lR,2S,5R)-2-isopropyl-5-methylcyclohexyl ester (Sa) and 
(3 as, 7aR)-2,2-Dioxo-3a,6, 7,7 a-tetrahydro-U6-1 ,2,3-benzoxathiazole-3-carboxylic 
acid-(lR,2S,5R)-2-isopropyl-5-methylcyclohexyl ester (5b) 
The general procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) using 1,3-cydohexadiene oxide (4) (186 mg, 2.0 mmol) as the starting 
material gave 257 mg (36%) of a 1: 1 mixture of diastereomers Sa and 5b after 
purification by flash column chromatography (hexanes/ethyl acetate, 8: 1). Colourless 
oil; Rf 0.68 (hexanes/ethyl acetate, 5:1); mp 115-118 °C (hexanes-ethyl acetate); Rf 
0.55 (4:1 hexanes-ethyl acetate); [a]D23 -54.5 (c 1.25, CHCh); IR (film) v 3443, 3031, 
2959,2930,2873, 1731, 1599, 1457, 1432, 1371, 1331, 1307, 1241, 1217, 1189, 
1170, 1125 em-I; IH NMR (300 MHz, CDCh) (rotamers) 0 0.74-0.85 {m, 3H), 0.87-
0.96 (m, 6H), 1.00-1.31 (m, 3H), 1.39-1.75 (m, 5H), 1.82-2.44 (m, 5H), 4.~6-4.84 (m, 
2H), 5.13-5.33 (m, IH), 5.56-5.85 (m, 1H), 6.02-6.28 (m, 1H) ppm; I3C NMR 
(rotamers) (75 MHz, CDCh) 0 18.7 18.7, 18.8, 18.9, 19.9,20.3,21.2,22.1,22.6,23.7, 
23.9, 24.2, 29.3, 29.3, 29.5, 32.0, 37.7, 37.9, 38.6, 44.7, 44.8, 44.9, 45.2, 51.5, 53.2, 
53.2,72.8,72.9,74.6,75.1,75.3,75.5,79.2,81.6,81.7, 117.9, 119.0, 119.0, 129.5, 
135.0, 147.9 ppm; MS (FAB) mlz (%): 358 (M+H+); (11),220(16), 140(14), 139(90), 
137(33), 97(24), 95(24), 83(100), 81(36), 80(11), 79(47), 69(43), 67(19), 57(35), 
55(49),53(12); HRMS calcd for C17H27NOsS 357.1610, found 357.1593. 
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O.2X
OEt 
7" . OH 
~ OH 
7 
6-Carboxymethyl-(lS,2S)-1,2-dihydroxycyclohexa-3,5-diene (7) 
From the fermentation of benzoate 576, (8.06 g, 43.4%, 45.6% based on recovered 
starting material) Colourless crystals, mp 48°C (ethyl acetatelhexanes); Rf 0.31 (1:2 
hexanes/ethyl acetate); [a]D23 +54.7 (c 3.8, CHCh); lR (film) v 3385, 2981, 2934, 
1700, 1280, 1243, 1104, 1068,825, 771 em-I; IH NMR (300 MHz, CDCh) () 7.04 (d, 
J = 5.3 Hz, IH), 6.15 (dt, J = 1.1, J = 9.4 Hz, IH), 6.03 (dq, J = 2.25, J = 9.22 Hz, 
IH), 4.49-4.55 (m, IH), 4.40-4.48 (m, IH), 4.22 (q, J = 7.0 Hz, 2H), 3.65-3.78 (m, 
2H), 1.28 (t, J = 7.2 Hz, 3H) ppm; I3C NMR (75 MHz, CDCh) () 167.1, 138.7, 134.1, 
128.7, 122.5, 69.8, 64.5, 60.9, 14.2 ppm; MS (El) mlz (%): 184{M+,9), 166(20), 
138(26), 122(33), 121 (52), 105(100), 77(39), 51(21), 45(20); HRMS ca1cd for 
C9HI20 4 184.0736, found 184.0731; Anal. ca1cd: C 58.69, H 6.57, found C 58.77, H 
6.60. 
02XOMe 7" OH 
~ OH 
18 
6-Carboxymethyl-(IS,2S)-1,2-dihydroxycyclohexa-3,5-diene (18). 
From the fermentation of benzoate 575, (12.92 g, 19.2%,75.8% based on recovered 
starting material) Pale yellow oil; Rf O.33 (1:2 hexanes/ethyl acetate); {a]D23 +71.3 (c 
1.6, CHCh); lR (film) v 3412, 2098, 1690, 1639, 1291,820, 772 em-I; IH NMR (300 
MHz, CDCh) () 7.05 (d, J = 5.3 Hz, IH), 6.17 (dd, J = 0.6, J = 10.3 Hz, IH), 6.05 (qd, 
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J = 2.2, J = 5.1 Hz, 1H), 4.50-4.56 (m, 1H), 4.41-4.50 (m, 1H), 3.77 (s, 3H), 3.52-
3.67 (m, 2H) ppm; I3C NMR (75 MHz, CDCh) cS 167.5, 138.6, 134.3, 128.4, 122.6, 
69.5, 64.8, 52.1 ppm; MS (EI) mlz (%): 170(M+, 33), 152(61), 139(22), 138(96), 
136(71), 121(100), 110(95), 109(66), 105 (23), 93(42), 92(22) 82(57), 81(56), 65(59), 
53(49),51(22); HRMS ca1cd for CgH IO0 4 170.0579, found 170.0580. 
OH 
d"~~B" 
~n 0 
231a 
N-[ (3R,4R)-I-benzyl-4-hydroxyazepan-3-yl]-4-(benzyloxy)benzamide (231 a) 
To a stirred solution of 539a (12 mg, 0.0263 mmo1) in freshly distilled THF (0.2 mL) 
was added 1 N NaOH (1 mL) at -20°C. The reaction was warmed to r.t. slowly over 
12 h before concentrating under reduced pressure. The reaction was concentrated, 
extracted into ethyl ether (5 x 1 mL), washed with brine and then dried over Na2S04. 
The crude product was subjected to flash column chromatography (3:1 hexanes-ethy1 
acetate) to yield 9 mg (81%) of the title compound as yellow oil. Rf0.19 (1:3 ethyl 
acetate-hexanes); [a]D23 --4.7 (c 0.02, CHCh); IR (film) v 3407, 3377, 2955, 1638, 
1611, 1298, 1140 cm-I; IH NMR (300 MHz, CDCh) b 1.55-1.99 (m, 4H), 2.50 (m, 
1H), 2.73 (dd, J = 1.9, 14.3 Hz, 1H), 2.93 (dd, J = 2.0, 14.2 Hz, 1H), 3.00 (m, 1H), 
3.42 (d, J = 13.2 Hz, 1H), 3.74-3.78 (m, 2H), 3.88 (m, 1H), 5.15 (s, 2H), 6.54 (d, J = 
8.7 Hz, 1H), 6.99 (d, J = 6.8 Hz, 2H), 7.22-7.50 (m, 12H) ppm; I3C NMR (150 MHz, 
CDCh) b 29.7,31.5,54.4,58.0,59.9,64.2, 70.1, 77.5, 114.5, 126.4, 127.4, 127.5 (2x 
C), 128.2, 128.7 (2x C), 128.9 (2x C), 129.0, 129.5 (2x C), 136.4, 161.4, 167.8 ppm; 
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MS (FAB) mlz (%) 431 (M + H+); 41(34), 43(43), 57(51),71(34),91(71), 149(100); 
Alternative method: To a stirred solution of 539a (21 mg, 0.0460 mmol) in THF 
(0.3 mL) was added 1 N NaOH (1.5 mL) at -20 °C. The reaction was warmed allowed 
to warm to r.t. slowly over 12 h before concentrating under reduced pressure. The 
resulting residue was diluted with H20 (1 mL) and extracted into EtOAc (5 x 1 mL), 
washed with brine (1 mL) and dried over Na2S04. The crude material was purified via 
flash column chromatography with a solvent system of 3:1 (hexanes-ethyl acetate) 
yield 231a (17 mg, 86 %) as a pale yellow oil; [o.]D23 -5.6 (c 0.2, CHCh) 
231b 
N-[ (3S,4S)-hexahydro-4-hydroxy-1-(phenylmethyl)-
1H-azepin-3-yl]-4-(phenylmethoxy)benzamido (231b) 
To a stirred solution of azepane 539b (12 mg, 0.026 mmol) in tetrahydtofuran (0.3 
mL) was added 1 N NaOH (1.5 mL) at -20 °C. The reaction mixture was allowed to 
warm to r.t. slowly over 12 h before concentrating under reduced pressure. The 
resulting residue was diluted with H20 (1 mL) and extracted into ethyl acetate (5 x 1 
mL), then the combined organic layers were washed with brine (1 mL) and dried over 
Na2S04. The crude material was purified via flash column chromatography with a 
solvent system of 3:1 (hexanes-ethyl acetate) yield 231b (6.5 mg, 56 %) as a pale 
yellow oil: RrO.31 (3:2 hexane-ethyl acetate); [o.]D23 + 5.77 (c 0.75, CHCh); IR (tl1m) 
v 3407, 3377, 2955, 1638, 1611, 1298, 1140 cm-I; IH NMR (600 MHz, CDCh) 0 
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7.22-7.50 (m, 12H), 6.99 (d, J = 6.8 Hz, 2H), 6.54 (d, J = 8.7 Hz, 1NH), 5.11 (s, 2H), 
3.88 (m, 1H), 3.69-3.78 (m, 1H), 3.63 (d, J = 13.2 Hz, 1H), 3.42 (d, J = 13.2 Hz, 
1H), 3.00 (m, 1H), 2.93 (dd, J = 2.0, 14.2 Hz, 1H), 2.73 (dd, J = 1.9, 14.3 Hz, 1H), 
2.50 (m, 1H), 1.85-1.95(m, 2H), 1.60-1.85 (m, 2H) ppm; J3C NMR (150 MHz, 
CDCh) 0 167.8, 161.4, 136.4(2xC), 129.5(2xC), 129.0, 128.9(2xC), 128.7(2xC), 
128.2(2xC), 127.5(2xC), 127.4(2xC), 126.4, 114.5(2xC), 77.5, 70.1, 64.2, 59.9, 58.0, 
54.4, 31.5, 29.7 ppm; MS (FAB) mlz (%): 431 (M+H+), 41(34), 43(43), 57(51), 
71(34),91(71), 149(100); HRMS ca1cd for C27H3IN203 431.2310, found 431.2312. 
E' 
N3 : OH 
NHAc 
416 
Ethyl(3R,4R,5S)-4-( acetyl amino )-5-azido-3-hydroxycyclohex-l-ene-l-
carboxylate (416) 
To a stirred solution of 648 (25 mg, 0.066 mmo1) in acetone:H201 10:1 (0.5 mL) was 
added sodium azide (43 mg, 0.66 mmo1). The resulting solution was stirred at r.t. for 
12 h and then concentrated under reduced pressure to provide ethyl 
(3aR,4R,6S, 7 R, 7 as)-7 -( acetylamino )-6-azido-2,2-dimethylhexahydro-l,3-
benzodioxole-4-carboxylate (656) which was used without further purification; data 
for 656: R{ 0.41 (1: 10 hexanes-ethy1 acetate); IR (film) 3583, 3284, 2987, 2108, 
1720, 1655, 1540, 1372, 1248, 1072 cm-I; IH NMR (300 MHz, CDCh) 0 5.77 (d, J = 
7.5 Hz, 1NH), 4.58 (dd, J = 4.0,4.8 Hz, 1H), 4.43 (dd, J = 4.8,8.6 Hz, IH), 4.13-4.29 
(m, 2H), 3.91 (dt,J= 3.4,11.7 Hz, 1H), 3.20 (dd,J= 8.1,11.1 Hz, IH), 2.85 (dt,J= 
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3.9, 13.2 Hz, 1H), 2.17 (dt, J = 3.9, 13.2 Hz, 1H), 2.02 (s, 3H), 1.91 (q, J = 13.l Hz, 
1H), 1.51 (s, 3H), 1.34 (s, 3H), 1.26 (s, 3H) ppm; MS (FAB) mlz (%): 327 (M+ H+), 
43(23),257(100),299 (33); HRMS ca1cd for CI4H23N405 327.1668, found 327.1670. 
To a stirred solution of crude azide in methylene chloride (150 j.lL) was added 1,8-
diazabicyc10[5.4.0]undec-7-ene (14.8 j.lL, 0.099 mmol) at 0 °C. The resulting solution 
was stirred until complete consumption of starting material (TLC analysis, ~ 12 h). 
The reaction was diluted with methylene chloride (500 j.lL), washed with 1 N HCl (3 
x 250 j.lL), and brine (1 x 500 j.lL) and then dried over Na2S04. The crude material 
was purified by flash column chromatography with a solvent system of 1:7 (hexanes-
ethyl acetate) to yield (416) (15 mg, 86% over 2 steps) as a yellow oil: Rf O.22 (1:10 
hexanes-ethyl acetate); [a]D23 +44.3 (c 0.65, CHCh); IR (film) v 3509, 2103, 1701, 
1690, 1510, 1214 cm-I; IH NMR (600 MHz, CDCh) D 6.83 {t, J = 2.4 Hz, 1H), 5.96 
(br s, 1NH), 5.28 (br s, 10H), 4.39 (d, J = 2.8 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.59-
3.66 (m, 2H), 2.98 (dd, J = 4.3, 15.9 Hz, 1H), 2.42-2.49 (m, 1H), 2. W (s, 3H), 1.30 (t, 
J = 7.2 Hz, 3H) ppm; 13C NMR (150 MHz, CDCh) D 173.6, 1-65.6, 138.l, 127.6, 71.2, 
61.4, 57.9, 57.6, 29.5, 23.2, 14.1 ppm; MS (FAB) mlz (%): 269 (M+ H+), 41(44), 
43(100), 56(54), 57(46), 84(22), 227 (55); HRMS calcd for CllH17N40 4 269.l250, 
found 269.1248. 
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NHAc 
: Br Br~o 
O~ 
428 
N-[ (3aR,4R,5S, 7aS}-4, 7 -dibromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-l,3-
benzodioxol-5-yl] acetamide (428) 
To a solution of N-bromoacetamide (309 mg, 2.25 mmol) in acetonitrile (40 mL) was 
added 0.28 mL SnBr4 (0.4 M in CH2Clz, 0.11 mmol) at -40°C in the dark. Diene 554 
(432 mg; 1.87 mmol) in acetonitrile (20 mL) was added slowly to the reaction 
mixture by syringe pump at the same temperature over 4 h. The resulting reaction 
mixture was stirred for 1 h, before saturated aqueous NaHC03 (10 mL) and Na2S03 
(10 mL) were carefully added. The phases were separated and the aqueous phase was 
extracted with CH2Clz (3 x 100 mL). The combined organic extracts were washed 
with brine (10 mL), dried over MgS04 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on neutral alumina (CH2Clz) to 
afford bromo amide 2 (526 mg, 76%) as colourless crystals: RrO.71 (CH2ClzIMeOH 
96:4); mp 181°C; [a]D23 +188.2 (c 0.50, CHCh); lR (film) v 3684,3019, 2400,1676, 
1498, 1425, 1216, 1064, 929, 757, 669, 497, 478, 472 cm-I; IH NMR (300 MHz, 
CDCh) 86.21 (d, J= 9.0 Hz, IH), 4.93 (m, 1H), 4.68 (d, J= 5.1 Hz, IH), 4.60 (t, 
J= 4.5 Hz, IH), 4.21 (t, J= 3.6 Hz, 2H), 1.97 (s, 3H), 1.51 (s, 3H), 1.42 (s, 3H) ppm; 
I3C NMR (75 MHz, CDCh) 8 169.0, 128.0, 124.7, 112.0, 77.8, 75.8, 50.3, 44.4, 27.8, 
26.5,23.3 ppm; MS (El) mlz (%): 366 (M), 354(6), 313(6), 294(6), 255(6), 253(12), 
251(7),232(33),230(34), 190(11), 189(6), 188(12), 187(5), 174(6), 173(10), 172(8), 
171(9), 165(8), 163(8), 151 (6), 109(22), 108(9), 93(7), 81 (8), 80(10), 65(8), 59(11), 
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55(8), 43(100), 42(11), 41(6); HRMS (EI) calcd for CIIHlS03NBr2 366.9419, found 
366.9418. Anal. calcd: C 35.80, H 4.10, found C 35.77, H 4.11. 
(3aS,4S,5S,7 as)-8-acetyl-7 -bromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-4,5-
epimino-l,3-benzodioxole (429) 
To a solution of amide 428 (17.61 g, 47.72 mmol) in dimethoxyethane (400 mL) was 
added n-Bu4NBr (16.33 g, 52.49 mmol) at O°C under argon. At this temperature 
potassium bis(trimethylsilyl)amide (100 mL, 0.5 M in toluene, 52.49 mmol) was 
added dropwise. The reaction mixture was stirred for 3 h at 0 °C and then quenched 
by the addition of potassium phosphate monobasic sodium hydroxide (350 mL, set to 
pH 7). The two-phase mixture was extracted with ethyl acetate (3 x 150 mL) and then 
the combined organic phases were dried over MgS04 and concentrated under reduced 
pressure. The crude material was purified by flash column chromatography with a 
solvent gradient of2:1 then 1:1 (hexanes-ethyl acetate) to afford 429 (9.21 g, 67%) as 
colourless crystals: Rf 0.44 (1:1, hexanes-ethyl acetate); mp 128°C; [a]o23 -57.6 (c 
0.75, CHCh); IR (film) v 3017, 2938, 1704, 1423, 1383, 1372, 1289, 1267, 1216, 
1161, 1063, 994, 967, 894, 868, 819, 756, 668, 619, 554, 510, 485, 468 cm-I; IH 
NMR (300 MHz, CDCh) 86.70 (d, J= 4.8 Hz, IH), 4.72 (dd, J= 0.9,6.9 Hz, IH), 
4.46 (dd,J=4.2, 6.9 Hz, IH), 3.19 (dd,J=5.1, 6.0 Hz, IH), 3.11 (ddd,J=0.9, 6.0, 
6.1 Hz, IH), 2.17 (s, 3H), 1.56 (s, 3H), 1.41 {s, 3H) ppm; I3C NMR (75 MHz, CDCh) 
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o 181.7, 129.9, 122.8, 108.5,76.6, 71.9, 39.6, 36.7, 27.0, 24.9, 23.2 ppm; MS (EI) mlz 
(%) 272 (M+-CH3), 232(9), 230(9), 208(5), 190(9), 189(8), 188(9), 187(7), 172(6), 
170(5), 160(13), 158(13), 150(18), 109(18), 108(45), 100(23),85(10),84(5), 81{9), 
80(17),79(7),78(7),59(9),53(7),52(6),51(10), 43(100), 42(6), 41(6); HRMS (EI) 
ca1cd for CIIHI403NBr 287.0157, found 287.0161. Anal. ca1cd: C 45.85, H 4.90, 
found C 45.84, H 4.95. 
459 
trans-2,2-Dioxide-hexahydro-3H-l,2,3-benzoxathiazole-3-carboxylic acid, methyl 
ester (459) 
To a solution of oxathiazolidine 466 (140 mg, 0.64 mmol) in CH3CN (3 mL) was 
added sequentially ruthenium(III)chloride hydrate (catalytic amount), sodium 
periodate (205 mg, 0.96 mmol), and H20 (3 mL) at 0 °C. The reaction mixture was 
allowed to warm to r.t. was stirred for 3 h. The reaction mixture was extracted three 
times with Et20. The organic layers were combined and washed with H20 and brine, 
then dried over anhydrous MgS04. Filtration, evaporation of the solvent and 
purification by flash column chromatography (hexanes/ethyl aceate) afforded 459 
(130 mg, 87 % as a colourless oil. R{ 0.55 (2:1, hexanes/ethyl aceate); IR (film) v 
3367,2958,2870,2255, 1746, 1444, 1384, 1329, 1299, 1193 em-I; IH NMR (300 
MHz, CDCh) 0 4.39 (dt, J = II Hz, 4 Hz, 1H), 3.88 (s, 3H), 3.73-3.84 (m, 1H), 2.59-
2.73 (m, 1H), 2.19-2.31 (m, IH), 1.81-2.05 (m, 2H), 2.05 (dq, J= 12 Hz, 4 Hz, 1H), 
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1.30-1.58 (m, 3H) ppm; l3C NMR (75 MHz, CDCh) () 151.6, 84.6,64.7,54.9, 29.D, 
28.3, 23.7, 23.5 ppm; MS (EI) mlz (%): 235, 155 (37), 150 (100), 140 (12), 124 (13), 
114 (19), 101 (52), 98 (26), 95 (22), 81 (44)69 (24), 59 (53); HRMS (El) calcd for 
CgH13NOsS: 235.0514, found, 235.0519; Anal. calcd: C 40.84, H 5.57, found C 41.18, 
H5.84. 
460 
cis-Hexahydro-2,2-dioxide-3H-l,2,3-benzoxathiazole-3-carboxylic acid methyl 
ester (460) 
The general procedure for the reaction of oxiranes with the Burgess reagent (8) using 
cyclohexene oxide (458) provided 460 in 64% yield (604 mg) as colourless crystals: 
mp 97-98 °C (ethyl acetate/hexanes); Rf 0.49 (hexanes : ethyl acetate, 1:1); lR (film) v 
2943, 1743, 1385, 1183 cm-I; IH NMR (300 MHz, CDCh) () 5.00 (bs, IH), 4.22 (bs, 
, " 13 IH), 3.90 (bs, 3H), 2.33 (bs, 2H), 1.45 - 1.85 (m, 4H), 1.16 - 1.33 (m, 2H) ppm; C 
NMR (75 MHz, CDCh) () 150.4,80.0,58.3,54.7,27.4,27.2,22.0, 19.1 ppm; HRMS 
(FAB) (M + H+) calcd for CgHI 40sNS: 236.0593, found 236.0608; Anal. calcd for 
CgHI3OsNS: C 40.84% H 5.70%, found C 40.98% H 5.70%. 
Alternatively, compound 460 was prepared by following procedure: 
To a solution of oxathiazolidine 469 (300 mg, 1.37 mmol) in CH3CN (5 mL) was 
added sequentially, ruthenium(IIl)chloride hydrate (catalytic amount), sodium 
periodate (439 mg, 2.05 mmol) and water (5 mL) at 0 °C. The reaction mixture was 
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warmed to r. t. and was stirred for an additional 3 h. The reaction mixture was 
extracted with Et20 (3 x 2 mL). The organic layers were combined, washed with 
water, then brine, and dried over anhydrous Mg2S04. Filtration, evapouration of the 
solvent, and purification by flash column chromatography (hexanes: ethyl acetate, 
4:1) afforded 287 mg (82%) of compound 460* as white solid after recrystallization 
from hexanes/ethyl acetate. The analytical data obtained for compound 460* is 
identical to data of compound 460. 
465 
trans-(2-Hydroxycyclohexyl)carbamic acid, methyl ester (465) 
Methyl chloroformate (0.3 mL, 3.94 mmol) was added dropwise to a vigorously 
stirred solution of trans 2-aminocyc1ohexanol hydrochloride (464) (0.5 g, 3.3 mmol) 
and NaHC03 (0.83 g, 9.9 mmol) in a 1:1 mixture of CHCh and H20 (30 mL). The 
mixture was allowed to stir at r.t. for 1 h, before the reaction mixture was neutralized 
~ 
with 1 M aq HCI. The aqueous layer was extracted three times with dichloromethane. 
The combined organic layers were washed with brine, dried over MgS04 and 
evaporation of the solvent and recrystallization from hexanes/ethyl acetate furnished 
465 as colourless solid (498 mg, 87%): mp 109-111 °C (hexanes/ethyl acetate); IR 
(film) v 3436,3156,2942,2863,2253,1708,1517,1452,1517,1452, 1384 cm-I; IH 
NMR (300 MHz, CDCh) 0 4.75-5.15 (bs, IH), 3.66 (s, 3H), 3.21-3.46 (m, IH), 
2.98-3.18 (bs, IH), 1.91-2.12 (m, 2H), 1.60-1.79 (m, 2H), 1.05-1.41 (m, 4H) ppm; 
13C NMR (75 MHz, CDCh) 0 158.4, 75.6, 57.5, 52.9, 34.6, 32.2, 25.1, 24.5 ppm; MS 
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(El) mlz (%): 173, 141 (18), 114 (75), 112 (22), 102 (12), 98 (100), 88 (42), 69 (26), 
56 (51), 51 (66); HRMS (EI) calcd for C8H I5N03: 173.1052, found, 173.1053; Anal. 
calcd: C 55.47, H 8.73; found C 55.16, H 8.73. 
466 
(3aR,7 aR)-Hexahydro-2-oxide-3H -1,2,3-benzoxathiazole-3-
carboxylic acid, methyl ester (466) 
To a solution ofthionyl chloride (0.84 mL, 11.6 mmol) in CH3CN (60 mL) was added 
a solution of methyl ester 465 (0.8 g, 4.62 mmol) in CH3CN (20 mL) dropwise at -35 
°C over 10 min. The reaction mixture was stilTed at the same temperature for 5 min 
before pyridine (1.8 mL, 23.11 mmol) was added dropwise. The reaction mixture was 
allowed to warm to r.t. over 3 h. The solvent was evaporated, and the residue was 
triturated with Et20. After filtration, the mixture was concentrated under reduced 
~ 
pressure. Flash column chromatography (hexanes/ethyl acetate, 5:1) of the residue 
afforded 466 as colourless solid {0.79 g, 78%): mp 51-54°C; RJ 0.5 (hexanes/ethyl 
acetate, 2:1); lR (film) v 3368, 2954, 2254, 1733, 1572, 1444, 13S4, 1328, 1300 em-I; 
IH NMR (300 MHz, CDCh) () 4.71 (dt, J = 11 Hz, 4 Hz, IH), 3.83 (s, 3H), 3.13 (dt, J 
= 13 Hz, 3 Hz, IH), 2.61-2.74 (m, IH), 2.20-2.34 (m, IH), 1.79-2.02 (m, 2H), 1.69 
(dq, J = 12 Hz, 4 Hz, IH), 1.19-1.54 (m, 3H) ppm; l3C NMR (75 MHz, CDCh) () 
154.7, 86.8, 63 .2, 54.0, 29.8, 29.5, 24.3, 23.9 ppm; MS (El) mlz (%): 219 (5), 140 
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(10), 114 (100), 81 (12), 59 (24), 44(17); HRMS (EI) ca1cd for C8HI3N04S: 
219.0565, found, 219.0565; Anal. ca1cd: C 43.82, H 5.98, found: C 44.12, H, 6.05. 
469 
cis-Hexahydro-2-oxide-3H -1 ,2,3-benzoxathiazole-3-
carboxylic acid, methyl ester (469) 
To a solution of thionyl chloride (0.83 mL, 11.41 mmol) in CH3CN (60 mL) was 
added a solution of methyl carbamate 468 (0.79 g, 4.56 mmol) in CH3CN (20 mL) 
dropwise at -35°C over 10 min. The reaction mixture was stirred at -35 °C for 5 min, 
before pyridine (1.84 mL, 22.82 mmol) was added dropwise. The reaction mixture 
was warmed to r.t. over 3 h. The solvent was evaporated, and the residue was 
triturated with Et20. The suspension was filtered, and the filtrate was concentrated 
under reduced pressure. Purification of the residue by flash column chromatography 
(hexanes/ethyl acetate, 5:1) afforded 0.63 g (63%) of 469 as colourless bil. Rf 0.75 
(hexanes/ethyl acetate, 1 :1); IR (film) v 2943, 2867, 1730, 1442, 1359, 1328, 1288, 
1187, 1148 em-I; IH NMR (300 MHz, CDCh) (two rotamers) 0 5.24-5.31 (bs, 
0.66H), 4.66 (q, J = 4.0 Hz, 0.33H), 3.94-4.12 (m, IH), 3.84 (s, IH), 3.82 (s, 2H), 
2.09-2.34 (m, 2H), 1.54-2.45 (m, 4H), 1.33-1.52 (m, IH), I.D8-1.31 (m, IH) ppm; 
13 C NMR (75 MHz, CDCh) (two rotamers) 0 152.9,85.0,80.0,55.6,54.1,53.7,53.6, 
28.8,28.4,27.9,26.8,22.6,22.2, 19.6, 19.5 ppm; MS (EI) mlz (%): 219 (12), 171 
(16), 155 (29), 154 (26), 140 (65), 127 (44), 126 (13), 124 (16), 77 (100), 75 (16),64 
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(33); HRMS (EI) calcd for CsHl3N04S: 219.0565, found 219.0561; Anal. cakd: C 
43.82, H 5.98, found C 43.90, H 6.01. 
475 
trans-2-Methylcarbonylamino-benzoic acid, cyclohexyl ester (475) 
To a solution ofbenzoxathiazole 460 (550 mg, 2.34 mmol) in dry DMF (10 mL) was 
added ammonium benzoate (651 mg, 4.68 mmol). The solution was heated to 55 °C 
until TLC analysis indicated full conversion of the starting material (18 h). The 
solvent was evapourated, and the residue was dissolved in THF (6 mL), three drops of 
water and three drops of conc. H2S04 were added. The reaction mixture was stirred at 
r.t. for 3 h, before the pH was adjusted to 8 with sat. aqueous NaHC03 solution. The 
layers were separated, and the aqueous layer was extracted three times with 
dichloromethane. The organic layers were combined and washed with H20 and brine. 
After the solvent was evaporated under reduced pressure, the residue was) purified by 
flash column chromatography (hexanes/ethyl acetate, 9: 1) affording 265 mg of 
colourless oil (41%). Rf 0.55 (hexanes/ethyl acetate, 2:1); IR (film) v 3339, 3064, 
2940, 2861, 1714, 1538, 1452, 1320, 1279, 1235, 1115, 713 cm-I; IH NMR (300 
MHz, CDCh) 0 8.04 (d, J = 7.5 Hz, 2H), 7.55 (m, IH), 7.43 (t, J = 7.5 Hz, 2H), 4.83 
(m, 2H), 3.71-3.88 (m, IH), 3.53 (s, 3H), 2.02-2.24 (m, 2H), 1.69-2.02 (m, 2H), 
1.49-1.68 (m, IH), 1.18-1.48 (m, 3H) ppm; l3C NMR (75 MHz, CDCh) 0 167.0, 
156.8,133.2, 130.3, 129.9, 128.5, 75.9, 54.5, 52.2, 32.6, 31.3,24.6,24.2 ppm; HRMS 
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(FAB) calcd for ClsH20N04: 278.1392, found, 278.1382; Anal. calcd: C 64.97, H 
6.91, found C 65.03, H 6.94. 
486a 486b 
(3aR,7 as)-rel-2,2-Dioxide-h exahydro-3H -1 ,2,3-benzoxathiazole-3-carboxylic 
acid, 5-methyl-2-(I-methylethyl)cyclohexyl ester (486a and 486b) 
The general procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) using cyclohexene oxide (458) (196 mg, 2.00 mmol) as starting material 
gave 215 mg (30%) of a 1: 1 mixture of diastereomers 486a and 486b after 
purification by flash column chromatography (hexanes/ethyl acetate, 15:1 to 3:1) as 
colourless oil. Rf 0.65 (hexanes/ethyl acetate, 3:1); lU]D23 -52.2 (c 1.00, CHCh); IR 
(film) v 3401,2958,2873,2254, 1728, 1457, 1383, 1314,908,738 cm-I; IH NMR 
(300 MHz, CDCh) 0 4.98-5.04 (bs, IH), 4.73 (dt, J = 10.7,4.5 Hz, IH), 4.15-4.27 
~ 
(m, IH), 2.28-2.40 (m, 2H), 1.97-2.17 (m, 2H), 1.43-1.89 (m, 9H), 1.02-1.37 (m, 
4H), 0.94 (d, J= 3.1 Hz, 3H), 0.92 (d, J= 3.1 Hz, 3H), 0.80 (d, J= 6.6 Hz, 3H) ppm; 
I3C NMR (75 MHz, CDCh) 0 149.9, 79.7, 79.3, 58.2, 58.1, 47.2, 47.1, 41.0, 40.9, 
34.3,31.8,27.6,27.5,27.4,26.1,23.5,23.4,22.30,22.25, 21.3, 21.2,19.3,16.4,16.3 
ppm; HRMS (EI) calcd for C17H29NOsS: 359.1766, found 359,1761; Anal. calcd: C 
56.80, H 8.12, found C 57.12, H 8.30. 
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487a 487b 
[(lR,2R)-2-(Benzoyloxy)cyclohexyl]carbamic acid, (lR,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl ester (487a) and [(lS,2S)-2-benzoyloxy)cyclohexyl]-
carbamic acid, (lR,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester (487b) 
The general procedure for the syntheses of benzoates using a mixture of 486a and 
486b (449 mg, 1.25 mmol) as starting materials gave a mixture of two diastereomers 
246 mg (49%), which were separated by flash column chromatography 
(CH2Ch/MeOH, 200:1). 
487a: mp 111-113 °C (ethyl acetatelhexanes); Rf 0.50 (CH2Ch/methanol, 100:1); 
[a]D20 -77.8 (c 1.05, CHCh); IR (film) v 3434,3368,3019,2954,2868, 1711, 1603, 
1585, 1513, 1452, 1370, 1318, 1279, 1216, 1115, 1038, 1028,757, 712, 668 em-I; IH 
NMR (300 MHz, CDCh) () 8.07 (d, J= 7.7 Hz, 2H), 7.55 (t, J= 7.2 Hz, 1H), 7.43 (t, 
J = 7.7 Hz, 2H), 4.83 (dt, J = 10.6, 4.5 Hz, 1H), 4.59 (d, J = 9.3 Hz, 1H), 4.34-4.46 
(m, 1H), 3.76-3.90 (m, 1H), 2.07-2.19 (m, 2H), 1.73-1.93 (m, 3H), 1.13-1:69 (m, 
10H), 0.91-1.06 (m, 1 H), 0.86 (d, J = 10.0 Hz, 3H), 0.75 (d, J = 6.6 Hz, 3H), 0.46-
0.68 (m, 4H) ppm; l3C NMR (75 MHz, CDCh) () 167.1, 156.5, 133.4, 130.6, 130.2, 
128.7, 76.6, 74.7, 54.3,47.5,41.2,34.6,32.8,31.5,26.6,25.0,24.5,23.8, 22.2, 21.1, 
16.8 ppm; HRMS (EI) calcd for C24H3SN04: 401.2566, found 401.2579; 
C24H3sN04(401): calcd. C 71.79, H 8.79, found C 71.82, H 8.80. 
487b: mp 138-141 °C (ethyl acetatelhexanes); Rf 0.45 (CH2Ch/MeOH, 100:1); [a]D20 
-15.8 (c 1.05, CHCh); IR (film) v 3685, 3435, 3D20, 2956, 2869,1711,1515,1452, 
1318, 1279, 1216, 1115, 1039,929,759, 714, 669 em-I; IH NMR (300 MHz, CDCh) 
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88.05 (d, J = 7.7 Hz, 2H), 7.55 (t, J = 7.1 Hz, IH), 7.43 (t, J = 7.7 Hz, 2H), 4.86 (dt, J 
= 10.6,4.5 Hz, IH), 4.69 (d, J = 9.3 Hz, IH), 4.35-4.49 (m, IH), 3.73-3.90 (m, IH), 
2.12 (d, J = 12.5 Hz, 2H), 1.98 (d, J = 11.9 Hz, IH), 1.73-1.88 (m, 2H), 1.08-1.68 
(m, 10H), 0.79-0.97 (m, 5H), 0.55 (d, J = 6.4 Hz, 3H), 0.30 (d, J = 6.4 Hz, 3H) ppm; 
l3C NMR (75 MHz, CDCh) 8 167.2, 156.3, 133.3, 130.4, 130.1, 128.7, 76.0, 74.6, 
54.4, 47.6, 41.8, 34.6, 33.2, 31.7, 31.6, 26.5, 24.9, 24.5, 23.9, 22.4, 20.7, 16.3 ppm; 
C 71.79, H 8.79, found C 71.84, H 8.76. 
488a 
(3aR,7aR)-3H-Hexahydrobenzoxazolidin-2-one (488a) 
Benzoic acid 2-menthylcarbonylaminocyclohexyl ester 487a (260 mg, 0.65 mmol) 
was dissolved in 1 M NaOH in MeOH (30 mL), and the reaction mixture was stirred 
at room temperature for 10 h. The reaction mixture was diluted with water (30 mL) 
and extracted three times with dichloromethane. The organic layers were {:ombined, 
washed with brine, dried over anhydrous magnesium sulfate, filtered and the solvent 
was evaporated. Flash column chromatography (hexanes/ethyl ac-etate, 4: 1) of the 
residue afforded [(lR,2R)-2-hydroxycyclohexyl]-carbamic acid menthol ester as 
colourless solid (152 mg, 79%): mp 130-132 °C (hexanes/ethyl acetate); Rf 0.15 
(hexanes/ethyl acetate, 1:1); [a]D20 -53.7 (c 1.35, CHCh); IR (film) v 3685,3620, 
3020,2870,2401, 1693, 1510, 1477, 1451, 1423, 1215, 1046, 1024,929 cm-I; IH 
NMR (300 MHz, CDCI3) 8 4.60-4.79 (bs, IH), 4.53 (dt, J = 11.2,4.0 Hz, IH), 3.21-
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3.44 (m, 2H), 3.00-3.21 Cbs, IH), 1.79-2.09 (m, 4H), 1.54-1.75 (m, 2H), 1.38-1.53 
(m, 2H), 0.66-1-38 (m, 17H) ppm; 13C NMR (75 MHz, CDCh) 8 158.1, 75.8, 75.4, 
57.2, 47.7, 41.7, 34.6, 34.5, 32.2, 31.7, 26.6, 25.0, 24.4, 23.8, 22.4, 21.2, 16.8 ppm; 
MS (El) mlz (%): 297 (1),158 (10),139 (27),138 (17),115 (19),114 (28), 98 (1{)0), 
97 (21), 96 (19), 95 (23), 83 (90), 82 (14), 81 (43), 71 (21), 70 (10), 69 (46),67 (13); 
HRMS (El) calcd for C I7H3IN03: 279.2304, found 297.2298; Anal. calcd: C 68.65, H 
10.51, found C 68.65, H 10.81. 
[(lR,2R)-2-Hydroxycyclohexyl]- carbamic acid menthyl ester (140 mg, 0.47 
mmol) was dissolved in THF (5 mL) and sodium hydride (42 mg, 1.04 mmol) was 
added in one portion. The reaction mixture was heated at reflux for 12 h until TLC 
indicated complete conversion of starting material. The reaction mixture was 
quenched by the addition of an aqueous saturated solution of NH4Cl. The aqueous 
layer was extracted with ethyl acetate (3 x 5 mL). The organic layers were combined, 
washed with brine, dried over anhydrous magnesium sulfate, filtered, and the solvent 
was evaporated. Flash column chromatography (hexanes/ethyl acetate, 2: 1 to 1: 1) of 
the residue afforded 488a as colourless solid (55 · mg, 83%): mp 1'33-134 °C 
(hexanes/ethyl acetate); [a]D22 +7.5 (c 1.0, EtOH); Rf 0.45 (hexanes/ethyl acetate, 
1:1); lR (film) v 3684,3622,3020,1757,1521,1476,1423,1215,1034,929 em-I; IH 
NMR (300 MHz, CDCh) 8 5.96-6.19 (bs, 1H), 3.81 (dt, J= 11.1,4.3 Hz, IH), 3.16-
3.33 (m, IH), 2.05-2.20 (m, IH), 1.93-2.05 (m, 1H), 1.67-1.90 (m, 2H), 1.49-1.65 
(m, IH), 1.14-1.47 (m, 3H) ppm; I3C NMR (75 MHz, CDCh) 8 161.2, 84.2, 61.3, 
29.5, 28.9, 24.1, 23.9 ppm; MS (El) mlz (%): 141 (32), 140 (11), 99 (6), 96 (5), 69 
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(42),57 (15), 56 (100), 54 (8), 43 (40); HRMS (EI) ca1cd for C7HIIN02: 141.0790, 
found 141.0788. 
488b 
(3 as, 7aS)-3H-Hexahydrobenzoxazolidin-2-one (488b) 
Benzoic acid 2-menthy1carbonylamino-cyc1ohexyl ester 487b (270 mg, 0.67 mmol) 
was dissolved in 1 M NaOH in MeOH (30 mL), and the reaction mixture was stirred 
at r.t. for 10 h, then diluted with water (30 mL) and extracted with dichloromethane (3 
x 10 mL). The organic layers were combined, washed with brine, dried over 
anhydrous magnesium sulfate and the solvent was evaporated. Flash column 
chromatography (hexanes/ethyl acetate, 4: 1) of the residue afforded 488b as 
colourless solid (179 mg, 89%): mp 151-153 °C (hexanes/ethylacetate); Rr 0.15 
(hexanes/ethyl acetate, 1:1); [a]D 20 -58.2 (c 1.2, CHCh); lR (film) v 3684, 3621, 
3437, 3020, 2939, 2869, 2400, 1693, 1510, 1477, 1451, 1424, 1389, 1215, 1046, 
1023,929 cm-I; IH NMR (300 MHz, CDCh) () 4.62-4.85 (bs, 1H), 4.55 (dt,J= 11.1, 
4.2 Hz, 1H), 3.21-3.42 (m, 2H), 2.98-3.21 (bs, 1H), 1.81-2.14 {m, 4H), 1.56-1.80 
(m, 2H), 1.39-1.55 (m, 2H), 0.60-1.39 (m, 17H) ppm; l3C NMR (75 MHz, CDCh) 8 
158.2, 75.8, 75.5, 57.3, 47.9, 41.8,34.6,34.5,32.1,31.8, 26.Q, 25.0, 24.4, 23.8, 22.4, 
21.2, 16.8 ppm; MS (EI) mlz (%): 297 (1), 160 (8), 159 (8), 158 (9), 139 (24), 138 
(17), 115 (19), 114 (28), 98 (100), 97 (22), 96 (23), 95 (30), 83 (96), 82 (18), 81 (49), 
71 (29), 70 (13), 69 (54), 67 (17); HRMS (El) ca1cd for C17H3IN03: 279.2304, found 
297.2303; C17H3IN03(279): calcd. C 68.65, H 10.51, found C 68.82, H 10.79. 
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Following the same procedure as for the preparation of compound 488a usmg 
[(1S,2S)-2-hydroxycyclohexyl]-carbamic acid menthol ester (160 mg, 0.54 mmol) and 
sodium hydride (32 mg, 1.33 mmol) as starting materials, gave 62 mg (82%) of 
compound 488b as colourless crystals: mp 131-133 °C (hexanes/ethyl acetate); {a]D 22 
-7.4 (c 1.1, EtOH); HRMS (EI) ca1cd for C7H 11N02: 141.0790, found 141.0785. 
489a 
(3aR, 7 aR)-3-( (S)-3,3,3-Triflu oro-2-methoxy-2-phenylpropanoyl)-
hexahydrobenzo [d] oxazol-2(3H)-one (489a) 
To a solution of cyclic carbamate 488a (20 mg, 0.14 mmol) in THF (2 mL) at 0 °C 
was added n-BuLi (2 M in THF, 78 JlL, 0.16 mmol). The reaction mixture was stirred 
at the same temperature for 1 h then cooled to -78°C. (S)-(+)-Mosher's chloride (43 
mg, 0.17 mmol) was added, and the reaction mixture was warmed to r.t. over 14 h. 
The reaction was quenched by the addition of a saturated aqueous solutiort ofNH4Cl. 
The aqueous layer was extracted with ethyl acetate (3 x 2 mL). The organic layers 
were combined, washed with brine and dried over anhydrous sodium sulfate. The 
organic layer was filtered and the solvent was evaporated. The crude residue was 
analyzed by 19F NMR (282 MHz, CDCh) () -72.61 (not detected), -69.30 (IF). 
Compound 489b as well as a racemic standard were prepared in the same manner, 
using 488b and a racemate of 488 as starting materials. Compound 489a: 19F NMR 
(282 MHz, CDCh) () -72.61 (IF), -69.31 (0.035F), Compound 489: -72.61 (IF), -
69.30 (IF). The results were confirmed by GC/MS analysis. 
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491a 491b 
(3 aR,6aS)-rel-2,2-Dioxide-tetrahydro-3(3 aH)-cyclopent-l ,2,3-
oxathiazolecarboxylic acid, 5-methyl-2-(l-methylethyl)cyclohexyl ester (491a and 
491b) 
The general procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) using cyclopentene oxide (490) (168 mg, 2.00 mmol) as starting material 
gave 305 mg (37%) of a 1:1 mixture of diastereomers 491a and 491b after 
purification by flash column chromatography (hexanes/ethyl acetate, 15:1 to 3:1). 
Colourless oil; Rf 0.81 (hexanes/ethyl acetate, 2: 1); [a]D 23 -79.2 (c 1:02, CHCh); IR 
(film) v 3400,3019,2962, 2400, 1731, 1522, 1423, 1383, 1307, 1030, 669 em-I; IH 
NMR (300 MHz, CDCh) 0 5.21 (t, J = 5.3 Hz, IH), 4.74 (dt, J = 10.9,4.4 Hz, IH), 
4.55 -4.63 (m, IH), 2.08-2.15 (m, 5H), 1.81-1.89 (m, 2H), 1.66-1.74 (m, 2H), 1.42-
1.50 (m, 2H), 1.10-1.18 (m, 2H), 0.88-0.95 (m, 7H), 0.76-0.85 (m, 3H) ppm; \3C 
C> NMR (75 MHz, CDCh) 8 150.1,83.8, 79.1, 78.3, 7L2, 61.4, 61.3, 46.7, 40.6, 40.5, 
33.9,32.75, 32.7, 32.3, 31.4, 31.4, 26.2, 26.0, 25.6, 23.3, 23.2, 22.9, 22.6, 21.9, 20.8, 
20.8 ppm; HRMS (FAB) (M+H+) calcd for CI 6H27NOsS: 346.1688, found 346.1659. 
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492a 492b 
trans-2-(Benzoyloxy)cyclopentyl]-carbamic acid, (1R,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl ester (492a and 492b) 
The general procedure for the syntheses of benzoates using a mixture of 491a and 
491b (433 mg, 1.25 mmol) as the starting material gave a mixture of diastereomers 
492a and 492b (252 mg, 52%), which were separated by flash column 
chromatography (CH2Clz/MeOH, 200:1). 
492a: mp 85-86 °C (ethyl acetate/hexanes); Rf O.73 (CH2Cb/MeOH; 400:1); Ia]D23 -
99.6 (c 1.00, CHCh); IR (film) v 3684,3019,2961,2400,1711,1512,1424,1031, 
929,669, 627 em-I; IH NMR (300 MHz, CDCh) () 8.03 (d, J = 7.2 Hz, 2H), 7.42-
7.52 (m, 3H), 5.16 (q, J = 5.8 Hz, IH), 4.91 (bs, lH), 4.40-4.48 (m, IH), 4.03-4.12 
(m, IH), 2.19-2.23 (m, 2H), 1.73-1.85 (m, 5H), 1.51-1.58 (m, 7H), 1.20-1.25 (m, 
2H), 0.67-0.85 (m, 7H) ppm; l3C NMR (75 MHz, CDCh) () 156.0, 132.9, 130.2, 
129.7, 128.3, 80.4, 75.0,47.3,41.3, 34.2, 31.3, 26.2, 22.0, 20.8 ppm; HI~MS (FAB) 
(M+H+) ca1cd for C23H33N04: 388.2488, found 388.2474. 
492b: mp 86-89 °C (ethyl acetate/hexanes); RfO.70 (CH2Clz/MeOH, 400:1); [a]D23_ 
5.59 (c 1.05, CHCh); IR (film) v 3436,3019,2960,2400,1711 , 1512, 1037,929,669 
em-I ; IH NMR (300 MHz, CDCh) 0 8.02 (d, J = 6.9 Hz, 2H), 7.50-7.57 (m, 3H) 
5.11-5.19 (m, IH), 4.78-4.82 (m, lH), 4.52-4.57 (m, lH), 4.11-4.14 (m, lH), 2.11-
2.21 (m, 2H), 1.80-1.83 (m, IH), 1.72-1.79 (m, 4H), 1.46-1.58 (m, 6H), 1.38-1.45 
(m, 4H), 0.80-1.25 (m, 6H) ppm; l3C NMR (75 MHz, CDCh) () 156.0, 132.9, 130.2, 
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129.7, 128.3,80.1, 74.7,47.3,41.4,34.2,31.3,29.7,26.2,23.5,22.0,20.7, 1{).3 ppm; 
HRMS (FAB) (M+H+) ca1cd for C23H33N04 : 388.2488, found 388.2481. 
o 
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494a 494b 
(3aR,8aS)-rel-2,2-dioxide-hexahydro-cyclohept-l,2,3-oxathiazole-3(3aH)-
carboxylic acid, 5-methyl-2-(l-methylethyl)cyclohexyl ester (494a and 494b) 
The general procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) cyclohepteneoxide (493) (224 mg, 2.00 mmol) as starting material gave 
211 mg (35%) of a 1: 1 mixture of diastereomers 494a and 494b after purification by 
flash column chromatography (hexanes/ethyl acetate, 15: 1 to 4: 1). colourless oil; Rf 
0.57 (hexanes/ethyl acetate, 4:1); [a]D23 -60.5 (c 0.75, CHCh); IR (film) v 2958, 
2931,1729, 1457, 1381, 1332, 1307, 1190 cm-I; IH NMR (300 MHz, CDCh) () 5.00-
5.17 (m, 1H), 4.72 (dt, J = 11.0,4.5 Hz, 1H), 4.21-4.36 (m, IH), 2.20-2.37 (m, IH), 
0,. 
1.63-2.18 (m, 10H), 1.35-1.58 (m, 4H), 1.03-1.33 (m, 3H), 0.85-1.00(m, 8H), 0.71-
0.84 (m, 3H) ppm; l3C NMR (75 MHz, CDCh) () 149.8, 149.8,81.6,81.6,79.1,79.0, 
63.1,63.0,46.8,46.7,40.6,40.5,33.9,31.5,31.4,30.2, 30.2, 29.2, 28.6, 28.5, 26.0, 
25.9,25.6,23.3,22.9,22.6,21.9,21.6,20.9,20.8,15.8 ppm; MS (FAB) mlz (%) 374 
(M+H+): 139 (52), 137 (22), 97 (19), 95 (44), 83 (100), 81 (37), 79 (11), 77 (12), 69 
(46), 67 (21), 57 (36), 55 (62), 53 (14); HRMS (FAB) (M+H+) Ca1cd for 
ClsH33NOsS: 374.2001, found 374.2018. 
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495a 495b 
trans-2-(BenzoyJoxy)cycloheptyJ]-carbamic acid, (lR,2S,SR)-5-methyJ-2-(1-
methyJethyJ)cyclohexyJ ester (495a and 495b) 
The general procedure for the syntheses of benzoates with a mixture of 494a and 
494b (468 mg, 1.25 mmol) as starting material gave a mixture of two diastereomers 
495a and 495b 389 mg (75%), which were separated by flash column 
chromatography (CH2Ch/MeOH, 200:1). 
495a: mp 89-91 °C (ethyl acetate/hexanes); Rf O.55 (CH2Ch/MeOH, 100:1); [a]D23 _ 
105.1 (c 0.8, CHCh); IR (film) v 3363, 2930, 2867,1714,1602,1585, 1526, 1452, 
1370, 1316, 1279, 1239,1179, 1117, 1070, 1028 em-I; IH NMR (600 MHz, CDCh) 0 
7.98 (d, J = 7.5 Hz, 2H), 7.46 (t, J = 7.5 Hz, IH), 7.35 (t, J = 7.5 Hz, 2H), 4.91 (dt, J 
= 9.0, 3.4 Hz, IH), 4.63 (d, J = 9.2 Hz, IH), 4.28--4.36 (m, IH), 3.83-3.93 (m, IH), 
1.85-1.94 (m, 2H), 1.74-1.93 (m, 2H), 1.47-1.71 (m, 10H), 1.36-1.44 (m, IH), 1.16-
1.27 (m, IH), 0.89-1.02 (m, IH), 0.81-0.88 (m, 2H), .0.77 (d, J = 7.0 H2, 3H), 0.67 
(d, J = 6.8 Hz, 3H), 0.56-0.61 (m, 3H) ppm; l3C NMR (150 MHz, CDCh) 0 166.5, 
155.9,132.9,130.3,129.8,128.3,127.8,78.4,74.4,56.2, 47.2, 40.9,34.2,32.0,31.2, 
26.2,25.9,23.9,23.5,22.4,21.9,20.7, 16.5 ppm; MS (EI) mlz (%): 415 (1), 137 (13), 
123 (11), 111 (20), 105 (100),97 (11), 95 (27), 83 (44), 82 (11),81 (20), 77 (23), 71 
(25), 69 (26), 67 (10), 57 (29), 56 (26), 55 (30); HRMS (EI) calcd for C2sH37N04: 
415.2723, found 415.2715. 
495b: mp 121-124 °C (ethyl acetateihexanes); Rf O.50 (CH2Ch/MeOH, 100:1); {a]D23 
-37.6 (c 0.75, CHCh); IR (film) v 3369, 2928, 2866,1714,1524,1452,1369,1315, 
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1279, 1180, 1116, 1070, 1028 cm-I; IH NMR (600 MHz, CDCh) () 7.96 (d, J = 7.4 
Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.35 (t, J = 7.4 Hz, 2H), 4.93 (dt, J = 8.7, 3.7 Hz, 
1H), 4.69-4.77 (m, 1H), 4.29-4.40 (m, 1H), 3.85-3.94 (m, 1H), 1.77-1.93 (m, 4H), 
1.64--1.74 (m, 2H), 1.43-1.62 (m, 8H), 1.31-1.41 (m, 1H), 1.04--1.11 (m, 1H), 0.76-
0.88 (m, 5H), 0.66-0.73 (m, 1H), 0.49 (d, J= 5.3 Hz, 3H), 0.27 (d, J= 0.48 Hz, 3H) 
ppm; l3C NMR (150 MHz, CDCh) () 166.6, 155.8, 132.9, 130.3, 129.7, 128.3, 127.8, 
78.2,74.3, 56.5, 47.3, 41.5, 34.3, 32.2, 31.3, 27.5, 26.2, 24.0, 23.6, 22.4, 22.0, 20.4, 
16.1 ppm; MS (EI) mlz (%): 415 (1), 155 (10), 138 (18), 137 (14), 123 (16), 111 (20), 
105 (100),97 (11), 96 (12), 95 (43),94 (10),83 (47), 82 (16), 81 (31),77 (23), 71 
(28), 69 (34), 67 (14), 57 (32), 56 (25), 55 (37); HRMS (EI) ca1cd for C25H37N04: 
415.2723, found 415.2720. 
497a 497b 
5-Butyl-2,2-dioxide-l,2,3-oxathiazolidine-3-carboxylic acid, 5-niethyl-2-(1-
methylethyl)cyclohexyl ester (497a and 497b) 
The general procedure for the reaction of oxiranes with the (-)-menthyl Burgess 
reagent (3) using 2-butyloxirane (496) (200 mg, 2.00 mmol) as staliing material gave 
159 mg (22%) of a 1: 1 mixture of diastereomers 497a and 497b after purification by 
flash column chromatography (hexanes/ethyl acetate, 20:1 to 5:1). Colourless oil; Rf 
0.68 (hexanes/ethy1 acetate, 5:1); [a]D23 -51.7 (c 2.3, CHCh); IR (film) v 3019,2961, 
2400,1730,1384,1316,1215,1046,928, 724, 669 cm-I; IHNMR (300MHz,CDCh) 
() 4.71-4.84 (m, 1H), 4.58-4.71 (m, 1H), 3.90-4.09 (m, 1H), 3.57-3.71 (m, 1H), 2.10 
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(m, 3H), 1.52-1.77 (m, 4H), 1.25-1.53 (m, 6H), 1.16-1.23 (s, 3H), 0.92-1.12 (m, 
2H), 0.85-0.91 (m, 6H), 0.70-0.74 (m, 3H) ppm; I3C NMR (75 MHz, CDCh) 8 
149.8,79.9,79.2,50.6,46.7,40.5,33.9,32.1,31.4, 29.7, 26.6, 25.8, 23.1,22.1,21.9, 
20.8, 16.0, 13.7 ppm; MS (El) mlz (%) 361 (1), 176 (44),83 (88),42 (60), 43 (39), 54 
(31),55 (61); HRMS (El) ca1cd for C17H3INOsS: 361.1923, found 361.1920. 
498a 498b 
[2-(Benzoyloxy)hexyl]-carbamic acid, 
(lR,2S,5R)-5-methyl-2- (l-methylethyl)cyclohexyl ester (498a and 498b) 
The general procedure for the syntheses of benzoates with a mixture of 497a and 
497b (451 mg, 1.25 mmo1) as starting materials gave a mixture of two diastereomers 
498a and 498b (181 mg, 36%), which were inseparable by flash column 
chromatography: mp 121-124 °C (ethyl acetate/hexanes); Rf 0.50 (CH2Ch/MeOH, 
100:1); [a]D23 -37.6 (c 0.75, CHCh); lR (film) v 3684,3401,3019,2961, &400, 1713, 
1517, 1423, 1215, 1046,929,641,669,627 em-I; IH NMR (300 MHz, CDCh) 8 7.97 
(d, J = 7.3, 2H), 7.46-7.54 (m, IH), 7.33-7.43 (m, 2H), 5.03-5.20 (m, IH), 4.70-4.86 
(m, IH), 4.35-4.54 (m, 1H), 3.33-3.49 (m, 2H), 1.88-2.01 (m, IH), 1.72-1.88 (m, 
2H), 1.46-1.73 (m, 6H), 1.23-1.44 (m, 6H), 1.08-1.22 (m, 2H), 0.90-1.06 (m, 2H), 
0.77-0.88 (m, 3H), 0.64-0.75 (m, 4H), 0.58 (d, J = 6.9 Hz, IH) ppm; I3C NMR (75 
MHz, CDCh) 8 163.9, 154.0, 130.6, 127.2, 125.9, 72.2, 71.7,44.9,41.9, 38.9, 31.8, 
29.0,28.9,28.8,24.9,23.8,21.1,20.1, 19.6, 18.3, 13.9, 13.9, 11.5 ppm; MS (El) mlz 
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(%) 403 (1), 221 (15), 176 (13), 55 (61), 54 (31), 43 (37); HRMS (El) ca1cd for 
499a 499b 
[(lS,6R)-2-(Benzoyloxy)cyclohex-2-enyl]-carbamic acid, (lR,2S,SR)-S-methyl-2-
(l-methylethyl)cycIohexyl ester (499a) and [(lR,6S)-2-(benzoyloxy)cyclohex-2-
enyl]-carbamic acid, (lR,2S,SR)-S-methyl-2-(1-methylethyl)cyclohexyl ester 
(499b) 
The general procedure for the syntheses of benzoates using a mixture of 5a and 5b 
(446 mg, 1.25 mmol) as starting materials gave a mixture of two diastereomers 499a 
and 499b (254 mg, 51%), which were separated by flash column chromatography 
(CH2Ch/MeOH, 400:1). 
499a: mp 103-105 °C (ethyl acetateihexanes); RJ O.67 (CH2Ch/MeOH, 400:1); [a]D 23 
-100.8 (c 0.25, CHCh); lR (film) v 3436,3019,2962, 1713, 1602, 1511, }424, 1277, 
1117,1048,1028 em-I; IH NMR (300 MHz, CDCh) 0 8.07 (d, J= 7.4 Hz, 2H), 7.56 
(t, J= 7.4 Hz, 1H), 7.44 (t, J= 7.8 Hz, 2H), 5.85 (d, J= 10.2 Hz, 1H), 5.69 {dd, J= 
9.5, 1.5 Hz, 1H), 5.04-5.11 (m, 1H), 4.66 (d, J = 9.2 Hz, 1H), 4.52-4.62 (m, 1H), 
4.46 Cdt, J= 10.7, 3.9 Hz, 1H), 2.25-2.28 (m, 2H), 2.08-2.11 (m, 1H), 1.96-2.00 (m, 
1H), 1.88-1.93 (m, 1H), 1.59-1.72 (m, 4H), 1.26-1.42 (m, 2H), 1.21-1.25 em, 1H), 
0.98-1.04 (m, 1H), 0.87 (d, J= 7.1 Hz, 3H), 0.78 (d, J= 6.6 Hz, 3H), 0.72 Cd, J= 5.8 
Hz, 3H) ppm; J3C NMR (75 MHz, CDCh) 0 166.5, 156.2, 133.0, 130.2, 129.8, 129.5, 
128.4, 128.3, 126.8, 77.2, 74.8, 73.9, 51.7, 47.2, 41.0, 34.2, 31.2, 26.4, 26.3, 24.0, 
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23.5, 21.9, 20.8, 16.5 ppm; HRMS (El)calcd for C24H33N04: 399.2410, found 
399.2403; Anal. calcd: C 72.15, H 8.33, found C 72.42, H 8.44. 
499b: mp 107-109 °C (ethyl acetate/hexanes); RJ O.62 (CH2Cb/MeOH, 400:1); [a]o23 
+ 16.2 (c 0.4, CHCh); lR (film) v 3369, 3033, 2954, 2928, 2869, 1714, 1523, 1277, 
1241, 1116, 1027 cm-1; lH NMR (600 MHz, CDCh) () 8.06 (d, J = 7.2 Hz, 2H), 7.56 
(t, J = 7.5 Hz, IH), 7.44 (t, J = 7.8 Hz, 2H), 5.84 (d, J = 8.6 Hz, IH), 5.59 (dq, J = 
9.8, 2.2 Hz, IH), 5.04-5.12 (m, IH), 4.70 (d, J = 9.5 Hz, IH), 4.55-4.61 (m, IH), 
4.49 (td, J= 10.8, 3.7 Hz, IH), 2.23-2.29 (m, 2H), 2.06-2.13 (m, IH), 1.91-2.03 (m, 
2H), 1.54-1.71 (m, 3H), 1.41-1.49 (m, IH), 1.21 (t, J = 11.5 Hz, IH), 0.85-0.97 (m, 
6H), 0.65 (d, J = 6.6 Hz, 3H), 0.42 (d, J = 6.6 Hz, 3H) ppm; l3C NMR (75 MHz, 
CDCh) () 166.5 156.0, 132.9, 130.1, 129.8, 129.3, 128.3, 127.0, 74.5, 73.7, 51.7,47.3, 
41.4, 34.2, 31.3, 26.6, 26.2, 24.0, 23.5, 22.0, 20.5, 16.1 ppm; HRMS (El) calcd for 
TSO~OTS 
509 
1,6-bis( 4-methylbenzenesulfonate) 1,6-Hexanediol (509) 
To a stirred solution of 1,6-hexanediol (508) (l g, 8.47 mmol), pyridine (1.36 mL, 
16.9 mmol), and DMAP (catalytic amount) in DCM (5 mL) was addedpTsOH (2.91 
g, 16.9 mmol) in 3 equal portions over 30 min at 0 °C. The reacton was allowed to stir 
for 12 h before diluting with DCM (5 mL) and washed with 1 N HCl (2 x 2 mL), 
brine (l x 3 mL) and dried over Na2S04. The crude material was recrystallized from 
ethyl acetate-hexanes to yield 509 (3.14 g, 87%). lR (film) v 3436, 2095, 1644, 1352, 
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1172,1097 cm-I; IH NMR (300 MHz, CDCh) 8 1.19-1.28 (m, 4H), 1.52-159 (m, 
4H), 2.43 (s, 6 H), 3.96 (t, J = 6.4 Hz, 4H), 7.32 (d, J = 8.3 Hz, 4H), 7.75 (d, J = 8.3 
Hz, 4H) ppm; I3C NMR (75 MHz, CDCh) 8 21.6, 24.8, 28.6, 70.2, 127.9, 129.9, 
133.4, 133.1, 144.8 ppm; MS (EI) mlz (%): 426 (M); 41(14), 54(11), 55(24), 67(10), 
82(12),83(100),91(49),155(19),172(11.5),173(17.1); HRMS ca1cd for C20H2606S2 
426.1170, found 426.1171 
o 
u 
510 
N-benzylazepane (510) 
Method 1: To a round-bottomed flask charged with abs. EtOH (10 mL), 509 (1.0 g, 
2.34 mmol) and benzyl amine (0.75 g, 7.0 mmol). The resulting solution was brought 
to reflux (78°C) and stirred for 48 h before cooling then diluting in 15 mL DCM. The 
combined organic layers were washed with brine, dried over Na2S0,f, and then 
filtered through a sintered glass funnel. The resulting crude mixture was SUbjected to 
flash column chromatography with a solvent gradient of 5:1, 3:1, 2:1 and 
1:I(hexanes-ethyl acetate) to yield 510 (88 mg, 20%) as a clear oil. 
Method 2: To a round-bottomed flask charged with toluene (4 mL), [Cp*IrChh (33 
mg, 0.42 mmol), and NaHC03 (7 mg, 0.085 mmol) was added benzyl amine (1.83 g, 
17.09 mmol) in a was added dropwise over a period of 1 min before the addition of 
1,6-hexane diol (508) (2.0 g, 16.9 mmol). The resulting solution was brought to reflux 
(110 °C) and stirred for 48 h before cooling, and concentrating under reduced 
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pressure. The crude mixture was subjected to flash column chromatography with a 
solvent gradient of 3:1, 1:2, and 1:8 (hexanes-ethyl acetate) to yield 510 (53 mg, 
67%) as a clear oil; IH NMR (300 MHz, CDC h) 8 1.52-1.67 (m, 8H), 2.53-2.61 (m, 
4H), 3.61 (s, 2H), 7.16-7.33 (m, 5H) ppm; I3C NMR (75 MHz, CDCh) 8 27.1, 28.3, 
55.5, 62.8, 126.5, 127.9, 128.5, 139.9 ppm; HRMS ca1cd for C13HI9N 189.1517, 
found 189.1518. 
OH ~ 6"~~ 
514 
2-Benzylamino-cyclohex-3-enol (514) 
A sealed tube was charged with iso-propanol (80 mL), oxirane 4 (10.0 g, 104 mmol), 
and benzylamine (11.1 g, 104 mmol) and then stirred at 80°C for 6 h before the 
solvent was removed under reduced pressure. Recrystallization of the crude material 
from ethyl ether-hexanes yielded 514 (18.9 g, 88%) as a white solid. mp 54-57°C 
(ethyl ether-hexanes); Rf 0.42 (1:1 hexanes-ethyl acetate); IR (film) v 3305, 3062, 
3026,2924,2838, 1454, 1066,699 cm-I; IH NMR (300 MHz, CDCh) 8 1.55-1.78 (m, 
IH), 1.84-1.97 (m, IH), 2.03-2.17 (m, 2H), 3.53-3.85 (m, 4H), 4.33 (d, J = 16.0, IH), 
4.51 (d, J = 17.3, IH), 4.61-4.83 (m, IH), 5.33 (d, J = 9.<i, IH), 5.61-5.88 (m, IH), 
7.10-7.45 (m, 5H) ppm; I3C NMR (75 MHz, CDCh) 8 140.5, 128.5, 128.4, 128.3, 
127.1, 126.8, 71.0, 61.1, 50.6, 29.0, 24.8; HRMS ca1cd for C13H17NO 203.1310, 
found 203.1307; Anal. ca1cd: C 76.81, H 8.43, found C 76.88, H 8.44. 
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515 
Benzyl-(6-hydroxy-cyclohex-2-enyl)-carbamic acid methyl ester (515) 
To a stirred solution of514 (9.25 g, 45.5 mmol) and Na2C03 (9.65 g, 91.0 mmol) in 
THF (75 mL) was added methyl chloroformate (4.30 g, 45.5 mmol) in 2 equal 
portions over 30 min. The reaction was stirred at r.t. for 14 h, concentrated and then 
extracted into DCM (5 x 40 mL). The combined organic layers were washed with 1 N 
HCI (3 x 10 mL), then dried over Na2S04. The crude material was subjected to flash 
column chromatography with a solvent gradient of 3: 1, 1: 1 hexanes-ethyl acetate to 
yield 515 (10.2 g, 86%) as a clear oil; Rf O.52 (2:1 hexanes-ethyl acetate); IR (film) v 
3426,3063,3029,2933, 1682, 1469, 1452, 1264 cm-I; IH NMR (300 MHz, CDCh) 0 
1.55-1.78 (m, 1H), 1.84-1.97 (m, IH), 2.03-2.17 (m, 2H), 3.53-3.85 (m, 4H), 4.33 {d, 
J = 16.0, 1H), 4.51 (d, J = 17.3, 1H), 4.61-4.83 (m, 1H), 5.33 {d, J = 9.6, 1H), 5.61-
5.88 (m, 1H), 7.10-7.45 (m, 5H) ppm; l3C NMR (75 MHz, DMSO) 0 24.7, 30.6,47.7, 
53.0, 61.8, 70.1, 126.6, 127.0, 128.6, 131.1, 139.4 ppm; MS (EI) mlz (%):261 (M), 
91(100), 217(39); HRMS calcd for ClsH19N03 261.1365, found 261.1366; Anal. 
calcd: C 68.94, H 7.33, found C 68.87, H 7.22. 
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528a 
(lR,2S ,5R)-2-isopropyl-5-methylcycIohexyl [(lR,6R)-6-hydroxycycIo hex -2-en-l-
yl]carbamate (528a) 
A round-bottomed flask was charged with benzoate 499a (122 mg, 0.305 mmol) and 
1 N NaOH (12 mL) in methanol. The resulting solution was stirred at r.t. for 1 h, and 
then concentrated before the residue was dissolved in 5 mL of water, and the aqueous 
layer was extracted with CH2Ch (3 x 7 mL). The combined organic layers were 
washed with brine, dried with Na2S04 and evapourated to give the crude product. 
Recrystallization of the crude material from ethyl ether-hexanes afforded 85 mg 
(94%) of 528a as a white solid: mp 115-116 °C (ethyl ether-hexanes); Rf 0.44 (2:1 
hexanes-ethyl acetate); [a]D23 -72.9 (c 0.775, CHCb); IR (film) v 3435, 2955, 2869, 
1645,1529,1455 cm-I. IH NMR (300 MHz, CDCb) 0 0.74 (d, J= 6.8 Hz, 3H), 0.84 
(d, J = 2.2 Hz, 3H), 0.86 (d, J = 2.2 Hz, 3H), 0.89-1.07 (m, 2H), 1.21-1.32 (m, 1 H), 
1.36-1.48 (m, 1 H), 1.54-1.63 (m, 2H), 1.63-1.69 (m, 1 H), 1.82-1.96 (m':) 2H), 1.96-
2.02 (m, IH), 2.03-2.13 (m, 2H), 3.01-3.18 (br s, IH), 3.60 (dq, J= 10.7 Hz, 3.6, IH), 
3.96-4.16 (m, IH), 4.51 (td,J= 9.9,1.6 Hz, IH), 4.73 (d,J= 6.4 Hz, IH), 5.36 (d,J= 
9.8 Hz, IH), 5.77 (d, J = 8.7 Hz, IH) ppm; 13C NMR (300 MHz, CDCh) 0 16.4,20.8, 
22.0, 23.4, 23.9, 26.2, 28.9, 31.3, 34.2, 41.3, 47.3, 55.3, 73.2, 75.4, 125.4, 130.9, 
157.8 ppm; MS (EI) mlz (%): 295; 41(58), 43(43), 54(29), 55(56), 56(21), 57(34), 
67(67), 68(23), 69(70), 71(68), 81(61), 82(32), 83(66), 95(100), 96(31), 113(75), 
123(28), 138(29); HRMS calcd for C17H29N03 295.2147, found 295.2147; Anal. 
ca1cd: C 69.12, H 9.89, found C 68.86, H 9.89. 
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529a 
(3aR,7 aR)-3a,6, 7,7 a-tetrahydro-l,3-benzoxazol-2(3H)-one (529a) 
To a suspension of NaH (60% in mineral oil, 33 mg, 1.35 mmol, prewashed with 
hexanes (5 mL x 3) in THF (15 mL) at 0 T was added dropwise to a solution of 
alcohol 528a (200 mg, 6.77 mmol) in freshly distilled THF (7 mL), then the reaction 
mixture was brought to reflux. After stirring for 12 h, the mixture was cooled to r.t. 
and the reaction was quenched by the addition of saturated NH4CI and then 
concentrated before extracting the aqueous layer with CH2Ch (3 x 15 mL). The 
combined organic layers were washed with brine, dried with Na2S04 and evapourated 
to give the crude product. Recrystallization of the crude material from ethyl ether-
hexanes to afforded 81 mg (86%) of the title compound as a white solid: mp 114-115 
°C (ethyl ether-hexanes); Rr 0.36 (1:1 hexane-ethyl acetate); [a]D23 -37.7 (c 1.37, 
CHCh); lR (film) v 3854,3435,3020, 1751, 1644, 1216,769 cm-I. IH NMR (300 
MHz, CDCh) () 1.92 (td, J= 9.8, 0.94 Hz, IH), 2.21-2.28 (m, IH), 2.29-2.50 \m, 2H), 
4.07 (t, J = 11.4 Hz, IH), 4.14 (td, J = 12.3, 1.1 Hz, IH), 5.50-5.65 (m, IH), 5.85 {dd, 
J= 9.1,0.77 Hz, IH), 5.88-6.15 (br s, IH) ppm; l3C NMR (300 MHz, CDCh) 0 24.5, 
25.3, 58.1, 81.3, 123.9, 128.4, 161.6 ppm; MS (El) mlz (%): 139; 41(22), 54(100), 
55(11), 67(55), 68(17), 95(13), 111(26); HRMS calcd for C7H9N02 139.0633, found 
139.0632; Anal. calcd: C 60.42, H 6.52, found C 60.55, H 6.62. 
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530 
(6-Hydroxy-cyclohex-2-enyl)-carbamic acid methyl ester (530) 
A round-bottomed flask was fitted with a cold finger gas trap, cooled to -45 °C, 
charged with NH3 gas until ~120 mL had condensed and then charged with freshly 
cut Na (1.43 mg, 0.016 mol). The resulting suspension was stirred for 5 min before 
the addition of 515 (8.15 g, 0.031 mol) dropwise as a THF (20 mL) solution. The 
resulting mixture was stirred for 2 h before the slow addition of NaHC03 (10 mL). All 
volatile components were removed under reduced pressure, before the aqueous layer 
was extracted with DCM (5 x 30 mL) and dried over Na2S04. Recrystallization from 
ethyl ether-hexanes yielded 530 as a white solid (4.92 g, 92%); mp 81-82 °C (ethyl 
ether-hexanes); RJ 0.33 (1:2 hexanes-ethyl acetate); IR (film) v 3429, 2951, 2W5, 
1648, 1536, 754 cm-I; IH NMR (300 MHz, CDCh) cS 1.65-1.78 (m, IH), 1.94-2.04 
(m, IH), 2.12-2.23 3.65-3.71 (m, IH), 3.74 (s, 3H), 4.10- 4.26 (m, IH), 4.98 {d, J= 
6.3 Hz, IH), 5.46 (d, J = 9.5 Hz, IH), (m, 2H), 5.86 (d, J = 9.0 Hz, lij) ppm; 13C 
NMR (75 MHz, DMSO-D6) cS 24.0, 29.0, 52.5, 55.4, 72.7, 125.5, 13.0.8, 158.2 ppm; 
MS (EI) mlz (%):171, 41(14), 59(14), 67(12), 68(35), 127(100), 128(10); HRMS 
ca1cd for CgH13N03 171.0895, found 171.0897; Anal. ca1cd: C 56.13, H 7.65, found C 
56.31, H 7.69. 
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531 
trans-3-benzoyl-3a,6, 7,7 a-tetrahydro-l,3-benzoxazol-2{3H)-one (531) 
To a stirred solution of cyclic carbamate 529 (55 mg, 0.395 mmol), triethylamine (48 
mg, 0.474 mmol), and DMAP (10 mg, 0.079 mmol) in DCM (1 mL) was added 
benzoyl chloride (66 mg, 0.474 mmol). The reaction was stirred at room temperature 
for 1.5 h before diluting with DCM (5 mL). The organic layer was washed with cold 
1 N HCl (3 x 1 mL), sat. NaHC03 (1 x 1 mL) and then extracted into DCM (5 x 5 
mL). The crude material was subjected to flash column chromatography with a 
solvent gradient of 12:1, then 5:1 hexane-ethyl acetate to yield 531 (74mg, 77%) as a 
white solid. mp 159-161 °C Rf 0.45 (1:2 hexanes-ethyl acetate); IR (film) v 3019, 
2400,1793,1423,1215,767,669 cm-I; IH NMR (300 MHz, CDCb) () 1.87-2.19 (m, 
1H), 2.27-2.60 (m, 3H), 4.30-4.46 (m, 1H), 4.55 (d, J = 10.7 Hz, 1H), 5.62-5.83 {m, 
1H), 6.22 (dd, J = 9.8 Hz, 1.5 Hz, 1H), 7.55-7.68 (m, 2H), 7.80 (d, J = 7.3 Hz, 1H), 
13 ' $. 8.15 (d, J = 7.3 Hz, 2H) ppm; C NMR (75 MHz, CDCb) () 24.4. 25.3, 60.3, 78.6, 
122.9, 128.1, 128.9, 129.8, 132.8, 133.1, 155.0, 171.0 ppm; MS {EI) mlz (%):243 
(M), 77(36), 105(100), 106(11); HRMS calcd for C I4H 13N03 243.0895, found 
243.0895; Anal. calcd: C 69.12, H 5.39, found C 69.14, H 5.44. 
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532 
3-benzoyl-4,5-dihydroxyhexahydro-l,3-benzoxazol-2(3H)-one (532) 
To a stirred solution of olefin 531 (100 mg, 0.286 mmol), 4-methylmorpholine N-
oxide (25 mg, 0.216 mmol), in DCM (3 mL) with H20 (3 drops) was added 
Osmium(VIIl)tetroxide (1 crystal). The reaction was stirred at r.t. for 6 h before 
filtering through celite and concentrating. The crude material was sUbjected to flash 
column chromatography with a solvent gradient of 1: 1, then 1:3 hexanes-ethyl acetate 
to yield 532 (97 mg, 89%) as a white solid; mp 184-186 °C (ethyl ether-hexanes); Rf 
0.57 (1:4 hexanes-ethyl acetate); lR (film) 3380, 3019, 1799, 1688, 1354, 1330, 
1215, 1138 em-I; IH NMR (300 MHz, CDCh) 0 1.57-1.80 (m, 3H), 2.00-2.13 {m, 
IH), 2.46-2.48 (m, IH), 3.57-3.73 (m, IH), 3.93 (dd, J = 10.9 Hz, 0.61 Hz), 4.46 (s, 
IH), 4.52-4.66 (m, IH), 4.78 (d, J = 5.9 Hz, 2H), 5.22 (d, J = 3.9 Hz, IH), 7.48 (t, J = 
7.8 Hz, 2H), 7.61 (t, J = 7.4 Hz, IH) 7.70 (d, J = 7.9 Hz, 2H) ppm; I3C NMR (75 
s . 
MHz, DMSO) 0 24.9, 26.9, 64.1, 66.9, 69.3, 74.9, 128.5, 129.8, 133.3, 133.6, 155.1, 
170.8 ppm; MS (El) mlz (%):277 (M), 77(26), 105(100); HRMS calcd for Cl4Hl5N05 
277.0950, found 277.0950. 
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534 
trans-5-Benzyl-3-benzoyl-octahydro-l-oxa-3,5-diaza-azulen-2-one (534) 
To a stirred solution of 532 (170 mg, 0.614 mmol) in acetone (10 mL) was added a 
suspension ofNaI04 (525 mg, 2.45 mmol) in distilled water. The reaction was stirred 
at room temperature for 4 h, then the solvent was removed. The crude residue was 
triturated with ethyl acetate (3 x 10 mL), then washed with brine (2 x 10 mL). The 
resulting solution was filtered through a plug of silica gel and concentrated under 
reduced pressure to yield (4S,5R)-3-benzoyl-2-oxo-5-(3-oxopropyl)-1,3-
oxazolidine-4-carbaldehyde (533) which was used without further purification. 
Dialdehyde 533 was dissolved in dry MeOH (9 mL) and cooled to -78°C in an 
acetone and liquid N2 bath. To this solution was added 3 A molecular sieves (300 
mg), followed by NaCNBH3 (42 mg, 0.676 mmol) then AcOH (70 ~L, 1.23 mmol) 
and finally benzylamine (80 ~L, 0.737 mmol). The reaction was warmed to r.t. slowly 
over 24 h before concentrating under reduced pressure. The resulting residue was 
triturated with ethyl acetate (3 x 10 mL) and washed with NaHC03 (1 x 5 mL). The 
organic layer was washed with brine (5 mL), then dried with Na2S04 before 
concentrating. The crude material was purified via column chromatogrpahy to yield 
133 mg (62%) of the title compound as a pale yellow oil: Rf O.62 (1:2 hexanes-ethyl 
acetate); IR (film) v 3029, 2835, 1783, 1679, 1604, 1300, 1253, 1119 cm- I ; IH NMR 
(300 MHz, CDCh) 8 1.69-1.78 (m, 3H), 2.33-2.45 (m, IH), 2.50-2.73 (m, IH), 3.40-
3.4 7 (m, 1 H), 3.68 (q, J = 18.6 Hz, 2H), 4.39 (q, J = 8.7 Hz, 2H), 4.90 (t, J = 8.5 Hz, 
IH), 5.11 (s, 2H), 6.98 (d, J = 8.6 Hz, 2H), 7.28-7.44 (m, 10H), 7.74 {d, J = 8.6 Hz, 
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2H) ppm; l3C NMR (75 MHz, CDCh) 8 26.3, 31.2, 51.4, 55.3, 61.8, 63.0, 70.l, 78.0, 
114.l , 125.2, 127.2, 127.5, 128.2, 128.4, 128.7, 132.3, 136.1, 138.9, 154.l, 162.8, 
169.7 ppm; MS (El) mlz (%): 412 (M-C02); 44(20), 91(100), 160(76), 161(10); 
HRMS (M-C02) ca1cd for C27H28N20 2 412.2151 , found 412.2151. 
S36a 
(3aR,7 aR)-3-[ 4-(benzyloxy)benzoyl]-3a,6, 7,7 a-tetrahydro-l,3-benzoxazol-2(3H)-
one (536a) 
To a stirred solution of 529a (57 mg, 0.409 mmol) in freshly distilled CH2Ch (7 mL) 
was added triethylamine (0.l1 mL, 0.819 mmol), and DMAP (17 mg, 0.122 mmol). 
The reaction was cooled to 0 °C, then 4-benzyloxybenzoyl chloride (101 mg, 0.409 
mmol) was added portionwise over a period of 30 min. The reaction was stirred for 
12 h before diluting with CH2Ch (5 mL). The organic layer was washed with cold 1 
~ . . 
N HCl (3 x 3 mL), and then with saturated NaHC03 (1 x 3 mL). The combined 
organic layers were washed with brine, dried with Na2S04 then evaporated. The 
crude product was subjected to flash column chromatography (6: 1 hexanes-ethyl 
acetate) then recrystallized from ethyl ether-hexanes to afford 102 mg (72%) of 536a 
as a white solid: mp 167-169 °C (ethyl ether-hexanes); RJ 0.47 (2:1 hexanes-ethyl 
acetate); [a]D23 -104.6 (c 0.5, CHCh); IR (film) v 2922, 1790, 1674, 1604, 1298, 
1140 em-I; IH NMR (300 MHz, CDCh) 8 1.97-2.07 (m, 1H), 2.27-2.45 (m, 2H), 
2.45-2.55 (m, 1H), 4.24-4.38 (m, IH), 4.50 (d,J= 8.6 Hz, IH), 5.10 (s, 2H), 5.68 (dd, 
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J = 6.6, 3.2 Hz, IH), 6.13 (dd, J = 9.6, 1.3 Hz, IH), 6.98 (d, J = 8.6 Hz, 2H), 7.31-
7.45 (m, 5H), 7.77 (d, J = 8.6 Hz, 2H) ppm; I3C NMR (300 MHz, CDC h) 5 24.4, 
25.3,60.4,70.2,78.5,114.3,123.1,125.1,127.6,128.3, 128.7, 128.8, 132.3, 136.2, 
155.2, 162.9, 169.9 ppm; MS (El) mlz (%): 349; 43(11), 83(10), 91(100), 113(10), 
167(56), 168(16), 183(18), 184(15), 211 (12), 226(27), 349(18); HRMS ca1cd for 
C21Hl9N04 349.1314, found 349.1314; Anal. ca1cd: C 72.19, H 5.48, found C 72.22, 
H 5.55. 
OBn 
;,{P 
~OH 
OH 
537a 
(3aR,4R,5S,7aR)-3-[4-(benzyloxy)benzoyl]-4,5-dihydroxyhexahydro-l,3-
benzoxazol-2(3H)-one (537a) 
To a stirred solution of 536 (93 mg, 0.266 mmol) in freshly distilled CH2Ch (5 mL) 
was added N-methylmorpoline-N-oxide (47 mg, 3.99 mmol), 'one drop:Df distilled 
water, and a catalytic amount of OS04. The reaction was stirred at room temperature 
for 36 h before filtering through a plug ofcelite and silica gel. The crude material was 
recrystallized from ethyl ether-hexanes and then dried over P205 to yield 84 mg 
(83%) of'537a as a white solid: mp 178-180 °C (ethyl ether-hexanes); RfO.35 (1:3 
hexanes-ethyl acetate); [a]D23 -67.2 (c 0.8, CHCh); lR (film) v 2922, 1790, 1674, 
1604, 1298, 1140 em-I; IH NMR (300 MHz, CDCh) 5 1.65-1.75 (m, 2H), 2.02-2.07 
(m, IH), 2.22-2.28 (m, lH), 3.75 (dd, J = 11.1, 0.93 Hz, IH), 3.81-3.91 (m, IH), 
4.60-4.68 (m, IH), 4.75-4.80 (m, lH), 5.10 (s, 2H), 6.98 (d, J = 7.9 Hz, 2H), 7.31-
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7.34 (m, IH), 7.36-7.42 (m, 4H), 7.76 (d, J= 8.2 Hz, 2H) ppm; I3C NMR (300 MHz, 
CDCl3) () 24.4, 25.3, 60.4, 70.2, 78.5,114.3,123.1,125.1,127.6,128.3,128.7,128.8, 
132.3, 136.2, 155.2, 162.9, 169.9 ppm; MS (EI) mlz (%): 349; 43(11), 83(10), 
91(100), 113(10), 167(56), 168(16), 183(18), 184(15), 211(12), 226(27), 349(18); 
HRMS calcd for C21H19N04 349.1314, found 349.1314. 
d°y-o f7(0Bn 
."NyV 
N ° Bn 
539a 
(3aR,8aR)-5-benzyl-3-[4-(benzyloxy)benzoyl]octabydro-2H-[1,3]oxazolo[4,5-
c]azepin-2-one (539a) 
To a stirred solution of 537a (58 mg, 0.151 mmol) in acetone (3 mL) was added a 
suspension of NaI04 (322 mg, 1.51 mmol) in distilled water. The reaction was stirred 
at room temperature for 6 h, then the solvent was removed. The crude residue was 
triturated with ethyl acetate (3 x 5 mL), then washed with brine (2 x 5 mL). The 
resulting solution was filtered through a plug of silica gel and concent~ated under 
reduced pressure to yield (4S,5R)-3-[4-(benzyloxy)benzoyl]-2-oxo-5-(3-oxopropyl)-
1,3-oxazolidine-4-carbaldebyde (538) which was used without further purification. 
Dialdehyde 538 was dissolved in dry MeOH (3 mL) and cooled to -78°C in an 
acetone and liquid N2 bath. To this solution was added 3 A molecular sieves (15'0 
mg), followed by NaCNBH3 (10 mg, 0.166 mmol) then AcOH (17.3 ilL, 0.302 mmol) 
and finally benzylamine (18.2 ilL, 0.166 mmol). The reaction was warmed to room 
temperature slowly over 24 h before {;oncentrating under redu{;ed pressure. The 
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resulting residue was triturated with ethyl acetate (3 x 5 mL) and washed with 
NaHC03 (l x 3 mL). The organic layer was washed with brine (3 mL), then dried 
with Na2S04 before concentrating. The crude material was recrystallized from ethyl 
ether-hexanes to yield 47 mg (68%) of the title compound as a pale yellow solid: mp 
126-128 °C (ethyl ether-hexanes); RjO.68 (2:1 hexanes-ethyl acetate); [a]o23 -17.9 (c 
0.07, CHCh; IR (film) v 3029, 2835,1783,1679,1604,1300,1253,1119 cm-I; IH 
NMR (300 MHz, CDCh) () 7.73 (d, J= 8.7 Hz, 2H), 7.37-7.43 (m, 4H), 7.32-7.37 (m, 
2H), 7.29-7.32 (m, 4H), 6.98 (d, J= 8.7 Hz, 2H), 5.11 (s, 2H), 4.90 (td, J= 3.2,10.5 
Hz, IH), 4.39 (td, J = 7.1, 9.6 Hz, IH), 3.71 (d, J = 13.2 Hz, IH), 3.64 (d, J = 13.2 
Hz, IH), 3.44 (dd, J = 6.6, 11.1 Hz, IH), 2.65-2.70 (m, IH), 2.60-2.65 (m, IH), 2.55-
2.60 (m, IH), 2.35-2.39 (m, IH), 1.73-1.77 (m, IH), 1.70-1.73 (m, IH), 1.66-1.70 (m, 
IH) ppm; I3C NMR (300 MHz, CDCh) () 169.7, 162.8, 154.1, 138.9, 136.1, 132.3, 
128.7, 128.4, 128.2, 127.5, 125.2, 114.1, 78.0, 70.1, 63.0, 61.8, 55.3, 51.4, 31.2,26.4 
ppm; MS (EI) mlz (%): 412 (M-C02); 44(20), 91(100), 160(76), 161(10); HRMS 
(M-C02) ca1cd for C27H28N202 412.2151, found 412.2151; Anal. calcd: C 73.66, H 
6.18, found C 73.55, H 6.20. C' . 
Alternative method: To a stirred solution of 569 (30 mg, 0.078 mmol) in 10: 1 
acetone-H20 (1 mL) was added Nal04 (167 mg, 0.78 mmol). The resulting 
suspension was stirred at room temperature for 6 h, then the solvent was removed and 
the crude residue was triturated with ethyl acetate (3 x 5 mL), then washed with brine 
(2 x 5 mL). The resulting solution was filtered through a plug of silica gel and 
concentrated under reduced pressure to yield (4S,5R)-3-[4-(benzyloxy)benzoyl]-2-
oxo-5-(3-oxopropyl)-1,3-oxazolidine-4-carbaldehyde (538), which was used 
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without further purification. The crude dialdehyde 538 was dissolved in dry MeOH (2 
mL) and cooled to -78°C in an acetone and liquid N2 bath. To this solution was 
added 3 A molecular sieves (75 mg), followed by NaCNBH3 (6 mg, 0.086 mmol), 
then AcOH (8.9 ilL, 0.156 mmol), and finally benzylamine (9.4 ilL, 0.086 mmol). 
The reaction was warmed to r.t. slowly over 24 h before concentrating under reduced 
pressure. The resulting residue was triturated with ethyl acetate (3 x 2 mL) and 
washed with NaHC03 (1 x 1 mL). The organic layer was washed with brine (1 mL), 
then dried over Na2S04. The crude material was recrystallized from ethyl ether-
hexanes to yield 539a as a pale yellow solid (23 mg, 64%); [a]023 -31.9 (c 0.8, 
CHCh). 
53gb 
(3 as, 7 as)-5-Benzyl-3-( 4-benzyloxy-benzoyl)-octahydro-l-oxa-3,5-diaza-azulen-2-
one (539b) 
A stirred solution of amide 574 (20 mg, 0.047 mmol) in 1 mL of 9:3:1 
(AcOH:tetrahydrofuran:H20) was brought to reflux for 16 h then cooled to r.t. and 
concentrated under reduced pressure. The resulting residue was triturated with 
benzene (2 x 1 mL) and CHCh (2 x 1 mL), filtered through a plug of Si02 then 
recrystallized from CHCh to yield (3aS,4S,5R,7aS)-3-(4-Benzyloxy-benzoyl)-4,5-
dihydroxy-hexahydro-benzooxazol-2-one (15 mg, 83%) as a white solid: mp 166-
167°C (hexanes-ethyl acetate); Rf 0.31 (1: 1 hexanes-ethyl acetate); [a]o 23 +8D.2 (c 
2{50 
0.47, CHCh); IR (film) v 3684, 3091,1794, 1604, 1511, 1422, 1303, 1215, 1029 cm-
I; IH NMR (300 MHz, CDCh) 8 7.68 (d, J = 8.8 Hz, 2H), 7.29-7.44 (m, 5H), 6.98 (d, 
J= 8.8 Hz, 2H), 5.93 (br s, 10H), 5.11 (s, 2H), 4.34 (dd, J= 9.7,11.1 Hz, 1H), 4.07 
(dd, J= 2.6,5.5 Hz, 1H), 3.95-4.05 (m, 1H), 3.87 (dd, J= 3.1, 9.6 Hz, 1H), 3.10 (br s, 
10H), 2.26 (ddd, J = 0.1, 3.1, 14.7 Hz, 1H), 2.01-2.10 (m, 2H), 1.54-1.59 (m, 1H) 
ppm; I3C NMR (75 MHz, CDCh) 8 173.6, 163.1, 153.6, 136.0, 132.1 (2xC), 128.7, 
128.3(2xC), 127.6(2xC), 124.6, 114.2(2xC), 77.6, 72.7, 70.2, 68.6, 64.6, 26.7, 22.2 
ppm; MS (EI) mlz (%): 383 (M), 43(12), 83(20), 84(10), 85(13), 91(100), 211(15); 
HRMS ca1cd for C2I H2IN06 383.1369, found 383.1369. 
To a stirred solution of (3aS,4S,SR,7aS)-3-(4-Benzyloxy-benzoyl)-4,S-dihydroxy-
hexahydro-benzooxazol-2-one (58 mg, 0.151 mmol) in 10:1 acetone-H20 (2 mL) 
was added Nal04 (600 mg, 3.00 mmol). The resulting suspension was stirred at r.t. for 
6 h, before the solvent was removed under reduced pressure. The crude residue was 
triturated with ethyl acetate (3 x 5 mL), then washed with brine (2 x 5 mL). The 
resulting organic layers were filtered through a plug of silica gel and concentrated 
under reduced pressure to yield (4 R,SS)-3-( 4-Benzyloxy-benzoyl)-2-oxo-.S-(3-oxo-
propyl)-oxazolidine-4-carbaldehyde, which was used without further purification. 
The dialdehyde species was dissolved in dry MeOH (2 mL) and cooled to -78°C in 
an acetone and liquid N2 bath. To this solution was added 3 A molecular sieves (100 
mg), followed by NaCNBH3 (10 mg, 0.166 mmol), then AcOH (17 ilL, 0.302 mmol), 
and finally benzyl amine (18 ilL, 0.166 mmol). The reaction was warmed to room 
temperature slowly over 24 h before concentrating under reduced pressure. The 
resulting residue was triturated with ethyl acetate (3 x 2 mL) and washed with 
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NaHC03 (1 x 2 mL). The organic layer was washed with brine (1 mL), then dried 
over Na2S04. The crude material was recrystallized from ethyl ether-hexanes to yield 
539b (38 mg, 60% over 2 steps) as a pale yellow solid: mp 126-128 °c (ethyl ether-
hexanes): Rf O.68 (2:1 hexanes-ethyl acetate); [a]D23 +31.1 (c 0.9, CHCh); IR (film) v 
3029,2835, 1783, 1679, 1604, 1300, 1253, 1119 cm-I; IH NMR (300 MHz, CDCh) () 
7.74 (d, J= 8.6 Hz, 2H), 7.28-7.44 (m, 10H), 6.98 (d, J= 8.6 Hz, 2H), 5.11 (s, 2H), 
4.90 (t, J= 8.5 Hz, IH), 4.39 (q, J= 8.7 Hz, IH), 3.68 (q, J= 18.6 Hz, 2H), 3.40-3.47 
(m, IH), 2.50-2.73 (m, 3H), 2.33-2.45 (m, IH), 1.69-1.78 (m, 3H) ppm; BC NMR (75 
MHz, CDCh) () 169.7, 162.8, 154.1, 138.9, 136.1, 132.5, 132.3(2xC), 128.8, 128.7, 
128.4(2xC), 128.2, 127.5(2xC), 127.2, 125.2, 114.2(2xC), 114.1, 78.0, 70.1, 63.0, 
61.8,55.3,51.4,31.2,26.3 ppm; MS (EI) mlz (%): 412 (M-C02), 44(20), 91(100), 
160(76), 161(10); HRMS (M-C02) calcd for C27H28N202 412.2151, found 412.2151. 
0° 
N 
Boc 
542 
tert-butyl 8-oxa-3-azabicycio[5.1.0]octane-3-carboxylate (542) 
6-. . 
A round-bottom flask was flame-dried and purged with argon. To this was added 6 
mL of freshly distilled DCM, olefin 548 (413mg, 2.09 mmol) and m-CPBA titrated to 
77% (1.41g, 6.28 mmol). The resulting solution was stirred at r.t. overnight. The 
reaction was quenched with 5ml of sat. Na2C03, then diluted with 7ml of DCM. The 
organic layer was washed with 10ml of NaHC03, then 10 ml of H20. The organic 
layer was then washed with brine then dried over MgS04 to yield 542 (410 mg, 92%); 
IR (film) v 3442, 2976, 1693, 1478, 1459, 1366, 1276, 1141, 943, 889, 757 cm- I ; IH 
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NMR (300 MHz, CDCh) () 3.97-3.64 (m, IH), 3.54-3.39 (m, 2H), 3.12-2.99 (m, 2H), 
2.95-2.73 (m, IH), 2.16-1.99 (m, IH), 1.98-1.82 (m, IH), 1.73-1.56 (m, 2H), 1.41 (s, 
9H) ppm; I3C NMR (75 MHz, CDCh) () 155.5, 79.6, 54.7, 54.5, 49.3, 48.9, 46.2, 
45.5, 28.4, 27.6, 23.8, 23.4 ppm; MS (EI) mlz (%): 213(M), 41(29), 42(17), 43(17), 
56(22),57(100), 158(12); HRMS calcd for CIIHI9N03 213.1365, found 213.1361 
Cf N 
Boc 
547 
tert-butyl allyl(pent-4-en-l-yl)carbamate (547) 
A flame-dried round bottom flask was charged with argon, 10 mL of distilled DMF, t-
butyl-N-allyl carbamate (545) (lg, 6.36 mmol) and 5-bromo-l-pentene (546){632mg, 
4.24 mmol). The resulting solution was cooled to 0 °C prior to the addition of NaH 
(102mg, 4.24 mmol). The reaction was stirred at 0 °C for 45 min, and then stirred for 
an additional 30 min at r.t. before the addition of H20 (10 mL) and EtOAc (10 mL). 
The aqueous layer was washed EtOAc (3 x 10 mL). Then the combined organic 
layers were washed H20 then brine. The organic layer was then dried over MgS04 to 
yield 547 as an colourless oil (735mg, 77%); lR (film) v 3429, 2977, 1695, 1642, 
1409, 1365, 1246, 1172,912, 771,665 cm-I; IH NMR (300 MHz, CDCh) () 5.85-5.66 
(m, 2H), 5.13-4.88 (m, 4H), 3.77 (s, 2H), 3.15 (s, 2H), 2.00 (q, J = 7.5 Hz, 2H), 1.57 
(m, J = 7.6 Hz, 2H), 1.42 (s, 9H) ppm; I3C NMR (75 MHz, CDCh) 0 155.3, 137.8, 
134.3, 114.7, 79.1, 46.1, 30.9, 28.3 ppm; MS eEl) mlz (%): 225(M), 41(39), 57(100), 
70(40), 114(23); HRMS calcd for CI3H23N02 225.1729, found 225.1737; Anal. ca1cd: 
C 69.29, H 10.29, found C 69.35, H 10.39. 
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o N Boc 
548 
tert-butyl 2,3,4,7 -tetrahydro-lH-azepine-l-carboxylate (548) 
A round bottom flask was flame-dried and purged with argon. Added was 2 mL of 
freshly distilled DCM, diene 547 (200 mg, 0.887 mmol) and benzylidene-
bis(tricyc1ohexylphosphine)dichlororuthenium (22 mg, 0.0266 mmol). The resulting 
suspension was placed in a pre-heated oil bath at 52 °C and stirred for 1 h. The 
reaction was then concentrated and purified by flash column chromatography with 12 
g of Si02, and a solvent system of 1: 1 (DCM-hexanes) to yield 548 as a yellow oil 
(150 mg, 86%); IR (film) v 3510, 3022, 2975, 2932, 1695, 1458, 1414, 1245, 1169, 
1113, 865, 770, 665 cm-I: IH NMR (300 MHz, CDCh) 8 5.78 (m, 2H), 3.86 (d, J = 
22.8 Hz, 2H), 3.56-3.40 (m, 2H), 2.21-2.11 (m,2H), 1.84-1.68 (m, 2H), 1.42 (s, 9H) 
ppm; l3C NMR (75 MHz, CDC h) 8 155.5, 131.9, 131.0,79.2,47.9,47.6,45.6,28.4, 
26.9, 26.7, 26.5 ppm; MS (El) mlz (%): 197(M), 41(31), 57(100), 68(11), 82(22), 
96(10), 124(13), 126(11), 140(21), 141(46); HRMS calcd for CIIHI9N02 197.1416, 
" 
found 197.1405; Anal. calcd: C 66.97, H 9.71, found C 66.97, H 9.71. 
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OAe 0:"NHAe + 
Br)l}"o 
O~ 
559 
QAe 0:"NHAe 
Br~"o 
O~ 
560 
(3aS,4S,5R,7 as)-4-( acetyl amino )-7 -bromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-l,3-
benzodioxol-5-yl acetate (559) and (3aS,4S,5S,7aS)-4-(acetylamino)-7-bromo-2,2-
dimethyl-3a,4,5,7 a-tetrahydro-l,3-benzodioxol-5-yl acetate (560) 
To a stirred solution of aziridine 429 (50 mg, 0.174 mmol), acetic acid (0.19 mL, 3.47 
mmol) in DCM (0.5 mL) was added trimethylsilyl trifluoromethanesulfonate (3.1 ilL, 
0.0174 mmol). The reaction was allowed to stir at room temperature for 12 h and then 
filtered through a plug of Si02 and Na2S04 before concentrating under reduced 
pressure. The crude material was subjected to flash column chromatography with a 
solvent gradient of3:1, 1:1 hexanes-ethyl acetate to yield 559 (43 mg, 70%) and 560 
(11 mg, 18%) as white solids. 
559: Rf 0.35 (1:3 hexanes-ethyl acetate); mp 168-169 °C (ethyl acetate-hexanes); 
[a]D23 -111.4 (c 1.00, CHCh); lR (film) v 3583, 3272,1743,1655,1371,1226,1043 
6- . 
cm-I; IH NMR (600 MHz, CDCh) 0 6.03 (d, J= 9.85 Hz, IH), 6.02 (d, J= 2.0 Hz, 
IH), 5.45 (dt, J= 2.1,9.3 Hz, IH), 4.62 (dd, J= 1.98,5.04 Hz, IH), 4.41 (td, J= 2.3, 
9.5 Hz, IH), 4.39 (t, J = 3.3 Hz, IH), 2.05 (s, 3H), 1.97 (s, 3H), 1.38 (s, 3H), 1.35 (s, 
3H) ppm; I3C NMR (150 MHz, CDCh) 0 171.1, 170.1, 129.4, 124.7, 110.7, 77.3, 
76.0, 69.4, 50.8, 27.4, 26.4, 23.3, 20.1 ppm; MS (El) mlz (%): 347 (M), 43(100), 
84(45), 142(79); HRMS ca1cd for CI3HISBrNOs 347.0368, found 347.03E4; Anal. 
ca1cd: C 44.84, H 5.21, found C 44.90, H 5.26. 
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560: RJ .0.21 (1:3 hexane-ethyl acetate); mp 95-97 °C (ethyl acetate-hexanes); [a]D23 
+ 1.02.6 (c 1.28, CHCh); IR (film) v 3391, 2947, 2835, 1731, 1653, 1375, 125D, 1.031 
cm-I; IH NMR (3.0.0 MHz, CDCh) 8 6.38 (d, J = 5.7 Hz, 1H), 6.14 (d, J = 9 . .0 Hz, 
1H), 5.17 (t, J = 5.1 Hz, 1H), 4.64 (d, J = 6 . .0 Hz, 1H), 4.54-4.61 (m, IH), 4.41-4.45 
(m, IH), 2 . .06 (s, 3H), 2 . .04 (s, 3H), 1.44 (s, 3H), 1.38 (s, 3H) ppm; l3C NMR (75 
MHz, CDCh) 8 17.0.4, 169.9, 129.6, 127.2, 111.3, 76.9, 75 . .0, 67.3,45.8, 27.3, 26.3, 
23.2,2.0.9 ppm; MS (EI) mlz (%): 347 (M), 43(1.0.0), 56(45), 57(52); HRMS ca1cd for 
Cl3HISBrNOs 347 . .0368, found 347 . .0368. 
(3aS,4S,5R,7 aR)-4-( acetylamino )-2,2-dimethylhexahydro-l,3-benzodioxol-5-yl 
acetate (561) 
To a stirred solution ofaziridine 559 (753 mg, 2.16 mmol), NEt3 (2.1 mL, 15.1 mmol) 
in ethyl acetate (3 mL) was added platinum(lV)oxide (12 mg, .0.433 mihol) before 
evacuating the reaction flask with H2. The reaction was stirred at r.t. with 1 atm ofH2 
for 36 h before filtering through a plug ofSi02 and concentrating. The crude material 
was purified via flash column chromatography with a solvent gradient of 1:2 then 1:5 
(hexanes-ethyl acetate) to yield 561 (493 mg, 84%) as a clear oil: RJ.o.3 (1:5 hexanes-
ethyl acetate); [a]D23 -49.2 (c 1.24, CHCh); IR (film) v 3286, 2939, 2988, 1735, 1657, 
1547, 1374, 1243, 1.041, 868, 755 cm-I; IH NMR (6.0.0 MHz, DMSO-D6) 87.99 (d, J 
= 8.7 Hz, 1H), 4.79 (dt, J = 5.8, 11.1 Hz, 1H), 4.29 (dd, J = 5.7, 11..0 Hz, 1H) 4.23 
266 
(dd, J = 3.2, 5.9 Hz, IH), 4.13 (td, J = 2.4,9.4 Hz, IH), 1.96 (m, IH), 1.94 .(s, 3H), 
1.82 (s, 3H), 1.73 (td, J = 4.4,9.3 Hz, IH), 1.47 (td, J = 4.4,9.1 Hz, IH), 1.42 (s, 3H), 
1.33-1.39 (m, IH), 1.24 (s, 3H) ppm; I3C NMR (150 MHz, CDCh) D 171.3, 170.0, 
108.7,75.7, 73.3, 70.0, 50.7, 27.3, 25.2, 25.1(2xC), 23.3, 21.1 ppm; MS (EI) mlz (%): 
256 (M-CH3+), 43(100),60(32), 84(43), 94(45), 111(48), 112(36), 153(57), 213(31); 
HRMS ca1cd for C12H1SNOs" 256.1180, found 256.1187; Anal. ca1cd: C 57.55, H 
7.80, found C 57.67, H 7.90. 
N- [(3aS,4S,5R, 7 aR)-5-hydroxy-2,2-dimethylhexahydro-l ,3-benzodioxol-4-
yl]acetamide (562) 
To a stirred solution of 559 (60 mg, 0.173 mmol), NEt3 (0.17 mL, 1.206 mmol) in 
methanol (0.7 mL) was added platinum(lV)oxide (9 mg, 0.0344 mmol) before 
~ 
evacuating the reaction flask with H2• The reaction was stirred at r.t. with 1 atm ofH2 
for 36 h before filtering through a plug of Si02 and concentrating. The crude material 
was purified via flash column chromatography with a solvent gradient of 1 :2, and 
then 1:5 (hexanes-ethyl acetate) to yield 562; R{0.2 (hexanes-ethyl acetate); IH NMR 
(300 MHz, CDCh) D 10.9 (s, IH), 6.32 (d, J= 5.6 Hz, IH), 4.18-4.30 (m, 2H), 3.98-
4.06 (m, IH), 3.71-3.83 (m, IH), 2.09 (s, 3H), 1.94-2.02 (m, IH), 1.79-1.87 (m, IH), 
1.47-1.63 (m, 2H), 1.46 (s, 3H), 1.30 (s, 3H) ppm; I3C NMR (75 MHz, CDCh) D 
172.3, 108.9, 75.6, 73.9,69.7, 54.4,46.2, 28.2, 27.6, 25.9, 25.5, 23.3, 8.63 ppm; MS 
267 
(El) mlz (%): 214 (M-CH3+), 43(100), 60(32), 84(43), 94(45), 111(48), 112(36), 
153(57),213(31); HRMS ca1cd for CIOH I6N04' 214.1079, found 214.1079. 
OAc 6:"NHAC 
o "OH 
OH 
563 
(IR,2R,3S,4R)-2-( acetyJamino )-3,4-dihydroxycyclohexyJ acetate (563) 
A solution of acetonide 561 (338 mg, 1.25 mmol), acetic acid (2 mL), H20 (0.5 mL) 
and THF (2 mL) was stirred at 80°C for 12 h and then triturated (benzene then Et20), 
dried over Na2S04 and concentrated. Recrystallization from MeOH-hexanes yielded 
563 (0.248 mg, 86%) as a white solid: mp 170-171 °C (MeOH-hexanes); Rr 0.21 
(10:1 CHCh-MeOH); IR (film) v 3434, 2524, 1641, 1559, 1262, 1057cm-1; IH NMR 
(600 MHz, DMSO-D6) 8 7.67 (d, J = 8.7 Hz, 1H), 4.84 (d, J = 3.8 Hz, 1H), 4.76 (td, J 
= 4.4, 10.8 Hz, 1H) 4.63 (d, J = 5.3 Hz, 1H), 3.77 (td, J = 1.9,9.6 Hz, 1H), 3.68 (br s, 
1H), 3.50 (t, J = 5.3 Hz, 1H), 1.91 (s, 3H), 1.81-1.84 (m, 1H), 1.80 (s, 3H), 1.64 (qd, J 
= 3.2, 12.5 Hz, 1H), 1.46-1.52 (m, 1H), 1.27 (qd, J = 3.3, 12.4 Hz, llt)'ppm; l3C 
NMR (150 MHz, DMSO) 8 170.6, 169.3, 72.2, 71.0, 70.0, 53.4, 27.2, 26.4, 23.1, 21.4 
ppm; MS (FAB) mlz (%): 232 (M+H+), 41(58), 43(100), 55(76), 57(66), 69(56), 
149(43),232(84); HRMS ca1cd for ClOHl 8NOs 232.1185, found 232.1185. 
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566 
Methyl [(3aS,4S,5R, 7 aR)-5-hydroxy-2,2-dimethylh exahydro-l ,3-benzodioxol-4-
yl]carbamate (566) 
To a stirred solution of acetate 561 (300 mg, 1.11 mmol) in methanol (5 mL) was 
added Na (254 mg, 11.1 mmol) portionwise until completely dissolved (30 min). The 
reaction mixture was brought to reflux and stirred for 18 h then cooled to r.t. and 
quenched by the addition of H20 (5 mL). The reaction mixture was concentrated 
under reduced pressure and then extracted into CHCh (5 x 1 mL). The 'combined 
organic layers were dried over Na2S04 and concentrated to yield (3aS,4S,5R,7aR)-4-
amino-2,2-dimethylhexahydro-l,3-benzodioxol-5-ol (565) as a pale yellow oil 
which was used without further purification: lH NMR (300 MHz, CD30D) 8 4.33-
4.39 (m, IH), 4.22 (dt, J = 5.6, 8.5 Hz, IH), 3.54 (td, J = 4.6,9.5 Hz, IH), 2.64 (dd, J 
= 3.6, 9.6 Hz, IH), 1.80-1.95 (m, 2H), 1.54-1.66 (m, IH), 1.48 (s, 3H), 1.35 (s, 3H), 
6. 
1.30-1.33 (m, IH) ppm; BC NMR (75 MHz, CD30D) 8 108.4, 77.0, 74.2, 70.6, 55.6, 
28.6,27.0,26.7,24.5 ppm. 
~-amino alcohol 565 (178 mg, 0.951 mmol), NEt3 (0.26 mL, 1.90 mmol), and DMAP 
(catalytic amount) in DCM (1 mL) was added methyl chloroformate (80.5 ~L, 1.05 
mmol) at 0 °C. The reaction was allowed to warm to r.t. over 12 h then diluted with 
DCM (1 mL), washed with sat. NaHC03 (1 x 1 mL) and brine (1 mL) then dried over 
Na2S04. The crude material was purified via flash column chromatography with a 
solvent system of60:1 (CHCh-MeOH) to yield 566 (197 mg, 73% over 2 steps) as a 
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yellow oil: Rf 0.43 (10:1 CHCh-MeOH); ,(a]o23 -24.7 ( c 0.7, MeOH); IR (film) v 
3433, 2988, 2940, 1695, 1645, 1241, 1219, 1035, 1077 cm-I; IH NMR (600 MHz, 
CO(CD3)2) b 5.98 (br d, J = 4.9 Hz, NH), 4.36 (dd, J = 3.6,5.5 Hz, IH), 4.29 (dd, J = 
2.8, 5.6, IH), 3.89 (br s, OH), 3.67-3.77 (m, 2H), 3.63 (s, 3H), 1.93-1.99 {m, IH), 
1.79-1.86 (m, IH), 1.53-1.61 (m, IH), 1.44 (s, 3H), 1.37-1.42 (m, IH), 1.28 (s, 3H) 
ppm; I3C NMR (150 MHz, CO(CD3)2) b 158.8, 107.9, 76.1, 73.8, 67.8, 55.9, 51.1, 
28.6, 27.2, 26.1, 24.8 ppm; MS (EI) mlz (%): 230 (M-CH/), 43(34), 59(43), 76(38), 
95(31), 99(34), 130(100), 143(33); HRMS calcd for C IOHI6N05 230.1028, found 
230.1028; Anal. calcd: C 53.87, H 7.81, found C 53.77, H 7.80. 
(3aR,5aR,8aS ,8bS)-2,2-dimethylhexahydro [1,3] dioxolo [4,5-e] [1,3] benzoxazol-
7(4H)-one (567) 
To a stirred suspension of NaH (128 mg, 5.34 mmol) in THF (4 mL) was added a 
solution of carbamate 566 (131 mg, 0.534 mmol) in THF (2.5 mL). The reaction 
mixture was brought to reflux and stirred for 24 h then cooled to r.t. and quenched by 
the addition of sat. NH4CI (5 mL). The reaction mixture was extracted into EtOAc (5 
x 2 mL), washed with brine (2 mL) and dried over Na2S04 and 'concentrated. 
Recrystallization from acetone yielded 567 (95 mg, 83%) as white needles: Rf 0.21 
(1:3 hexanes-ethyl acetate); mp 179-181 °C (acetone); {a]o23 -19.7 (c 0.75, CHCh); 
IR (film) v 3459, 2983,2925, 1733, 1639, 1136 em-I; IH NMR (300 MHz, CDCh) b 
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5.49 (br s, 1 NH), 4.61 (m, IH), 4.43-4.51 (m, 2H), 3.49 (dd, J = 1.9, 12.1 Hz, IH), 
2.22-2.37 (m, IH), 1.99-2.17 (m, IH), 1.76-1.94 (m, 2H), 1.53 (s, 3H), 1.34 (s, 3H) 
ppm; I3C NMR (75 MHz, CDCh) 8 160.6, 109.5, 73.8, 73 .5, 70.9, 58.3, 58.2, 26.1, 
23.8, 22.2, 21.9 ppm; MS (EI) mlz (%): 213 (M), 43(92), 59(41), 67(45), 94(42), 
99(100), 198(64); HRMS ca1cd for C IOHISN04 213.1001, found 213.0998. 
(3aR,5aR,8aS,8bS)-8-[4-(benzyloxy)benzoyl]-2,2-
dimethylhexahydro[1,3]dioxolo[4,5-e] [1,3]benzoxazol-7( 4H)-one (568) 
To a stirred solution of cyclic carbamate 567 (40 mg, 0.188 mmol), NEt3 (1 04 ~L, 
0.750 mmol), and DMAP (catalytic) in DCM (0.25 mL) was added 4-
benzyloxybenzoyl chloride (51 mg, 0.206 mmol) at 0 DC. The reaction mixture was 
allowed to warm to r.t. slowly over 16 h then diluted with DCM (0.5 mt), washed 
with cold 1 N NaOH (1 x 0.5 mL), brine (1 x 0.5 mL) and dried over Na2S04. The 
crude material was purified via flash column chromatography with a solvent gradient 
of 6:1 then 4:1 (hexanes-ethyl acetate) to yield 568 (65 mg, 82%) as a white solid: Rf 
0.38 (2:1 hexanes-ethyl acetate); mp 153-154 °C (MeOH); [a]D23 -163.8 (c 0.425, 
CHCh); IR (film) v 3433, 1638, 1259, 1027 cm-I; IH NMR (600 MHz, CO(CD3)2) 8 
7.79 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 7.6 Hz, 2H), 7.45 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 
7.6 Hz, IH), 7.12 (d, J = 8.7 Hz, 2H), 5.26 (s, 2H), 4.94 (dd, J = 3.4, 7.2 Hz, IH), 
271 
4.77 (ddd, J = 7.7, 10.2, 12.1 Hz, 1H), 4.66 (dt, J = 3.2, 7.2 Hz, 1H), 4.11 (dd, J = 3.4, 
12.1 Hz, 1H), 2.27-2.36 (m, 1H), 2.14-2.20 (m, 2H), 1.89-1.98 (m, 1H), 1.53 (s, 3H), 
1.32 (s, 3H) ppm; I3C NMR (150 MHz, CO(CD3)2) 8 169.2, 162.6, 154.2, 136.9, 
132.0, 128.5, 128.0, 127.7, 125.8, 114.0, 108.9, 73.9, 71.3, 70.1, 69.8, 60.2, 25.4, 
23.2, 21.6, 20.9 ppm; MS eEl) mlz (%): 423 (M), 43(24), 83(23), 91(100), 211(26), 
423(21); HRMS calcd for C24H2SN06 423.1682, found 423.1662; Anal. calcd: C 
68.07, H 5.95, found C 68.15, H 5.99. 
(3aR ,4S,5R, 7 aR)-3-[ 4-(benzyloxy )benzoyl] -4,5-dihydroxyhexahydro-l ,3-
benzoxazol-2(3H)-one (569) 
A stirred solution of 568 (65 mg, 0.153 mmol) in 1 mL of 9:3:1 (AcOH:THF:H20) 
was brought to reflux for 16 h then cooled to r.t. and concentrated under reduced 
pressure. The resulting residue was triturated with benzene (2 x 1 mL) and CHCh (2 
x 1 mL), filtered through a plug of Si02 then recrystallized from CHCh to yield 569 
(52 mg, 88%) as a white solid: Rf O.33 (1:3 hexanes-ethyl aceate); mp 174-175 °C 
(CHCh); [a]o23 -68.4 (c 0.05, MeOH); IR (film) v 3435, 2918, 1786, 1660, 1604, 
1220, 1036 em-I; IH NMR (600 MHz, CDCh) 8 7.78 (d, J = 8.7 Hz, 2H), 7.38-7.44 
(m, 4H), 7.34 (t, J= 7.1 Hz, 1H), 7.00 (d, J= 8.7 Hz, 2H), 5.12 (s, 2H), 4.79-4.82 (m, 
1H), 4.66 (td, J = 3.5 Hz, 11.6, 1H), 3.86-3.91 (m, IH), 3.78 (dd, J = 1.5, 11.5 Hz, 
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1H), 2.24-2.29 (m, 1H), 2.02-2.09 (m, 1H) 1.65-1.80 (m, 2H) ppm; l3C NMR (150 
MHz, CDCh) 8 170.0, 162.9, 154.7, 136.1, 132.4, 128.7, 128.3, 127.6, 127.5, 124.9, 
114.3, 73.6, 70.2, 69.6, 67.3, 64.3, 27.4, 25.4 ppm; MS (EI) mlz (%): 383 (M), 43(15), 
65(10), 91(100), 92(25), 121(13), 211(19); HRMS ca1cd for C2I H2IN06 383.1369, 
found 383.1372. 
9H 
0 NHTS Br~"'o 6-} 
571 
N-( (3aS,4 R,SS, 7 as)-7 -Bromo-S-hydroxy-2,2-dimethyl-3a,4,S, 7 a-tetrahydro-
benzo[1,3]dioxol-4-yl)-4-methyl-benzenesulfonamide (571) 
To a stirred solution of N-tosyl aziridine (570) (200 mg, 0.499 mmol), in dimethyl 
sulfoxide (1.5 mL) was added 10% KOH (1.5 mL). The reaction was heated to 40°C 
and then stirred for 2 h. The reaction mixture was then neutralized with sat. NH4CI 
and extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried 
• (J. 
over Na2S04, filtered and concentrated. The crude material was recrystallized from 
hexane-ethyl acetate to yield (196 mg, 94%) as white crystals: mp 155-156 °C 
(hexanes-ethyl acetate); Rf 0.43 (1:1 hexanes-ethyl acetate); [a]D23 -22.7 (c 0.7, 
CHCh); IR (film) v 3445, 2993, 2087, 1646, 1216, 1065 cm-I; IH NMR (300 MHz, 
CDCh) 8 7.79 (d, J= 8.1 Hz, 2H), 7.32 (d, J= 8.1 Hz, 2H), 6.24 (d, J= 3.1 Hz, 1H), 
5.48 (br s, 1 NH), 4.58( d, J = 5.6 Hz, 1 H), 4.17 (t, J = 6.7 Hz, 1 H), 3.99 (br s, 10H), 
3.79 (d, J = 4.7 Hz, lH), 3.33 (t, J = 6.8, 1H), 2.41 (s, 3H), 1.28 (s, 3H), 1.06 (s, 3H) 
ppm; l3C NMR (75 MHz, CDCh) 8 144.2, 135.9, 134.1, 129.9, 127.6, 120.6, 111.4, 
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76.3, 75.9, 70.0, 56.7, 27.2, 25.9, 21.6 ppm; MS (El) mlz (%): 402(M-CH3+), 43(40), 
59(32), 65(30), 91 (85), 92(16), 97(15), 98(48), 99(68), 139(30), 155(26), 254(100), 
255(15); HRMS ca1cd for C1sH17BrNOsS 402.0011, found 402.0004; Anal. ca1cd: C 
45.94, H 4.82, found C 45.88, H 4.80. 
QH 
0:NHTS 
: 0 b-t-
572 
N-( (3aS,4 R,5S, 7 aR)-5-Hydroxy-2,2-dimethyl-hexahydro-benzo [1,3] dioxol-4-yl)-
4-methyl-benzenesulfonamide (572) 
To a stirred solution of allylic alcohol 571 (196 mg, 0.468 mmol), in MeOH (2 mL) 
was added K2C03 (10 mg), and platinum(lV)oxide (catalytic amount) before purging 
the reaction flask with H2. The reaction mixture was stirred at r.t. and 1 atm of H2 for 
36h before filtering through a plug of Si02 and concentrating. The crude material was 
purified via flash column chromatography with a solvent graciient of Ill . then 1:2 
(hexanes-ethyl acetate) to yield 572 (123 mg, 77%) as a white solid: mp 155-156 °C 
(hexanes-ethyl acetate); RJ 0.30 (1:2 hexanes-ethyl acetate); {a]D23 -105.2 (c 1.32, 
CHCh); lR (film) v 3381, 3255, 2985, 2934, 2893, 2765, 1597, 1155, 1088, 753 cm-
I; IH NMR (300 MHz, CDCh) 0 7.81 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.1 HZ,2H), 
5.48 (d, J = 6.9 Hz, 1H), 4.17-4.1 0 (m, 1H), 3.72 (dd, J = 8.4, 4.9 Hz, 1H), 3.51 (d, J 
= 3.0 Hz, IH), 3.50-3.35 (m, IH), 2.97, (q, J= 17.4,8.3 Hz, IH), 2.39 (s, 3H), 2.11-
2.03 (m, 1H), 1.88-1.80 (m, IH), 1.72-1.57 (m, 2H), 1.18 (s, 3H), 0.937 (s, 3H), ppm; 
l3C NMR (75 MHz, CDCh) 0 143.4, 137.1, 129.7, 129.4, 127.8, 127.4, 108.9, 78.7, 
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73.6, 70.7, 63.0, 27.5, 27.4, 26.1, 23.2, 21.5 ppm; MS (El) mlz (%): 341(M), 43(21), 
59(34),65(29),82(35), 83(20), 91(100), 100(28), 128(65), 155(34), HRMS calcd for 
C16H23NOsS 341.1297 found 341.1297; Anal. ca1cd: C 56.29, H 6.79, found C 56.21, 
H6.70. 
573 
(3aR,5aS,8aR,8bS)-2,2-dimethyl-8-(toluene-4-sulfonyl)-hexahydro-
[1,3]dioxolo[4' ,5':3,4]benzo[2,1-d]oxazol-7-one (573) 
To a stirred solution of sulfonamide 572 (600 mg, 1.76 mmol), in methylene chloride 
(5 mL) was added pyridine (1.42 mL, 17.6 rnrnol) then triphosgene (625 mg, 2.11 
mmol). The reaction was stirred at 0 °C for 30 min before being quenched by the 
addition of water (10 mL) and extracted into methylene chloride (3 x 10 mL). The 
combined organic layers were dried over Na2S04, filtered arid concentrated. The 
crude material was purified via flash column chromatography with a solvent gradient 
of 2:1, 1:1 then 1:2 (hexanes-ethyl acetate) to yield 573 (567 mg, 93%) as a white 
solid: mp 197-198 °C (hexanes-ethyl acetate); Rf 0.58 (1: 1 hexanes-ethyl acetate); 
[a]D23 -2.56 (c 0.56, CHCh); lR (film) v 3557, 3027, 2987, 2890, 1797, 1597, 1495, 
1438,1379,1180, 1153 cm-1; IH NMR (300 MHz, CDCh) 0 8.01 (d, J = 8.1 Hz, 2H), 
7.30 (d, J = 8.0 Hz, 2H), 4.59 (dd, J = 7.6,5.5 Hz, IH), 4.38-4.32 (m, 1H), 3.90 (td, J 
= 11.7, 3.5 Hz, 1H), 3.38 (dd, J = 11.6, 8.0 Hz, 1H), 2.42 (s, 3H), 2.32-2.22 (m, 1H), 
2.06-1.97 (m, 1H), 1.90-1.74 (m, 1H), 1.73-1.65 (m, 1H) 1.46 (s, 3H), 1.40 (s, 3H) 
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ppm; 13C NMR (75 MHz, CDCh) () 151.9, 145.6, 133.8, 130.1, 129.7, 128.8, 128.6, 
108.9, 76.4, 76.1, 73.2, 68.4, 28.5, 25.9, 24.7, 22.4, 21.7 ppm; MS eEl) mlz (%): 367 
(M), 41(23), 43(52), 65(29), 83(69), 85(45), 91(100), 155(47), 352(48) HRMSca1cd 
for C17H2IN06S 367.1089, found 367.1089; Anal. calcd: C 55.57, H 5.76, found C 
55.67, H 5.60. 
574 
(3aR,5aS,8aR,8bS)-8-( 4-Benzyloxy-benzoyl)-2,2-dimethyl-hexahydro-
[1,3]dioxolo[4' ,5' :3,4]benzo{2,1-d]oxazol-7-one (574) 
To a stirred solution of N-tosyl cyclic carbamate 573 (560 mg, 1.52 mmol), in 
tetrahydrofuran (2 mL) was added sodium naphthalide (0.5 M.) at -78 T until a 
green colour persisted. The reaction mixture was stirred at -78°C for 30 min before 
being quenched by the addition of sat. NH4CI (5 mL) and extracted into diethyl ether 
(3 x 10 mL). The combined organic layers were dried over Na2S04, filtered and 
concentrated. The crude reaction mixture was purified via flash column 
chromatography with a solvent gradient of 2: 1, 1: 1 then 1:2 (hexanes-ethyl acetate) to 
yield (3aR,5aS,8aR,8bS)-2,2-dimethyl-hexahydro[1,3]dioxolo [4' ,5' :3,4] benzo[2,1-
d]oxazol-7-one (300 mg, 92%) as a white solid: mp 134-136 °C (hexanes-ethyl 
acetate); RJ O.31 (1:1 hexanes-ethyl acetate); [a]D23 -89.2 (c 2.9, CHCh); IR {film) v 
3450,3305,2987,2938,2894, 1860, 1855, 1647, 1547, 1466, 1383, 1239,1061 cm-I; 
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IH NMR (300 MHz, CDCh) 0 5.16 (s, br, IH), 4.30-4.25 (m, IH), 4.07 (dd, J= 8.8, 
5.0 Hz, IH), 3.81 (td, J = 11.5,3.6 Hz, IH), 3.48 (dd, J = 11.5,9.1 Hz, IH), 2.42-2.27 
(m, IH), 2.10-2.03 (m, IH), 1.89-1.79 (m, IH), 1.57 (s, br, IH), 1.47 (s, 3H), 1.32 (s, 
3H) ppm; I3C NMR (150 MHz, CDCh) 0 160.1, 109.4, 77.9, 77.7, 73.3, 62.9, 28.4, 
25.9, 24.7, 24.0 ppm; MS (EI) mlz (%): 213 (M), 41(31), 43(100), 55(28), 59(34), 
67(48), 82(35), 83(21), 85(22), 98(23), 99(80), 127(22), 198(87), HRMS calcd for 
C IOHI5N04 213.1001, found 213.1001; anal. calcd C 56.33, H 7.09, found C 56.23, H 
7.02. 
To a stirred solution of NaH (18.5 mg, 0.774 mmol) in THF (1 mL) was added 
(3aR,5aS,8aR,8bS)-2,2-Dimethyl-hexahydro-[1,3] dioxolo[4' ,5' :3,4]benzo[2,1-
d]oxazol-7-one (110 mg, 0.516 mmol), in tetrahydrofuran (1 mL) dropwise at 0 °C. 
The reaction was allowed to warm slowly to r.t. and stirred for 1 h before the addition 
of 4-benzyloxy benzoyl chloride (127 mg, 0.516 mmol) in four portions over 2 h. The 
reaction mixture was stirred for 12 h before being quenched by the addition of sat. 
NH4CI (2 mL). The tetrahydrofuran was removed under reduced pressure and the 
aqueous layer was extracted into ethyl acetate (3 x 5 mL). The combined organic 
layers were dried over Na2S04, filtered and concentrated. The crude reaction mixture 
was purified via flash column chromatography with a solvent gradient of 4:1,2:1 then 
1: 1 (hexanes-ethyl acetate) to yield 574 (220 mg, 91 %) as a white solid: mp 149-150 
°C (hexanes-ethyl acetate); RrO.62 (1:1 hexanes-ethyl acetate); lU]D23 + 0.72 {c 2.1, 
CHCh); IR (film) v 3682, 3531, 3379, 3066, 3019, 2989, 2937, 2889, 2587, 1952, 
1786, 1697, 1603, 1382, 1256, 1216 cm-I; IH NMR (600 MHz, CDCh) 0 7.82 (d, J = 
8.3 Hz, 2H), 7.31-7.42 (m, 5H), 6.97 (d, J= 8.3 Hz, 2H), 5.10 (s, 2H), 4.29 (dd, J= 
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4.2, 7.9 Hz, 1H), 4.20-4.27 (m, 2H), 3.94 (dd, J = 3.8, 11.3 Hz, 1H), 2.31-2.36 (m, 
1H), 2.15-2.20 (m, 1H), 1.93-1.97 (m, 1H), 1.88-1.93 (m, 1H), 1.68 (s, 3H), 1.34 (s, 
3H) ppm; 13C NMR (150 MHz, CDCh) () 169.9, 163.3, 155.1, 136.1, 132.6(2xC), 
128.7, 128.3(2xC), 127.6(2xC), 125.4, 114.3(2xC), 109.6, 78.2, 75.4, 73.7, 70.2,63.8, 
27.9,25.9,24.7,23.5 ppm; MS (EI) mlz (%): 423 (M), 43(67), 65(20), 83(24), 85(68), 
91(100), 92(25), HRMS calcd for C24H2SN06 423.1682, found 423.1682; anal. calcd 
C 68.07, H 5.95, found C 68.14, H 5.96. 
o&on_pr 
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583 
6-Carboxypropyl-(lS,2S)-1,2-dihydroxycyclohexa-3,5-diene (583) 
From the fermentation of benzoate 583, (711 mg, 5.8%, 65.0% based on recovered 
starting material) waxy solid; RfO.15 (1:1 ethyl acetatelhexanes); [a]D22 +58.8 (c 1.1, 
CHCh); IR (film) v 3398,2968, 1700, 1280, 1240 em-I; IH NMR (300 MHz, CDCh) 
() 7.08 (d, J = 5.4 Hz, 1H), 6.20 (dd, J = 9.5, J= 2.5 Hz, 1H), 6~09 (ddd, J =:= 9.5, J= 
5.4, J = 2.2 Hz, IH), 4.58 (d, J = 6.3 Hz, 1H), 4.48 (ddd, J = 6.3, J = 2.5, J = 2.2 Hz, 
1H), 4.16 (t, J= 6.7 Hz, 2H), 3.40 (bs, 2H), 1.72 (qt, J= 7.4, J= 6.7 Hz, 2H), 0.98 (t, 
J= 7.4 Hz, 3H) ppm; l3C NMR (75 MHz, CDCh) () 167.1, 138.4, 133.9, 128.7, 122.6, 
69.4, 66.6, 64.8, 22.0, 10.4 ppm; MS (EI) mlz (%): 198(M+, 18), 180(22), 138(100), 
121(81),110 (54),105 (77); HRMS calcd for C9H1204 198.0892, found 198.0892. 
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584 
6-Carboxyisopropyl-(IS,2S)-I,2-dihydroxycyclohexa-3,5-diene (584) 
From the fermentation of benzoate 578, (488 mg, 4.1 %, 34.0% based on recovered 
starting material); colourless crystals; mp 83-85 °C (ethyl acetatelhexane); RI 0.31 
(6:4 ethyl acetate/hexane); [a]D22 +64.70 (c 1.1, CHCh); lR (KBr) v 3274, 2981, 
1698,1263,1241 em-I; IH NMR (300 MHz, CDCh) 0 7.05 (ddd, J= 5.5,1.0,0.5 Hz, 
1H), 6.20 (ddt, J = 9.6, 2,7, 0.9 Hz, 1H), 6.08 (ddd, J = 9.6, J = 5.5, J = 2.2 Hz, 1H), 
5.l2 (hept, J= 6.3 Hz, 1H), 4.58 (dd, J= 6.4, J= 0.5 Hz, 1H), 4.48 (br m, 1H), 3.60-
3.25 (br s, 2H), 1.30 (d, J = 6.3 Hz, 6H) ppm; 13C NMR (75 MHz, CDCh) 0 166.5, 
138.2, 133.6, 128.9, 122.63, 99.4 69.2, 68.5, 64.9, 21.8 ppm; MS (EI) mlz (%): 
198(M+, 19), 180(16), 156(14), 138(100); HRMS (El) calcd for C IOHI40 4 : 198.08921, 
found: 198.08896. Anal. Calcd. for C IOHI40 4: C, 60.59; H, 7.l2. Found: C, 60.68; H, 
7.19. 
6- . 
°Xo~ 
U OH 
587 
6-Carboxyallyl-(IS,2S)-I,2-dihydroxycyclohexa-3,5-diene (587) 
From the fermentation of benzoate 581, (5.79 g, 52.0%, 73.6% based on recovered 
starting material), colourless crystals; mp 48-50 °C (ethyl acetate/hexane). RI 0.23 
(1:1 ethyl acetatelhexane); [a]o22 +72.54 (c 1.6, CHCh); IR (KBr) v 3394, 1704, 
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1273, 1238 em-I; IH NMR (300 MHz, CDCh) () 7.12 (d, J = 5.5 Hz, 1H), 6.23 (ddt, J 
= 9.6, J = 2,7, J = 1.0 Hz, 1H), 6.11 (ddd, J = 9.5, J = 5.5, J = 2.2 Hz, 1H), 5.98 (ddt, 
J = 17.2, J = 10,4 J = 5.7 Hz, 1H), 5.37 (dt, J = 17.2, J = 1.5 Hz, 1H), 5.28 ,edt, J = 
10.4, J = 1.3 Hz, 1H), 4.72 (ddd, J = 5.7, J = 1.5, J = 1.3 Hz, 1H), 4.61 (br s, 1H), 
4.50 (br s, 1H), 3.25 (d, J = 3.8 Hz, 1H), 3.18 (bd, J = 7.3 Hz, 1H) ppm; l3C NMR (75 
MHz, CDCh) () 166.6, 138.8, 134.4, 131.9, 128.4, 122.4, 118.3,69.6,65.5,64.5 ppm; 
MS (El) mlz (%): 196(M+, 20), 178(18), 138(80), 121(95),41(100). HRMS (El) caled 
for C IOH120 4: mlz 196.07356, found: 196.07364. Anal. Calcd. for C IOH120 4 + 1/8 
H20: C, 60.52; H, 6.22. Found: C, 60.52; H, 6.26. 
)0:: 
U OH 
588 
6-Carhoxyisopropyl-(lS,2S)-1,2-dihydroxycyclohex-3-ene (S88) 
From the fermentation of benzoate 582, (9.20g, 69.1%, 75.8% based on recovered 
starting material); colourless crystals; mp 70-72 T (ethyl acetatelhexatte). Rf 0.31 
(6:4 ethyl acetatelhexane); [a]o22 +88.20 (c 1.6, CHCh); lR (KBr) v 3385, 3291, 
1707, 1270, 1234 em-I; IH NMR (300 MHz, acetone-d6) 0 7.01 (dd, J = 5.3, J = 1.1 
Hz, 1H), 6.16 (dq, J = 9.5, J = 1.4 Hz, 1H), 6.09 (ddd, J = 9.5, J = 5.3, J = 2.2 Hz, 
1H), 4.86 (dd, J = 15.8, J = 2.5 Hz, 1H), 4.80 (dd, J = 15.8, J = 2.5 Hz, 1H), 4.50-4.23 
(m, 2H), 4.10 (d, J= 7.4 Hz, 1H), 3.96 (d, J= 5.0 Hz, 1H), 3.06 (t, J= 2.5 Hz, 1H) 
ppm; l3C NMR (75 MHz, acetone-d6) () 167.2, 142.5, 136.3, 131.1, 123.5,80.0,77.3, 
72.5, 65.5, 53.4 ppm; MS (El) mlz (%): 194(M+, 7%), 176(28), 138(47), 121(100); 
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HRMS (El) ca1cd for CIOHIO04: mlz 194.0579, found: 194.0581. Anal. Cal'Cd. for 
CIOHIO0 4: C, 61.85; H, 5.19. Found: C, 62.08; H, 5.18. 
592 
Ethyl (5S, 6R)-5,6-dihydroxycyclohex-l-ene-l-carboxylate (592) 
Method A - To a stirring solution of 1,2-diol 593 (155 mg, 0.832 mmol) and 2,2 
dimethoxypropane (0.71 mL, 5.83 mmol) in acetone (1 mL) was added a catalytic 
amount of p-TsOH. The reaction was allowed to stir at room temperature for 2 h, and 
then diluted with ethyl acetate (5 mL) and washed with saturated NaHC03 (3 x 2 
mL). The combined organic layers were washed with brine (1 x 3 mL) then dried with 
Na2S04. The crude material was purified via flash column chromatography with a 
solvent gradient of 2: 1 hexanes-ethyl acetate to yield 592 (173 mg, 92%) as a pale 
yellow oil. 
Method B - To a stirring solution of vinyl bromide 590 (500 mg, 2.14 mmol) in Et20 
(4 mL) was added tBuLi (4.4 mL, 0.82 M) dropwise at -78°C and then stirred for 45 
min prior to the addition of solid CO2 (2 g, 45.4 mmol). The reaction was allowed to 
warm to r.t. slowly over 12 h and then diluted with Et20 (7 mL) and washed with 
saturated NaHC03 (3 x 10 mL). The organic layer was diluted with H20 (3 mL) 
before adjusting the pH to 3.5 (10% citric acid) and extracting with ethyl acetate (3 x 
5 mL). The combined organic layers were washed with brine (1 x 5 mL), dried over 
Na2S04 and concentrated under reduced pressure to yield carboxylic acid 591 which 
as used without further purification. To a stirring solution of 591 (244 mg, 1.23 
mmol) 111 DCM (2 mL) was added l-ethyl-3-(3'dimethylaminopropyl) 
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carbodiimide'HCI (260 mg, 1.35 mmol), DMAP (15 mg, 0.123 mmol), and finally 
absolute EtOH (0.22 mL, 3.69 mmol) at 0 0c. The reaction was allowed to stir for 12 
h, then diluted with DCM (2 mL) and washed with saturated NH4CI (1 x 3 mL), 
saturated NaHC03 (1 x 3 mL) and then H20 (1 x 3 mL). The combined organic layers 
were washed with brine (1 x 5 mL) and dried over Na2S04. The crude material was 
purified via flash column chromatography with a solvent gradient of 2: 1 hexanes-
ethyl acetate to yield 592 (243 mg, 50% over 2 steps) as a pale yellow oil. 
Rf O.56 (1:1 hexanes-ethyl acetate); [a]o23 +74.6 (c 4.02, CHCh); IR {film): v 3018, 
2987,2936,1712,1651,1425,1380,1259,1155,1031 , 917, 856, 697, 667, 512 em-I; 
IH NMR (300 MHz, CDCh) () 7.06 (dd, J = 5.3, 3.1 Hz, IH), 4.84 (d, J = 5.7 Hz, 
IH), 4.28-4.41 (m, IH), 4.07-4.26 (m, 2H), 2.21-2.45 (m, IH), 1.99-2.16 (m, IH), 
1.86-1.99 (m, IH), 1.58-1.72 (m, IH), 1.33 (d, J = 10.2 Hz, 6H), 1.24 (t, J = 7.2 Hz, 
3H) ppm; I3C NMR (75 MHz, CDCh) () 166.2, 142.3, 130.0, 108.5, 72.6, 70.4,60.5, 
27.8, 26.2, 25.1, 20.9, 14.2 ppm; MS (EI) mlz (%) 226 (M+-CH3+), 41(14), 43(82), 
55(11),59(10), 67(14),79(76),83(11),95(13),105(17), 123(100), 169(17), 181(15), 
211(77); HRMS (M+-CH3+) ea1cd for C12HIS0 4 211.0970, f~und 211.0969; Anal. 
ealed: C 63.70, H 8.02, found C 63 .72, H 8.05. 
02XOEt -:?' OH 
OH 
593 
6-Carboxyethyl-(lS,2S)-1,2-dihydroxycycIohex-3-ene (593) 
To a stirring solution of5 (445 mg, 2.42 mmol) and potassium a20dicarboxylate (1.41 
g, 7.25 mmol) in MeOH (4 mL) was added glacial acetic acid (0.97 mL, 16.9 mmol) 
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dropwise at -15 °c. The reaction was allowed to wann to r.t. slowly over 14 h, then 
quenched by the addition ofNa2C03 (7 mL) and concentrated under reduced pressure 
and extracted with ethyl acetate (5 x 5 mL). The combined organic layers were 
washed with brine (1 x 7 mL) and dried over Na2S04. Recrystallization of the crude 
material from ethyl acetate-hexanes yielded 6 (378 mg, 84%) as a white solid. mp 91-
92 °c (ethyl acetate-hexanes); RrO.29 (1:1 hexanes-ethyl acetate); [a]o23 -53.3 (c 1.6, 
CHCh); lR (film) v 3400, 2981, 2937, 2909,1731,1647,1372,1251,1105,1073, 
993,921,878,761,670; IH NMR (300 MHz, CDCh) (j 7.09 (t, J= 4.1 Hz, IH), 4.50 
(d, J = 3.8 Hz, IH), 4.22 (q, J = 7.2 Hz, 2H), 3.81-3.93 (m, IH), 3.51 (s, OH), 2.69 (s, 
OH), 2.37-2.50 (m, IH), 1.79-1.94 (m, IH), 1.66-1.75 (m, IH), 1.29 (t, J = 7.2 Hz, 
3H) ppm; BC NMR (75 MHz, CDCh) (j 167.1, 143.1, 130.1,67.7,65.7,60.9,25.0, 
23.9, 14.2 ppm; MS (El) mlz (%) 186(M), 41(12), 67(10), 68(38), 96(100), 97(16), 
105(12), 142(90), 143(12); HRMS calcd for C9H140 4 186.0892, found 186.0892; 
Anal. calcd: C 58.05, H 7.58, found C 57.97, H 7.51. 
c;., . 
601 
ethyl (3aR,7 as)-2,2-diethyl-3a, 7a-dihydro-l,3-benzodioxole-4-carboxylate (601) 
To a stirred solution of cis-dihydrodiol 7 (1.15 g, 6.24 mmol) in 3,3 
dimethoxypentane (4.5 mL) was added 3-pentanone (2 mL). The resulting solution 
was cooled to 0 T prior to the addition of a catalytic amount of p-TsOH. The reaction 
was allowed to wann to r.t. overnight. The reaction was diluted with EtOAc (10 mL), 
washed with 1 N NaOH (3 x 3 mL), brine (1 x 5 mL) and then dried over MgS04. 
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The crude material was purified via flash column chromatography with a solvent 
system of 2:1 (hexanes-ethyl acetate) to yield 601 (1.52 g, 97%) as a clear and 
colourless oil: Rf 0.41 (1:2 hexanes-ethyl acetate); [a]o23 +9.31 (c 3.7, CHCh); lR 
(film) v 3408,2975,2939, 1713, 1589, 1463, 1295,1224, 1171, 1083, 1025,931, 
759, 706 cm-I; IH NMR (300 MHz, CDCh) 8 7.05 (dd, J = 6.0, 0.7 Hz, 1H), 6.06-
5.97 (m, 2H), 4.87 (d, J = 8.3 Hz, 1H), 4.81 (dd, J = 9.1,2.7 Hz, 1H), 4.21 (q, J = 7.2 
Hz, 2H), 1.70-1.60 (m, 2H), 1.56 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H), 0.91(t, 
J= 7.5 Hz, 3H), 0.75 (t, J= 7.6 Hz, 3H) ppm; I3C NMR (75 MHz, CDCh) 8 166.3, 
133.8, 133.5, 126.5, 121.1, 109.2, 72.6, 68.2, 60.8, 29.2, 29.1, 14.2,8.5, 7.9 ppm; MS 
(El) mlz (%): 252 (M), 57(100), 65(10), 77(15), 95(49), 105(13), 121(32), 123(13), 
139(23), 167(24), 223( 33); HRMS calcd for CI4H2004 252.1362, found 252.1366. 
602 
Ethyl(3aR,5aR,6aR,6bR)-2,2-diethyl-3a,5a,6a,6b-
tetrahydrooxireno [e) [1,3] benzodioxole-4-carboxylate (602) 
To a stirred solution of 1,3-diene 601 (300 mg, 1.189 mmol) in methylene 'chloride (5 
mL) was added m-CPBA (264 mg, 1.189 of 77.6%) at 0 °C. Upon complete 
consumption of starting material, the reaction was quenched by the addition of sat. 
NH4CI (5 mL). The reaction mixture was extracted with Et20 (5x 15 mL), before the 
combined organic layers were washed with brine (1 x 5 mL) and dried over MgS04. 
The crude mixture was purified via flash column chromatography with 10% 
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deactivated 'Si02 and a solvent gradient of 100:0, 25:1, 15:1, 8:1 (hexanes-ethyl 
acetate) to yield 602 (209 mg, 69%) as a clear and colourless oil: Rr 0.55 (1:2 
hexanes-ethyl acetate); [a]D23 +33.31 (c 3.2, CHCh); lR (film) v 3408, 2975, 2939, 
1713, 1589, 1463, 1295, 1224, 1171, 1083, 1025,931, 759, 706 cm-I; IH NMR (300 
MHz, CDCh) 0 7.09 (d, J = 3.8 Hz, IH), 4.79 (q, J = 8.0 Hz, 2H), 4.27 (q, J = 7.0 Hz, 
2H), 3.57 (dd, J = 3.4 Hz, 1.1, IH), 3.44 (t, J = 3.7 Hz, IH), 1.73 (m, 4H), 1.32 (t, J = 
7.2 Hz, 3H), 0.88 (t, J = 7.5 Hz, 3H), 0.83 (t, J = 7.5 Hz, 3H) ppm; I3C NMR (75 
MHz, CDCh) 0 165.1, 133.7, 133.6, 114.7, 71.14,68.6, 61.1, 50.9, 46.3, 29.9, 29.5, 
14.2, 8.3, 7.8 ppm; MS (El) mlz (%): 268 (M), 57(100), 65(10), 77(15), 95(49), 
105(13), 121(32), 123(13), 139(23), 167(24), 223( 33); HRMS calcd for CI4H2oOS 
268.1311, found 268.1371. 
606 
Ethyl (5S,6R)-5-{ [tert-butyl( dimethyJ)silyl]oxy }-6-hydroxycyclohexa-\,3-diene-l-
. , 
carboxylate (606) 
To a stirred solution of cis-dihydrodiol 7 (770 mg, 4.18 mmol) in DMF (5 mL) was 
added imidazole (369 mg, 5.43 mmol) and tert-butyldimethylsilyl chloride (693 mg, 
4.59 mmol) at 0 DC. The reaction was left to stir for 20 min before being capped and 
placed in a -15°C freezer overnight. The reaction was then diluted with Et20 (50 
mL) and then washed with H20 (20 x 2 mL), 5% citric acid (3 x 20 mL), and brine (1 
x 5 mL) before the organic layer was dried over MgS04• The resulting crude mixture 
was purified via column chromatogprahy with a solvent system of 8:1 (hexanes-ethyl 
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aoetate) to yield 606 (306 mg, 52%) as a clear and colourless oil: Rf 0.44 (1: 1 
hexanes-ethyl acetate); [a]D23 +59.66 (c 1.2, CHCh); IR (film) v 3408, 3502, 2954, 
2930,1710,1471,1373,1230,1080,997,898,838,777 em-I; IH NMR (300 MHz, 
CDCh) 0 7.02 (d, J = 4.9 Hz, IH), 6.03-5 .88 (m, 2H), 4.49 (d, J = 5.7 Hz, IH), 4.33 
(d, J= 5.8 Hz, IH), 4.24-4.11 (m, 2H), 2.62 (s, OH), 1.23 (t, J= 7.16 Hz, 3H), 0.86 
(s, 9H), 0.07 (s, 6H) ppm; l3C NMR (75 MHz, CDCh) 0 166.6, 138.8, 134.4, 128.6, 
122.4, 71.9, 64.4, 60.8, 41.5, 25.8, 18.2, 14.3, -4.7, -4.8 ppm; MS (El) mlz (%): 
298(M), 45(12), 57(11), 73(34), 75(100), 77(14), 105(11), 120(12), 121(15), 151(20), 
167(19), 195(48), 223(11); HRMS ca1cd for CI5H2604Si 298.1600, found 298.1603. 
&x:: 
608 
(3 as, 7 as)-4-bromo-2,2-diethyl-3a, 7 a-dihydro-l,3-benzodioxole (608) 
To a stirred solution of cis-dihydrodiol 6 (3.00 g, 15.7 mmol) III 3,3 
dimethoxypentane (12 mL) was added 3-pentanone (5 mL). The resultiJlg solution 
was cooled to 0 °C prior to the addition of a catalytic amount of p-TsOH. The reaction 
was allowed to warm to r.t. overnight. The reaction was diluted with EtOAc (15 mL), 
washed with 1 N NaOH (3 x 5 mL), brine (1 x 7 mL) and then dried over MgS04. 
The crude material was purified via flash column chromatography with a solvent 
system of 2:1 (hexanes-ethyl acetate) to yield 608 (3 .68 g, 91%) as a clear and 
colourless oil: Rr0.42 (1:1 hexanes-ethyl acetate); [a]D23 +109.0 (c 1.25, CHCh); IR 
(film) v 3248,3050,2973,2939,2881,1724,1584,1463,1202, 1170,1071,1055, 
924,728,636 em-I: IH NMR (300 MHz, CDCI]) 0 6.30 (d, J= 6.1 Hz, IH), 5.96 (dd, 
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J= 9.5,3.1 Hz, 1H), 5.84 (q, J= 5.3 Hz, 1H), 4.78-4.65 (m, 2H), 1.71-1.61 {m, 4H), 
0.92 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H) ppm; \3C NMR (75 MHz, CDCh) ~ 
125.4, 125.0, 124.3, 123.9, 110.2, 76.0, 72.6, 29.4, 28.9, 8.4, 7.8 ppm; MS (El) mlz 
(%): 258 (M), 57(100), 65(12), 77(13), 94(16), 173(25), 175(24), 229(14), 231 (14); 
HRMS calcd for CIIHISBr02 258.0255, found 258.0242; Anal. ca1cd: C 50.98, H 
5.83, found C 50.87, H 5.70. 
Sr 
609 
(3aR,4R,5S,7 as)-4, 7 -dibromo-2,2-diethyl-3a,4,5, 7 a-tetrahydro-l,3-benzodioxol-5-
01 (609) 
To a stirred solution of 1,3-diene 608 (5.75 g, 22.2 mmol) in acetone (70 mL) and 
H20 (30 mL) was added 1,3-dibromo-5,5- dimethylhydantoin (5.07 g, 17.8 mmol) in 
5 portions over a total of 30 mins. After 3 h the reaction was quenched by the addition 
of 10% NaS203 (50 mL). The acetone was removed on a rotary evaporator prior to 
extracting the aqueous layer with methylene chloride (4 x 30 mL). The combined 
organic layers were washed with 1 N NaOH (3 x 5 mL) and dried over Mg2S04• The 
crude material was purified via flash column chromatography with a solvent system 
of2:1 (hexanes-ethyl acetate) to yield 609 (4.41 g, 56%) as a clear and colourless oil: 
RrO.23 (1:2 hexanes-ethyl acetate); {a]D23 +10.72 (c 0.6, CHCh); IR (film) v 3435, 
2973, 2940, 1724, 1644, 1463, 1383, 1353, 1244, 1204, 1172, 1055, 921, 636 em-I; 
IH NMR (300 MHz, CDCh) ~ 6.35 (d, J= 4.6 Hz, 1H), 4.70 (d, J= 5.3 Hz, 1H), 4.63 
(t, J = 5.5 Hz, 1H), 4.37-4.27 (m, 2H), 3.03 (d, J = 9.0 Hz, OH), 1.80-1.65 (m,4H), 
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0.98 (t, J = 6.0 Hz, 3H), 0.93 (t, J = 6.1, 3H) ppm; I3C NMR (75 MHz, CDCh) 8 
130.4, 124.6, 116.2, 78.1, 76.6, 76.0, 70.46, 47.9, 30.3, 29.5, 8.4, 8.2 ppm; MS (EI) 
mlz (%): 353(M), 57(100), 172(14), 174(13), 253(13), 325(19), 327(36), 329(18); 
HRMS calcd for CIIHI6Br203 353.9466, found 353.9376 
610 
(3aS,5aS,6aS,6bS)-4-bromo-2,2-diethyl-3a,5a,6a,6b-
tetrahydrooxireno[e] [1,3]benzodioxole (610) 
To a stirred solution of ~-bromo hydroxyl 609 (3.41g, 9.58 mmol) in 
dimethoxymethane (20 mL) was added 10% NaOH (4.02 mL, 10.0 mmol) dropwise. 
Upon complete consumption of starting material (TLC) the reaction was diluted with 
H20 (10 mL), extracted with Et20 (5 x 15 mL), washed with brine (1 x 5 mL) and 
dried with MgS04• The crude mixture was purified via flash column chromatography 
with 10% deactivated Si02 and a solvent system of 6: 1 (hexanes-ethylsacetate) to 
afford 610 as a clear and colourless oil (1.16 g, 44%): Rr 0.55 (2:1 hexanes-ethyl 
acetate); [a]o23 -2.46 (c 4.98, CHCh); IR (film) v 3400, 2973, 2940, 2881, 1643, 
1462, 1356, 1171, 1079,993,922,880,800,580 em-I; IH NMR (300 MHz, CDCh) 8 
6.58 (d, J= 4.1 Hz, 1H), 4.65 (dd, J= 6.9, 0.8 Hz, 1H), 4.47 (dd, J= 6.9,2.9 Hz, 1H), 
3.63-3.55 (m, 1H), 3.35 (t, J= 4.1 Hz, 1H), 1.72 (q, J= 7.5 Hz, 2H), 1.60 (q, J= 7.5 
Hz, 2H), 0.94-0.83 (m, 6H) ppm; I3C NMR (75 MHz, CDCh) 8 129.3, 126.1, 110.6, 
76.8, 73.7, 54.6,49.9, 29.5, 28.3, 8.5, 8.1 ppm; MS {EI) mlz (%): 274(M), 57(100), 
109(21),245(22),247(22); HRMS .calcd for CIIH1SBr03 274.02,05, found 274.0414. 
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619 620 
N-[ (3aS,4S,5R, 7 as)-7 -Bromo-5-(1-ethylpropoxy)-2,2-dimethyl-3a,4,5, 7 a-
tetrahydro-1,3-benzodioxol-4-yl] acetamide (619) 
N-[ (3aS,4S,5S, 7 as)-7 -Bromo-5-(1-ethylpropoxy)-2,2-dimethyl-3a,4,5, 7 a-
tetrahydro-1,3-benzodioxol-4-yl] acetamide (620) 
To a solution of aziridine 429 (7.78 g, 27.0 mmol) in 3-pentanol (30 mL) was added 
copper(II) trifluoromethanesulfonate (976 mg, 2.70 mmol) at 0 °C. The reaction 
mixture was stirred for 16 h before concentrating under reduced pressure. The crude 
residue was dissolved in methylene chloride (20 mL), washed with sat. NaHC03 (3 x 
5 mL), and brine (1 x 10 mL) and then dried over Na2S04. The residue was purified 
by flash column chromatography with a solvent gradient of 3: 1 then 1: 1 (hexanes-
diethyl ether) to afford 619 (7.64 g, 76%) and 620 {1.09 g, 11 %) as clear oils. 
619: Rf 0.40 (diethyl ether); [a]o23 -100.0 (c 1.0, CHCh); IR (film) v 3439, 3019, 
2971, 2936, 2879, 1675, 1514, 1463, 1384, 1373, 1342, 1514, 1463, f384, 1373, 
1342, 1216, 1163, 1095, 1046,965,931,888,865,758,669,502 cm-I; IH NMR c{600 
MHz, CDCh) 06.14 (d, J= 1.5 Hz, IH), 5.83 (d, J= 9.0 Hz, IH), 4.57 (dd, J= 1.5, 
5.3 Hz, IH), 4.40 (dd, J= 2.4,5.1 Hz, IH), 4.30 (dt, J= 2.4,8.9 Hz, IH), 3.89 (dd, 
J= 1.5,8.9 Hz, IH), 3.24 (quin., J= 5.6 Hz, IH), 2.00 (s, 3H), 1.43-1.49 (m, 4H), 
1.38 (s, 3H), 1.34 {s, 3H), 0.87 (t, J = 7.4 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H) ppm; l3C 
NMR (150 MHz, CDCh) 0 169.9, 132.5, 122.7, 110.2, 82.4, 77.3, 7{).0, 73.6, 51.2, 
27.4,26.3,26.1,25.6,23.5,9.6,9.2 ppm; MS (EI) mlz (%) 375 (M), 232(8), 231(7), 
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230(9),229(5),190(21),189(16),188(22),187(13), 166(6), 164(6), 143(22), 
142(100), 137(9), 136(8), 126(6), 125(6), 110(5), 109(32), lOE(7), 100(30), 85'(6), 
84(61), 83(9), 80(9), 71(8), 70(9), 60(9), 59(12), 43(73), 41(7); HRMS (EI) ea1cd for 
CI6H26BrN04 375.1045, found 375.1045; Anal. ca1cd: C 51.07, H 6.96, found C 
51.07, H 6.98. 
620: R1 0.45 (diethyl ether); [a]D23 +41.5 (c 1.0, CHCh); IR (film) v 3439, 3019, 
2971, 2936, 2879, 1675, 1514, 1463, 1384, 1373, 1342, 1514, 1463, 1384, 1373, 
1342, 1216, 1163, 1095, 1046,965,931,888,865,758,669,502 em-I; IH NMR (600 
MHz, CDCh) 86.35 (d, J=8.7Hz, INH), 6.31 (d, J=5.3Hz, IH), 4.57 (d, 
J= 5.3 Hz, IH), 4.40-4.44 (m, 2H), 3.90 (t, J= 5.3 Hz, IH), 3.19 (quin., J= 5.8 Hz, 
IH), 2.03 (8, 3H), 1.41-1.55 (m, 4H), 1.46 (8, 3H), 1.36 (8, 3H), 0.88 (t, J= 7.6 Hz, 
6H) ppm; I3C NMR (150 MHz, CDCh) 8 169.6, 129.0, 127.5, 111.1,81.6, 76.7, 75.3, 
70.6, 46.6, 27.5, 26.6, 26.4, 25 .9, 23.3, 9.8, 9.6 ppm; MS (EI) mlz (%) 375 (M), 
232(8), 231 (7), 230(9), 229(5), 190(21), 189(16), 188(22), 187( 13), 166(6), 164(6), 
143(22), 142(100), 137(9), 136(8), 126(6), 125(6), 110(5), 109(32), 108(7), 100(30), 
85(6), 84(61), 83(9), 80(9), 71(8), 70(9), 60(9), 59(12), 43(73), 41(7); HRMS (El) 
ea1cd for CI6H26BrN04 375.1045, found 375.1045. 
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CO#t 
~o,.¢::x 
NHAc 
621 
Ethyl (3aR,6R,7S,7aS)-7-(acetylamino)-6-(I-ethylpropoxy)-
2,2-dimethyl-3a,6,7, 7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (621) 
To a solution of vinyl bromide 619 (6.50g, 17.27 mmol) in toluene (300 mL) and 
ethanol (82 mL) was passed CO gas (1 atm). After 10 min triethylamine (84.19 mL, 
604.6 mmol) was added followed by tetrakis(triphenylphosphine)palladium(O) (998 
mg, 0.864 mmol) at r.t.. The resulting solution was heated to 60°C while a 
continuous flow of CO gas (1 atm) was passed through the reaction mixture. After 2 h 
dichlorobis(triphenylphosphine)palladium(II) (1.212 g, 1.727 mmol) was added in 
two portions over 15 min. The reaction mixture was brought to reflux for 4 h, cooled 
to r.t., and filtered through a plug of celite. The crude material was purified by flash 
column chromatography with a solvent gradient of 2: 1 then 1: 1 (hexanes-ethyl 
acetate) to yield 621 (4.34 g, 68%) as a colourless solid: Rf 0.22 (96:4, methylene 
chloride/methanol); mp 112-115 °C;[a]o23 -122.7 (c 1.0, CHCb); IR (firm) v 3383, 
3022, 2975, 2879, 1711, 1663, 1576, 1464, 1374, 1254, 1218, 1094, 1068, 929, 776, 
cm-I; IH NMR (600 MHz, CDCh) () 6.90 (d, J = 1.9 Hz, IH), 5.82 (d, J = 8.7 Hz, 
INH), 5.03 (dd, J= 0.76,5.7 Hz, IH), 4.49 (dd, J= 2.6,5.7 Hz, IH), 4.22-4.31 (m, 
3H), 4.04 (d, J = 9.0 Hz, IH), 3.34 (quin, J = 5.6 Hz, IH), 2.03 (s, 3H), 1.48-1.56 (m, 
4H), 1.37 (s, 3H), 1.34 (s, 3H), 1.30 (t, J = 7.0 Hz, 3H), 0.92 (t, J = 7.5 Hz, 3H), 0.89 
(t, J = 7.2 Hz, 3H) ppm; l3C NMR (150 MHz, CDCb) () 169.9, 165.5, 141.1, 129.9, 
109.5, 82.6, 74.7, 72.0, 71.6, 61.1, 51.9, 27.3, 26.1, 25.9, 25.5, 23.6, 14.2, 9.6, 9.3 
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ppm; MS (El) m/z (%) 369(M+-CH3), 228(10), 182(12), 181(11), 154(6), 153(8), 
143(8), 142(88), 136( 1 0), 112(8), 11 0(7), 109(7), 100(17), 88(6), 87( 13), 86(32), 
85(8), 84(100), 83(9), 80(6), 71(12), 70(11), 69(5), 60(8), 59(13), 58(5), 57(11), 
55(11), 49(10), 47(11), 43(87), 42(6), 41(13); HRMS (El) ca1cd for CIsH2SN06 
354.1917, found 354.1919; Anal. ca1cd: C 61.77, H 8.46, found C 61.74, H 8.40. 
622 
Ethyl (3R,4R,5S,6R)-4-( acetylamino )-3-(l-ethylpropoxy )-5,6-dihydroxycyclohex-
1-ene-1-carboxylate (622) 
To a solution of ethyl ester 621 (1.13 g, 3.06 mmol) in ethanol (20 mL) was added 6 
M HCL (500 ilL) at room temperature. The resulting solution was stirred for 5 h at 
60 DC before the addition of H20 (500 ilL). The reaction was stirred for an additional 
1 h at 60 DC before cooling to room temperature and concentrating under reduced 
pressure. The crude material was purified by flash column chromatography with a 
solvent system of 24: 1 (methylene chloride/methanol) to yield 622 (715 mg, 71 %) as 
white solid: RrO.71 (9:1, methylene chloride/methanol); [a]D23 -44.1 (c 0.47, CHCh); 
mp 154 DC; IR (film) v 3380, 3020, 2970, 2937, 2879, 1715, 1661, 1576, 1464, 1374, 
1244, 1217, 1094, 1060, 929, 756, 667 cm-I; IH NMR {600 MHz, (CD3)2CO) 0 7.36 
(d, J= 6.4 Hz, INH), 6.78 (d, J= 3.8 Hz, IH), 4.86 (d, J= 4.2 Hz, 10H), 4.64 (t, 
J= 3.9 Hz, IH), 4.21-4.25 (m, IH) 4.21 (dq, J= 1.1, 7.2 Hz, 2H), 4.01-4.15 (m, 2H), 
3.96 (dd, J= 4.3,6.6 Hz, IH), 3.56 (quin, J= 5.8 Hz, IH), 1.87 (s, 3H), 1.44-1.58{m, 
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4H), 1.28 (t, J= 7.2 Hz, 3H), 0.91 (t, J= 7.6 Hz, 3H), 0.87 (t, J= 7.6 Hz, 3H) ppm; 
J3C NMR (150 MHz, (CD3)2CO) & 169.2, 165.9, 137.7, 132.6, 81.4, 73.4, 67.0, 65 .7, 
60.4, 53.1, 26.1, 26.0, 22.4, 13.6, 9.2, 8.8 ppm; MS (FAB) mlz (%) 330 (M+), 
260(21), 242(25), 224(13), 182(23), 178(14), 152(11), 136(13), 112(11), 110(21), 
109(16), 81(13), 71(13), 69(17), 67(10), 60(19), 57(19), 55(31), 43(100), 41(34), 
39(16),29(45); HRMS ca1cd for CI6H2SN06+ 330.1917, found 330.1919. 
'I ~~H 
~O\"yOMS 
NHAc 
624 
Ethyl (3R,4S,5S,6R)-4-( acetyl amino )-3-(1-ethylpropoxy)-
6-hydroxy-5-[ (methylsulfonyl)oxy] cyclohex-l-ene-l-carboxylate (624) 
To a stirred solution of 1,2-diol 622 (20 mg, 0.061 mmol) in pyridine (0.5 mL) was 
added mesyl chloride (5 ilL, 0.061 mmol) at 0 0c. The resulting solution was stirred 
for 24h before diluting with Et20 (1 mL) and H20 (1 mL). The layers were separated 
and the aqueous layer was extracted with Et20 (10 x 0.2 mL). The combiiied organic 
layers were washed with brine (1 x 1 mL) and dried over Na2S04. The crude material 
was purified via flash column chromatography with a solvent gradient of 1 :20 then 
1:10 (hexane-ethyl acetate) to yield 624 (21 mg, 86%) as a white solid: Rf0.47 (1:15 
hexanes-ethyl acetate); IH NMR (300 MHz, CDCh) & 6.91 (d, J= 4.1 Hz, 1H), 6.83 
(d, J = 6.8 Hz, 1NH), 5.09 (t, J = 3.6 Hz, 1H), 4.95 (d, J = 4.2 Hz, IH), 4.42 (dt, J = 
3.7,7.3 Hz, 1H), 4.28 (q, J= 7.1 Hz, 2H), 4.14 (t, J= 4.2 Hz, 1H), 3.69 (br s, lOH), 
3.53 (qn, J = 5.7 Hz, IH), 3.13 )s, 3H), 1.98 (s, 3H), 1.48-1.60 (m, 4H), 1.33 (t, J = 
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7.1 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.5 Hz, 3H) ppm; MS (El) mlz (%): 
362 (M-C2HsO+), 43(100), 112(66), 136(39), 149(25), 158(32), 181(29), 182(21), 
228(44); HRMS ca1cd for CIsH24N07S 362.1270, found 362.1278; Anal. ca1cd: C 
50.11, H 7.17, found C 50.16, H 7.31. 
'I ~~H 
~O"'~OTS 
NHAc 
625 
Ethyl (3R,4S,5S,6R)-4-( acetyl amino )-3-(1-ethylpropoxy)-
6-hydroxy-5-{ [( 4-methylphenyl)sulfonyl] oxy }cyclohex-l-ene-l-carboxylate (625) 
To a solution of 1,2-diol 622 (2.32 g, 7.04 mmol) in dry pyridine (15 mL) was added 
4-toluenesulfonyl chloride (1.48 g, 7.74 mmol) portion wise over 5 min. The reaction 
mixture was stirred at room temperature for 48 h and then diluted with methylene 
chloride (10 mL). The organic layer was washed with cold 1 N HC! (3 x 5 mL), brine 
(1 x 10 mL) and dried over Na2S04. The crude mixture was purified by flash column 
chromatography with a solvent system gradient of 99:1 then 96:4 'bhethylene 
chloride/methanol) to yield 625 (1.76 g, 76%, based on 0.587 g recovered starting 
material) as clear oil; R{ 0.71 (96:4, methylene chloride! methanol); .[a]D23 -36.6 (c 
2.5, CHCh); IR (film) v 3375, 2971, 2937, 2879, 2733, 2458, 2252, 1920, 1716, 
1660, 1598, 1527, 1463, 1444, 1372, 1248, 1218, 1190, 1178, 1121, 1096, 1059, 
1002,970,915,848,815, 769, 704, 666, 556, 486 cm-I; IH NMR {600 MHz, CDCh) 
87.81 (d, J= 8.3 Hz, 2H), 7.35 (d, J= 8.3 Hz, 2H), 7.14 (d, J= 6.8 Hz, INH), 6.87 
(d, J= 4.9 Hz, IH), 4.95 (t, J = 3.5 Hz, IH), 4.76 (t, J= 3.8 Hz, IH), 4.26 (q, 
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J= 7.2 Hz, 2H), 4.15 (dt, J= 3.2,6.8 Hz, 1H), 4;{)8 (dd, J= 2.6,4.9 Hz, 1H), 3.45 
(quin,J= 5.8 Hz, 1H), 3.25 (d,J= 3.4 Hz, 10H), 2.45 (s, 3H), 1.92 (s, 3H), 1.45-1.51 
(m, 2H), 1.34-1.40 (m, 1H), 1.32 (t, J= 7.2 Hz, 3H), 1.24-1.26 (m, 1H), 0.84 (t, 
J= 7.4, 3H), 0.70 (t, J= 7.2 Hz, 3H) ppm; I3C NMR (150 MHz, CDCh) 8170.3, 
165.3, 145.4, 137.4, 132.9, 131.2, 130.1 (2 x C), 128.0 (2 x C), 82.2, 74.6, 72.6,64.6, 
61.6, 50.9, 26.3, 25.9, 23.4, 21.7, 14.2, 9.8, 8.9 ppm; MS (FAB) mlz (%) 484(M+), 
29(13), 39(10), 41(13), 43(27), 55(12), 57(8), 69(6), 77{5), 91(8), 136(8), 178(5), 
224(7), 396(5); HRMS (F AB) ca1cd for C23H34N08S 484.2005, found 484.1998. 
Jo"<X:~ 
NHAc 
626 
Ethyl (3R,4R,5R,6R)-4-( acetylamino )-5-azido-3-
(1-ethylpropoxy)-6-hydroxycyclohex-l-ene-l-carboxylate (626) 
To a stirred solution of O-tosy1ate 625 (24 mg, 0.049 mmol) in dimethoxyethane (2 
mL) was added tetrabutylammonium azide (141 mg, 0.49 ~mol). TKe > resulting 
suspension was heat to reflux for 16 h, cooled and concentrated under reduced 
pressure. The crude material was purified by flash column chromatography with a 
solvent system of 2:1 (hexanes-ethyl acetate) to yield 626 (12 mg, 69%) as a pale 
yellow oil: RrO.27 (1:1 hexanes-ethyl acetate); [a]D23 -39.71 (c 1.00, CHCh); mp 112-
115 DC (hexanes-ethyl acetate); IR (film) v 3684, 3019, 2400, 1676, 1498, 1425, 
1216, 1064,929, 757, 669, 497, 478, 472cm- l ; IH NMR (600 MHz, CDCh) 8 6.87 
(dd, J = 0.94,2.8 Hz, IH), 6.10 (d, J = 7.9 Hz, INH), 4.71 (ddd, J = 0.94, 1.1,6.4 Hz, 
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1H), 4.48 {dd, J = 6.4, 9.4 Hz, 1H), 4.43 (ddd, J = 2.1, 2.7, 6.8 Hz, 1H), 4.28 (dq, 
J= 2.7,7.1 Hz, 2H), 3.82 (ddd, J= 6.7,7.9,9.4 Hz, 1H), 3.47 (quin, J= 5.8 Hz, 1H), 
2.01 (s, 3H), 1.48-1.56 (m, 4H), 1.33 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H), 0.91 
(t, J= 7.5 Hz, 3H) ppm; I3C NMR (150 MHz, CDCh) 0 170.2, 166.0, 139.4, 130.3, 
82.5, 73.0, 71.3, 61.5, 58.9, 55.9, 26.1, 25.8, 23.5, 14.2, 9.6, 9.4 ppm; MS (EI) mlz 
(%): 366 (M), 354(6), 313(6), 294(6), 255(6), 253(12), 251(7), 232(33), 230(34), 
190(11), 189(6), 188(12), 187(5), 174(6), 173(10), 172(8), 171(9), 165(8), 163(8), 
151(6), 109(22), 108(9), 93(7), 81'(8), 80(10), 65(8), 59(11), 55(8), 43(100), 42(11), 
41(6); HRMS (EI) calcd for C16H26N40S 354.1903, found 354.1900. 
dX~x 
ACN(:: 0 
632 
Ethyl (3aS,4S, 7 R, 7aS)-8-acetyl-2,2-dimethyl-7, 7a-dihydro-4, 7-( epoxyimino )-1,3-
benzodioxole-4(3aH)-carboxylate (632) 
To a stirred solution of cis-dihydrodiol 7 (5 g, 27.1 mmol) in 2,2-dimeth0xypropane 
(80 mL) was added p-toluenesulfonic acid (catalytic amount) at r.t.. After complete 
consumption of starting material (TLC analysis), the solution was cooled 0 °C before 
the addition of H20 (10 mL). On a preparative scale the intermediate acetonide was 
not isolated (analytical samples were purified via flash column chromatography with 
a solvent system of 3:1 (hexanes-ethyl acetate)). Data for the intermediate ethyl 
(3aR,7 as)-2,2-dimethyl-3a, 7 a-dihydro-l,3-benzodioxole-4-carboxylate: Rf 0.56 
(1:1 hexanes/ethyl acetate); [a]o23 +74.6 (c 4.02, CHCh); IR {film): v 3018, 2987, 
2936,1712,1651,1425,1380,1259,1155,1031,917,856, 697, 667, 512 em-I; IH 
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NMR (300 MHz, CDCh) 0 7.06 (dd, J = 5.3, J = 3.1 Hz, 1H), 4.84 (d, J = 5.7 Hz, 
1H), 4.28-4.41 (m, 1H), 4.07-4.26 (m, 2H), 2.21-2.45 (m, 1H), 1.99-2.16 (m, 1H), 
1.86-1.99 (m, 1H), 1.58-1.72 (m, 1H), 1.33 (d, J = 10.2 Hz, 6H), 1.24 (t, J = 7.2 Hz, 
3H) ppm; l3C NMR (75 MHz, CDC h) 0 166.2, 142.3, 130.0, 108.5, 72.6, 70.4, 60.5, 
27.8,26.2,25.1,20.9, 14.2 ppm; MS (El) mlz (%): 226 (M+-CH3), 211(77), 181(15), 
169(17), 123(100), 105(17), 95(13), 83(11), 79(76), 67(14), 59(10), 55(11), 43(82), 
41(14); HRMS (M+-CH3) calcd for C12HI60 4 211.0970, found 211.0969; Anal. calcd: 
C 64.27; H 7.19. Found C 64.52; H 7.08. 
Nal04 (5.80 g, 27.1 mmol) was added to the reaction vessel prior to the addition of a 
solution of acetohydroxamic acid (2.03 g, 27.1 mmol) in MeOH (25 mL) dropwise 
over 5 min. The resulting solution was stirred at room temperature for 16 h, quenched 
by the slow addition of sat. NaHS03 (10 mL) and extracted into Et20 (3 x 100 mL). 
The combined organic layers were washed with brine (2 x 30 mL) and dried over 
Na2S04. The crude material was purified via flash column chromatography with a 
solvent system of2:8 (hexanes-ethyl acetate) to yield 632 (5.65 g, 70% over 2 steps) 
as a white solid: Rf 0.33 {3:7 hexanes- ethyl acetate}; mp 89-90 °C (hexanes-ethyl 
acetate); [a]D23 -18.0 (c 0.54, CHCh); lR (film) v 3466, 2938, 2987, 1747, 1684, 
1620, 1372, 1275, 1086 cm-I; IH NMR (600 MHz, CDCh) () 6.57-6.65 (m, 2H), 5.47-
5.52 (m, 1H), 4.71 (d, J = 6.8 Hz, 1H), 4.56 (dd, J = 4.7,6.6 Hz, 1H), 4.38 (q, J = 7.2 
Hz, 2H), 2.01 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H), 1.32 (s, 3H), 1.30 (s, 3H) ppm; l3C 
NMR (150 MHz, CDCh) () 173.9, 166.6, 132.4, 128.4, 111.7, 79.2, 76.1, 72.8, 62.7, 
50.0, 25.6, 25.4, 21.7, 14.1 ppm; MS (El) mlz (%): 297 (M), 43(100), 96(30), 
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100(32), 105(35), 124(52); HRMS calcd for C14HI9N06 297.1212, found 297.1215; 
Anal. calcd: C 56.56, H 6.44, found C 56.67, H 6.45. 
NHAc 
633 
Ethyl (3aR,6S, 7 R, 7 as)-7 -( acetylamino )-6-azido-2,2-dimethyl-
3a,6,7,7a-tetrahydro-l,3-benzodioxole-4-carboxylate (633) 
To a stirred solution of O-mesylate 650 (40 mg, 0.11 mmol) in 3:1 - acetone:H20 (1 
mL) was added sodium azide (69 mg, 1.1 mmol) at r.t.. The resulting solution was 
stirred for 24 h, and then extracted with ethyl acetate (5 x 1 mL). The combined 
organic layers were washed with brine (I x I mL) and then dried over Na2S04. The 
crude material was recrystallized from hexanes-ethyl acetate to yield 633 (30 mg, 
87%) as a pale yellow solid: Rf O.24 (1:5 hexanes-ethyl acetate); mp 90°C (hexanes-
ethyl acetate); [a]D23 +65.5 (c 1.15, CHCh); lR (film) v 3298, 2983, 2103, 1722, 
1658, 1372, 1251 cm-I; IH NMR (600 MHz, CDCh) 8 6.91 (d, J = 2.0 H~, ·lH), 6.14 
(d, J= 8.2 Hz, 1NH), 4.93 (d, J= 5.6 Hz, 1H), 4.54 (dd, J= 2.0,10.1 Hz, IH), 4.46 
(ddd, J = 1.7, 5.6, 10.1 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.68 (dt, J = 8.2,9.6 Hz, 
1H), 2.05 (s, 3H), 1.49 (s, 3H), 1.41 (s, 3H), 1.31 (s, 3H) ppm; I3C NMR (150 MHz, 
CDCh) 8 171.4, 164.5, 140.4, 129.3, 110.9,74.1,70.7,61.5,58.9,54.3,28.2,26.1, 
23.7, 14.1 ppm; MS (El) mlz (%): 309 (M-CH/), 41(44), 43(100), 56(54), 57(46), 
84(22); HRMS calcd for C13H17N40 S 309.1199, found 309.1200. 
298 
NHAc 
634 
Ethyl (3aS,4S, 7 R, 7 as)-7 -( acetylamino )-4-hydroxy-2,2-dimethyl-
3a,4,7, 7a-tetrahydro-l,3-benzodioxole-4-carboxylate (634) 
To a stirred solution of oxazine 632 (955 mg, 3.21 mmol) in 15:11 CH3CN:H20 (10 
mL) was added molybdenum hexacarbonyl (848 mg, 3.21 mmol) at r.t.. The reaction 
was brought to reflux for 3 h, and then cooled before the addition of activated 
charcoal (spatula tip). The resulting suspension was stirred for 30 min and then 
filtered through a plug of celite. The crude material was purified via flash column 
chromatography with a solvent system of 1:9 (hexanes-ethyl acetate) to yield 634 
(720 mg, 75%) as a white solid: Rr 0.20 (ethyl acetate); mp 97-99 °C (hexanes-ethyl 
acetate); [a]D23 -94.3 (c 0.79, CHCh); IR{film) v 3433, 2094, 1644, 1271, 1217, 1060 
cm- I ; lH NMR (600 MHz, CDCh) 0 6.25 (d, J= 8.7 Hz, 1NH), 5.98 (dd, J= 3.8, 9.8 
Hz, 1H), 5.94 (dd, J= 0.9, 9.9 Hz, 1H), 4.77-4.81 (m, 1H), 4.37 (t, J= 8.3 Hz, 1H), 
4.34 (dd,J= 4.3,7.7 Hz, 1H), 4.22-4.29 (m, 2H), 4.12{s, 10H),' 1.99 (s, 3H), 1.35 (s, 
3H), 1.32 (t, J = 7.4 Hz, 3H), 1.28 (s, 3H) ppm; l3C NMR (150 MHz, CDCh) 0 172.7, 
170.0, 132.9, 129.6, 109.3, 81.0, 76.3, 74.5, 62.8, 48.8, 26.2, 24.2, 23.5, 14.0 ppm; 
MS (EI) mlz (%): 284 (M-CH3+), 43(90), 83(47), 84(100), 86(61), 96(37), 125(36), 
153(38), 199(99); HRMS calcd for CJ3HISN06 284.1130, found 284.1137; Anal. 
calcd: C 56.18, H 7.07, found C 56.27, H 7.11. 
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NHAc 
635 
Ethyl (3aS,4S, 7 R, 7 as)-7 -( acetyl amino )-4-( acetyloxy)-2,2-dimethyl-
3a,4, 7,7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (635) 
To a stirred solution of allylic alcohol 634 (527 mg, 1.76 mmol) in acetic anhydride 
(3 mL) was added DMAP (catalytic amount) at r.t.. The resulting solution was stirred 
for 1 h before diluting with EtOAc (2 mL) and H20 (2 mL). The reaction was 
quenched by the slow addition of NaHC03, and then extracted into EtOAc (3 x 2 
mL). The combined organic layers were washed with brine (1 x 2 mL), dried over 
NaS04 and concentrated under reduced pressure. The crude material was purified via 
flash column chromatography with a solvent system of 1:9 (hexanes-ethyl acetate) to 
yield 635 (565 mg, 94%) as a white solid: Rf 0.26 (2:8 hexanes-ethyl acetate); mp 
189-190 °C (hexanes-ethyl acetate); [a]D23 +69.4 (c 0.27, CHCh); IR (film) v 3429, 
3264, 2916, 1758, 1630, 1374, 1226, 1050 cm-I; IH NMR (600 MHz, CDCh) 8 6.59 
(d, J = 10.2 Hz, 1H), 6.14 (dd, J = 5.9, 10.0 Hz, 1H), 5.52 (d, J =- 8.7 Hz, 4NH), 4.79 
(ddd, J= 2.7,5.8,8.8 Hz, 1H), 4.64 (dd, J= 0.76,6.8 Hz, 1H), 4.51 (dd, J= 2.6, 6.8 
Hz, 1H), 4.21-4.31 (m, 2H), 2.10 (s, 3H), 1.99 (s, 3H), 1.34 (s, 3H), 1.27-1.30 (m, 
6H) ppm; I3C NMR (150 MHz, CDCh) 8 169.3, 168.5, 167.8, 131.9, 128.5, 109.5, 
78.0, 77.1, 75.7, 62.0, 46.9, 26.1, 24.5, 23.6, 21.0, 14.0 ppm; MS (El) mlz (%): 326 
(M-CH3+), 43(100),136(12),153(13),199(17),282(10); HRMS calcd for CIsH20N07 
326.1240, found 326.1235; Anal. calcd: C 56.30, H 6.79, found C 56.40, H 6.80. 
300 
NHAc 
636 
Ethyl (3aR,6R,7 R, 7 as)-7 -( acetylamino )-6-azido-2,2-dimethyl-
3a,6,7,7 a-tetrahydro-l ,3-benzodioxole-4-carboxylate (636) 
A solution of allylic acetate 635 (102 mg, 0.299 mmol) and trimethylsilyl azide (138 
mg, 1.20 mmol) in THF (1 mL) was brought to reflux prior to the addition of freshly 
prepared tetrakis(triphenylphosphine)palladium (17 mg, 0.0149 mmol) in one portion. 
The reaction was allowed to reflux for 1 h, then cooled to r.t. and concentrated under 
reduced pressure. The crude material was purified via flash column chromatography 
with a solvent system of 7:3 (hexanes-ethyl acetate) to yield 636 (75 mg, 77%) as a 
pale yellow solid: R/O.51 (8:2 hexanes-ethyl acetate); mp 156-157 °C (CHCh); {a]D23 
-183.6 (c 0.34, CHCh); IR (film) v 3583, 3284, 2987, 2lO8, 1720, 1655, 1540, 1372, 
1248,1072 em-I; IH NMR (600 MHz, CDCh) () 6.97 (d, J= 4.5 Hz, 1H), 5.64 {br s, 
1NH), 4.96 (d,J= 5.7 Hz, 1H), 4.54 (t,J=4.3 Hz, 1H), 4044 (td,J=4A, 7.9 Hz, 1H), 
4.25-4.32 (m, 3H), 2.04 (s, 3H), 1.43 (s, 3H), 1.41 (s; 3H), 1.3'3 (t, J = 7.2 Hz, 3H) 
ppm; I3C NMR (150 MHz, CDCh) () 170.8, 164.7, 136.2, 132.0, 11004, 73.1, 70.1, 
61.6, 56.7, 50.2, 27.7, 25.9, 23.3, 14.2 ppm; MS (EI) mlz (%): 309 (M-CH/), 
43(100), 84(37), 167(15), 224(10), 309(18); HRMS calcd for C 13H17N40S 309.1200, 
found 309.1197. 
301 
Ethyl (3aR,5aR,8aR,8bS)-2,2, 7 -trimethyl-3a,5a,8a,8b-tetrahydro [1,3] dioxolo [4,5-
e) [1,3 ]benzoxazole-4-carboxylate (641) 
To a stirred solution of allylic alcohol 634 (400 mg, 1.33 mmol) in methylene 
chloride (5 mL) was added NEt3 (0.74 mL, 4.0 mmol), DMAP (catalytic amount) and 
methanesulfonyl chloride (0.16 mL, 1.4 mmol) at r.t.. The resulting solution was 
stirred for 4 h before being quenched by the slow addition of sat. NaHC03 (5 mL), 
and then extracted into ethyl acetate (3 x 5 mL). The combined organic layers were 
washed with brine (1 x 2 mL), dried over NaS04 and concentrated under reduced 
pressure. The crude material was purified via flash column chromatography with a 
solvent system of 1:2 (hexanes-ethyl acetate) to yield 641 {204 mg, 54%) as a white 
yellow solid: Rf 0.40 (1:4 hexanes-ethyl acetate); mp 54-55°C (hexanes-.ethyl 
acetate); [a]D23 +150.4 (c 1.25, CHCh); IR (film) v 3543, 2986, 1722, 1667, 1372, 
~ 
1218 ern-I ; IH NMR (600 MHz, CDCh) 0 6.56 (d, J =3.0 H2, IH), 5.14 (dct, J = 2.9, 
8.5 Hz, IH), 4.93 (d, J = 5.2 Hz, IH), 4.86 (dd, J = 2.7, 5.1, Hz, IH), 4.58 (d, J = 8.4 
Hz, IH), 4.27-4.34 (m, 2H), 1.97 (d, J = 1.3 H2, 3H), 1.42 {s, 3H), 1.34~t, J = 7.2 Hz, 
3H), 1.32 (s, 3H) ppm; I3C NMR (150 MHz, CDCh) 0 165.9, 165.6, 133.3, 130.5, 
109.1,73.6,73.2,68.9,64.3,61.2,27.8,26.3, 14.2, 14.1 ppm; MS (EI) mlz (%): 266 
(M-CH3+), 43(52), 136(19),266(100); HRMS calcd for CI3HI 6NOs 266.1028, found 
266.1032. 
302 
NHAc 
643 
Ethyl (3aR,6R,7 R,7 as)-7 -( acetylamino )-6-hydroxy-2,2-dimethyl-
3a,6,7,7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (643) 
To a stirred solution of oxazoline 641 (800 mg, 2.86 mmol) in 1: 11 ethanol:water (8 
mL) was added calcium carbonate (570 mg, 5.69 mmol) at r.t.. The reaction mixture 
was brought to reflux for 48 h before concentrating. The crude residue was dissolved 
in ethyl acetate and then filtered through a plug of celite. The crude material was 
purified via flash column chromatography with a solvent system of 1:4 (hexanes-ethyl 
acetate) to yield 643 (616 mg, 72%) as a white solid: Rr 0.23 (96:4 methylene 
chloride-methanol); mp 115-118 °C (hexanes-ethyl acetate); [a]D23 -54.33 (c 1,7, 
CHCh); IR (film) v 3307,2624,2247, 1718, 1655, 1541, 1247, 1069 em-I; IH NMR 
(300 MHz, CDCh) 87.01 (d, J = 3.1 Hz, INH), 5.76 (br s, INH), 5.01 (d, J = 5.6 Hz, 
IH), 4.73 (t, J = 3.4 Hz, IH), 4.53 (q, J = 5.9 Hz, IH), 4.47 (t, J = 5.8 Hz, IH), 4.26-
.6. 
4.31 (m, 2H), 3.07 (bs, 10H), 2.04 (s, 3H), 1.42 (s, 6H), 1.36 (t, J = 7.1 Hz, 3H) ppm; 
l3C NMR (150 MHz, CDCh) 8 171.6, 165.4, 141.0, 130.3, 109.9,73.8,69.8,68.8, 
61.3, 52.3, 27.48, 25.7, 23.4, 14.2 ppm; MS (FAB) mlz (%): 299 (M+), 29(34), 
43(71), 136(29), 182(23), 242(100); MS (EI) mlz (%): 284 (M-CH3+), 43(100), 
84(25), 142(23), 284(17); HRMS calcd for Cl3HI8N06 284.1134, found 284.1132; 
Anal. calcd: C 56.18, H 7.07, found C 56.22, H 7.17. 
303 
NHAc 
645 
Ethyl (3aR,4R,6R, 7 R, 7aS)-7 -( acetylamino )-6-hydroxy-2,2-dimethyl hexahydro-
1,3-benzodioxole-4-carboxylate (645) 
A hydrogenation vial was charged with ethyl acrylate 643 (150 mg, 0.501 mmol), 5% 
RhlAlz03 (60 mg) and 85% ethanol (2 mL) before evacuating with H2• The reaction 
was stirred at r.t. and 60 psi for 144h before filtering through a plug of Si02 and 
concentrating. The crude material was purified via flash column chromatography with 
a solvent gradient of 1: 1 (hexanes-ethyl acetate) then methanol to yield 645 (143 mg, 
95%) as a white solid: Rf 0.66 (90:10 CHCh-methanol); mp 156-158 °C (CHCh); 
[a]o23 -90.15 (c 1.1, CHCh); IR (film) v 3305, 2986, 1722, 1666, 1553, 1374, 1219, 
1066, 771 cm-I; IH NMR (600 MHz, (CO(CD3)2) 8 7.17 (d, J = 7.7 Hz, 1NH), 4.59 (t, 
J=4.1 Hz, IH),4.38 (brs, 10H), 4.21 (dq,J=7.2, 10.9 Hz, IH), 4.14 (dd,J=4.6, 
9.0 Hz, IH), 4.11 (dq, J = 3.3, 7.0 Hz, IH), 4.00-4.03 (m, IH), 3.85 (td, J = 2.2, 4.5 
(\ 
Hz, IH), 3.24 (dt, J = 4.3, 12.6 Hz, 1H), 1.92 (s, 3H), 1.88-2.00 (m, 2H), 1.42 (s, 3H), 
1.28 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H) ppm; MS (EI) mlz (%): 301 (M), 43(38), 47(29), 
49(24), 47(100), 86(80), 91(20); HRMS ca1cd for CI4H23N06 301.1525, found 
301.1524. 
304 
648 
Ethyl (3aR,4R,6R,7 S, 7aS)-7 -( acetylamino )-2,2-dimethyl-
6-[ (methylsulfonyl)oxy] h exahydro-l ,3-benzodioxole-4-carboxylate (648) 
To a stirred solution of alcohol 645 (50 mg, 0.17 mmol) and triethylamine (93 ~L, 
0.66 mmol) in methylene chloride (100 ~L) was added methanesulfonic anhydride 
(58 mg, 0.33 mmol) at 0 DC. The reaction was slowly raised to r.t. over 24 h before it 
was diluted with methylene chloride (500 ~L), and then washed with 1 N HCI (2 x 
500 ~L), sat. NaHC03 (2 x 500 ~L) and brine (1 x 1 mL). The crude material was 
purified via flash column chromatography with a solvent gradient of 1:2 then 1:5 
(hexanes-ethyl acetate) to yield 648 (46 mg, 73%) as a white solid: Rf 0.47 (1:10 
hexanes-ethyl acetate); mp 101-102 °C (CHCh); [a]D23 -49.91 (c 1.21, CHCh); IR 
(film) v 3307, 2628, 1719, 1651, 1361 cm cm-I; IH NMR (600 MHz, CDCh) () 5.15-
5.17 (m, IH), 4.74 (d, J = 8.9 Hz, INH), 4.62 (t, J = 4.1 Hz, IH), 4.22-4.28 (m, IH), 
4.15-4.19 (m, IH), 4.03 (dd, J= 4.6,8.6 Hz, IH), 3.58 Cdt, J= 2.7,8.8 Hz, IH), 3.12 
(s, 3H), 2.92 (dt, J= 4.2,13.3 Hz, IH), 2.25 (dt, J= 4.2,14.9 Hz, IH), 2.09-2.13 (m, 
IH), 2.08 (s, 3H), 1.55 (s, 3H), 1.37 (s, 3H), 1.26 (t, J= 7.1 Hz, 3H) ppm; I3C NMR 
(150 MHz, CDCh) () 170.6, 169.7, 109.9, 77.7, 73.8, 73.3, 61.1, 56.4, 42.6, 37.6, 
28.1,26.2,25.2,21.0, 14.1 ppm; MS (FAB) mlz (%): 380 (M+ H+), 43(23), 257(100); 
HRMS calcd for CISH26NOsS+ 380.1379, found 380.1366. 
305 
NHAc 
650 
Ethyl (3aR,6R, 7 S, 7 as)-7 -( acetylamino )-2,2-dimethyl-6- [(methylsulfonyl)oxy]-
3a,6, 7,7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (650) 
To a stirred solution of allylic alcohol 643 (40 mg, 0.13 mmol) and triethylamine (37 
ilL, 0.27 mmol) in methylene chloride (100 ilL) was added methanesulfonyl chloride 
(13 ilL, 0.16 mmol) at 0 °C. The reaction was slowly raised to room temperature over 
12 h before extracting into EtOAc (5 x 1 mL). The combined organic layers were 
washed with sat. NH4Cl (2 x 1 mL), brine (1 x 1 mL), and dried over Na2S04. The 
crude material was purified via flash column chromatography with a solvent gradient 
of 1: 1 then 1:3 (hexane-ethyl acetate) to yield 650 (45 mg, 90%) as a white solid: Rf 
0.22 (1:5 hexanes-ethyl acetate); mp 163-165 °C (hexanes-ethyl acetate); [a]o23 -
109.6 (c 1.25, CHCh); IR (film) v 3307, 2628,1719,1651,1361 cm-I; IH NMR{300 
MHz, CDCh) 5 6.98 (d, J= 4.3 Hz, IH), 5.68 (d, J= 8.3 Hz, INH), 5.46 (t, J= 4.1 
(; 
Hz, IH), 5.01 (d, J= 5.3 Hz, IH), 4.58 (td, J= 4.0, 4.1 Hz, IH), 4.34 (dd, I= 5.5,8.1 
Hz, IH), 4.24-4.32 (m, 2H), 3.07 (s, 3H), 2.05 (s, 3H), 1.43 (8, 3H), 1.42 (s, 3H), 1.34 
(s, 3H) ppm; l3C NMR (75 MHz, CDCh) 5 170.8, 164.5, 134.7, 133.5, 110.7, 73.5, 
73.0,69.9,61.7,49.8,38.7,27.6,25.9,23.3, 14.1 ppm; MS {FAB) mlz (%): 378 (M+ 
H+), 29(17), 43(39),102(100),136(24), 182(19),224(18),320(53),378(41); HRMS 
calcd for CI5H24NOsS+ 378.1223, found 378.1195; Anal. calcd: C 47.74, H 6.14, 
found C 47.80, H 6.04. 
306 
C02Et 
c,Oj< 
NHAc 
651 
Ethyl (3aR,6S, 7S, 7aS)-7-(acetylamino )-6-chloro-2,2-dimethyl-
3a,6, 7,7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (651) 
To a stirred solution of allylic alcohol 643 (40 mg, 0.13 mmol) and pyridine (22 ilL, 
0.13 mmol) in methylene chloride (100 ilL) was added methane sulfonyl chloride (13 
ilL, 0.16 mmol) at 0 °C. The reaction was slowly raised to room temperature over 12 
h before extracting into EtOAc (5 x 1 mL). The combined organic layers were washed 
with sat. NH4CI (2 x 1 mL), brine (1 x 1 mL), and dried over Na2S04. The crude 
material was purified via flash column chromatography with a solvent gradient of 1: 1 
then 1:3 (hexane-ethyl acetate) to yield 651 (36 mg, 88%) as a clear oil. RJ O.27 (96:4 
methylene chloride - methanol); IH NMR (300 MHz, CDCh) 8 7.05 (d, J = 2.0 Hz, 
1H), 5.79 Cd, J = 7.7 Hz, 1NH), 5.15 (dt, J = 1.1, 9.8 Hz, 1H), 4.98 (d, J = 5.6 Hz, 
1H), 4.61 (dd, J = 5.6, 9.9 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.68 (q, J = 9.2 Hz, 1H), 
:> 
2.06 (s, 3H), 1.52 (s, 3H), 1.43 (s, 3H), 1.35 (s, 3H) ppm; MS (EI) mlz (%): 302 (M-
CH3+), 43(100),106 (14), 266 (16); HRMS calcd for C13H17CIN05 302.0795, found 
302.0800. 
307 
Lox N3)ylO 
NHTs 
664 
N-[ (3aS,4R,5S, 7 as)-5-azido-7 -bromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-l,3-
benzodioxol-4-yIJ-4-methylbenzenesulfonamide (664) 
To a stirred solution of N-tosyl aziridine 570 (200 mg, 0.499 mmol) in DMF (2 mL) 
was added NH4Cl (400mg) and NaN3 (324 mg, 4.99 mmol) at 0 °C. The reaction 
mixture was stirred for 12 h, extracted into Et20 (5 x 1 mL), washed with H20 (20 x 
0.5 mL), washed with brine (1 x 1 mL) and dried over Na2S04. The crude material 
was recrystallized from CHCh-hexanes to yield 664 (203 mg, 92%) as a white solid: 
Rj 0.53 (2:1 hexanes-ethyl acetate); mp 119-120 °C (CHCh-hexanes); {a]D23 +82.36 
(c 3.5, CHCh); IR (film) v 3435, 2108, 1645, 1599, 1219, 1159 em-I; IH NMR (600 
MHz, CDCh) () 7.80 (d, J = 8.3 Hz, IH), 7.31 (d, J = 8.2 Hz, 2H), 6.14 (d, J = 3.4 Hz, 
IH), 5.61 (d, J= 8.3 Hz, IH), 4.58 (d, J= 5.6 Hz, IH), 4.19 (dd, J= 5.8,6.9 Hz, IH), 
3.73 (dd, J = 3.0, 6.4 Hz, IH), 3.56 (q, J = 7.5 Hz, IH), 2.45 (s, 3H), 1.37 (s, 3H), 
13 . ' . ' ~ . . 1.34 (s, 3H) ppm; C NMR (150 MHz, CDCh) () 143.6, 137.5, 129.7, 129.0, 127.3, 
127.2, 127.1, 127.0, 124.0, 111.3, 75.9, 75.6, 60.5, 55.2, 27.5, 25.9, 21.5 ppm; MS 
(EI) mlz (%): 442 (M), 43(47), 91(100), 155(35); HRMS calcd for ClsH16N404BrS· 
442.0076, found 442.0072. 
308 
Lox 
BOCHN¥O 
NHTs 
667 
tert-butyl{ {3aS,4R,5S, 7 as)-7-bromo-2,2-dimethyl-4-
{[ {4-methylphenyl)sulfonyl]amino }-3a,4,5, 7 a-tetrahydro-l,3-benzodioxol-5-
yl)carbamate (667) 
To a stirred solution of azide 664 (41 mg, 0.092 mmol) in 12:1 THF:H20 (1 mL) was 
added triphenylphosphine (48 mg, 0.18 mmol). The reaction mixture was stirred for 
12 h, extracted into diethyl ether (5 x 0.5 mL), washed with brine (1 x 1 mL) and 
dried over Na2S04 to provide N-{{3aS,4R,5S,7aS)-7-bromo-2,2-dimethyl-5-
[(triphenylphosphoranylidene )amino ]-3a,4,5, 7 a-tetrahydro-l,3-benzodioxol-4-
yl}-4-methylbenzenesulfonamide (668). To a stirred solution of the crude 
Staudinger intermediate 668 (0.092 mmol) in DCM (1 mL) and triethylamine (50 ilL) 
was added (Boc hO (29 mg, 0.14 mmol) at 0 °C. The reaction mixture was stirred for 
12 h, extracted into CHCh (5 x 0.5 mL), washed with sat. NH4CI (2 x 1 mL), washed 
j , 
with brine (1 x 1 mL) and then dried over Na2S04. The crude material was purified by 
flash column chromatography with a solvent gradient of 10:1, 6:1 then 3:1 (hexane-
ethyl acetate) to yield 667 (36 mg, 77%): RlO.31 (2:1 hexanes-ethyl acetate); mp 153-
154°C (EtOAc-hexanes); [a]D23 +15.467 (c 2.l, CHCh); IR {film) v 3408, 2090, 
1642, 1161 cm-I; IH NMR (600 MHz, CDCh) 8 7.77 (d, J = 7.9 Hz, IH), 7.27.(d, J = 
7.9 Hz, 2H), 6.17 (d, J = 3.4 Hz, IH), 5.32 (d, J = 8.9 Hz, IH), 5.26 (d, J = 8.2 Hz, 
IH), 4.60 (d, J = 5.6 Hz, IH), 4.23 (dd, J = 6.2,6.9 Hz, IH), 4.08-4.l3 (m, IH), 3.46 
(q, J = 7.4 Hz, IH), 2.40 (s, 3H), 1.43 (s, 9H), 1.29 (s, 3H), 1.18 (s, 3H) ppm; l3C 
3D9 
NMR (150 MHz, CDCh) () 155.6, 143.5, 137.5, 132.7, 129.6, 127.32, 121.4, 110.9, 
80.3, 76.4, 76.3, 55.0, 51.2, 28.3, 27.3, 25.9, 21.5 ppm; MS (EI) mlz (%): 516 (M), 
57(46), 91(81), 98(62), 99(97), 139(48), 254(100); HRMS ca1cd for C21Hz9Nz06SBr 
516.0930, found 516.0930.0940; Anal. ca1cd: C 48.75, H 5.65, found C 48.81, H 5.69. 
NHTs 
669 
Ethyl (3aR,6S,7 R,7 as)-6-[ (tert-butoxycarbonyl)amino ]-2,2-dimethyl-
7 -{ [( 4-methylphenyl)sulfonyl] amino }-3a,6, 7,7 a-tetrahydro-l,3-benzodioxole-4-
carboxylate (669) 
A solution of vinyl bromide 667 (2 g, 3.86 mmol), ethanol (15 mL) and triethylamine 
(15 mL) in toluene (70 mL) was purged with CO (g) for 10 min. The solution was 
charged with CO(g), Pd(PPh3h (223 mg, 0.193 mmol) and then heated to 60°C for 1 
h before the addition of Pd[(PPh3)z(Cl)z] (271 mg, 0.386 mmol). The reaction was 
6 
then heated to reflux for 6 h, cooled to r.t. and filtered through a plug of Si02. The 
crude material was purified by flash column chromatography to yield 669 (888 mg, 
45%) as a yellow oil: Rf 0.46 (1:1 hexanes-ethyl acetate); {a]DZ3 -11.77 {c 0.72, 
CHCh); IR (film) v 3434, 2099, 1647, 1160 cm-I; IH NMR (300 MHz, CDCh) () 
7.78 (d, J= 8.2 Hz, 2H), 7.26 (d, J= 8.2 Hz, 2H), 6.89 (d, J= 2.2 Hz, IH), 5.36 (d, J 
= 8.2 Hz, IH), 5.23 (d, J= 8.3 Hz, IH), 4.92 (d, J= 5.6 Hz, IH), 4.23 (q, J= 7.0 Hz, 
2H), 4.10 (dd, J = 6.0, 8.9 Hz, IH), 3.38 (q, J = 8.7 Hz, IH), 2.39 (s, 3H), 1.46 (s, 
9H), 1.29 (t, J = 7.1 Hz, 3H), 1.26 (s, 3H), 1.05 (s, 3H) ppm; l3C NMR (75 MHz, 
310 
CDCh) 8 171.1, 143.5, 136.7, 129.6, 127.6, 109.5,78.3,74.0,60.7,42.9,28.7,27.4, 
26.0, 21.5, 20.5, 14.1 ppm; MS (El) mlz (%): 510 (M), 43(100), 57(52), 84(54); 
HRMS calcd for C24H34N20SS 510.2036, found 510.2038; Anal. ca1cd: C 56.45, H 
6.71, found C 56.39, H 6.80. 
r7'Y°x BOCHN~O 
NHTs 
670 
tert-Butyl «3aS,4R,5S, 7 aR)-2,2-dimethyl-4-{ [( 4-methylphenyl)sulfonyl] amino}-
3a,4,5,7 a-tetrahydro-l,3-benzodioxol-5-yl)carbamate (670) 
To a stirred solution of vinyl bromide 667 (730 mg, 1.41 mmol), N(iPr)2Et (1.93 mL, 
21.6 mmol), abs. ethanol (6 mL) in THF (30 mL) was added Ni[(PPh3)2(CO)2] (1.35g, 
2.12 mmol). The reaction mixture was heated to 60°C and stirred for 24 h, cooled to 
r.t. and charged with activated charcoal (1 g). The resulting mixture was stirred for 1 
h and then filtered through a plug of celite and Si02. The crude material was purified 
via flash column chromatography with a solvent gradient of 3: 1 then l:J (hexanes-
ethyl acetate) to yield (16) (488 mg, 79%) as a clear oil: R{ 0.52 (1: 1 hexanes-ethyl 
acetate); IH NMR (300 MHz, CDCh) 87.77 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 8.2 Hz, 
2H), 5.80-5.82 (m, 1H), 5.22 (d, J = 9.1 Hz, 1H), 4.88 (d, J = 7.5 Hz, 1H), 4.55 (dd, J 
= 2.4, 6 Hz, 1H), 3.99-4.10 (m, 1H), 3.31 (q, J = 8.8 Hz, 1H), 2.38 (s, 3H), 1.44 (s, 
9H, 1.22 (s, 3H), 1.08 (s, 3H) ppm; MS (El) mlz (%): 438 (M), 41(91), 85(100), 
91(70),99(51), 139(41); HRMS ca1cd for C21 H30N20 6S 438.1825, found 438.1829. 
311 
671 
Ethyl (3aS,4R,5R,7 aR)-2,2-dimethyl-8-[ (4-methylphenyl)sulfonyl] 
-3a,4,5,7 a-tetrahydro-4,5-epimino-1 ,3-benzodioxole-7 -carboxylate (671) 
To a stirred solution of ethyl (3aR,7aS)-2,2-dimethyl-3a,7a-dihydro-1,3-
benzodioxole-4-carboxylate (500 mg, 2.23 mmol) and Cu(acach (58 mg, 0.223 
mmol) in MeCN (1 mL) was added PhI=NTs (832 mg, 2.23 mmol) at 0 °C. The 
resulting solution was stirred for 5 h before filtering through Si02 and concentrating. 
The crude material was purified via flash column chromatography with a solvent 
gradient of 10:1,6:1 then 3:1 (hexane-ethyl acetate) to yield 671 (359 mg, 41%) as 
colourless crystals: Rf 0.46 (2: 1 hexanes-ethyl acetate); mp 106-107 T (MeOH-
hexanes); [a]D23 -52.526 (c 0.62, CHCh); IR (film) v 3434,2099, 1647, 1160 em-I; IH 
NMR (600 MHz, (CO(CD3)2) 8 7.86 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 
6.97 (d, J = 4.5 Hz, 1 H), 4.73 (d, J = 6.9 Hz, 1 H), 4.62 (dd, J = 0.9, 6.9 Hz, 1 H), 4.14-
4.21 (m, 2H), 3.56 (dd, J= 4.5,6.2 Hz, 1H), 3.34 (dd, J= 1.1,6.4 Hz, IN), 2.45 (s, 
3H), 1.32 (s, 3H), 1.31 (s, 3H), 1.23 (t, J= 7.1 Hz, 3H) ppm; I3C NMR (150 MHz, 
CDCh) 8 164.6, 145.2, 134.7, 134.1, 131.2, 130.0 (2x C), 127.9 (2x C), 110.3, 70.0, 
68.6, 60.7, 37.5, 35.3,27.0, 24.9,20.8, 13.6 ppm; MS (El) mlz (%): 393 (M), 43(38), 
47(29), 49(24), 47(100), 86(80), 91(20); HRMS calcd for CI9H23N06S 393.1246, 
found 393.1239; Anal. calcd: C 58.00, H 5.89, found C 58.02, H 5.90. 
312 
C02Et 
~OX N3~O 
NHTs 
672 
Ethyl(3aR,6S,7 R,7 as)-6-azido-2,2-dimethyl-7 -{[ (4-methylphenyl)sulfonyl] amino} 
-3a,6,7,7 a-tetrahydro-l,3-benzodioxole-4-carboxylate (672) 
To a stirred solution of N-tosyl aziridine 671 (25 mg, 0.0636 mmol) and NH4CI (51 
mg, 0.953 mmol) in DMF (0.5 mL) was added NaN3 (8 mg, 0.127 mmol) at 0 °C. The 
resulting suspension was stirred for 3 h before diluting with Et20 (1 mL) and H20 (1 
mL). The layers were separated and the aqueous layer was extracted with Et20 (10 X 
0.2 mL). The combined organic layers were washed with brine (1 x 1 mL) and dried 
over Na2S04. The crude material was purified via flash column chromatography with 
a solvent gradient of 4:1 then 2:1 (hexanes-ethyl acetate) to yield 672 (22 mg, 79%) 
as a white solid: Rf 0.43 (1: 1 hexanes-ethyl acetate); mp 116-118 °C (hexanes-ethyl 
acetate); IR (film) v 3432, 2102, 1655, 1598, 1219, 1165 cm-I; IH NMR (300 MHz, 
CDCh) 87.83 (d, J= 8.3 Hz, 2H), 7.30 (d, J= 8.3 Hz, 2H), 6.87 (d, J= 2.6 Hz, lH), 
6-
4.99 (d, J= 7.8 Hz, IH), 4.91 (d, J= 5.5 Hz, IH), 4.26 (q, J= 7.1 Hz, 2H), 4.10 (dd, J 
= 5.7, 9.1 Hz, IH), 3.93 (dd, J = 2.6, 9.0 Hz, IH), 3.45-3.54 (m, IH), 2.42 (s, 3H), 
1.32-1.37 (m, 4H), 1.28-1.32 (m, 5H) ppm; MS (FAB) mlz (%): 437 (M+ H+), 43(18), 
91(100), 136(20), 139(39), 152(23), 155(72), 167(24), 168(22), 181(27), 196(38), 
437(27); HRMS calcd for CI9H25N406S 437.1495, found 437.1494 
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675 
N-[ (3aS,4R,5S, 7 as)-5-azido-7 -bromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-l,3-
benzodioxol-4-yl] -N-[( 4-methylphenyl)sulfonyl] acetamide (675) 
As solution of azide 664 (65 mg, 0.146 mmol) in triethylamine (0.5 mL) and AC20 
(0.5 mL) was stirred at r.t. for 12 h, diluted with EtOAc (2 mL) and washed with H20 
(3 x 1 mL), washed with brine (1 x 1 mL) and dried over Na2S04. The crude material 
was purified via flash column chromatography with a solvent gradient of 3: 1 then 1: 1 
(hexanes-ethyl acetate) to yield 675 (73 mg, 90%) as a clear oil: RrO.62 (2:1 hexanes-
ethyl acetate); IR (film) v 3427, 2109, 1666, 1599, 1144 cm-I; IH NMR (300 MHz, 
CDCh) () 8.07 (d, J= 8.2 Hz, 2H), 7.36 (d, J= 8.2 Hz, 2H), 6.30-6.34 (m, 1H), 5.00-
5.11 (m, IH), 4.75-4.84 (m, 2H), 4.53-4.66 (m, 1H), 2.45 (s, 3H), 2.21 {s, 3H), 1.60 
(s, 3H), 1.43 (s, 3H) ppm; MS (EI) mlz (%): 558 (M), 43(1{)O), 65(44), 91(92), 
155(86),214(60); HRMS ca1cd for C23H3IBrN207S 558.1035, found 558.1034 
314 
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677 
Ethyl(3aR,4R, 7 R, 7 as)-2,2-dimethyl-7 -{ [( 4-methylphenyl)sulfonyl] amino} 
hexahydro-l,3-benzodioxole-4-carboxylate (677) 
A round-bottomed flask was charged with N-tosyl aziridine 671 (25 mg, 0.0636 
mmol), and platinum(IV)oxide (catalytic amount) and methanol (0.5 mL) before 
evacuating with H2. The reaction was stirred at room temperature with 1 atm ofH2 for 
12 h before filtering through a plug of Si02 and concentrating. The crude material 
was purified via flash column chromatography with a solvent gradient of 3: 1 then 1: 1 
(hexanes-ethyl acetate) to yield 677 (21 mg, 84%) as a white solid: Rr 0.34 (1:1 
hexanes-ethyl acetate); IH NMR (300 MHz, CDCh) () 7.77 (d, J= 8.3 Hz, 2H), 7.30 
(d, J = 8.3 Hz, 2H), 4.64 (d, J = 4.8 Hz, 1NH), 4.50 (t, J = 4.2 Hz, 1H), 4.08-4.25 (m, 
2H), 3.70 (dd, J = 4.6, 8.6 Hz, 1H), 2.90-3.02 (m, 1H), 2.60-2.70 (m, 1H), 2.41 (s, 
3H), 2.12-2.23 (m, 1H), 1.68-1.83 (m, 2H), 1.20-1.25 (m, 6H), 1.07-1.20 (m, 1H), 
0.96 (s, 3H) ppm; 13C NMR (75 MHz, CDCh) () 171.1, 143.5, 136.7, 129.6, 127.6, 
109.5,78.3, 74.0, 60.7, 42.9, 28.7, 27.4, 26.0, 21.5, 20.5, 14.1 ppm; MS (El) mlz (%): 
382 (M-CH3+), 43(52), 47(39), 69(31), 83(99), 84(100), 85(64), 86(60), 91(94), 
138(49), 155(53), 184(88), 196(75); HRMS ca1cd for ClsH24N06S 382.1320, found 
382.1326 
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678a 
Ethyl (3aR,4R,6S,7 R, 7aS)-6-[ (tert-butoxycarbonyl)amino ]-2,2-dimethyl-7 -{ [(4-
methylphenyl)sulfonyl]amino} hexahydro-l ,3-benzodioxole-4-carboxylate (678a) 
A hydrogenation vial was charged with ethyl acrylate 669 (240 mg, 0.470 mmol), and 
5 % RhlAb03 (60 mg) and 85% ethanol (1.5 mL) before evacuating with H2. The 
reaction was stirred at r.t. and 55 psi for 144 h before filtering through a plug of Si02 
and concentrating. The crude material was purified via flash column chromatography 
with a solvent gradient of 3: 1 then 1: 1 (hexanes-ethyl acetate) to yield 678a (228 mg, 
95%) as a white solid: Rr0.49 (1:1 hexanes-ethyl acetate); mp 246-247 °C (CHCh); 
lR (film) v 3434, 2099, 1647, 1160 cm-I; IH NMR (600 MHz, CDCh) & 7.78 (d, J = 
8.3 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 5.30 (d, J = 8.6 Hz, IH), 5.12 (d, J = 8.3 Hz, 
IH), 4.46 (t, J = 4.3 Hz, IH), 4.18-4.25 (m, IH), 4.09-4.15 (m, IH), 3.86 (dd, J = 5.1, 
8.8 Hz, IH), 3.40 (dq, J = 1.3, 10.2 Hz, IH), 3.21 (q, J = 9.3 Hz, IH), 2.81 (dt, J = 
3.8,12.6 Hz, IH), 2.42 (s, 3H), 2.13 (dt, J= 3.7,13.5 Hz, IH), 1.80 (q, J= 12.8 Hz, 
IH), 1.45 (s, 9H), 1.22 (t, J= 6.9 Hz, 3H), 1.18 (s, 3H), 1.16 (s, 3H) ppm; 13C NMR 
(150 MHz, CDCI3) & 170.3, 156.4, 142.8, 138.6, 129.1, 127.4, 109.4,80.1, 79.2, 73.8, 
60.9, 60.2, 50.4, 41.2, 28.5, 28.4, 27.7, 26.0, 21.4, 14.1 ppm; MS (El) mlz (%): 497 
(M-CH3), 41(52), 43(44), 57(100), 91(99), 100(35), 155(44), 182(46), 240(47), 
257(79); HRMS calcd for C23H33N20gS 497.1958, found 497.1962. 
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680 
(3aS,4R,5R,7 as)-7 -Iodo-2,2-dimethyl-8-[ (4-methylphenyl)sulfonyl]-3a,4,5, 7 a-
tetrahydro-4,5-epimino-l,3-benzodioxole (680) 
To a stirred solution of (3aS,7aS)-4-iodo-2,2-dimethyl-3a,7a-dihydro-l,3-
benzodioxole (5.16 g, 18.6 mmol) and Cu(acach (484 mg, 1.85 mmol) in MeCN (15 
mL) was added PhI=NTs (4.8 g, 12.9 mmol) at 0 °C in 3 portions over 2 min. The 
resulting mixture was stirred for 30 min before the solid material was collected by 
filtration, dissolved in EtOAc and washed with 1 N HCI (2 x 5 mL) and sat. NaHC03 
(2 x 5 mL). The crude material was recrystallized from ethyl acetate-hexanes to yield 
680 (4.56g, 55%) as a white solid: Rr O.64 (2:1 hexanes-ethyl acetate); mp 193-194 °C 
(EtOAc-hexanes); [a]D23 +23.629 (c 1.175, CHCh); IR (film) v 3435, 2890, 1651, 
1644, 1159 cm-I; IH NMR (600 MHz, CDCh) & 7.79 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 
8.3 Hz, 2H), 6.65 (dd, J= 1.5,4.8 Hz, IH), 4.61 (dd, J= 1.4,6.3 Hz, IH), 4.27 .(dd, J 
= 1.1,6.5 Hz, IH), 3.45 (dd, J= 1.8, 6.6 Hz, IH), 3.13 (dd, J= 5.1, 6.5 Hz, -lH), 2.48 
(s, 3H), 1.45 (s, 3H), 1.38 (s, 3H) ppm; I3C NMR (150 MHz, CDCh) & 145.1, 134.2, 
131.4, 129.9, 128.0, 111.3, 108.5, 75.5, 70.7, 37.7, 36.2, 27.5, 26.3, 21.7 ppm; MS 
(El) mlz (%): 447(M), 43(69), 79(52), 91(100), 155(34), 165(56), 206(40), 262(62); 
HRMS ca1cd for CI6HI8IN04S 447.0001, found 447.0004; Anal. calcd: C 42.96, H 
4.06, found C 42.96, H 4.06. 
317 
N'Jx:X 
NHTs 
681 
N-[(3aS,4R,5S,7aS)-5-azido-7-iodo-2,2-dimethyl-3a,4,5,7a-tetrahydro-l,3-
benzodioxol-4-yIJ-4-methylbenzenesulfonamide (681) 
To a stirred solution of N-tosyl aziridine 680 (2 g, 4.47 mmol) in DMF (15 mL) was 
added NH4CI (4 g) and NaN3 (377 mg, 5.8 mmol) at O°C. The reaction mixture was 
stirred for 12 h, extracted into Et20 (5 x 5 mL), washed with H20 (20 x 1 mL), 
washed with brine (1 x 5 mL) and dried over Na2S04. The crude material was 
recrystallized from EtOAc-hexanes to yield 681 (1.97 g, 90%) as a white solid: Rf 
0.39 (2:1 hexanes-ethyl acetate); mp 151°C (EtOAc-hexanes); IR (film) v 3435, 
2108, 1645, 1599, 1219, 1159 cm-I; IH NMR (600 MHz, CDCh) 8 7.80 (d, J = 8.3 
Hz, 1H), 7.31 (d,J= 8.2 Hz, 2H), 6.42 (d,J= 3.0 Hz, 1H), 5.48 (d,J= 8.3 Hz, 1H), 
4.58 (d, J = 5.6 Hz, 1H), 4.15 (dd, J = 5.7, 7.2 Hz, 1H), 3.69 (ddd, J = 0.9, 3.2, 6.5 
Hz, 1H), 3.56 (q, J = 7.5 Hz, 1H), 2.42 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H) ppm; I3C 
6 
NMR (150 MHz, CDCh) 8 143.8, 137.5, 136.5, 129.7, 127.2, 110.8,99.9, 78.1, 75.2, 
61.4, 55.0,27.5, 25.9, 21.5 ppm; MS (EI) mlz (%): 490(M), 43(55), 79(53), 91(100), 
165(50), 206(33), 262(62); HRMS calcd for CI6HI9IN404S 490.0172, found 
490.0171. 
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684 
N-[ (3aS,4R,SS, 7 as)-S-Azido-7-iodo-2,2-dimethyl-3a,4,S, 7 a-tetrahydro-l,3-
benzodioxol-4-yl]-N-[(4-methylphenyl)sulfonyl]acetamide (684) 
As solution of azide 681 (300 mg, 0.612 mmol) in triethylamine (0.7 mL) and AC20 
(0.7 mL) was stirred at r.t. for 12 h, diluted with EtOAc (3 mL) and washed with H20 
(3 x 1 mL), washed with brine (1 x 1 mL) and dried over Na2S04. The crude material 
was purified via flash column chromatography with a solvent gradient of 3: 1 then 1: 1 
(hexanes-ethyl acetate) to yield 684 (283 mg, 87% as a clear oil: Rr 0.61 (2:1 
hexanes-ethyl acetate); lH NMR (300 MHz, CDCh) 8 8.04 (d, J = 7.9 Hz, 2H), 7.34 
(d, J = 7.9 Hz, 2H), 6.55 (d, J = 1.5 Hz, IH), 4.91-5.07 (m, IH), 4.69-4.82 (m, 2H), 
4.50-4.61 (m, IH), 2.44 (s, 3H), 2.19 (s, 3H), 1.58 (s, 3H), 1.40 (s, 3H) ppm; MS (EI) 
mlz (%): 517 (M-CH3+), 43(100), 91(58), 155(86), 214(60); HRMS ca1cd for 
;\ . 
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685 
N-( (3aS,4R,5S, 7 as)-7 -Iodo-2,2-dimetbyl-4-{ [( 4-metbylpbenyl)sulfonyl] amino}-
3a,4,5,7 a-tetrabydro-l,3-benzodioxol-5-yl)acetamide (685) 
To a stirred solution of azide 684 (30 mg, 0.056 mmol) in THF (0.5 mL) was added 
Smh (0.2 M in THF) dropwise until the reaction maintained a blue colour for 5 min. 
The reaction was quenched by the addition of 10% Na2S203 until the reaction mixture 
became clear. The organics were extracted into EtOAc (5 x 1 mL), washed with brine 
(1 x 1 mL) and dried over Na2S04. The crude material was purified via flash column 
chromatography with a solvent gradient of 3: 1 then 1: 1 (hexanes-ethyl acetate) to 
yield 685 (25 mg, 88% as a clear oil: Rf O.73 (1:1 hexanes-ethyl acetate); IH NMR 
(300 MHz, CDCh) 8 7.77 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 6.59 (d, J = 
7.9 Hz, 1H), 6.43 (d, J = 2.6 Hz, 1H), 5.79 (d, J = 7.6 Hz, 1H), 4.64 (d, J = 5.6 Hz, 
1H), 4.41 (dd,J= 6.8,8.3 Hz, 1H), 4.17 (dd,J= 6.0,7.9 Hz, 1H), 3.38 (q,J= 8.1 Hz, 
j. < 
1H), 2.40(s, 3H), 2.01 (s, 3H), 1.27 (s, 3H), 1.08 (s, 3H) ppm; I3C NMR (150 MHz, 
CDCh) 8 170.9, 143.5, 141.1, 137.6, 129.5, 127.3, 110.0,95.1, 79.0, 76.8, 75.8,54.9, 
51.5,27.1,25.7,23.2,21.5 ppm; MS (EI) mlz (%): 506 (M), 43(74), 91(47), 99(54), 
253(48), 254(72), 277(100), 278(42); HRMS calcd for CI8H23IN20sS 506.0372, 
found 506.0376. 
32D 
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697 
tert-Butyl (3aS,4R,5R,7 as)-7 -bromo-2,2-dimethyl-3a,4,5, 7 a- tetrahydro-4,5-
epimino-l,3-benzodioxole-8-carboxylate (697) 
To a stirred solution of 1,3-diene 554 (1.45 g, 6.27 mmol), tert-butyl 4-nitrophenyl-
sulfonyloxycarbamate (696) (19.9 g, 62.7 mmol) and benzyltriethylammonium 
chloride (715 mg, 3.14 mmol) in methylene chloride (19 mL) was added a solution of 
NaHC03 (6.32 g, 73.7 mmol) in H20 (19 mL). The reaction was stirred at r.t. for 12 h 
before the layers were separated and the aqueous layer was extracted with methylene 
chloride (3 x 5 mL). The combined organic layers were washed with brine (1 x 5 mL) 
and concentrated under reduced pressure. The crude material was purified via flash 
column chromatography with a solvent gradient of 10:1 then 5:1 (hexane-ethyl 
acetate) to yield 697 (955 mg, 44%) as a white crystal solid: RJ 0.45 (4:1 hexanes-
ethyl acetate); mp 93-95 °C (CHCh); [a]D23 -88.91 (c 1.1, CHCh); IR (film) v 2983, 
- I 1 . ' 1723, 1281, 1156 cm ; H NMR (600 MHz, CDCh) 8 (j.45 (dd, J = 1.1, 4'.9 Hz, IH), 
4.86 (dd, J=0.7, 6.4 Hz, IH), 4.35 (d, J= 6.4 Hz, IH), 3.08 (dd, J= 1.7, 5.4 Hz, IH), 
2.86 (t, J= 5.2 Hz, IH), 1.43 (s, 9H), 1.42 (s, 3H), 1.39 (s, 3H) ppm; l3C NMR (150 
MHz, CDCh) 8 160.4, 128.0, 126.2, 111.2, 82.3, 73 .9, 72.2, 35.2, 34.8, 27.8, 27.5, 
26.1 ppm; MS (EI) mlz (%): 345 (M), 41(62), 43(75), 58(31), 59(35), 108(43), 
135(36); HRMS ca1cd for CI4H2oBrN04 345.0576, found 345.0575. 
321 
698 
tert-Butyl [(3aS,4R,5S,7 as)-5-azido-7 -bromo-2,2-dimethyl-3a,4,5, 7 a-tetrahydro-
1,3-benzodioxol-4-yl]carbamate (698) 
To a stirred solution of N-Boc aziridine 697 (100 mg, 0.289 mmol) in N,N-
dimethylformamide (1 mL) was added NH4CI (150 mg), and then NaN3 (75 mg, 1.16 
mmol) at 0 °C. The reaction was slowly raised to room temperature over 12 h before 
extracting into diethyl ether (5 x 1 mL). The combined organic layers were washed 
with H20 (20 x 0.5 mL), brine (1 x 2 mL) and dried over Na2S04. The crude material 
was purified via flash column chromatography with a solvent gradient of 8:1 then 4:1 
(hexane-ethyl acetate) to yield 698 (87 mg, 77%) as a white solid; Rf 0.33 (4:1 
hexanes-ethyl acetate); mp 88-89 °C (ethyl acetate-hexanes); [a]D23 +104.7 (cI.4, 
CHCh); IR (film) v 3432, 2102, 1655, 1598, 1219, 1165 em-I; IH NMR (300 MHz, 
CDCh, 50°C) 0 6.19 (d, J= 2.6 Hz, IH), 4.73 (d, J= 7.9 Hz, IH), 4.63 (dt, J= 0.6, 
5.4 Hz, IH), 4.38-4.45 (m, IH), 4.18-4.27 (m, IH), 3.52 (q, J= 8.5 Hz, IH), 1.55 (s, 
3H), 1.48 (s, 9H), 1.43 (s, 3H) ppm; I3C NMR (75 MHz, CDCh) 0 155.2, 131.4, 
110.9,80.5, 74.7, 59.9, 54.5, 28.3, 28.0, 26.0 ppm; MS (FAB) mlz (%): 389 (M+ H+), 
41(30),57(100), 333(31), 335(29); HRMS calcd for C12H22N4BrO/ 389.0824, found 
389.0905. 
322 
699 
(3aS,SaR,8aR,8bS)-4-bromo-2,2-dimethyl-3a,8,8a,8b-tetrahydro[1,3]dioxolo[4,5-
e] [1,3]benzoxazol-7(SaH)-one (699) 
To a stirred solution of aziridine N-Boc aziridine 697 (20 mg, 0.058 mmol) in 
methylene chloride (100 !J.L) was added trifluoroacetic acid (400 !J.L) at 0 °C. The 
reaction was slowly raised to r.t. over 12 h before being poured into sat. NaHC03 (1.5 
mL) and extracted into chloroform (3 x 1 mL). The combined organic layers were 
washed with brine (1 x 1 mL), dried over Na2S04 and concentrated under reduced 
pressure. The crude material was purified via flash column chromatography with a 
solvent gradient of 3: 1 then 1: 1 (hexane-ethyl acetate) to yield 699 (15 mg, 89%) as a 
clear oil: Rr0.42 (1:2 hexanes-ethyl acetate); [a]D23 -27.71 (c 0.9, CHCh); IR (film) v 
3444,2099, 1717, 1647, 1260, 1101 em-I; IH NMR (600 MHz, CDCh) () 6.20 (d, J = 
3.2 Hz, 1H), 5.80 (br s, 1NH), 5.07 (dd, J = 3.0, 7.2 Hz, IH), 4.63 (d, J = 4.7 Hz, 1H), 
(i . 
4.55 (d, J = 7.3 Hz, IH), 4.51 (d, J = 2.8, 4.7 Hz, 1H), 1.43 (s, 3H), 1.42 (s, 3H) ppm; 
l3C NMR (150 MHz, CDCh) () 158.2, 128.5, 124.9, 110.7, 73.9, 73.3, 72.3, 51.2, 
27.5, 26.4 ppm; MS (EI) mlz (%): 273 (M - CH3'), 43(45), 83(50), 84(100), 85(37), 
86(82); HRMS calcd for C9H9BrN04" 273.9715, found 273.9710; Anal.ca1cd: C 
41.40, H 4.17, found C 41.44, H 4.15. 
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